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E. Coli Antibodies Do Not Cause 
False-positivity in Recombinant Anti-HIV
Assays
E. Ú jhelyi,1 G. Illei,1 U. Böhm,2 G. F üst,1*, M. M. D ierich ,3 J. Szelényi,1 
K. M erétey,2 J. H ofbauer,3 S. R. H ollán1
1NationaI Institute of Haematology and Blood Transfusion, Budapest, POB 44, H-1502, 
Hungary, 2National Institute of Rheumatology and Physiotherapy, Budapest, institute for 
Hygiene, University Medical School, Innsbruck, Austria
(Received 16 November, 1988; accepted 19 December, 1988)
129 sera with known antibody titres against E. coli 026 and E. coli 055 strains 
were tested with the Abbot second generation anti-HTLV III recombinant screening 
assay. No difference in the O.D. values was found between sera with high, normal 
and low anti-E. coli titres. In addition, no false-positive reactions were observed with 
the anti-HIV negative sera containing E. coli antibodies in high titres in a Western 
blot assay in which recombinant env antigen was applied. These results suggest that
E. coli assays in which E. coli-produced recombinant antigens are used.
Keywords: E. coli antibodies, recombinant anti-HIV assay, false positivity
Introduction
As a result of the development of HIV serology, improved, second genera­
tions ELISA tests are more and more frequently used for screening blood donors 
and members of high risk groups for HIV antibodies. In most second generation 
assays, plates or beads are coated with recombinant env and/or core antigens. 
In addition, recombinant HIV antigens are applied in some experimental Western 
blot assays as well [2, 5]. Use of these antigens excludes the possibility of false- 
-positive reactions due to anti-HLA and other anti-lymphocyte antibodies [3,4,6]. 
Since, however, recombinant antigens are produced mostly in different strains of 
E. coli, theoretically it is possible that some antigens of bacterial origin can be 
present even in the purified HIV env and core antigen preparations. If recombinant 
HIV antigens are really contaminated with bacterial antigens, false-positive anti- 
-HIV reactions can develop when serum samples containing anti-E. coli antibodies 
in high titres are tested.
* To whom correspondence should be addressed
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In order to address this possibility, we have investigated 129 sera with 
known titres against two E. coli strains in the recombinant anti-HTLV III screen­
ing assay of Abbott, strictly according to the recommendations of the manu­
facturer. A part of these sera were tested in a recombinant HIV env Western blot 
assay (PEX-41) as well. No false-positive reactions were obtained in either type 
of anti-HIV assays.
Materials and Methods
Serum samples tested
The sera used were obtained from 129 patients with different rheumatic 
diseases, mostly with juvenile and adult rheumatoid arthritis.
Measurement o f E. coli antibodies
Antibodies against E. coli 026 and E. coli 055 strains were measured by 
passive haemagglutination [1] and were expressed as log2 of the highest serum 
dilution showing a haemagglutination reaction. Normal values for these anti­
bacterial antibodies were determined in the sera of 22 blood donors.
ELISA assay with recombinant antigen
Serum samples were tested in the Abbott recombinant HTLV UI EIA kit 
strictly according to the recommendations of manufacturer.
PEX-41 Western blot assay
The recombinant HIV env protein PEX-41 expressed in E. coli POP 2136 
[5] was separated in SDS-PAGE using a discontinous system, with a 4.5% start­
ing gel and a 12.5% separating gel. The sample was electrophoresed for 5 hours 
at 35 mA. The proteins were transferred electrophoretically to nitrocellulose 
paper in a Bio-Rad Transblot apparatus overnight at 250 mA. Before using the 
strips, they were incubated in PBS containing 5% skim milk and 0.1 % Triton 
X-100 for 1 hour to block aspecific binding sites. Next, the strips were incubated 
in the tested sera, washed, incubated with horseradish peroxidase conjugated 
anti-human IgG, washed 3 times and stained with diaminobenzidine tetrahydro- 
chloride. The washing procedure was done in the above mentioned buffer except 
the last wash which was in PBS.
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Results
Titres o f E. coli antibodies in the sera o f blood donors
Titres of E. coli antibodies expressed in log2 dilution values were determined 
in sera of 22 blood donors. Normal values (mean ±  2 S.D.) were found to be 
4.13 ± 1.5 for the E. coli 026 and 3.45 ± 1.94 for the E. coli 055 antibodies. 
On the basis of these data, anti-026 titres of < 2.5, 3 to 5.5, and > 6.0 were con­
sidered as low, normal, and high, respectively. For the anti-055 titres, the same 
categories were defined as < 1.5, 2 to 5, and >  5.5, respectively.
Comparison of serum samples containing E. coli antibodies in low, normal and high 
titres in a recombinant HIV screening assay
No O.D. value above cut-off O.D. was observed in any of the sera tested. 
No significant differences were observed in the O.D. values when sera with low, 
normal, and high level of anti-E. coli antibodies were compared to each other 
(Table 1). Similarly, there was no significant negative or positive correlation 
between O.D. values in the Abbott assay and the titres of either the E. coli 026 
or E. coli 055 antibodies (correlation coefficients were -0.05, and 0.13, respec­
tively), whereas a significant correlation (R =  0.45) was observed between anti- 
-026 and anti-055 titres.
Table 1
O. D. values obtained in the Abbott recombinant anti-HIV screening assay with sera 
containing antibodies against two 
E. coli strains in different amounts
Level o f  E. 
coli a n t i ­
bodies
A nti-026 Anti-055
num ber of 
sera
O. D. value 
m ean  ±  S. D.
n u m b e r
sera
o f  O. D . value 
mean ±  S. D.
Low* 16 0.18+ 0.06 21 0.14+ 0.06
Normal** 76 0.13 ±  0.07 80 0.14+ 0.08
High*** 37 0.15+ 0.06 28 0.15+ 0.04
*<2,5; <1.5, ** 3 — 5.5; 2 — 5, *** >6.0; >5.5 for the anti-026 and anti-055 antibodies, 
respectively
Study o f sera with low and high anti-E. coli titres in a recombinant Western blot 
assay
Nine and 8 sera, respectively with low and high anti-026 and/or anti-055 
titres were selected for investigation in the PEX-41 Western blot assay (Fig. 1). 
On the control strip incubated with a confirmed anti-FHV positive serum sample,
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Fig. 1. Western blot reaction performed with recombinant-derived HIV envelope antigens. 
The strips were incubated with a confirmed HIV-seropositive serum sample (first strip to 
the left), with HIV-seronegative serum samples containing E. coli 026 and/or 055 antibodies 
in low titres (9 samples, A) or high titres (8 samples, B)
2 bands could be seen with an apparent molecular weight (m. w.) of 160, and 
40 kD. No bands of the same m. w. were observed on the strips incubated with 
the 17 serum samples with known anti-E. coli levels. Several aspecific bands were 
observed on these strips; there was no difference in the number or intensity of 
these bands when the groups of sera with low and high titres were compared, 
although great variations were found among the individual sera in both groups.
Discussion
According to the present work, antibodies against two E. coli strains, E. 
coli 026 and E. coli 055 do not induce false-positive reactions in a recombinant 
anti-El IV enzyme immunoassay. Since antibodies against different E. coli strains 
cross-react with each other (a strong correlation between anti-026 and 055 anti­
bodies was found in this study as well) our results suggest that E. coli antibodies 
present in the tested sera do not disturb EHV-serology performed with solid 
phase enzyme immunoassays using E. coli-produced recombinant antigens.
In the PEX-41 recombinant Western blot assay, no sera, not even those 
containing E. coli antibodies in high titre, showed the two bands (160 and 40 kD) 
characteristic for the assay [2, 5]. (The 160 kD protein consists of the HIV env
H aem ato lo g ia  23, 1990
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fragment and the 117 kD cro-beta-gal fusion protein derived from the vector 
PEX-2, whereas the 40 kD protein is thought to correspond to the isolated env 
fragment [5].) The aspecific bands observed on the strips incubated with the HIV 
negative sera probably represent E. coli antigens, since we have observed similar 
pattern in Western blot test performed with an other E. coli-expressed HIV- 
-antigen preparation, too. Since, however, the aspecific bands are not in the same 
m. w. range as the specific 160 and 40 kD bands, their presence did not disturb 
evaluation of the PEX-41 Western blot assay. False-positivity may have serious 
consequences at anti-HIV screening and confirmation in the low-risk populations 
[6], therefore our present findings may have practical importance.
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1,25-Dihydroxyvitamin D3 Induces Normal 
Mononuclear Blood Cells To Differentiate 
in the Direction of Monocyte-Macrophages
U. Choudhuri, J. A. Adams, N. Byrom, D. M. M cCarthy,* J. Barrett
Department of Haematology, Westminster Hospital, Dean Ryle Street, 
Horseferry Road, London SW1P 2AP, England
(Received 17 August, 1988; accepted 13 January, 1989)
Normal blood mononuclear cells incubated in the presence of 1,25-dihydroxy- 
vitamin D.) [l,25-(OH),D3] in suspension culture showed increased differentiation to 
adherent macrophages. The effect was specific to l,25-(OH)2D3 as the closely related 
metabolite 25-hydroxyvitamin D3 did not increase macrophage numbers. Giant 
multinuclear cells were observed in increased numbers in l,25-(OH),D3-treated cul­
tures. However this effect was not specific to l,25-(OH)2D3 but due to cell crowding 
as these cells were also plentiful when cultures without l,25-(OH)2D3 were incubated 
at high cell densities. Increased numbers of macrophages were seen after six days of 
incubation; this effect of l,25-(OH)2D3 occured also if the mononuclear cells were 
depleted of T-cells or exposed to X-irradiation at doses up to 25Gy. Addition of 
l,25-(OH)2D3 to cultures in semi-solid media did not, however, increase the numbers 
of monocyte-macrophage colonies. These results suggest that the target cell for 1,25- 
(OH)2D3 is of the monocyte-macrophage lineage and is at a relatively late stage of 
maturation.
Keywords: monocyte-macrophage differentiation, 1,25-dihydroxyvitamin D3.
Introduction
1,25-dihydroxyvitamin D3 (1,25-(OH)2D 3) the active hormonal metabolite 
of vitamin D 3 has multiple effects on hematopoiesis in vitro. It induces human 
promyelocytic leukemia (HL-60) cells to differentiate to monocytes and macro­
phages [1, 2]; this event is associated with decreased expression of the proto- 
-oncogene c-myc [3]. It also suppresses in vitro proliferation of megakaryocytes [4] 
and fibroblasts [5] from normal human bone marrow. l,25-(OH)2D3 induces 
normal bone marrow cells to differentiate in the direction of monocytes and 
macrophages in vitro [1, 6] and we here report that l,25-(OH)2D3 has a similar 
but not identical effect on mononuclear cells taken from normal human peripheral 
blood. We do not know precisely what type of cell differentiates in response to
* To whom correspondence should be addressed
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l,25-(OH)2D3. Previous work has suggested that relatively late precursors and 
even cells such as promyelocytes and myelocytes, conventionally considered to 
have undergone committment to the granulocytic pathway of differentiation, may 
be induced by l,25-(OH)2D3 to differentiate in the direction of monocytes and 
macrophages [7]. Monocytes and activated T- and B-lymphocytes have receptors 
for l,25-(OH)2D 3 [8] but the absence of receptor for 1,25-(OH).,D3 does not 
preclude the possibility of an effect: a non-receptor mediated mechanism for 
monocytic differentiation of HL-60 cells has been proposed [9]. We have at­
tempted to identify the target cell by observing the effect of l,25-(OH)2D3 on 
initially adherent, non-adherent and T-cell depleted mononuclear cells. Also, 
by observing the period of time taken for maximal numbers of monocytes to 
form we have attempted to estimate how far the target cell is removed along 
the differentiation pathway from the mature monocyte.
Materials and Methods
Isolation o f cells
Blood was taken from normal volunteers into preservative-free heparin 
(Paines and Byrne Ltd, Greenford, Middx, UK) 10 iu/ml. The blood was layered 
onto lymphoprep (Nyegaard Ltd, Oslo, Norway) and centrifuged at 800# for 
20 minutes. The mononuclear cell layer was then washed and resuspended at 
a cell concentration of 1 x 109/1 in McCoys 5A medium (Flow Labs, UK) supple­
mented with 15% pooled, heat-inactivated human serum.
Incubation method
l,25-(OH)2D 3 (Roche Products Ltd, UK) was initially dissolved in ethanol 
then further diluted to suitable concentrations in culture medium. 50-100 pi of 
solution were added to 10 ml cultures of mononuclear blood cells. Control cultures 
were incubated with the same volume of 25-hydroxyvitamin D 3 (25-OHD3) or 
ethanol.
The cultures were incubated in 25 cm3 tissue culture flasks in a 5 % C 0 2/air 
atmosphere at 37 °C for variable intervals. For some experiments the non-adherent 
cells were collected after 24 hours and incubated separately. The remaining 
adherent cells were washed once in situ and fresh McCoys medium containing 
15% human serum (10 ml) was added. Incubation was continued as above with 
],25-(OH)oD3 or 25-OHD3.
Irradiation
The culture flasks to be irradiated were exposed to X-irradiation from a 
Caesium-137 source in a Gammacell-1000 blood irradiator (Atomic Energy
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of Canada Ltd, Ottawa, Canada) for a suitable period of time (0-6 mins) at the 
start of the incubation period.
Assessment o f monocyte-macrophage (MM)  numbers
When the incubation period was complete non-adherent cells were decanted 
and the adherent cell layer was washed with McCoys 5A medium. The cells were 
stained with May-Grunwald Giemsa and in some cases with Sudan Black and 
for a-naphthyl-acetate esterase (ANAE) by standard techniques [10]. An area 
7 cm X  5 cm was marked on the outside of the flask and all the cells within that 
area were counted by light microscopy. The number of adherent cells was ex­
pressed as cells X  105/m2.
Granulocyte-macrophage colony assay
The technique of Pike and Robinson [11] was used with minor modifica­
tions. Blood was obtained from normal laboratory volunteers and mononuclear 
cells separated over Lymphoprep (Nyegaard, Oslo). Peripheral blood mono­
nuclear cells (0 .5x l06/ml) were incubated with giant-cell conditioned medium 
(GCT-CM; Gibco Ltd, UK; 20% v/v) in 35 m nr culture dishes (Sterilin, UK). 
Pooled human serum was used throughout. After 10 days incubation at 37 °C and 
5 % C 0 2 the agar gel was transferred to a glass slide, dried and stained with May- 
-Grunwald Giemsa and for a-naphthyl-acetate esterase activity. Results are ex­
pressed as mean and standard deviations of triplicate cultures from 6 donors for 
total groups (>  10 cells). Colonies were not specifically counted as their numbers 
were so low.
T-cell depletion
T-cells were depleted by resetting with sheep red blood cells (SRBC: Tissue 
Culture Services, Slough, UK). Briefly, mononuclear cells (15 x 10lJ/l) were centri­
fuged with AET-treated SRBC (10% SRBC in 40% fetal calf serum/phosphate- 
buffered saline) at 100# for 5 minutes. The button was resuspended, the suspension 
layered on lymphoprep and centrifuged at 600# for 20 minutes. The mono­
nuclear layer was washed twice with Hanks BSS. The mononuclear cells were 
assessed for residual T-cells by using an Immune Monotoring Kit in a FACS- 
-analyser I (Becton-Dickenson, Mountain View, California 94039).
Results
Monocyte-macrophage numbers
The number of MM adherent cells after 14 days in culture was highly vari­
able between individuals but in all cases the number was greatly increased by 
addition of l,25-(OH)2D3. There was an approximate dose-response relationship
H aem ato lo g ia  23, 1990
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Table 1
Monocyte-macrophage numbers in cultures of peripheral mononuclear cells incubated
vitamin D3 metabolites for 14 days 
Number of monocyte-macrophages* 
Incubation  C ond itions
E xperim en t
n u m b er
Level of 
l,25 -(O H )2 
D 3(M )
C o n tro l 2 5 -O H D 3
1, 25-(O H )2D 3- 
treated
I « 7 280* 310 1345
l КГ8 510 605 1100
Ю"9 425 450 1050
10"7 30 61 680
2 10 '8 45 40 350
10-9 40 35 275
1e r 7 320 360 1050
3 10-* 380 500 1180
10“9 400 410 995
% increase in macrophage numbers 10~7M — 1022+ 627 
with 1, 25-(OH),D3** 10-ЧѴГ- 435 +  174
10~9M -  311+ 63
* Each figure represents the numbers of monocyte-macrophages which were adherent in 
the flask expressed as cellsx 105/m2.
** Each figure represents the percentage increase in the number of monocyte-macro- 
phages (mean +  SEM) compared to control numbers. These increases are significant with 
P <  0.025 (10~7, 10-8) and P <  0.05 (10-9). Control cultures contained the same quantity of 
ethanol vehicle as did the cultures which contained 25-OHD3 or 1, 25-(OH)2D3.
in the range of 1СГ9-1 0 “7 M. MM numbers were the same in cultures containing 
ethanol or 25-OHD3 (Table 1). in both control and treated cultures MM numbers 
were maximal at day 14 although the maximum difference in numbers between 
control and treated cultures occurred at day 20. At all of the time points studied 
from days 6 to 20 MM numbers were significantly higher in the l,25-(OH)2D3- 
-treated cultures (P <0.01, n = 5) (Fig. 1). Because of the wide variation in MM 
numbers between individuals the data were processed using the paired Student 
/-test. There was no difference detectable at days ! and 3. The ANAE reaction 
was strongly positive in more than 80% of MM.
Monocyte-macrophage numbers after irradiation
X-irradiation of the mononuclear blood cells before incubation decreased 
the number of MM in both control and l,25-(OH)3D 3-treated cultures (Fig. 2). 
However after irradiation to 25Gy the 1,25-(OH)3D 3-treated cultures contained
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Fig. 1. MM numbers from days 3 to 20 (mean +  SD, n =  5). Results are expressed as a per­
centage of the control figure on day one. Clear bars represent control cultures containing 
25-OHD3 and hatched bars represent cultures containing l,25-(OH)2D3 (10~8 M)
Fig. 2. MM numbers after exposure of cultures at the start of incubation to X-irradiation 
(mean +  SEM, n =  3). Black diamond sign indicates cultures incubated with l,25-(OH)2D 3 
(10~8 M). White diamond sign indicates cultures incubated with 25-OHD3. The incubation
period was 14 days
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Fig. 3. MM numbers after various incubation periods. Solid lines indicate unirradiated 
cultures. Broken lines indicate cultures exposed to 25Gy X-irradiation before the start of 
incubation. Black square or triangle indicate cultures with l,25-(OH)2D3 (10-8 M). White 
square or triangle indicate cultures with 25-OHD3 (10~8 M). Results represent mean +  SEM,
n =  4
Fig. 4. MM numbers after 14 days in cultures of adherent, non-adherent and mixed adherent 
and non-adherent cells. Results represent mean +  SEM, n =  3. Clear bars represent control 
cultures containing 25-OHD3 (К Г 8 M) and hatched bars represent cultures containing
l,25-(OH)2D 3 (1СГ8 M)
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approximately 10 times as many MM as controls when assessed after 12 days 
incubation. In fact even after 50Gy MM numbers were still increased after in­
cubation with l,25-(OH)2D 3 in comparison to the control numbers (results not 
shown). Some multinucleate giant cells were seen in the irradiated cultures espe­
cially in areas where the cells were crowded.
MM numbers were increased to a significant extent by l,25-(OH)2D3 after 
only six days incubation, but X-irradiation (25Gy) prevented this initial increase. 
Cultures examined after longer periods of incubation clearly contained more 
MM in the presence of l,25-(OH)2D 3 than the controls despite irradiation (P <
0.05, n = 4 for days 12, 20) (Fig. 3).
Multinucleate giant cells
Multinucleated giant cells were increased in number in cultures which con­
tained l,25-(OH)2D 3 but when the mononuclear cells at very low density (starting 
concentration 5 x lO'/l) were incubated with l,25-(OH)2D3 a very much lower 
proportion of multinucleate cells were seen mainly in crowded areas of the flasks. 
Irradiation to 25Gy did not prevent their formation.
Monocyte-macrophage numbers after adherence and T-cell depletion
When initially adherent cells were co-cultured with initially non-adherent 
cells the expected rise in macrophage numbers with l,25-(OFt)2D s occurred. 
A similar but lesser rise occurred when non-adherent cells alone were cultured 
with l,25-(OH)2D 3(P < 0.05, n = 3). The small l,25-(OH).,D3-induced rise seen 
with initially non-adherent cells was not statistically significant (Fig. 4).
The number of monocytes in the non-adherent fraction was 2.6 + 0.9 
(x  107/1) on day 1, 3.2 + 0.8 (x  107/1) on day 20 in control cultures and 7.3 ±1.8 
(x  107/1) on day 20 in cultures treated with 1,25-(OH),D3. (Control v treated
U n trea ted T-cell depleted
Control* 100** 9 5 + 8
l,25-(OH)2D;i 129 ±  5 122+ 6
* Control cultures contained equal quantity of ethanol vehicle as those containing 
l,25-(OH),D3.
** Figures represent MM numbers expressed as percentage (mean +  SEM, n =  3) 
of untreated control figures.
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Table 3
Types of colony grown from peripheral blood mononuclear cells 
(numbers/2x 105 cells; M +  SD, n =  6)
M onocy tic
G ra n u lo ­
cyte-
m acrophage
N eu troph il E osinoph il
Control* 3 + 2 2 + 2 5 + 3 10+ 5
l,25-(OH),D3(1 0 '8M) 4 +  1 2 + 2 6 + 4 9 + 4
* Ethanol vehicle (0.1 % v/v) was added.
P < 0.01, n = 3). Depleting the cultures of T-cells did not prevent the increase 
in MM numbers with 1,25-(OH)2D3 (Table 2) despite the fact that 98% of the 
T-cells were removed.
CFU-GM assay (Table 3)
The l,25-(OH)2D 3 treated cultures contained 4 +  1 (n = 6) monocyte- 
-macrophage clusters and colonies compared to 3 + 2 in the control (ethanol 
vehicle alone) cultures. The majority of non-MM colonies were eosinophilic and 
the corresponding numbers were 17 + 4 (l,25-(OH)2D3) and 17 ± 4 (control).
Discussion
The increase in MM numbers which we observed in the cultures incubated 
with l,25-(OH)2D3 was clearly a specific response because the closely related 
vitamin D 3 metabolite 25-OHD3 did not cause any increase. This strongly sug­
gests that the effect is mediated by binding of l,25-(OH)3D3 to a specific receptor 
in the responsive cell. Monocytes and probably their immediate precursors con­
tain l,25-(OH)2D 3-receptors and cells of this lineage are therefore most likely 
to be the immediately responsive cells. This interpretation is supported by our 
findings that the MM numbers induced from initially adherent cells were very 
much greater than those from initially non-adherent cells and not much less than 
the numbers induced by l,25-(OH)2D 3 from the total mononuclear cell popula­
tion. l,25-(OH)2D3 is not simply an adhesion-inducing agent because the numbers 
of MM in the non-adherent fraction were also increased. Although activated 
T-lymphocytes contain receptors for l,25-(OH)2D 3 and conceivably could pro­
duce a lymphokine in response to l,25-(OH)2D3 that induced precursor cells to 
differentiate to MM our finding that depleting the mononuclear cells of T-cells 
had no detectable impact on the inductive effect of 1,25-(OH)2D 3 is not 
readily compatible with this idea.
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The cell which is stimulated to differentiate by l,25-(OH)2D 3 is likely to 
be a relatively late MM-precursor which does not require to undergo mitosis 
before it becomes identifiable as an adherent monocyte-macrophage. This is so 
firstly because the numbers of MM were clearly increased as early as six days 
after adding l,25-(OH)2D3, secondly because the numbers of MM colonies were 
not increased by 1,25-(OH)2D 3 and thirdly because a substantial proportion of 
MM derived from the stimulated cells even after irradiation. Although irradiation 
to 25Gy (and in some experiments to 50Gy) reduced the numbers of MM formed 
in response to l,25-(OH)2D 3 these numbers were still increased in comparison 
to the control cultures. Irradiation to much less than this level completely ablates 
formation of haemopoietic colonies in vitro. Whether the inducing effect is 
entirely to influence cells to mature to adherent MM is not clear. Although the 
well documented ability of l,25-(OH)2D3 to induce maturation and adherence 
of other cell types such as HL-60 cells may suggest that this is also its primary 
role in the present system it remains possible that additional mechanisms such 
as continuing activation of the MM are involved.
There was no detectable increase in the size or number of the cell groups 
in l,25-(OH),D3-treated cultures. In contrast MM colony formation from normal 
human bone marrow MNC is induced by l,25-(OH)2D3 [4, 6]. This apparent 
difference may be explained by the fact that MM-colony-forming cells exist in 
numbers which are too low in peripheral blood for an effect to be detectable. 
However marrow and blood progenitor cells differ in many respects [12, 13, 14], 
and varying responses to differentiation inducers may result from differing age 
distributions. In a murine system Nagler et al. [11] also recently found that 
whereas low doses of cytosine arabinoside increased the numbers of MM in 
liquid cultures they did not alter the numbers of MM colonies.
The number of multinucleate giant cells [15] in related culture systems is 
increased by l,25-(OH)2D3, a finding which lends support to the disputed idea 
that these cells are closely related to osteoclasts. Although we observed an increase 
in the multinucleate cells in cultures with l,25-(OH)2D3 this effect appears to 
result from crowding of macrophages as a result of their increased number rather 
than from any specific reaction of l,25-(OH)2D3 because the proportion of multi­
nucleate cells was much less when cells were cultured at a lower concentration. 
Our data support the notion that cell fusion is the mechanism responsible for 
multinucleation in culture because irradiation which should prevent endomitosis 
did not prevent formation of multinucleate giant cells.
These results are similar to those reported for normal human bone marrow 
cells and for peripheral blood cells from patients with chronic granulocytic leukae­
mia. In those studies we identified the cells positively as MM by functional and 
cytochemical criteria and by identifying surface antigens specific for MM with 
a panel of monoclonal antibodies. In this study the cells were indistinguishable 
by morphological and cytochemical criteria from those we have previously 
reported.
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It is not clear if this in vitro effect of l,25-(OH)2D 3 has a counterpart in 
vivo. On the one hand we used concentrations of l,25-(OH)2D3 one to two logs 
higher than circulating levels. On the other hand the number of MM is a crude 
measure of effect, and the dissociation constant (Kd) for l,25-(OH)2D3 in mono­
cytes [8] and in CGL buffy coat cells [16] is close to the physiological range 
although a higher Kd was found for HL-60 cells [17]. Also monocytes may syn­
thesize l,25-(OH)2D3 and in this synthesis may powerfully be stimulated by y- 
-interferon [18]. Thus concentrations of l,25-(OH)2D 3 in the microenvironment 
of developing monocytes in vivo could lie within the concentration range em­
ployed in our experiments. Low circulatory levels have been reported in leukaemia 
[19] and responses to treatment with l,25-(OH)2D3 have been described in myelo­
fibrosis with rickets [20, 21, 22]. However whether l,25-(OH)2D3 has a physio­
logical role as a modulator of haematopiesis remains an open question.
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31 patients with successful kidney grafts were studied. Ep, Ht, Hb and T lym­
phocytes were determined. Native and grafted kidneys were studied by ultrasono­
graphy. After KT, 45% of patients had PTE and in 71% of these a spontaneous 
regression was observed. Mean serum Ep activity in patients with and without PTE 
was significanthly higher than in healthy controls. Different erythroid colony growth 
sensibility and responsiveness to higher serum Ep (PTE and non-PTE patients) may 
be due to T3 cell interaction with BFU-E.
Keywords: erythropoietin, erythrocytosis, kidney transplant
Introduction
Erythrocytosis, a common late complication in patients after successful 
kidney transplantation (KT) has been previously reported [1, 2]. Moreover, in 
these patients an elevated peripheral erythropoietin (Ep) concentration was also 
found [2]. To elucidate the role of Ep in kidney transplanted patients, we deter­
mined serum Ep levels and performed a retrospective analysis of factors that may 
influence the development of post-transplant erythrocytosis (PTE). Furthermore, 
in all p;itients the ultrasonography of native and grafted kidney was performed.
Materials and Methods
31 patients (18 males, 13 females; age 41 + 9, range 24-57 years) with 
successful grafts were studied. Ep, Ht, Hb and T lymphocytes were determined 
from blood samples.
For the evaluation of the Ep level, we analyzed the capacity of studied 
serum to stimulate labelled iron uptake in Guinea pig bone marrow cultures 
according to the method of Goldwasser et al. [3]. Bone marrow cell suspensions 
(10-15 X 10® nucleated cells/ml) from femurs of 3-4 months old Guinea pigs
VSP Utrecht, Tokyo 
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were cultured in a medium of 65% NCTC 109 containing 30% fetal calf serum, 
5% human test serum and penicillin-streptomycin (100 U/ml and 100 ftg/ml). 
A volume of 200 /Л of the cellular suspension was placed in sterile microtiter 
plates and incubated for 20 hours at 37 °C in a humidified 5 % C 02-air incubator. 
Hereafter, 10 /Л of a solution containing 50% normal AB human serum, 40% 
NCTC 109, 5% 0.9 M N aH C 03 and 5% o9Fe was added to each microtiter well 
and plates reincubated for 5 hrs. Cells were removed, collected into glass tubes, 
washed and heme was extracted using acid ethylmethylketone. a9Fe incorporation 
into heme was determined by measuring radioactivity in aliquots of the solvent 
layer in a gamma-counter. Ep level was calculated by the following formula [4]:
о/ T- , , cmp patients serum% Ep level =  ------—t---------------------- X 100
cpm normal AB serum
The pooled AB sera of 30 normal subjects was used to determine the control 
values of Ep.
T cells were determined using murine monoclonal antibodies directed 
against pan-T cells (OK.T3).
Table 1
Clinical aspects and kidney serum Ep activity in 31 transplanted patients
P T E -P atien ts N on-P T E patien ts C o n tro ls
— Mean time (months) 
between KT and Ep 
measurement
66 +  39 (8 -  100) 43 +  34 (4 -  104) -
— Mean serum 
erythropoietin 
(% of control)
*160 +  30 (120 -  200) *160+ 20 (130 -  190) 100 +  15
— Mean azathioprine dose 
(mg/kg body wt)
2 .0+  5 2.2+ 7 —
— Spontaneous regression 
of erythrocytosis 
(1 — 68 months)
64% - -
— Intermittent phlebotomy 
(Ht 57 +  6)
36% — —
— Hypertension 100% 90% -
— Transplant artery 
stenosis
— 6%
— Active hepatitis - 9.6%
* P <  0.005 vs controls
PTE =  post-transplant erythrocytosis
K.T =  kidney transplantation
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Ultrasonography: commercially available real time sector scanners with 
3.5 MHz transducers were used (AUC 940, Ansaldo).
Results were evaluated by Students’ unpaired /-test and simple linear 
regression analysis.
Results and Discussion
In 45% of patients PTE (Ht = 52 + 4%) with normal white cell and plate­
let count was found at different times after KT (average 7 + 3 months). In pati­
ents without PTE (Ht = 48%), the normalization of Ht was average 4 +  1 
months [5].
Spontaneous regression of PTE occured in 71 % of the patients. Intermittent 
phlebothomy (Ht = 5 7  + 6%) was performed in 4 patients to prevent thrombo­
embolic events.
Mean serum Ep concentration (Table 1) was significantly higher (P <  0.001) 
in 63% of all patients (with or without PTE) than serum Ep titers in healthy 
controls. There was no significant difference between the two studied groups 
of patients (with or without PTE) concerning mean azathioprine dose [6], trans-
Fig. I. Native kidney (dx) ultrasound, showing fibrotic alterations and acquired cystic disease 
in patient with high Ep (15 yrs. from HD start; 10 yrs. post KT)
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plant artery stenosis, severe hypertension and active hepatitis (Table 1), implicated 
causes of erythrocytosis. A relationship between OKT3 count (%) and Ht was 
found statistically significant (n = 20; r =  0.466; P = < 0.05), while no cor­
relation was found between Ht and total white cell counts. In all patients ultra­
sound pictures of native kidneys showed fibrotic alterations; in some cases ac­
quired cystic disease was found. (Fig. 1). In one patient a moderate graft 
hydronephrosis was discovered. (Fig. 2).
The above mentioned anatomical conditions of the native kidneys may 
produce a persistent local hypoxia that leads to an increased Ep production 
according to studies by Thevenod et al. [5].
In conclusion, our results confirm that the increase of Ep production may 
be due to changes in the native kidneys. Only 35% of patients with high EP 
levels had PTE.
Different erythroid colony growth sensibility and responsiveness to higher 
serum Ep may be due to T3 cell interaction with BFU-E, as reported by Lampert 
et al. [7] and suggested by the correlation found between Ht and T3 cells.
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Fig. 2. Graft ultrasound, showing moderate hydronephrosis in patient with high Ep
(13 months post KT)
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Seventy-two consecutive and previously untreated adults with acute non­
lymphoblastic leukaemia (ANLL), having a median age of 36 years (range 12 to 71), 
were prospectively randomised to receive conventional doses of cytosine arabinoside 
and doxorubicin combined with either etoposide (CTR III) or 6-thioguanine (DAT). 
Morbidity was comparable between the two regimens and complete remission (CR) 
rates of 52% and 62% respectively (p >  0.50) were not influenced by age above or 
below 50 years, initial white cell count, French-American-British classification, or 
race. However, growth pattern in the GM : CFUc assay was found to identify a sub­
group of patients who had a significantly higher CR rate. Similarly, the secretion of 
tissue plasminogen activator by leukaemic blasts in vitro uniformly predicted for 
primary drug resistance, whereas a CR rate of 68% was associated with production 
of the urokinase type or a mixture of both enzymes. Remission duration and survival 
did not differ between these two forms of chemotherapy, nor were they influenced 
by immunotherapy with C. parvum or the duration of maintenance therapy, whereas 
age below 50 and the species of plasminogen activator secreted were significant prognos­
tic factors. It is concluded that etoposide can be substituted for 6-thioguanine in these 
cytosine arabinoside and doxorubicin-containing regimens and that for both com­
binations the most sensitive prognostic factor for CR and survival is the species of 
plasminogen activator secreted in vitro by the leukaemic blasts.
Keywords: etoposide, DAT, GM : CFUc, TPA secretion
Introduction
Optimal survival in acute nonlymphoblastic leukaemia (ANLL) depends 
upon achieving the highest possible complete remission (CR) rate combined with 
prevention of subsequent relapse. The most effective induction regimens contain 
cytosine arabinoside and an anthracycline antibiotic [1]. Etoposide, an epipodo- 
phyllotoxin designated VP16-213, has been shown to be a useful agent in the 
treatment of ANLL [2, 3] and in previous studies this agent has been successfully 
combined with cytosine arabinoside and an anthracycline antibiotic [4, 5]. Al-
* Correspondence: Dept, of Haematology, University of Cape Town, Medical School, 
Anzio Road, Observatory 7925, Cape, South Africa
VSP Utrecht, Tokyo 
Akadémiai Kiadó, Budapest
though many regimens contain additional drugs, any benefit so derived remains 
to be documented [6, 7]. 6-thioguanine has been advocated in this context and 
at the time this study was initiated a 5-day course of these three agents, designated 
DAT, was reported to have a CR rate of 85% [8]; this figure has, in subsequent 
larger studies, dropped to 66% [9]. The current study was designed to prospec­
tively compare the replacement of 6-thioguanine by etoposide as a third drug 
in the treatment of ANLL. Two additional aims of the present investigation were 
to extend our experience with the duration of maintenance therapy [4] and to 
evaluate the benefit of C. parvum as a form of immunotherapy [10].
28 P. Jacobs et a i:  Chemotherapy o f adult acute nonlymphoblastic leukaemia
Materials and Methods
Patients
Seventy-two adults were entered into this study between March, 1981 and 
January, 1985; the protocol had received approval by institutional review boards. 
Informed consent was required and all those who completed the first course of 
chemotherapy were considered evaluable. Patients with acute leukaemia second­
ary to the myelodysplastic syndrome or who had received previous chemotherapy 
or radiotherapy were excluded.
Laboratory studies
All patients were classified according to the French-American-British 
recommendation [11 ], based on examination of peripheral blood and bone marrow 
aspiration. At presentation, additional studies included full blood count, bio­
chemical profile, in vitro bone marrow culture for GM : CFUc [12], and charac­
terisation of the type of plasminogen activator produced by leukaemic cells [13, 
14]; these were repeated serially, where appropriate.
Immunotherapy was assessed by serial in vitro studies of the peripheral 
blood mononuclear cell fraction, isolated on a ficoll : hypaque gradient (specific 
gravity 1.077 g/ml) from both control patients and those receiving C. parvum. 
Under standardised conditions 5 x 10’ mononuclear cells/ml were suspended in 
RPMI tissue culture medium (Gibco Limited, Scotland) containing 25% heat 
inactivated human pooled AB serum in the presence of three different mitogens: 
concanavalin A (Calbiochem Behring Corporation, Hoechst, Lucerne, Switzer­
land), 250 /(g/ml; phytohaemagglutinin (Wellcome, Dartford, U.K.), 450 /ig/ml; 
and pokeweed (Flow Laboratories, Herts, U.K.), 20 /ig/ml [15]. Following 
3 days’ incubation at 37 °C, each well was pulsed for 18 hours with 1 uCi tritiated 
thymidine (Amersham Radiochemical Centre, U.K.) and, after harvesting, radio­
nuclide incorporation was determined by liquid scintillation counting (Tricarb 
Model C2425-Packard, Downers Grove, Illinois, U.S.A.). Simultaneous studies
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were carried out using the mixed lymphocyte reaction [16], in which 5 x 10° 
mononuclear cells/ml were exposed to alloantigen in the form of an equal number 
of mitomycin treated lymphocytes for 5 days, pulsed with tritiated thymidine, 
and a stimulation index established by scintillation counting. All studies were 
carried out in triplicate and responses expressed as a percentage of pretreatment 
values.
Supportive care
Patients were treated in general medical wards, without prophylactic anti­
biotics. With the development of sustained fever, appropriate blood cultures were 
taken and the patients started on a combination of broad spectrum antimicrobial 
therapy. Packed red cells were transfused to maintain the haemoglobin above 
12 g/dl. Platelet transfusions were used for thrombocytopenic bleeding and allo­
geneic granulocytes infused in patients with unresponsive infections.
Chemotherapy
Patients were randomly assigned to receive a 3-drug combination regimen 
(CTR III) comprising cytosine arabinoside (80 mg/m2 by continuous intravenous 
infusion on days 1 through 5), doxorubicin (50 mg/m2 on day 1) and etoposide 
(80 mg/m2 on days 1 through 5 as a half-hour infusion). The alternative 3-drug 
regimen (DAT) consisted of cytosine arabinoside (100 mg/m2 every 12 hours on 
days i through 5 as a half-hour intravenous infusion), doxorubicin (50 mg/m2 
on day 1), and 6-thioguanine (100 mg/m2 orally every 12 hours on days 1 through 
5).
Patients with persistent leukaemia on day 21 after initiating therapy were 
designated as treatment failures and a second course of induction therapy was 
commenced. Up to four such cycles were given before they were regarded as 
having refractory disease and removed from the study. Consolidation therapy 
consisted of two further monthly courses of the same drugs, given immediately 
after complete remission (CR) had been achieved.
Patients in CR were randomised to either the short (6 months) or extended 
(15 months) arm of the maintenance programme. In the short course, cyclo­
phosphamide was infused intravenously once in each of three consecutive months, 
starting at a dose of 1250 mg/m2 and escalating this to achieve a nadir of granulo­
cyte count below 1.5 x 109/1 and platelet count below 50 x 109/1. Thereafter, 
three different drugs were administered monthly for 3 months. Methotrexate was 
given in a loading dose of 0.5 mg/kg over 30 minutes, followed by a 24 hour 
infusion of 125 mg/m2, after which the patient underwent folinic acid rescue. 
In the same 24 hours 2 mg of vincristine was infused. On the second day 250 mg/m2 
of cytosine arabinoside was infused over 24 hours and the dose titrated in the 
second and third courses to achieve granulocyte and platelet counts comparable 
to those obtained during the cyclophosphamide infusion. In the extended course
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there were also two phases. In each of the first 9 months a 24 hour course of 
chemotherapy was given, comprising continuous infusion of cytosine arabinoside 
(400 mg/m2), etoposide (400 mg/m2) in five divided doses, and doxorubicin (50 mg/ 
/m2) given as a single injection. The dose of cytosine arabinoside was again 
adjusted to achieve the desired suppression of granulocyte and platelet counts. 
In the ensuing 6 months the patients received identical chemotherapy to that 
given during the short course. Patients were randomly allocated to receive C. 
parvum (Corpovax, Burroughs Wellcome, England), 2.5 mg once a week by 
intravenous infusion throughout the period of induction, consolidation and 
maintenance.
Surveillance
Bone marrow examination was performed monthly during treatment and 
every 3 months after completion.
Definition o f therapeutic endpoints
Complete remission was defined as less than 5% blasts in a normocellular 
marrow, with return of peripheral blood counts to normal. Relapse was defined 
as the appearance of circulating leukaemic blasts or greater than 5% blasts in 
the bone marrow.
Statistical analysis
Survival duration was measured from the day of the first treatment to the 
day of death. Remission duration was measured from the time of detection of 
bone marrow remission to the date of relapse. The probability of staying in 
remission or of being alive was calculated according to the Kaplan-Meier method 
[17]. Response rates were compared using the chi-squared test with Yates’ con­
tinuity correction or Fisher’s exact test for small numbers. Remission and sur­
vival curves were compared by using the Generalised Wilcoxon and the Mantel- 
-Cox tests, employing the BMDP-1L computer program.
Results
Remission induction chemotherapy
Thirty four patients were randomised to receive CTR III and 38 to receive 
DAT, but two were subsequently excluded from analysis due to major protocol 
violations. Age, sex distribution, FAB subtype and white cell count were not 
statistically different between the two treatment groups (Table 1). The CR rate
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of 52% (17/33) achieved in patients receiving the CTR III regimen was not sig­
nificantly different from the 62% (23/37) in those who received DAT (p > 0.05). 
Of the pretreatment characteristics analysed for power to predict response rate 
there was no significant influence by age, pretreatment white cell count, FAB 
subtype, or race.
Table 1
Characteristics of the two treatment groups
C T R  III D A T
Number 33 37
*Age (Years)
— Median/Mean 45/38.1 31/34.0
— Range 12-68 17-71
Males 20 17
Females 13 20
FAB Ml 14 15
М2 10 13
М3 1 1
M4 6 6
M5 2 2
**White cell count
(X 100/1)
— Median/Mean 12.5/34.9 12.9/30.3
— Range 2.2-200.0 0.4-238.0
Table 2
Predictive value of growth pattern in the GM: CFUc assay
Type  of N u m b er o f  pa t ie n t s
% C R
pat tern Total Ach ie ving  C R
l 18 12 67
2 23 11 48
3 7 7 100
Type 1 =  No growth; Type 2 =  Clusters only; Type 3 =  Clusters and colonies; 
Clusters equal aggregate containing less than 50 cells each. Colonies equal aggregate containing 
more than 50 cells each.
Chi-square =  6.446, d.f. =  2, p =  0.039; Comparing “2” and “3” Fisher’s p =  0.015; 
Comparing “ 1” and “3” Fisher’s p =  0.10; Comparing “ 1” and “2” Fisher’s p =  0.18
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Table 3
Predictive value of plasminogen activator for complete remisson
Type o f  p lasm inogen
N u m b e r  o f  patients
C R
(%)ac t iva to r
Total
Achieving
C R
Tissue 10 0 0
Mixed or
urokinase 53 36 6 8
In vitro bone marrow assay for GM : CFUc was performed on samples 
aspirated from 48 patients and the results grouped according to the growth 
pattern observed (Table 2). Those individuals where no growth was obtained 
(Type 1) had a CR rate of 67%; this is not statistically significantly different 
from the CR rate of 48% which was achieved by those patients where cluster 
formation alone, defined as cell aggregates of less than 50 in number (Type 2), 
was found. In contrast, those patients whose marrow cultures gave rise to both 
clusters and colonies, the latter defined as more than 50 cells in an aggregate 
(Type 3), had a significantly superior CR rate of 100% (p =  0.039).
The species of plasminogen activator secreted by the leukaemic blasts was 
studied in 63 patients. In those individuals where predominantly tissue type 
enzyme was found none achieved CR, whereas 68% of those patients whose cells 
secreted predominantly urokinase or a mixture of both types of plasminogen 
activator achieved this status (p > 0.001) (Table 3).
Remission failure
Thirty patients failed to achieve a CR. The pattern of remission failure [18] 
is shown in Table 4. The CTR III regimen was associated with more Type V 
treatment failures than occurred with DAT (Fisher’s p = 0.04).
Remission duration
The median durations of CR were 27.5 weeks and 30 weeks for the CTR 
III and the DAT regimens, respectively. There was no significant difference in 
remission duration when these two regimens were used as induction and con­
solidation therapy (Fig. 1). The species of plasminogen activator secreted by the 
leukaemic blasts was found to influence the duration of remission in those patients 
on these cells when such studies were performed. Where this was predominantly 
urokinase, remissions were significantly longer than when a mixed pattern
H aem ato log ia  23, 1990
Chi-square =  13.9, p =  0.0002 
Fisher’s p =  0.00007
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Table 4
Pattern of remission failure
Type o f  remiss ion C T R  III 
failure
D A T
I 1 3
и 7 8
hi 0 0
IV 0 1
V 8* 2
* Fisher’s p =  0.04
was found (p = 0.04; Fig. 2). For the entire group only 3 patients remain in 
remission.
Maintenance therapy
Thirty-two patients were randomised to the maintenance programme. 
Thirteen patients received the short course and 19 patients the extended course. 
Eight patients who achieved CR did not receive maintenance therapy; 2 patients 
underwent bone marrow transplantation, 2 refused maintenance chemotherapy, 
and 4 patients died while aplastic during consolidation therapy. Analysis of the 
data revealed no statistically significant difference in remission duration, being 
24 weeks for the short course and 35 weeks for the extended course when analysed 
regardless of the induction regimen. Patient numbers were too small to examine
Fig. 1. Comparison of the two induction regimens. Kaplan-Meier plot of cumulative pro­
portion of patients surviving in remission. CTR III is cytosine arabinoside, doxorubicin and 
etoposide and DAT is cytosine arabinoside, doxorubicin and 6-thioguanine. Ticks indicate 
patients remaining in complete remission
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Fig. 2. The influence of plasminogen activator secretion on survival. Kaplan-Meier plot of 
cumulative proportion of patients surviving in remission. Ticks indicate patients remaining 
in complete remission. One patient who is alive in CR is not shown on this graph since these 
studies were not carried out in that individual
separately the effect of maintenance therapy in conjunction with the type of 
induction regimen used.
Immunotherapy
Twenty-nine patients were randomised to receive C. parvum, commencing 
with the initiation of induction chemotherapy. This agent had no significant 
influence on the CR rate, duration of remission or survival.
The in vitro studies of peripheral blood mononuclear cell response to mito­
gens or alloantigen showed no change from pretreatment levels in patients receiv­
ing C. parvum. Furthermore, using the same laboratory techniques, serial studies 
performed throughout the induction, consolidation and maintenance phases of
Time in days
Fig. 3. The influence of age on survival. Kaplan-Meier plot of cumulative proportion of 
patients surviving in remission. Ticks indicate patients remaining alive
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both chemotherapy programmes showed no differences between those patients 
who did or did not receive C. parvum. Similarly, when serial GM : CFUc assays 
were carried out on these patients no effect was demonstrable.
Survival
Median duration of survival for all patients treated with CTR 111 was 
27 weeks; this is not significantly different from the 34 weeks achieved with those 
receiving DAT. Patients over the age of 50 were shown to have a significantly 
shortened duration of survival (p =  0.003) (Fig. 3). The survival curves have not 
reached a plateau.
Discussion
Several studies have shown that treatment of acute nonlymphoblastic 
leukaemia is most effective with regimens containing cytosine arabinoside and 
an anthracycline antibiotic [1]. The reported remission rates vary widely, ranging 
from less than 50% to greater than 80% [8, 9, 19, 20] as a result of many factors, 
of which the most important is age [19, 21, 22] but which also includes other 
variables such as the level of expertise and supportive care available.
At the time the present study was initiated the best combination of chemo­
therapy had not been clearly defined. In at least two small series of patients a CR 
rate exceeding 80% was achieved with regimens that included 6-thioguanine 
(DAT) [8, 20]. As our previous experience had been gained using etoposide in 
combination with cytosine arabinoside and an anthracycline antibiotic [4, 5, 23] 
it was decided to prospectively evaluate this programme in comparison to DAT. 
These regimens differ, however, in two ways. Firstly, the cytosine arabinoside 
in CTR III is given as a continuous intravenous infusion, whereas in DAT, bolus 
injections are given at 12-hourly intervals. Secondly, in CTR III, etoposide 
replaces the 6-thioguanine used in DAT. Although the CR rate achieved with 
DAT was marginally higher than with CTR III this difference was not statistically 
significant. Furthermore, the duration of remission and survival with both regi­
mens is similar. It is noteworthy that in this study the median duration of remis­
sion in patients receiving DAT was only 30 weeks in contrast to the 64 weeks 
reported by the British Medical Research Council, based on results obtained by 
a number of centres using a comparable regimen [9]. It is difficult to explain this 
difference other than by chance occurrence.
Type 1 and 2 remission induction failures for both chemotherapeutic regi­
mens are comparable, suggesting equal anti-leukaemic efficacy. Type V failures 
were statistically greater with CTR HI, but since the number of patients in these 
groups is relatively small, this difference may be fortuitous, particularly as sup­
portive care was uniform. It is difficult to comment about toxicity because these 
patients died within 7 days of completing chemotherapy and could not be reliably 
evaluated [18].
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Subsequent to the commencement of the present study, a number of reports 
have appeared suggesting that a more intensive regimen, in which cytosine arabi- 
noside is extended to 7 or even 10 days by continuous intravenous infusion and 
an anthracycline antibiotic is overlapped for the first 3 days, may be a more 
effective approach than the lesser chemotherapy given in programmes such as 
CTR III and DAT [19, 24-26]. It is, however, noteworthy that when a large 
number of patients are studied, the overall complete remission rate for these 
programmes is 53% and extending the duration of cytosine arabinoside from 7 to 
10 days confers no additional benefit [19]. The main advantage of a more intensive 
induction and consolidation regimen may be evident, not so much in an improved 
CR rate as in the duration of remission, particularly in those patients who remain 
relapse-free for 5 years or more and where the survival curves have reached 
a plateau, indicating a higher probability of cure. Of the 40 patients in the present 
study who achieved CR 3 remain relapse free at 58+ , 115+ and 121 + weeks. 
Follow-up is still short, but these results are disappointing in terms of cure rates 
for leukaemia using chemotherapy alone, where more intensive combination drug 
programmes have achieved 15% to 25% long term disease-free survival [24, 27]. 
We have therefore intensified the chemotherapy used for induction and con­
solidation, giving 7 days of both cytosine arabinoside and etoposide combined 
with 3 days of an anthracycline antibiotic, as has been employed by others [3].
The role of maintenance therapy in acute nonlymphoblastic leukaemia 
remains controversial [1] and there are reports that suggest this is without bene­
fit [26], although conflicting studies in support of postremission therapy have 
been published [28-30]. Here again, there is evidence that when large numbers 
of patients are studied no benefit accrues from extended periods of maintenance 
[19]. In the present study it was not possible to examine the basic issue of efficacy 
of maintenance therapy since there was no control group that was denied post- 
-remission treatment, but we are able to comment on the question of duration, 
chemotherapeutic agents and schedule in this context. In an extension of a previous 
study [4], we have been unable to show an advantage for either remission duration 
or survival following a longer course of maintenance therapy. It seems probable 
that for therapy to be effective when administered after consolidation it would 
need to be intensive if residual leukaemic cells are to be eliminated. The present 
experience would suggest that the maintenance programmes employed in this 
study may well have been ineffective. Accordingly, our current practice is to 
administer high doses of chemotherapy, with or without additional radiotherapy, 
followed by allogeneic or autologous bone marrow transplantation as a better 
approach to post-remission therapy aimed at extending the duration of disease- 
-free survival [31].
Of the prognostic factors evaluated, the present study confirms the sensitiv­
ity of the species of plasminogen activator secreted by leukaemic blasts in pre­
dicting response [14, 32] to these less intensive chemotherapy programmes. It 
remains to be established whether this observation holds true when chemo­
therapy is intensified. Similarly, the in vitro growth pattern, using the GM : CFUc
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assay [33, 34], may be an independent variable predicting for response and further 
studies are needed to standardise the criteria used in reporting these results. 
Age [19, 21, 22] is said to be a significant factor determining response to chemo­
therapy and we were able to demonstrate an effect of this variable on the duration 
of survival. Of the other prognostic factors described, no influence could be 
demonstrated in terms of the pretreatment white cell count [35, 36], the FAB 
classification [37] or race [38, 39].
Immunotherapy, including the use of C. parvum, has been shown in many 
trials to be of little or no benefit in the treatment of acute nonlymphoblastic 
leukaemia [40-42]. The administration of this agent was based on studies sug­
gesting that it is active as an immunotherapeutic anticancer agent [43] and has 
T-cell dependent activities in tumour systems [44], as well as having an effect 
on colony stimulating factor [45, 46]. However, the infusion of C. parvum is 
known to have significant side effects [47, 48] and in our experience patient 
acceptance of the immunotherapy was poor, being frequently associated with 
rigors and pyrexial reactions which could not always be blocked pharmacologi­
cally. In keeping with previous reports, we have been unable to show any benefit 
in remission rate, duration or survival of the patients receiving C. parvum. In 
addition, serial laboratory studies on the effect of mitogens and alloantigen on 
the mononuclear cell population harvested from patients receiving immuno­
therapy showed no difference from control values. Similarly, C. parvum admi­
nistration to patients was found to be without effect on the in vitro GM : CFUc 
assay.
It is concluded that the substitution of etoposide (CTR III) for 6-thio- 
guanine (DAT) in a chemotherapy regimen containing 5 days of cytosine arabino- 
side and a single injection of doxorubicin has no significant advantage. The 
question remains unanswered as to the benefit that may accrue when either of 
these agents is added to programmes containing cytosine arabinoside and 
anthracycline antibiotic. We have demonstrated no benefit in extending the 
duration of maintenance chemotherapy or the use of C. parvum as a form of 
immunotherapy in the treatment of adult patients with acute nonlymphoblastic 
leukaemia.
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Thirty-nine adults with clinical stage III or IV diffuse large cell lymphoma were 
prospectively randomised to receive etoposide with doxorubicin (Group 1 : n =  17), 
the same schedule of etoposide with carminomycin (Group 2: n =  8), or BACOP 
(Group 3: n =  14). The complete remission rates were respectively 24%, 25% and 
28%, and further good partial remissions were 41%, 25% and 14%. The incidence 
of adverse prognostic factors was examined with the first two groups combined for 
comparison to patients receiving BACOP. The low complete remission rates were 
attributable to bone marrow invasion in 64% (16/25) of patients in groups 1 and 2, 
and 64% (9/14) in group 3; to extensive gastrointestinal tract involvement in 24% 
(6/25) of patients in groups 1 and 2, and 36% (5/14) in group 3; and to high bulk 
disease in 24% (6/25) of patients in groups 1 and 2, and 36% (5/14) in group 3. Actu- 
arially predicted survival has not been reached for group 1, is 12 months for group 2, 
and 8 months for group 3; these different trends are not statistically significant. The 
trial was discontinued when it became clear that there was no difference between the 
two- and five-drug treatment regimens and that unacceptably low remission rates 
were obtained in patients having a high incidence of these poor prognostic factors, 
particularly when compared with results being reported in regimens that contain high 
or intermediate doses of methotrexate.
Keywords: etoposide, doxorubicin, carminomycin, BACOP
Introduction
Late stage diffuse large cell lymphoma follows a rapidly progressive clinical 
course when untreated [1] and, while early attempts at chemotherapy were rela­
tively ineffective, a significant cure rate was reported with combination chemo-
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of Cape Town Medical School, Anzio Road, Observatory 7925, Cape, South Africa
VSP Utrecht, Tokyo 
Akadémiai Kiadó, Budapest
therapy [2]. This important observation has subsequently been confirmed and 
similar results achieved with comparable multi-drug programmes such as BACOP 
[3] and C-MOPP [4] regimens, where complete remission rates where in the region 
of 45%. It is relevant that only 5% of patients with stage III and IV disease 
achieved complete remission with single agent chemotherapy [5], but superior 
results were obtained with etoposide, when this drug was used either alone or 
in combination with only an anthracycline antibiotic, when remission rates were 
found to match those for the BACOP and C-MOPP regimens [6, 7]. However, 
patients treated with the latter regimens showed a superior disease-free remission 
rate and survival curve when compared to those who received etoposide and 
doxorubicin. To determine whether these differences could be ascribed to infe­
riority of the two-drug regimen or whether different institutional practice or 
patient population could influence the outcome of therapy, direct comparison 
was undertaken between the two regimens, paying particular attention to prog­
nostic factors known to influence response rates [4, 8].
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Materials and Methods
Thirty-nine patients with clinical stage III and IV diffuse large cell lym­
phoma [4, 8] were prospectively entered on a trial and randomised using a com­
puter generated programme to compare etoposide (60 mg/m2 as a 1 hour intra­
venous infusion on 5 consecutive days) and doxorubicin (40 mg/m2 over 5 minutes 
on day 1), followed by a 9 day rest period (Group 1 : n =  17) to the same schedule 
of etoposide with carminomycin (20 mg/m2 over 5 minutes by intravenous in­
fusion on day 1), also followed by a 9 day rest period (Group 2: n = 8) or BACOP 
(Group 3: n = 14): in all three groups responding patients received 8 cycles of 
therapy. The trial was approved by institutional review boards and entry required 
informed consent.
All patients had a history taken and underwent full physical examination, 
after which they were clinically staged. Laboratory investigations included full 
blood count, bone marrow aspiration and trephine biopsy [9], biochemical 
profile [10], chest radiology and bipedal ascending lymphangiography or com­
puterised axial tomography. Lymph node biopsy demonstrated diffuse large cell 
lymphoma [11 ] and immunophenotyping [12] showed these to be B-cell tumours. 
Prognostic factors were carefully documented in each patient, using published 
criteria [4, 8], with emphasis on bone marrow invasion, gastrointestinal tract 
involvement, or the presence of high bulk disease.
The side effects of the chemotherapy were limited to alopecia in groups 1 
and 2, and variable pancytopenia in all three groups, leading to appropriate 
dosage adjustment with each cycle of chemotherapy.
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Results
The age and sex distribution of the patients is given in Table 1.
It is noteworthy that in this study there was a large proportion of individ­
uals with biopsy proven marrow invasion, gastrointestinal tract involvement, or 
high bulk disease (Tables 2a and 2b).
The response rates for the patients were defined using established criteria 
[13]: the complete remission rate for Group 1 was 24%, for Group 2 was 25%, 
and for Group 3 was 28%, with further good partial remissions in 41%, 25% 
and 14%, respectively (Table 3): the median duration of these complete remissions
Table 1
Demographic details of patients
G r o u p  1 
E toposide  a n d  
D o x o ru b ic in
G r o u p  2 
E topos ide an d  
Carm in om yc in
G r o u p  3 
B A C O P
Male : Female 9 : 8 3 : 5 10 : 4
Median age 56 years 63.5 years 53 years
Range 18—70 years 29 — 71 years 29—77 years
Table 2
a) Prognostic factors in the initial three groups
Prognost ic  fac tors  G ro u p  1 G r o u p  2 G ro u p  3
Bone marrow
Positive 12/17 71% 4/8 50% 9/14 64%
Gastrointestinal 
Involvement 3/17 18% 3/8 38% 5/14 36%
High bulk disease 4/17 24% 2/8 25% 5/14 36%
b) Prognostic factors combining groups 1 and 2
Prognos t ic  factors G r o u p s  1 and 2 G r o u p  3
Bone marrow 
Positive 16/25 64% 9/14 64%
Gastrointestinal
involvement 6/25 24% 5/14 36%
High bulk disease 6/25 24% 5/14 36%
Groups 1 and 2 were pooled for this analysis as remission rates for the two anthra- 
cycline-containing arms were indistinguishable.
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Table 3
Analysis of remission rates and survival at median follow-up of 36 months
G ro u p  1 
Etoposide and 
Doxorubicin
G ro u p  2 
Etoposide and 
Carm inomycin
G roup  3 
BA COP
Alive 10/17 59% 2/8 25% 4/14 28%
Early
deaths
2/17 12% 1/8 12.5% 1/14 7%
Partial
remission
7/17 41% 2/8 25% 2/14 14%
Complete
remission
4/17 24% 2/8 25% 4/14 28%
was 18 months, 3 months and 33 months. These numbers are too small for reliable 
statistical analysis.
Withdrawal of carminomycin from the market unfortunately prevented 
entry of further patients to this arm of the study. The actuarially predicted sur­
vival rate has not been reached for group 1, is 12 months for group 2, and 
8 months for group 3: despite this trend in favour of group 1, there is no statis­
tically significant difference between any of these curves (Figure 1). However, 
the relatively small number of patients entered before the study was terminated 
on ethical grounds do not yield comparisons with sufficient power to exclude 
anything other than major differences.
Fig. 1. Actuarially predicted survival curve. The median survival has not been reached in 
patients who received etoposide and doxorubicin (Group 1 ; n =  17) (black dots), is 12 months 
for those receiving etoposide and carminomycin (Group 2; n =  8) (black triangles), and 
8 months for BACOP (Group 3; n =  14) (white squares)
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Results and Discussion
Jt has previously been demonstrated [6, 7] that etoposide has activity in 
diffuse large cell lymphoma when used on its own. Furthermore, when this agent 
was combined with doxorubicin the remission rate improved markedly and then 
approximated that obtained with the C-MOPP and BACOP programmes [4, 8].
In the present study an equivalent complete remission rate was again found 
when BACOP was directly compared to etoposide with either of the anthracycline 
antibiotics. However, these figures are lower than in our previous studies, now 
attributable to an unusually high incidence of poor prognostic factors, with the 
latter being uniformly distributed throughout the patient population. The ex­
planation for this finding is not clear, but it does emphasize two points. Firstly, 
there is the question of historical controls, even within a single institution, since, 
unless very large numbers of patients are entered into each study, erroneous con­
clusions may result when data from consecutive series are compared. This is 
exemplified by the difference in survival curves for our two groups of patients 
receiving etoposide and doxorubicin, despite there being no reason to believe that 
the overall referral pattern had in any way changed. However, the number of 
individuals with poor prognostic factors was much greater in the present series 
and had comparison been attempted between these two consecutive trials the 
discrepant results might have been more difficult to explain. On the other hand, 
randomisation within a single study has corrected for this unexplained pre­
ponderance of adverse features and revealed a close similarity in response to all 
three treatment options. Secondly, it might be anticipated that an even greater 
disparity would exist between patient populations at different institutions, a point 
previously pointed out [7]. This latter point is evident when an American [4, 8] 
and South African [6, 7] experience are compared. Thus, the remission rate for 
both groups using comparable chemotherapy is similar, whereas the American 
patients have a higher stable disease-free plateau, suggesting that the greater 
incidence of poor prognostic factors that characterises the South African patients 
adversely affect the durability of their remission status. Failure to appreciate this 
fundamental difference between the two patient populations might therefore have 
legitimately raised a question about the combination of etoposide with doxo­
rubicin being less effective than BACOP.
Another feature of the current series is the frequent co-existence of poor 
prognostic factors. In only 6 of the 39 patients (15%) was either extensive gastro­
intestinal tract involvement or high bulk disease present without unequivocal 
marrow involvement on the trephine biopsy. Unfortunately, in view of the limited 
number of patients available, it was not possible to reliably determine whether 
a negative marrow in the presence of the other poor prognostic features had 
a similar adverse effect on response to therapy.
A further point of interest is the survival of the patients who received eto­
poside with doxorubicin (group 1). Although only 4/17 (24%) achieved complete
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remission, 10/17 (59%) were alive at the time of analysis, in contrast to groups 2 
and 3 where a more usual outcome was found in which survival directly corre­
lated with the achievement of complete remission. There is no obvious explanation 
for this unexpected finding since the patients in all three groups were generally 
well matched for the variables, but analysis shows that the 6 patients who achieved 
partial remission in group 1 had only minimal residual disease evident and each 
of these patients then responded to salvage therapy with BACOP and abdominal 
radiotherapy, although only 1 achieved a second complete remission.
In conclusion, it is emphasized that recent advances in chemotherapy have 
impressively raised remission rates and resulted in both improved disease-free 
duration and survival curves [7, 13-15]. Furthermore, it is clear that these more 
aggressive regimens are diminishing the value of traditional prognostic factors in 
predicting the outcome when patients were treated with older programmes such 
as C-MOPP and BACOP. Under these circumstances, this comparative study 
was terminated with the recognition that neither etoposide combined with an 
anthracycline antibiotic nor BACOP, despite their equivalence in achieving remis­
sion rate and similarity of survival curves, is appropriate for treating stage III 
and IV diffuse large cell lymphoma. This latter observation would be particularly 
pertinent in the type of population seen at our institution, where the majority 
of patients present with an unusually high prevalence of adverse prognostic 
factors. Finally, since the significant difference between BACOP and the clearly 
superior m-BACOD regimen apparently resides in the addition of methotrexate 
[16, 17] this latter programme is presently being directly compared to the pre­
viously described etoposide and doxorubicin combination to which an equi­
valent amount of methotrexate with folinic acid rescue have been added.
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The aim of the present study is to analyze the relationship between serum 
immunglobulin (Ig) levels and the immunological phenotype and the clinicohaematolo- 
gical features of B-cell chronic lymphocytic leukaemia (B-CLL) in a series of 126 
patients. Eighty-eight of the cases (70%) had a decreased concentration of at least one 
Ig. IgM and IgA were the most frequently decreased (60% and 49% respectively). 
A serum monoclonal gammapathy was found in 4 patients, Ig M/k in two cases and 
IgM/1 and IgG/k in one case.
Patients with hypogammaglobulinaemia had a similar surface phenotype as 
patients with normal Ig levels (MRFC+, s lg+ , CD20+, HLA/DR+, FMC7—, 
CD 5+, CD9+ ). On the other hand the cases with hypogammaglobulinaemia displayed 
the features of a more advanced disease, a higher incidence of organomegalies 
(p <  0.05), anaemia and/or thrombopenia (p <  0.05), a diffuse bone marrow pattern 
(p <  0.05), advanced clinical stages (p < 0.05) as well as higher levels of both periph- 
erial blood (p <  0.02) and bone marrow lymphocytosis (p <  0.02). These findings 
suggest that the presence of hypogammaglobulinaemia in B-cell patients is probably 
more related to a higher tumor burden than to either certain stages of B-cell differentia­
tion or a particular cellular phenotype.
Keywords; surface phenotype, immunglobulin levels, B-CLL
Introduction
Chronic lymphocytic leukaemia (CLL) is a lymphoproliférative disorder, 
usually of B-cell origin [1]. A common finding as an alteration of the humoral 
response, furtheron a decreased immunglobulin (lg) level in most patients and 
occasionally a monoclonal gammapathy, [2, 3, 4]. Most studies on Igs in CLL 
have focused in studying “in vitro” whether these alterations are due to an in­
trinsic B-cell defect or to abnormalities in T-cell subsets [5, 6, 7, 8, 9, 10, 11]. 
However, there are few studies in which attempts have been made to explore 
whether the serumlg levels in B-CLL are related to certain stages of B-cell differen­
tiation or whether they are related to some particular cellular phenotype.
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In the present study we analyzed the relationship between serum Ig levels and 
the immunological phenotype of neoplastic B-cells in 126 untreated B-CLL 
patients according to the presence or absence of hypogammaglobulinaemia.
Materials and Methods
The present study includes 126 untreated patients with the diagnosis of B- 
-CLL according to clinicohaematologic criteria [12]: peripherial lymphocytosis 
( >  15 X 10° lymphocytes/1), bone marrow involvement (>40%  lymphocytes), 
spontaneous mouse rosette-forming cells (MRFC) and/or surface Ig (slg) positivity 
in more than 20% of cells. All patients were classified according to Rai’s staging 
[12] and the International Workshop on CLL, staging systems [13]. Bone marrow 
biopsy was performed in 69 patients and four histopathologic patterns were 
considered according to Hernández-Nieto et al. [14].
Serum IgG, IgA and IgM levels were detected by nephelometry (Auto ICS 
Analyser II, Beckman Instrument). Hypogammaglobulinaemia was considered to 
exist when IgG levels were lower than 600 mg/dl and/or IgA lower than 120 mg/dl 
and/or IgM lower than 80 mg/dl [15].
Immunological studies: Mononuclear cells from peripheral blood (PB) were 
obtained by Ficoll-Hypaque (Pharmacia Fine Chemicals) density gradient centri­
fugation and tested for: a) spontaneous rosette-forming cells with AET-treated eryth­
rocytes (SRFC); b) spontaneous rosette-forming cells with mouse erythrocytes 
(MRFC); c) surface immunglobulins (slg) detected by direct immunfluorescence 
with rabbit F(ab)’2 antisera conjugated with fluorescein isothiocyanate (FITC); and 
d) surface antigens assessed by indirect immunofluorescence with monoclonal anti­
bodies (McAb): GRBI (anti class II MHC antigen) [16], B1 (anti p35 antigen or 
CD20) [16], Fmc7 (which recognises a subpopulation of normal PB B lymphocytes 
and the majority of cells in B-cell prolymphocytic leukaemia and hairy cell leuka­
emia) [17], Fmc56 (anti p24 antigen or CD9) [16], and Crisl (antip67antigen or 
CD5) [16].
The percentage of M RFC+ , slg+ ,Fm c7+ and Cris 1+  cells was referred to 
B lymphocytes after removing the percentage of SRFC-T cells.
To estimate the significance between means, the Mann-Whitney “U ” test 
was used. A contrast for dichotomous variables was employed for binomial 
parameters (positive or negative cases).
Results
The mean values of each Ig in the current series were : IgG : 984 + 557 mg/dl, 
IgA: 140 ±  90 mg/dl and IgM: 92 + 94 mg/dl. Eighty-eight of 126 (70%) patients 
had a decreased concentration of at least one immunglobulin. IgM and IgA were 
the most frequently decreased (60% and 49% of cases, respectively). A simulta-
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neous decrease of the three Igs was detected in only 13 patients (10%), while two 
Igs were diminished in 45 cases (36%). In this latter group the most common 
association was IgA and IgM (39 cases) followed by IgG and IgM (4 cases) and 
IgA and IgG (2 cases). Finally, 30 patients (23%) showed decreased levels of only 
one Ig: IgM in twenty, IgA in eight, and IgG in two patients.
Four patients showed a serum monoclonal gammapathy : IgM/k in two 
cases and IgM/1 and IgG/k in one case.
The clinical and haematologic characteristics of the patients with normal and 
low serum Ig levels are shown in Table 1. There was a greater proportion of acci­
dentally discovered cases in the group of patients with normal Ig levels (p <  0.1) 
while the cases with hypogammaglobulinaemia showed a higher incidence of 
adenopathies (p <  0.01), hepatomegaly (p < 0.05), splenomegaly (p < 0.05), 
anaemia and thrombopenia (p <  0.05) as well as higher PB lymphocyte counts 
(p <  0.02). Moreover, patients with low serum Ig levels displayed a greater
N o r m a l  Ig levels 
( N  = 38)
H y p o g a m m a ­
globul inaemia  
(N  -  88)
P
Age* 67+ 10 68+ 10 n.s.
Male/female ratio 1.9 2.3 n.s.
Accidental discovery 55% 41% <  0.1
Adenopathies 58% 72% <  0.1
Splenomegaly 32% 48% <  0.05
Hepatomegaly 18% 33% <  0.05
Extralymphatic
infiltration 3% 6% n.s.
Anaemia 
(Hb <  10g/dl) 11% 19% n.s.
WBC count* 
( X  109/1) 43+41 76+84 <  0.02
Thrombocytopenia 
«  1009x 10/1) 8% 18% <  0.05
LDH levels (IU/1)* 281+110 287+ 154 n.s.
Uric acid (mg/dl)* 6.0+2.2 5.1+ 1.6 n.s.
ESR (mm/h)* 28+41 27+34 n.s.
% of lymphocytes 
in BM* 65+20% 74+19% <  0.02
Diffuse BM pattern 22% 43% <  0.05
Second tumor 3% 10% n.s.
* Results expressed as Mean +  SD
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Table 1
Clinical and haematological features of B-CLL patients according to serum immunoglobulin
levels
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Table 2
Immunglobulin levels and clinical stages
N o r m a l  ig levels 
(n  -  38)
H y p o g a m m a ­
globul inaemia  
(n =  88)
P
RAI
Stage 0 39% 20% <  0.05
Stage I 21% 20% n.s.
Stage II 24% 27% n.s.
Stages III/IV 16% 33% < o.os
International Workshop
Group A 63% 44% <  0.05
Group B 21% 27% n.s.
Group C 16% 29% <  0.05
proportion of diffuse bone marrow pattern (p < 0.05) and a higher percentage of 
bone marrow lymphocytic infiltration (p < 0.02).
The distribution of patients according to the classification proposed by Rai 
et al. and the International Workshop is shown in Table 2. In both staging systems 
the cases with normal Ig levels included a significantly larger proportion of patients 
in early stages (p < 0.05). Conversely, there was a significantly higher incidence of 
advanced clinical stages within the group of patients with hypogammaglobulina- 
emia (p < 0.05). No differences were observed regarding the intermediate stages.
In 9 of the 88 patients (10%) with hypogammaglobulinaemia there was 
another malignancy associated with B-CLL; in cases of normal Ig levels this was 
found in only one patient (3%).
Comparing the patients with normal Ig levels to those with low ones, no 
significant differences were observed in the slg heavy and light chain classes or in 
the expression of other surface antigens (Table 3).
The four patients with a serum monoclonal gammapathy expressed slg of 
the ix + ô + heavy chain class and in all cases the slg light chain isotype was 
identical to the monoclonal serum Ig light chain: K in three cases and A in one’ 
These four patients expressed MRFC, slg and reactivity for the McAbs: Bl, 
Crisl and GRB1 in more than 30% of B-cells. Positivity for FMC7 and FMC56 
McAb was observed in one of these cases.
Discussion
Hypogammaglobulinaemia is one of the most commonly reported ab­
normalities associated with B-CLL [2, 3, 4]. Reduced concentrations of at least
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Table 3
Relationship between surface markers and serum immunglobulin levels
N o r m a l  Ig levels 
(n =  38)
H y p o g a m m a ­
g lobul inaemia
( i = 8 8 )
P
SRFC 14+ 14 11 +  9 n.s.
MRFC 51+24
(91%)
54+ 25 
(94%) n.s.
slg 50+34
(83%)
53+35
(64%) n.s.
K/L ratio 1.6 2.9 n.s.
B1(CD20) 66+ 26 
(97%)
68+27
(98%) n.s.
GRBl(HLA-DR) 83+21
(100%)
85+ 19 
(100%) n.s.
FMC7 14+23
(27%)
9+20
(17%) n.s.
Crisl(CD5) 46+29
(83%)
50+33
(82%) n.s.
FMC56(CD9) 29+29
(57%)
41+35
(64%) n.s.
one of the major serum Igs, primarily IgM, was observed in most of our cases. 
Patients with low serum Ig levels, also displayed features of a more advanced 
disease: a higher incidence of organomegalies, thrombopenia, an increased level 
of both peripheral blood and bone marrow lymphocytosis. In these patients a 
higher proportion of advanced clinical stages and a higher percentage of cases 
with diffuse bone marrow pattern were observed as also reported by other goups 
[3, 18, 19]. Such findings suggest that the presence of hypogammaglobulinaemia 
in B-CLL is probably related to a higher tumor burden and a greater replacement 
of normal B-cell populations by neoplastic lymphocytes. However, there is evid­
ence that other factors may also be involved in the hypogammaglobulinaemia 
of B-CLL patients. The increase in supressor T-cell (CD8+) with a defective 
function of the helper T-cells (CD4+) reported in other series [20, 21, 22] also 
seem to contribute to the reduced serum Ig levels present in these cases.
It has been suggested that defective Ig production could be associated with 
a decrease in immunosurveillance and a higher incidence of neoplastic disease
[23] . Moreover, it is well known that when compared to normal population of 
the same age, B-CLL patients display a higher proportion of other malignancies
[24] . Analysing the incidence of a second tumor in our series, we observed that
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patients with hypogammaglobulinaemia at the moment of diagnosis had a higher 
proportion of other neoplastic diseases compared to those B-CLL cases with 
normal serum Ig levels. B-CLL is the result of the monoclonal proliferation of 
small lymphocytes of B-cell origin. These leukaemic B-cells usually have slg of 
either the \i +  or ц + ô + heavy chain class as well as CD20, HLA-DR, CD9 
and CD5 antigens. In addition, these cells form rosettes with mouse erythrocytes 
although they usually lack the FMC7 antigen [25, 26], as has also been found 
in the present series.
The serum Ig levels were found to be independent of the immunophénotype, 
which suggests that the presence of low serum Ig concentration is not correlated 
with a particular stage of B-cell maturation nor with a special phenotype in 
B-CLL.
Four of our 126 patients had a monoclonal component. In all cases the 
serum light chain was identical to the slg light chain isotype expressed by the 
neoplastic B-cells. Other authors have also previously demonstrated that serum 
monoclonal proteins in B-CLL are closely related to the slg of leukaemic B-cells 
[27]. The slg heavy chain was of the ц + ö + isotype in these four patients, 
suggesting that cases with a detectable monoclonal serum Ig could represent the 
proliferation of a monoclonal B-cell at a more advanced stage of maturation [28] 
However, the expression of other differentiation antigens such as FMC7 [17, 
29] was similar to that observed in the whole series. This finding, together with 
the results reported by Qian et al. [27], suggests that in such patients the neo­
plastic cell is arrested at a similar stage of maturation as the classical B-CLL 
although it displays a more incomplete blockage of Ig secretion.
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Coulombel et al. [1] reported that Philadelphia (Ph) chromosome-negative 
progenitors, even when present at undetectable levels in the initial marrow speci­
men, may thus become demonstrable within two to four weeks of long-term mar­
row culture, whereas the Ph-positive population rapidly declines. Dubé et al. [2] 
observed that in some CML patients Ph-negative mitoses can be found in blood 
progenitors whereas all metaphases from marrow progenitors were abnormal. 
On the other hand, it is well documented that CML primitive progenitors respond 
to colony stimulating factors as the granulocyte/macrophage colony stimulating 
factor (GM-CSF) or the granulocyte colony stimulating factor (G-CSF) [3].
On the basis of these findings, we examined the PHA-LCM-stimulated 
whole blood liquid suspension culture of a patient with Ph-positive CML for 
leukaemic cell differentiation and for chromosome content and karyotypes.
I. N. (born 13. 06. 1978) was admitted to our Pediatric Department as an 
8-year-old boy for respiratory tract infection associated with hepatosplenomegaly 
and anaemia. The marrow aspiration showed hypercellularity and contained 7% 
myeloblasts, 17% promyelocytes, 5% myelocytes, 3% metamyelocytes, 15% 
bands, 14% segmented neutrophils, 11 % eosinophils, 6% basophils, 17% lympho­
cytes, 2% reticulum cells, and 3% normoblasts. The peripherial blood WBC was 
24 X 109/1, with G APA score of 26 (very low). The patient was treated with bu- 
sulphan, hydroxyurea, prednisolone, and vincristine. His spleen was irradiated, 
but remission could not be achieved. The patient currently receives supportive 
treatment 6 months after diagnosis.
For cytological examination, a cell suspension from the 6-day culture was 
stained with May-Griinwald-Giemsa. Preparation of phytohemagglutinin-stimul­
ated leukocyte-conditioned medium (PHA-LCM) was made as described by Park 
et al. [4]. Chromosome examination was performed during the supportive treat-
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Table 1
Comparison of the cytological examination data
Leukocy te  differential 
co u n t  %
Peripheral
blood
6 day 
cu l tu re
Atypical blasts 39 34
Myeloblasts 6 11
Myelocytes 11 -
Granulocytes - 14
Basophils ■- 4
Eosinophils 2 -
Lymphocytes 40 3
Normoblasts - 9
Monocytes 2 -
Macrophages - 25
ment. For routine cytogenetic analysis, a 24 h unstimulated whole blood culture 
was investigated [5]. The liquid suspension culture method was performed as 
follows: 2 ml of heparinized whole blood from the patient was cultured in 10 ml 
of TC 199 (Difco) medium, supplemented with 10% fetal calf serum, 10% PHA- 
-LCM, penicillin and streptomycin. The cells were cultured at 37 °C for 6 days 
in an Erlenmeyer flask closed with a sterile rubber stopper. On the 4th day of 
culturing, half of the medium was changed for fresh TC 199 medium supplemented 
with 10% fetal calf serum. GTG-banded chromosome preparations were made by 
the method of Autio & Schröder [6]. Karyotype analyses were carried out with 
the short version of ISCN [7]. The cytological examination (Table 1) showed 
that immature blast cells with both progenitor and mature cells of erythroid and 
granulocyte/macrophage lineage were present in the PHA-LCM-stimulated 6-day 
culture of the patient’s blood, in contrast to his peripheral blood, in which the 
WBC was 14 X I07I, the leukocyte differential count included mainly atypical 
blasts, lymphocytes, myelocytes, myeloblasts, eosinophils, and monocytes.
Chromosome examinations: twenty-eight (56%) of the fifty cells examined 
contained 45 chromosomes, while sixteen cells (32%) contained 46 chromosomes. 
In four mitoses (8%), the chromosome number was in the near-tetraploid region, 
while in two mitoses (4%) 44 chromosomes were found.
Table 2 shows that both numerical and structural aberrations were found 
in the twenty-five karyotypes examined. Three cytogenetically distinct clones were 
present: cells with the normal 46,XY karyotypes (in 6 cases), cells with the char­
acteristic t(9; 22) (q34; q 11 ) for the Ph-positive CML (in five karyotypes), and, 
cells with 45,XY,-7 karyotypes (in eight cases). The other aberrations were each 
observed in single mitoses. Only Ph-positive leukaemia cells were found in the
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Table 2
Numerical and structural chromosome aberrations
Type  o f  abe rra tion N u m b e r  o f  cells with  ab e rra t io n
44, XY, - 7 ,  -1 6 , t(9; 22) (q34; q ll) l
44, XY, - 7 ,  -1 7 l
45, XY, - 7 8
45, XY, - 7 ;  t(9; 22) (q34; qll) 1
46, XY 6
46, XY, t(9; 22) (q34; ql l) 5
86, XXYY, (4n+ )— 7, -1 2 , -1 7 , -1 8 , -2 1 , -2 2  
88, XXYY, (4 n + )-6 , - 7 ,  - 8 ,  -1 2 , t(9; 22) (q34; ql l)  
92, XXYY, t(9; 22) (q34; qll)
1
1
1
ten karyotypes examined from the unstimulated 24-h culture of the patient’s 
blood prepared at the same time as the liquid culture was made.
The results presented here show that in the PHA-LCM-stimulated 6-day 
whole blood suspension culture, the leukocyte differential count changed toward 
the granulocyte/macrophage lineage compared to the peripheral blood of the 
patient. The presence of some near-tetraploid mitoses in the culture proves the 
ability of these cells to fuse with normal or leukaemia cells under these circum­
stances. Ph-positive leukaemic cells could be detected with this method. Cells 
with normal karyotypes can be primitive, Philadelphia chromosome-negative 
progenitors which were found in long-term marrow cultures [1]. The dominant 
clone was 46, XY, —7 in the culture. This chromosome loss occurs in only 
3% of patients during the acute phase of CML [8]. Monosomy 7 was found in a 
patient with lymphoid transformation and a precursor B-cell phenotype [9], and 
in several cases documented by Mitelman [10]. The presence of cells with 45, XY,-7 
karyotypes in the PHA-LCM stimulated 6 day whole blood culture of our patient 
indicated the lymphoid transformation of his CML, because the following dif­
ferential leukocyte count was found in a later examination of his peripherial 
blood: (WBC : 16 x 109/l) 20% atypical blasts, 16% neutrophils, 2% eosinophils, 
and 62% lymphocytes.
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Cross bonding and stiffening o f the red cell 
membrane. Th. M. Fischer (Institut für 
Physiologie, Medizinische Fakultät, Rhei­
nisch-Westfälische Technische Hochschule, 
Aachen, F.R.G.). Biochim. Biophys. Acta 
985, 218 (1989).
Cross bonding and stiffening of the hu­
man red cell membrane was studied using 
treatments with SH, amino, and carboxyl 
reagents, oxidizing and denaturing treat­
ments and acidification. Membrane cross 
bonding was initiated when, after red cell 
treatment, opposite areas of the cytoplasmic 
face of the red cell membrane were brought 
into contact by cell shrinking. Membrane 
cross bonding was detected by light micro­
scopy when this contact persisted upon 
swelling the cells in a hypotonic medium. 
Membrane stiffening was recorded as a 
decrease in elongation of red cells in the 
shear field of a viscous dextran solution. 
No correlation was found between membrane 
cross bonding and membrane stiffening. 
The results are explained by the existence 
of two modifications of spectrin, type I 
causing solely membrane stiffening, type II 
causing membrane cross bonding as well 
as membrane stiffening. The amino and 
carboxyl reagents caused only type I modi­
fication. The other treatments caused both 
types of modification although with varying 
proportions. The results support the pre­
viously suggested mechanism of membrane 
cross bonding which involves a rearrange­
ment of spectrin similar to dénaturation by 
heat or urea, a decrease in associations 
within the membrane skeletal network, and 
a lateral aggregation of membrane pro­
teins. These changes are proposed to occur 
by the type II modification. The data further 
substantiate the membrane stiffening effect 
of inter- and intra-molecular cross linking 
of spectrin which is identified with the type 
I modification. Finally, hypotheses are 
presented concerning the mechanism of 
membrane stiffening due to type II modifica­
tions of spectrin.
Unta Szász
Abnormalities in erythrocyte membrane band 
3 in chronic myelogenous leukemia. M. Kundu, 
J Basu, M. M. Rakshit and P. Chakra- 
barti (Department of Chemistry, Bose In­
stitute and Hematology Unit, N.R.S. Medi­
cal College and Hospital, Calcutta, India). 
Biochim. Biophys. Acta 985, 97 (1989).
The anion transport activities of erythro­
cytes from patients with chronic myelo­
genous leukemia (CML) and normal donors 
were comparable. In CML erythrocytes, 
significant reduction in the number of an- 
kyrin-binding sites, present in the cytoplas­
mic domain of band 3, may lead to partial 
loss of cytoskeletal anchorage to the bilayer 
and account for their increased Con-A 
agglutinability and heat-sensitivity.
Ilma Szász
A study to see whether phosphatidylserine, 
partial proteolysis and EGTA substitute for 
calmodulin during activation o f the Co2+- 
- ATPase from red cells membranes by ATP. 
J.P.F.C. Rossi and A.F. Rega (Instituto de
VSP Utrecht, Tokyo 
Akadémiai Kiadó, Budapest
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Quimica Fisicoquimica Biologicas, Facultad 
de Farmacia y Bioquimica, Junin Buenos 
Aires, Argentina), Biochim. Biopltys. Acta 
996, 153 (1989).
(1) The effects of treatments that mimic 
calmodulin in increasing the apparent affin­
ity for Ca2+ were tested to see whether, like 
calmodulin, they also change the activation 
of the Ca2+-ATPase from human red cell 
membranes by ATP at the low-affinity site. 
(2) Short incubations with either trypsin 
or acidic phospholipids such as phosphatidyl- 
serine increased the apparent affinity for 
ATP at the low-affinity site. (3) Under con­
ditions in which it increased the apparent 
affinity of the Ca2+-ATPase for Ca2+, 
EGTA failed to change the activation by 
ATP. (4) As in calmodulin-bound Ca2+- 
ATPase, compound 48/80 inhibited the 
activity of the enzyme in the presence of 
phosphatidylserine by lowering the apparent 
affinity for ATP at the low-affinity site, 
leaving the maximum velocity of the enzyme 
unaltered. (5) Compound 48/80 also inhibited 
the Ca2+-ATPase after partial proteolysis, 
but in this case it lowered the maximum 
activity, leaving the apparent affinity of the 
enzyme for ATP at the low-affinity site 
unaltered. (6) Inhibition of the Ca2+-ATPase 
by compound 48/80 in the absence of cal­
modulin suggests that the inhibitor can act 
directly on the enzyme.
Agnes Enyedi
Morphological alterations in erythrocyte 
membranes induced by 9-amino-l,2,3,4-tetra- 
hydroacridine and 9-aminoacridine. D.A. 
Palmieri, R. J. Jacob, and D. Allan Butter­
field (Department of Chemistry and the 
Center of Membrane Sciences, University 
of Kentucky, Lexington, Kentucky, USA). 
Biochem. Biophys. Res. Comm. 163, 1351 
(1989).
The effects of 9-amino-l,2,3,4-tetra- 
hydroacridine (THA) and its fully aromatic 
analogue 9-aminoacridine (9-AA) on ery­
throcyte membrane morphology were in­
vestigated via scanning electron microscopy. 
The ghost population was categorized into 
four distinct classes and alterations in the
relative amounts of these populations with 
drug addition were noted. The samples in­
cubated in 9-AA had a significantly higher 
(p <  0.001) flat, two-dimensional cell popu­
lation. This shift in morphology may be 
attributable to the unwinding of spectrin 
and the subsequent collapse of the membrane.
Agnes Enyedi
Ca2+ transients and Mn2+ entry in human 
neutrophils induced by thapsigargin. B. Foder,
O. Scharff and O. Thastrup (Department 
of Clinical Physiology and Nuclear Medi­
cine, University Hospital, Copenhagen, Den­
mark). Cell Calcium 10, All (1989).
Human neutrophils, preloaded with the 
fluorescent probe, Fura-2, were exposed 
to Ca2+-releasing agents. The monitored 
traces of fluorescence were transformed by 
computer to cytosolic Ca2+ concentration 
([Ca2+]i). Due to quenching of Fura-2, the 
addition of Mn2+ enabled us to compute 
the cytosolic concentration of total manga­
nese ([Mn])i). The agents used were the 
novel Ca2+-mobilizing agent, thapsigargin 
(Tg), the chemotactic peptide, formyl-me- 
thionyl-leucyl-phenylalanine (FMLP), and 
the divalent cation ionophore, A23187. The 
agents caused transient rises of [Ca2+]/' and 
monotonous rises of [Mn]i, suggesting in­
flux but no efflux of Mn2+. The rise time 
of [Ca2+]i and the time constants and 
magnitude of the apparent Mn2+ influx 
were strongly dependent on the sequence 
of addition of the agonist and Ca2+. Con­
trary to FMLP, Tg needed several minutes 
to exert its full effect on the rise of [Са2+]г 
and on the influx of Mn2+, the latter being 
dependent on two phases, activation and 
partial inactivation. Pretreatment with phor- 
bol 12-myristate 13-acetate (PMA) inhibited 
the responses of Tg, FMLP and A23187. 
For comparison, human red blood cells were 
tested. Contrary to A23187, Tg did not 
induce Ca2+ uptake in ATP-depleted red 
cells but increased the Ca2+ pump flux in 
intact red cells by 10%. The experimental 
data and computer simulations on the gra­
nulocyte data suggest that time-dependent 
changes of both passive Ca2+ flux into the
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cystol and Ca2+ flux of the plasma membrane 
pump are involved in the transient [Ca2+]/ 
response.
Ilma Szász
Phosphoinositide hydrolysis in mitogen-stimu­
lated human peripheral-blood T lymphocytes. 
S. King, G. Whitley, M. Salmon and A. 
Johnstone (Departments of Immunology 
and Pharmacology St. George’s Hospital 
Medical School, Cranmer Terrace, London, 
SW17 ORE, UK). Biochem. J. 262, 747 
(1989).
Both phytohaemagglutinin and anti­
bodies to the CD3 molecule induced proli­
feration and phosphoinositide hydrolysis 
in human peripheral-blood T lymphocytes, 
but the magnitude of the inositol phosphate 
response was small and the rate of accumula­
tion slow (significant increases in Ins(l,4,5)P3 
were observed only after 10 min). Hence 
this response differs from the well-character­
ized Ins(l,4,5)P3 responses of many other 
systems. This slow response, its abrogation 
in Ca2+-depleted medium, the slow and 
maintained increase in Ca2+ as measured 
by Quin-2, and the ability of the Ca2+ 
ionophore A23187 to stimulate Ins(l,4,5)P:l 
accumulation all suggest that the increase 
in Ins(l,4,5)P3 occurs, at least in part, as a 
result of receptor-mediated Ca2+ influx in 
mitogen-stimulated T lymphocytes.
Agnes Enyedi
Structure, function and subcellular localization 
o f a human platelet Ca2+-ATPase. W. L. 
Dean (Department of Biochemistry, Uni­
versity of Louisville, Kentucky, USA). Cell 
Calcium 10, 289 (1989).
Human platelets contain a Ca2+-ATPase 
in internal membranes that is essential for 
Ca2+ homeostasis. This Ca2+ pump has 
enzymatic properties quite similar to the 
sarcoplasmic reticulum (SR) Ca2+ pumps. 
Antibodies against the SR Ca2+ pump cross- 
react with the human platelet protein. Howe­
ver, the platelet Ca2+-ATPase is approxi­
mately 10 kD larger than the SR pumps 
and exhibits a larger mRNA coding for the 
protein in a megakaryocyte tumor cell line.
In addition, the platelet Ca2+-pump may 
be localized in specialized internal membrane 
structures that function in Ca2+ uptake and 
release. These results suggest that the plate­
let Ca2+-ATPase may represent a new class 
of internal membrane Ca2+-pumps.
11. Sarkadi
Calcium induces membrane translocation o f  
12-lipoxygenase in rat platelets. A. Baba, 
S. Sakuma, H. Okamoto, T. Inoue and H. 
Iwata (Department of Pharmacology, Fa­
culty of Pharmaceutical Sciences, Osaka 
University, 1—6 Yamada-Oka, Suita, Osaka 
565, Japan). J. Biol. Chem. 264, 15790(1989).
Translocation of soluble 12-lipoxygenase 
to membranes was examined in rat platelets. 
Preincubation of platelet homogenates with 
0.1 — 10 |(íM Ca2+ resulted in an increase in 
12-lipoxygenase activity of the particulate 
fraction with a concomitant decrease in that 
of the soluble fraction. Kinetic parameters 
of 12-lipoxygenase of the soluble and mem­
brane fractions were not changes in the 
presence of 10 /iM Ca2+. Ca2+-induced as­
sociation of 12-lipoxygenase to the particu­
late fraction was dependent on the amounts 
of platelet-soluble and membrane fractions 
but not on the incubation temperature. 12- 
Lipoxygenase activity associated with the 
particulate fraction was completely dissociat­
ed by reducing the concentration of Ca2+ 
to 10 nM. Ca2+-induced association of 
the enzyme also occurred in the boiled- 
and trypsin-treated membranes but was 
significantly reduced in the phospholipase 
A2-treated membranes. Soluble 12-lipoxy­
genase also associated to liposomes in a 
Ca2+-dependent manner. Pretreatment of 
platelets with thrombin (0.5 — 5 units/ml) 
significantly caused a translocation of so­
luble 12-lipoxygenase to particulate fraction; 
in the time course study, the translocation 
was observed at the thrombin pretreatment 
of 1, 5, and 10 min. These results suggest 
that stimulation of platelets is followed by 
the translocation of soluble 12-lipoxygenase 
to membranes, which is mediated by physio­
logical concentration of Ca2+.
II. Sarkadi
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Further characterization o f the plasma mem­
brane- and intracellular membrane-associated 
platelet Cat+ transport systems. J. Enouf,
R. Bredoux, N. Bourdeau, B. Sarkadi and
S. Levy-Toledano (Unité Inserm, No. 150, 
Hôpital Lariboisière, Paris Cedex 10, France). 
Biochem. J. 263, 547 (1989).
Biochemical characterization of the Ca2+- 
ATPases isolated from human platelet intra­
cellular and plasma membranes is reported. 
A comparative study of the previously 
partly described plasma membrane Ca2+- 
ATPase and the intracellular membrane 
Ca2+-ATPase obtained simultaneously shows 
differences in the following parameters: (1) 
different kinetics of the two enzymes; (2) 
similar apparent affinity towards Ca2+ 
(10_7M), though the intracellular membrane 
enzyme was inhibited at Ca2+ concentra­
tions above 10-7M; (3) different pH depend­
ence with an activity maximum at pH 7 for 
the intracellular membrane Ca2+-ATPase 
and no detectable pH maximum for the 
plasma membrane Ca2+-ATPase; (4) a 
10-fold difference in the ATP requirement 
of the two Ca2+-ATPases; (5) different pat­
terns of inhibition by vanadate. Finally, the 
possible regulation of the Ca2+-ATPases 
was examined by studying the effect of 
chlorpromazine on the two Ca2+-ATPase 
activities, with only the plasma membrane 
enzyme being inhibited. It is concluded that 
the two platelet Ca2+ transport systems 
show biochemical differences in spite of the 
previously shown similarity in the molecular 
masses of their Ca2+-ATPases, thus con­
ferring a definite specificity to the platelet 
system.
B. Sarkadi
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Changes in Nucleolar Morphology 
during Macrophage Development in Non-Hodgkin’s 
Lymphoma: a Morphometric Study
R. J. Sokol*
Department of Haematology, University of Sheffield, Sheffield S10 2RX,
United Kingdom
(Received 1 February, 1989; accepted 8 May, 1989)
Nucleolar ultrastructure of macrophages developing in suspension culture 
from monocytes was studied in 20 patients with non-Hodgkin’s lymphoma and 20 
normal subjects. Morphometric measurements of nucleolar volume, surface area, 
volume fraction, surface-to-volume ratio and number of profiles per section were made 
over a 6 day period. Multivariate analysis of variance showed that culture time and 
subject group had significant effects: changes during macrophage development were 
less marked in the patient group, nucleoli were fewer, rounder and possibly smaller 
than normal. The results indicate disturbed macrophage development in non-Hodgkin’s 
lymphoma and may be related to mononuclear phagocyte dysfunction.
Keywords: electron microscopy, macrophages, malignant lymphoma, mono­
cytes, morphometry, nucleoli
Introduction
Previous studies in patients with malignant lymphoma demonstrated the 
presence of ultrastructural changes in both peripheral blood monocytes [1] and 
skin window macrophages [2, 3] which were thought to be the morphological 
counterparts of the mononuclear phagocyte dysfunction known to occur in these 
conditions [4]. Since nucleoli have a key role in the regulation of cell growth 
and protein synthesis and provide an essential link between nucleus and cyto­
plasm [5], it seemed important to investigate whether nucleolar morphology of 
mononuclear phagocytes was also affected in lymphoma patients. A preliminary 
ultrastructural study in blood monocytes suggested that it was, patients’ cells 
having smaller nucleolar volumes and volume fractions within the nucleus, 
together with fewer nucleolar profiles per section, as compared to normal [6]. 
The question then arose whether similar changes would be present at the macro­
phage stage of development. In the present work, a method previously employed
* Correspondence ; R. J. Sokol, Regional Blood Transfusion Centre, Longley Lane, 
Sheffield S5 7JN, UK
1* VSP, Utrecht, Tokyo 
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to investigate the development of monocytes into macrophages in normal sub­
jects [7] has been used and morphometric measurements made on the nucleoli 
of mononuclear phagocytes of patients with non-Hodgkin’s lymphoma (NHL), 
as well as on those of a group of healthy individuals.
Materials and Methods
Studies were made on blood samples from 20 patients with NHL and 20 
normal subjects.
There were 11 males and 9 females in the NHL group, none of whom had 
received specific treatment; their mean age +  standard error (SEM) was 55 + 3 
years. According to the classification of Gerard-Marchant et al. [8], 7 patients 
had centroblastic diseases, 5 had peripheral T cell lymphoma, 4 were of the 
centroblastic-centrocytic follicular type, 2 of the centrocytic type, 1 had lympho­
blastic (Burkitt’s) lymphoma and 1 had thymic lymphoma. The lymphoma was 
thought to be of B cell origin in 14 cases, of T cell origin in 5 and one (thymic 
lymphoma) was unclassifiable. All 4 disease stages and both A and B symptom 
categories [9] were represented. 17 patients had reduced cellular immunity (as 
assessed by the response to phytohaemagglutinin compared with age and sex- 
matched controls and by decreased numbers of T lymphocytes in peripheral 
blood using a sheep red cell rosette test [10]).
Ten males and 10 females were included in the normal group; their mean 
age +  SEM was 33 + 2 years. All were in good health at the time of sampling 
and denied taking any medication.
Cell preparation and electron microscopy
Approximately 35 mis of venous blood was obtained from each subject 
and defibrinated under sterile conditions. As described previously, mononuclear 
cells were separated, washed, divided into aliquots and cultured in suspension 
with autologous serum [11]. One aliquot of cells was studied prior to culture 
(Day 0 specimen) while others were examined after 1, 2, 4 and 6 days in culture, 
respectively. Following assessment of viability by trypan blue exclusion, the 
cells were prepared for electron microscopy by standard methods [7, 12]. Ultrathin 
sections of consistent thickness (silver-gold) were examined in a Philips 400T 
electron microscope. Mononuclear phagocytes were recognised by their charac­
teristic ultrastructural appearances [13]: the complex surface microvilli and 
pinocytic vesicles, and the presence of typical lysosomal granules were particularly 
useful features in identification, while nuclear profile configuration and chromatin 
pattern were less useful. Lymphocytes, also present, were easily distinguished.
Nucleated profiles of mononuclear phagocytes were selected in an identical, 
predetermined and random manner. Starting at the centre of the grid, all nucleated 
macrophages showing complete profiles were photographed sequentially as they
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were encountered in the line of drive ; 11 to 18 micrographs were obtained from 
each subject at each culture interval (i.e. approximately 1300 cells per group in 
total). A standard graticule was used to calculate magnifications; these ranged 
from x7000 to x 14000. Nucleoli were identified by their electron microscope 
appearances, taking care to distinguish “nucleolus associated chromatin” [14, 15].
Morphometry
Morphometric analysis was carried out using principles and methods 
similar to those described previously and was based on the concept of a model 
cell: assuming that nuclei formed a monodispersed population with respect to 
size and were spherical [7, 16]. The micrographs were covered with transparent 
test grids. Point and intersect counting was carried out on nuclear and nucleolar 
profiles using grid lattices of 1 cm and 0.5 cm, respectively. The counting was 
performed without knowledge of the subject group. Profile areas, areal fractions 
and surface-to-volume ratios were calculated, appropriate compensation being 
made for non-equatorial sectioning of the nuclei [7, 16]. The following nucleolar 
measurements were then obtained : volume (Vn), surface area (Sn), volume fraction 
within the nucleus (vVn), surface-to-volume ratio (S/Vn) and number of nucleolar 
profiles per section. Sampling adequacy was confirmed by the mean values for 
relative standard error (vVn) and SEM/x (nucleolar profile numbers) ranging 
from 0.05 to 0.07 [17].
Statistical analysis
Multivariate analyses of variance (MANOVA) were carried out on the 
overall nucleolar measurements to examine the effect of culture interval, subject 
group, age and sex. Prior to the computations, the data were transformed to 
natural logarithm values in order to improve conformity to model assumptions 
of multivariate normality and homoscedasticity. As the mean ages of the subject 
groups differed greatly, age was treated as a covariate in the between groups 
comparison; whether such age differences could account for any of the findings 
was also examined. Univariate analyses of variance (ANOVA) were carried out 
on the separate nucleolar measurements to aid in the interpretation of the 
MANOVA results. The analyses were carried out on an Olivetti M24SP micro­
computer using a SPSS/PC+ statistical package. Probabilities of p < 0.05 and 
p < 0.01 were chosen as the a priori levels of significance for MANOVA and 
ANOVA, respectively. The more stringent requirement for the latter was to take 
into account the 5 separate comparisons [7], an individual significance level (a) 
of 0.01 being required to give an overall significance level (S) of 0.05 (S = 1 
— (1 — a)0). In NHL patients, subgroupings based on histology, B/T cell type, 
disease stage, symptom category and cellular immunity status were considered 
to be too small for valid statistical testing.
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Table 1
Nucleolar measurements: summary of quantitative analysis
R esults a t each perio d  o f  cu ltu re (x ±  SEM ) A N О V A
D ay 0 D ay 1 D ay 2 D ay  4 D ay  6 Effect o f  
tim e (p)
N o rm al vs 
N H L  (p)
Volume (fl) Normal 1.24+0.10 1.69+0.19 1.53+0.23 4.21+ 1.01 4.28+0.91 0.00 0.03NHL 1.07+0.10 1.33+0.09 1.36+0.18 2.30+0.33 3.13+0.65 0.03
Surface area /mi2) Normal 11.36+0.65 13.11+ 1.11 11.48± 1.29 21.71+4.14 20.06+2.88 0.01 0.00NHL 10.21+0.71 11.04+0.69 10.14+ 1.07 12.63+ 1.43 15.32+ 2.22 0.38
Volume fraction Normal 1.42+0.12 1.82+0.17 1.57+0.21 2.97+0.44 2.93+0.32 0.00 0.35within nucleus (%) NHL 1 34+0.12 1.69+0.12 1.64+0.19 2.29+0.29 2.59+0.37 0.11
Surface-to-volume Normal 9.50+0.36 8.24+0.49 8.97+0.64 6.49+0.44 5.70+0.39 0.00 0.32ratio (jitn2 fl ■) NHL 10.28+0.55 8.40+0.31 8.28+ 0.35 6.73+0.64 6.80+ 0.92 0.00
Number of profiles Normal 1.02+0.05 0.94+0.06 0.81+0.06 0.86+0.08 0.80+0.04 0.05 0.01per section NHL 1.02+0.06 0.88+ 0.06 0.76+0.07 0.65+0.06 0.69+0.04 0.00
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Results
The results of the morphometric analysis are shown in Table 1. MANOVA 
showed that there were highly significant effects on the nucleolar measurements 
due to culture time (p <  0.001 for both patients and normals) and to subject 
group (p =  0.003). Age had no effect on the results in either group and the group 
effect was independent of the differences in age. No evidence was found of signif­
icant differences between males and females in either group.
The results of the ANOVA on the individual measurements in respect of 
the culture interval are given in Table 1 (Effect of time). Unlike the normal group, 
the increases in Vn, Sn and vVn in the NHL patients were not significant. Using 
‘spheres of equivalent volume’ (Se) to assess nucleolar irregularity [7], the ratio 
Sn/Se decreased during culture from 2.02 to 1.48 in the NHL group and from 
2.04 to 1.57 in the normal subjects, indicating that the decrease of (S/V)n in both 
groups during the 6 days were due to the nucleoli becoming rounder as well as 
to the volume increases. The results of the ANOVA comparing the subject groups 
are also shown in Table 1 (Normal vs NHL), values for Sn and number of nucleolar 
profiles per section being significantly smaller in NHL.
Discussion
The results are interpreted as showing that while the nucleolar morphology 
changed over the period of culture in both groups, there were significant dif­
ferences between the NHL patients and the normals, in particular nucleoli were 
fewer and rounder in the patient group. The volumes of the nucleoli were also 
consistently smaller, though p at 0.03 for the differences in Vn was only sug­
gestive of significance, not meeting the reqired value for the ANOVA of p < 0.01.
The findings are in keeping with other reports of ultrastructural disturbances 
in mononuclear phagocytes in NHL in vivo [1—3, 6]. Compared with normal 
subjects, skin window macrophages in NHL patients had less mature surface 
appearances [2] and their monocytes had larger nuclei with more euchromatin 
and a relatively smaller heterochromatin-euchromatin interface, cell profile 
areas were larger with smaller surface-to-volume ratios [1]. In a morphometric 
study of nucleoli of uncultured blood monocytes, values for Vn, Sn, vVn and 
number of profiles per section were 19 — 32% smaller than normal [6]. Lurther 
studies of skin window cells suggested premature activation of macrophages in 
lymphoma patients associated with a subsequent defect in phagocytic poten­
tial [3]. Such changes are unlikely to be specific to NHL as similar findings have 
been reported in patients with Hodgkin’s disease [1—3, 6]. However, the present 
results are consistent with a disturbed pattern of transformation of monocytes 
into macrophages in NHL, and this is supported also by other morphological 
studies during culture. The cells of NHL patients appeared to grow less, show 
less elaboration of surface features and have reduced nuclear and mitochondrial
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development, the latter affecting mitochondrial numbers rather than size [18]. 
The ultrastructural changes may be related to the mononuclear phagocyte dys­
function observed in other investigations. Phagocytosis [19, 20], antigen depen­
dent cellular cytotoxicity [21], microbicidal activity [22 — 25], superoxide anion 
production [26] and glucose metabolism [27] have all been reported as either 
enhanced or decreased in patients with NHL, although normal functions have 
also been found [23, 28].
Knowledge of the spatial organisation within mononuclear phagocytes is 
important in relation to understanding their multiplicity of defensive and regula­
tory functions. Nucleoli are key organelles in cell metabolism and the present 
results indicate that morphometry offers a relatively simple method of providing 
objective data on changes in their morphology. The experimental system used 
here has several advantages. Culturing mononuclear phagocytes with autologous 
lymphocytes and serum allows each sample to act as its own control, particularly 
in respect of effects due to being in vitro; yet the system would readily permit 
the assessment of individual factors which may modify nucleolar development: 
these include the co-cultured lymphocytes, serum factors (eg interleukins) and 
changes intrinsic to the mononuclear phagocytes themselves. The findings would 
likely add to our basic understanding of NHL.
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Serum aldolase concentrations were determined in 78 patients with acute 
myelogenous leukaemia (AML). Mean serum aldolase concentration (+  SD) at the time 
of diagnosis was 28.3 U/L (+19.4). 71.8% of AML patients had increased serum 
aldolase concentrations. The highest hyperaldolasaemia were observed in patients 
with acute myelomonocytic leukaemia and acute monoblastic leukaemia. The mono­
cytic involvement in AML patients was significantly related to serum aldolasaemia. 
Human aldolase gene has been located on chromosome 16, whose structural aberra­
tions are frequent in AML patients with monocytic involvement, explaining the link 
between serum hyperaldolasaemia and the monocytic involvement in AML patients.
Keywords: erythropoiesis, fructosediphosphate aldolase, monoblastic leukaemia, 
myeloblastic leukaemia
Introduction
Mammalian fructose 1,6-diphosphate aldolase is a tetrameric glycolytic 
red cell enzyme with three subunit types: aldolase A is predominantly high in 
muscle, aldolase B is found exclusively in liver and aldolase C exists predominantly 
in brain and nervous tissue [1]. All patients with hepatic malignancies had in­
creased serum levels of aldolase which is the predominant isoenzyme in fetal 
tissue, suggesting an oncofetal reversion [2]. Further on, all patients with chronic 
myeloid leukaemia (CML) had increased serum levels of aldolase, which was 
consistent with a fetal erythropoiesis and increased glycolytic rate [3]. In patients 
with acute leukaemia, the production of fetal haemoglobin has been reported [4]. 
The present study was undertaken to define the initial serum aldolase concentra­
tions in patients with AML and to correlate them to the various subtypes of 
AML. The results showed that 71.8% of AML patients had hyperaldolasaemia, 
which was significantly related to the monocytic involvement of their blast cells, 
suggesting a malignant reversion to fetal erythropoiesis in AML patients, particu­
larly in those with monocytic involvement.
* Correspondence: H. T. Hassan, Darwin College, Silver Street, Cambridge CB3 9EU, 
England
VSP, Utrecht, Tokyo 
Akadémiai Kiadó, Budapest
74 H. T. Hassan et al.: Hyperaldolasaemia in A M L
Materials and Methods
Patients
Seventy eight patients (34 females and 44 males) with AML were studied. 
Mean age was 49.8 years (range 20 — 83). The diagnosis was based on cell morpho­
logy and cytochemistry and organised according to the French — American — British 
(FAB) classification scheme [5, 6]. All AML patients had normal liver function 
tests at the time of diagnosis.
Measurement o f serum aldolase
Serum aldolase concentrations were measured in blood samples obtained 
from each AML patient at the time of diagnosis as described previously [7]. 
Control serum aldolase concentrations were measured in 40 normal blood donors 
and varied from 5.2 U/l to 7.6 U/l (mean 6.5 ±  1.8). Hyperaldolasaemia was 
defined as serum aldolase concentration higher than 7.6 U/l, which was the upper 
limit of normal serum aldolase concentration in the controls.
Results
At the time of diagnosis, the mean serum aldolase concentrations for the 
various FAB subtypes of AML patients were significantly increased compared 
to the normal controls (Fig. 1). Fifty-six of the 78 AML patients (71.8%) showed 
hyperaldolasaemia. The highest serum aldolase levels were observed in patients 
with acute monoblastic leukaemia (AMoL)M5 (Fig. 1). The results also showed 
a significant difference (p < 0.001) in serum hyperaldolasaemia between patients 
with AMoL(M5) and patients with other FAB subtypes of AML (Table 1). 
A similar significant difference (p < 0.001) in serum hyperaldolasaemia was
Fig. 1. Hyperaldolasaemia in acute myeloid leukaemia
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Table 1
Effect of monocytic involvement on serum aldolase concentration in AML patients
FA B  sub types o f  A M L
A M y L (M l)  +  A M L (M 2) +  
A P L (M 3) +  A M M oL (M 4) 
(n =  65)
A M oL (M 5) 
(n  -  13) P
Serum aldolase
concentration (U/L) 21.4+ 18.7*  69.0+44.9 <0.001
AMyL: acute myeloblastic leukaemia, AML: acute myeloblastic leukaemia with 
differentiation, APL: acute promyelocytic leukaemia, AMMoL: acute myelomonocytic 
leukaemia, AMoL: acute monoblastic leukaemia.
* Mean +  Standard deviation.
Table 2
Significance of monocytic involvement on serum hyperaldolasaemia in AML
patients
A M y L (M l)  +  A M L (M 2) +  A M M oL (M 4) 
FA B sub types  o f  A M L  +  A PL (M 3) + A M o L (M 5 )
(n =  54) (n  -  24)
Serum aldolase
concentration (U/L) 17.3+ 12.0* 56.3+38.5 <0.001
AMyL: acute myeloblastic leukaemia, AML: acute myeloblastic leukaemia with 
differentiation, APL: acute promyelocytic leukaemia, AMMoL: acute myelomonocytic 
leukaemia, AMoL: acute monoblastic leukaemia.
* Mean +  Standard deviation.
found between AML patients with monocytic involvement (acute myelomonocytic 
leukaemia and acute monoblastic leukaemia) versus those without monocytic 
involvement (acute promyelocytic leukaemia and acute myeloblastic leukaemias) 
(Table 2).
Discussion
The reappearance of fetal haemoglobin has been reported in human leu­
kaemia [8]. In acute leukaemia, the reversion to a fetal form of erythropoiesis 
suggests the existence of a dyserythropoietic state in which the basic process is 
a disturbance of gene control mechanism leading to various metabolic alterations 
and post-synthetic modifications of proteins [9]. The major finding of the present 
study is that the serum hyperaldolasaemia which was manifested in 70% of AML 
patients, is significantly related to the monocytic involvement of their blast cells 
(Tables 1, 2). The highest serum aldolase level was observed in AML patients
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with monocytic involvement (Fig. 1). Fluman aldolase gene has been recently 
located on chromosome 16 [10]. Structural aberrations of chromosome 16 has 
been very frequently reported in AML patients with monocytic involvement: 
acute myelomonocytic leukaemia (AMMoL) M4 [11, 12, 13] and AMoL M5 
[14, 15, 16], which may explain the link between serum hyperaldolasaemia and 
the monocytic involvement in AML patients. Further studies to determine which 
of the three forms of aldolase (Aldolase —A, — B or — C) is the predominant 
cause of serum hyperaldolasaemia in AML patients with monocytic involvement 
may provide information on the types of fetal haemoglobin involved in human 
leukaemia.
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The aim of this work was to evaluate the phytohaemagglutinin-induced aggre­
gation of circulating neutrophils isolated from 25 patients affected by chronic myelo­
proliferative syndromes (polycythaemia vera, chronic myeloid leukaemia in chronic 
phase, and essential thrombocythaemia).
The results showed a lesser aggregating capacity in chronic myeloid leukaemia 
(CML) and an opposite behaviour in polycythaemia vera and essential thrombo­
cythaemia.
Patients with polycythaemia vera whose neutrophils showed a greater aggre­
gating capacity were shown to have had various vascular complications.
Keywords: aggregation, CML, essential thrombocythaemia, phytohaemaggluti- 
nin, neutrophils, polycythaemia vera
Introduction
The aggregation of neutrophils represents an interesting event in acute 
inflammatory response. This neutrophilic function can be induced in vitro with 
various substances (zymosan activated serum, phytohaemagglutinin, calcium 
ionophore A23187, arachidonic acid, phorbol myristate acetate, thrombin, 
formyl-methionyl-leucyl-phenylalanine, leukotriene B4), and it leads to the 
production of lipo- and cyclo-oxygenase metabolites, which have a wide spectrum 
of activity in the modulation of immunity phenomena [1].
The aggregation of neutrophils has been, and still is, studied in various 
human pathological conditions, such as neutropenia, shock lung syndrome, 
angina pectoris and myocardial infarction, in which a possible pathogenetic 
role is attributed to the neutrophil aggregation itself (e.g. the vascular margination 
of neutrophils or the neutrophil-endothelium interaction [2 — 4].
To our best knowledge, the aggregation of neutrophils has not yet been 
studied in myeloproliferative diseases, in which various neutrophil functional 
defects have been noted [5].
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The aim of this study was to evaluate the aggregation of neutrophils induced 
by phytohaemagglutinin (PHA) in 25 patients affected by chronic myeloprolif­
erative diseases. Lectins, in fact, are often used as stimuli for neutrophils: their 
action results in a number of alterations of cell function and structure [6, 7]. 
A study aimed at characterizing lectin-binding surface proteins has been published 
recently [7], this, however, did not involve PHA.
Materials and Methods
Subjects studied
Thirteen healthy volunteers were studied together with 25 patients affected by 
chronic myeloproliferative syndromes: 9 with polycythaemia vera (PV), 8 with 
chronic myeloid leukaemia (CML) in chronic phase and 8 with essential thrombo- 
cythaemia (ET) (Table 1).
The patients with ET were studied at the moment of diagnosis; those 
affected by CML were studied at least 8 weeks after any applied therapy; those 
affected by PV were studied at least 4 weeks after haemophlebotomy. One of 
these latter patients had been previously treated with pipobroman.
At the time of the study, none of the patients showed any symptoms attri­
butable to vascular complications.
PV and ET were diagnosed according to the criteria of the American Poly­
cythaemia Vera Study Group. The diagnosis of CML was based on clinical para­
meters, morphological study of bone marrow and the results of cytogenetic 
studies.
In the group of patients affected by PV we retrospectively evaluated any 
relationship between the results of neutrophil aggregation and the vascular symp­
toms (myocardial infarction, transient attacks of ischemia, venous thrombosis, 
microvascular thrombosis, haemorrhage) shown by any single subject throughout 
his/her illness.
Table 1
General characteristics of the patients studied
D iagnosis n
Sex Age (years) N eu troph ils P latelets
M F X range (x lO '/l)
PV* 9 5 4 65 49-86 2.8- 13.5 200- 861
ET** 8 4 4 63 40-72 3.0-20.0 700- 1850
CML*** 8 5 3 52 30-75 15.0-40.0 250- 750
* Polycythemia vera.
** Essential thrombocythemia.
*** Chronic myeloid leukemia in chronic phase.
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Neutrophil preparation
Neutrophils were obtained as described earlier [9] with modifications. 
Heparinized venous blood (10 units heparin/ml) was centrifuged at 700 rpm for 
15 min and the supernatants were discarded in order to reduce platelet conta­
mination. The blood was sedimented with dextran 1 : 1 (v/v) for 30 minutes at 
37 °C. The leucocyte-enriched plasma was centrifuged at 160 g for 10 minutes. 
The cells were resuspended and washed twice at 160 g for 5 minutes in PBS 
containing neither calcium nor magnesium, sedimented on Lymphoprep and 
centrifuged at 400 g for 30 minutes. After the removal of the contaminating red 
blood cells by means of hypotonic lysis, the precipitated neutrophils were washed 
in PBS and re-suspended in the same solution containing bovine serum albumin
0.25%, calcium and magnesium at a concentration of 12x10° cells/ml. The 
cellular suspensions were stained by M ay— Grunwald — Giemsa and alpha- 
Naphtylacetate-esterase stains: lymphocyte and monocyte contamination was 
< 1 %. Platelet contamination was < 1 %. Samples from patients suffering from 
CML contained metamyelocytes < 1 —2%. The neutrophil viability, checked by 
means of trypan blue exclusion, was always greater than 99 %.
Neutrophil aggregation
The aggregation was measured in a platelet aggregometer (Aggrecorder 
PA-3210, Menarini S. p. A., Florence, Italy), rotating continuously at 900 rpm. 
The aggregating agent was PHA (Difco), at final concentrations which varied 
fom 6 to 120 /tg/ml. 250 p\ of the neutrophil suspension was added to siliconized 
cuvettes. After heating the cells at 37 °C for 2 minutes, 50 p\ of PHA was added. 
The registration system of the aggregometer was calibrated with PBS (containing 
bovine serum albumin 0.25%). Quantitation of granulocyte aggregation during
Table 2
Neutrophil aggregation in patients affected by chronic myeloproliferative syndromes
Diagnosis
P H A  Cug/ml)
120 60 6
PV* 4 3 . 4 + 4 . 0 8 3 7 . 6 + 5 . 7 4 Я 1 3 . 6 + 3 . 5 2
ET** 4 1 . 0 + 3 . 0 3 3 5 . 2 + 3 . 7 6 Ö K 1 5 . 2 + 3 . 7 6
CML*** 3 7 . 6 + 4 . 2 8 “ 3 2 . 3 + 4 . 2 1 1 2 . 2 + 4 . 2 7
Controls 4 3 . 2 + 2 . 9 9 2 9 . 2 + 4 . 8 8 1 8 . 5 + 7 . 6 0
Aggregation values are expressed in cm2 (means +  SD).
* Polycythemia vera; ** Essential thrombocythemia; *** Chronic myeloid leukemia in 
chronic phase; # p <  0.01; tt#  p o.02; a p <  0.005.
In no case was spontaneous aggregation noted.
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the initial 5 min was made using a compensating polar planimeter (Mod 236, 
Salmoiraghi S. p. A., Milan, Italy) and the results were expressed in square 
centimeters. Aggregation was verified by phase contrast microscopy.
Statistics
The results were analyzed by Student’s t test for unpaired data.
Results
PhA induced irreversible and dose-dependent aggregation.
The results are shown in Table 2. In 5 patients affected by PV and in 4 
patients affected by ET, we observed an increase in neutrophil aggregation with 
PHA 60 /Tg/ml (p <  0.01 and < 0.02, respectively). In patients with PV this 
concentration of PHA seemed to be related to the vascular symptoms of each 
individual (Table 3).
Neutrophils isolated from patients with CML showed in 4 of 8 patients 
a reduction in aggregation with PHA 120 /ig/ml (p <  0.005).
Table 3
Patients affected by polycthemia vera. Relationship between neutrophil 
aggregation obtained with PHA 60 /ig/ml and vascular symptoms
C ase
A ggrega­
tion
T h ro m ­
bosis1 T IA 2 M I3 M icr1
H aem o r­
rhage
î — No No No No No
2 = No No No No No
3 = No No No No No
4 NT No YES No No No
5 T No YES No No No
6 r No No No YES No
7 r YES YES No No No
8 Î No No YES No No
9 T No No No No YES
NT : Not tested; =  : Normal aggregating function; Î  : Increased aggregating function; 
1 : Venous thrombosis; 2 : Transient attacks of ischemia; 3: Myocardial infarction;4: Micro- 
vascular thrombosis.
H aem ato lo g ia  23, 1990
G. Carulli et al.: Neutrophil aggregation 83
Discussion
PHA-induced neutrophil aggregation is an irreversible phenomenon and 
the aggregation curves vary in morphology and values of aggregation according 
to the final concentration of PHA. In a preliminary paper [10] we observed that 
PHA-induced aggregation showed an evident dependence upon the trans­
membrane flow of calcium ions and calmodulin function; a limited dependence 
upon microtubular function; a response to the effect of cytochalasin B which 
varied according to the final concentration of this drug: an increase in aggregation 
at concentrations between 2 and 5 /rg/ml, and a reduction in aggregation at the 
concentration of 10 цg/ml. Those results were in agreement with those reported 
by other authors who had used different aggregating agents [1, 11, 12].
Our results show that in some patients suffering from chronic myeloprolif­
erative syndromes there are some anomalies in granulocyte aggregation. The 
aggregation behaviour seems to differ according to the disease in question: 
in the case of CIVIL there seem to be above all a lesser aggregative capacity, while 
in the case of PV and ET the defect seems to be the opposite. Because of the 
relatively low number of cases studied, it is not possible to affirm that the 3 dif­
ferent diseases present typical profiles with regard to neutrophil aggregation. 
H owever, the different neutrophil aggregation behaviours shown could be a con­
sequence of structural and/or functional anomalies related to the derivation of 
a part of the circulating neutrophils from one or more neoplastic clones.
Former studies have shown various anomalies in neutrophil functions and 
ultrastructure in CML patients [13 — 15]. More recently it has been shown that 
neutrophils both from subjects of acute and chronic myeloproliferative diseases 
can present various functional anomalies, which seem to be associated with 
a worse prognosis [5]. All these abnormalities could be compatible, in some 
patients, with aggregation anomalies in vitro.
Cooper et al. [16] have noted that neutrophils from patients affected by 
PV present a metabolic state which is higher both in the resting and in the phago­
cytic phase: an increase in the ingestion of latex particles, in the clumping during 
the phagocytic process and in the NBT reduction test.
Furthermore, to our best knowledge, no data are available on neutrophil 
functions in ET.
The tendency towards a higher aggregative capacity in PV may play a role 
in the pathogenesis of thrombo-embolic phenomena, particularly frequent in 
this myeloproliferative syndrome [17]. In fact, even if the cases studied are few 
in number, the 5 patients affected by PV, whose neutrophils have shown a greater 
aggregating capacity, were shown to have suffered from various vascular symp­
toms.
Venous thrombi partly consist of neutrophils, and it is possible that granu­
locyte-endothelium interaction and the phenomenon of intravascular neutrophil 
aggregation represent stages in the formative process of the thrombus. Recent 
in vitro studies support this hypothesis [18].
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In conclusion, the study of neutrophil aggregometry could represent an 
interesting field of research in human pathology. Further studies are needed in 
order to confirm the results of this paper and determine the mechanisms respon­
sible for the modifications in neutrophil aggregation in chronic myeloproliferative 
syndromes.
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The complement functions of 42 patients with non-Hodgkin’s lymphoma have 
been examined. The patients were divided into groups according to the severity of 
their disease: 1st — patients with high-grade lymphomas, 2nd — with low-grade 
lymphomas and 3rd — with chronic lymphocytic leukaemia. The adopted methods 
were the measurements of complement-mediated immune complex solubilizing capacity 
(CMSC) and the complement-mediated immune complex precipitation inhibition 
capacity (IPIC). The CMSC and IPIC values were examined parallel with CH50, C3 
complement levels and with levels of circulating immune complexes (CIC) in the sera 
of patients. The results indicated that the acquired deficiency of complement functions 
could be established by CMSC and IPIC measurements in the sera of patients with 
high-grade lymphomas. These defects were found to be milder in the group with 
low-grade lymphomas, and were not detectable in CLL. The changes of CH50 levels 
were found to be similar to that of IPIC values and the decrease in C3 levels was 
detectable in high-grade and low-grade lymphomas too. Elevated CIC levels were 
found in those cases in which both CMSC and IPIC were decreased.
Keywords: non-Hodgkin’s lymphoma, acquired complement deficiency, 
complement-mediated immune complex solubilization, complement-mediated immune 
complex precipitation inhibition
Introduction
Patients with malignant lymphomas are at an increased risk of infections. 
There are many factors predisposing to infection in this patient population: 
specific deficiencies in host defense mechanisms due to certain malignant processes 
and deficiencies in host resistance secondary to conventional chemotherapy. 
In the sera of these patients we frequently found elevated levels of circulating 
immune complexes (CIC). There are various clinical symptoms based on immune 
complex pathomechanisms observed in these patients, for example immun- 
haemolytic anaemia or vasculitis. The acquired defects in the complement system 
are an important aspect of these two abnormalities occurring in patients with 
lymphomas.
VSP, Utrecht, Tokyo 
Akadémiai Kiadó, Budapest
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Deficiency of complement-related opsonic activity or defects in the other 
protective complement functions may contribute to an increased incidence of 
bacterial infections and on the other hand cause an imbalance in the metabolism 
of immune complexes. The role of complement deficiencies in increased risk 
bacterial infections has been discussed by other authors [1, 2]. It is well-known 
that there are direct correlations between the impaired complement functions 
and the increasing levels of pathogenic immune complexes. Details of the mechan­
isms of this phenomenon have become clearer [3, 4, 5].
In 1975, Miller and Nussenzweig showed that complement components 
can solubilize preformed immune precipitates in vitro [6]. In the following years 
the complement-mediated immune complex solubilizing capacity (CMSC) was 
characterised as a function of the alternative complement pathway. The classical 
pathway is able to enhance this reaction but cannot promote an effective solu­
bilization by itself [7]. After a few years Schifferly, Naama and their co-workers, 
studying the in vitro formation of immune complexes in normal sera, identified 
a new complement function: the complement-mediated immune complex pre­
cipitation inhibition capacity (I PIC) [8, 9, 10]. This function depends on the 
activity of the classical complement pathway. Both processes — the solubilization 
and the precipitation inhibition — result in the formation of soluble immune 
complexes with modified structures which form a covalent bond with complement 
fragments, similar to the complexes in vivo [5, 11 ].
In this study we adopted the methods, based on two phenomena, to examine 
the integrity of the complement system of our patients with non-Hodgkin’s 
lymphoma. The CMSC and IPIC values were examined parallel with CH50, 
C3 complement levels and CIC levels in sera of patients. These patients were 
divided into groups according to the severity of their disease.
M aterials and Methods
Palién Is and controls
Serum samples were obtained from 42 patients with non-Hodgkin's lym­
phoma and from 30 healthy subjects. The patients were divided into groups 
according to their histological diagnosis based on the Kiel Lymph Node Re­
gistry [12]. The three groups were: 14 patients suffering from high-grade, 14 
others from low-grade lymphomas and a third group of 14 patients with chronic 
lymphocytic leukaemia (CLL). The CLL group was separated from other low- 
grade lymphomas. The patients were in complete or incomplete remission. They 
were not given cytostatic agents for more than one month before blood was 
taken and they had no bacterial or viral infections.
Serum samples
The blood was allowed to clot at room-temperature for one hour and then 
at + 4°C  for two hours. Thereafter, the serum was separated by centrifugation
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and divided into aliquots for the different tests. The serum samples for CM SC 
and 1PIC were used freshly immediately after the separation.
Measurement o f CMSC
The antigen components of the artificially produced complexes were radio- 
labelled. Bovin serum albumin (BSA) was labelled with 125I by the chloramine-T 
method [13]. Cleaned rabbit IgG produced against BSA (Philaxia) was used for 
preparing the complex. At weighing the labelled BSA with anti-BSA, an approxi­
mately fourfold antibody excess was applied. The reaction mixture was incubated 
at 37 °C for two hours and then at 4 °C for 12 hours. The precipitate was separated 
by centrifugation at 1600 g for 15 minutes and was washed six times in PBS 
buffer (physiological NaCl solution buffered with phosphate). The washed pre­
cipitate was dispersed by repeated sucking through a thin cannule. The volume 
of complexes was adjusted to produce 70 — 80% CMSC in freshly mixed healthy 
sera and background CMSC with buffer or heat-inactivated sera was less than 
10—15%. This precipitate was stored in small aliquots at — 20 °C until used. 
The measurement of CMSC in sera of patients and controls was performed as 
described previously [14]. Briefly : 400 g\ of the 1 : 2 dilution of serum was prepared 
with PBS + + (containing 0.15 mmol/1 Ca + + and Mg + + ions). It was added to 
20 gl IC solution in duplicate. The mixture was incubated at 37 C for two hours. 
The reaction was stopped by ice-cold PBS. Segregation of the non-soluble pre­
cipitate and supernatant was performed by centrifugation at 1600 g for 15 minutes 
in a cooled centrifuge. After the segregation of supernatant and pellet the radio­
activity of each was measured. Calculation of the rate of solubilization was per­
formed by the formula:
% CMSC = activi,y 0f “ I*™“ "1 X 100 
activity of supernatant + pellet
The CMSC value of the mixed healthy sera was always defined as 100% and the 
values of the samples were compared to this standard.
Measurement o f IPIC
Five/d 12oI labelled BSA solutions were measured into the polystirol tubes 
(«  1.5 gg BSA). Thereafter 100 /d of 1 : 2 dilutions of serum samples were 
added to each tube. The sera were diluted with PBS + +. Afterwards 10 gl of 
anti-BSA solution («  4 gg anti-BSA) was measured into each mixture. The 
tubes were incubated at 37 °C for one hour. The reaction was stopped by ice-cold 
PBS. Segregation of precipitated immune complexes from the supernatant which 
contained the small soluble complexes was performed by centrifugation at 1600 д 
for 15 minutes. After the separation of the supernatant and pellet, the radioactiv­
ity of each was counted. The concentrates of antigen and antibody solutions 
were adjusted to produce 80 — 85% IPIC values in mixed healthy sera and back-
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ground IPIC with buffer alone was less than 10%. Calculation of IPIC was per­
formed by the formula:
%  I P I C
activity of supernatant — C 
(activity of supernatant + pellet) — C
X 100
C = activity of supernatant of buffer control.
The IPIC value of mixed healthy sera was always defined as 100% and 
precipitation inhibition values of the serum samples were compared to this 
standard. Our method was an adoptation based on the method of Füst et al. 
(personal communication).
Measurement o f CH50 and C3 complement levels
The total haemolytic activity of classical pathway, (CH50), was measured 
according to Mayer [15]. Concentration of C3 was determined by single radial 
immundiffusion, using monospecific antiserum.
Measurement o f CIC levels
The levels of circulating immune complexes were measured by a comple­
ment test according to Johnson et al. [16].
Statistical analysis
The results were expressed as mean + standard deviation (SD). The 
analysis of results was performed with Student’s t test.
Results
In Table 1, the mean solubilization capacity of patients and the controls 
are shown. The CMSC values of samples from both low- and high-grade lympho­
mas were found to be significantly lower than that of healthy controls. In 
Table 1, the number of the samples which were decreased in each group are 
shown.
The precipitation inhibition values are summarized in Table 2. In the group 
of patients suffering from high-grade lymphomas, more than half of the serum 
samples showed decreased IPIC values. In the low-grade group only five samples 
out of 14 were found to be decreased. The mean of IPIC showed a significant 
decrease in the group of high-grade lymphomas.
The values of the total haemolytic activity of the classical complement 
pathway (CH50) are shown in Table 3. The mean of patients with high-grade 
lymphomas was significantly lower than that of controls. The eight patients with
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Table 1
The complement-mediated immune commplex solubilization capacity (CMSC) in
sera of patients
P atien ts D ecreased  + C M S C  %
High-grade lymphomas 6/14 77.50+ 16.72 p <  0.001
Low-grade lymphomas 4/14 85.50+ 14.99 p <  0.05
CLL 0/14 100.85+ 14.90 n. s.
Controls 0/30 95.13+8.74
n. s. =  not significant
+ =  number of levels below control’s mean - 2  SO
Table 2
The precipitation inhibition capacity (IPIC) in sera of patients
P atien ts D ecreased  + IP IC  %
High-grade lymphomas 8/14 85.64+ 12.23 p <  0.001
Low-grade lymphomas 5/14 93.62+ 9.16 p <  0.05
CLL 0/14 100.92+ 4.82 n .  S.
Controls 3/30 99.00+ 3.81
n. s. =  not significant 
+ =  number of levels below control’s mean - 2  SD
Table 3
The total haemolytic activity of the classical complement pathway (CH50) in
sera of patients
P atien ts D ecreased  ( < 4 9  C H 50/m l) СН50/Ш І
High-grade lymphomas 
(n =  14)
8/14 56.50+21.89 p <  0.001
Low-grade lymphomas 
(n =  14)
2/14 71.58+ 16.60 n .  S.
CLL 
(n =  14)
0/14 85.01+ 13.98 n .  S.
Control 
(n =  30)
2/30 79.37+ 14.92
n. s. =  not significant
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high-grade lymphoma and three patients with low-grade lymphoma had decreased 
values.
The mean values of the C3 complement levels are shown in Table 4. The 
mean values of high-grade and low-grade lymphomas were found to be signif­
icantly decreased, compared to the mean of controls. The number of values 
below 0.8 g/1 were 6 out of 14 in the high-grade group. In the low-grade group, 
only 1 out of 14 was decreased. The mean of this group is significantly lower 
because the normal range of C3 levels is relatively wide.
In Table 5, the values of CIC are summarised. Six out of 14 were elevated 
in the group of high-grade lymphomas and four of 14 in the group of low-grade 
lymphomas. The mean values of these two groups were significantly elevated 
as compared to that of controls.
P atients
D ecreased C3 levels
^  0 .80  g/1 g /i
High-grade lymphomas 6/14 0.63+0.19 p <  0.001
(n =  14)
Low-grade lymphomas 1/14 0.98+0.26 p <  0.01
(n =  14)
CLL 0/14 1.32+0.14 n. s.
(n =  14)
Control 0/14 1.29 + 0.24
n. s. =not significant
Table 5
The circulating immune complex level (CIC) in sera of patients
P atients C IC  %> 1 5 %
High-grade lymphomas 6/14 26.23+ 19.14 p <  0.001
(n =  14)
Low-grade lymphomas 4/14 14.25 +  7.72 p <  0.01
(n =  14)
CLL 0/14 3.43 +  2.48 n. s.
(n =  14)
Control 0/14 2.90 +  3.80
n. s. =  not significant
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Discussion
The prognosis of patients suffering from malignant lymphomas are relatively 
favourable in our days as a result of intensive therapeutic modalities. Successful 
therapy may result in remission, longer survival or sometimes recovery. The host 
resistance, which is impaired in these patients, permits frequent life-threathening 
infections, both during the active period of the disease and remission. The acquired 
deficiency of the complement system is a more important aspect of predisposition 
for serious infection and, on the other hand, causes disturbance in the immune 
complex metabolism. It is possible that failure of the complement-mediated 
immune complex formation results in more pathogenic complexes and may play 
a role in the development of immune complex diseases [4, 17, 21 ]. The syndromes 
based on immune complex mechanisms frequently appear in these patient groups. 
The acquired complement deficiency is well documented in CLL: defects in the 
early components of the classical pathway were found in some cases by other 
authors [18].
Increase in the circulating immune complex levels was frequent in lymphoid 
malignancy [19, 20]. The evaluation of this fact widely differs in literature. Some 
of the authors interpreted the elevated CIC levels as a prognostic factor [19, 20, 22], 
while others failed to observe a close correlation between the worse prognosis 
and a higher CIC level. It seems that the elevated CIC levels do not correlate 
directly with disease activity but mean first of all the deficiency of complement 
functions. These impaired functions may cause defects in actual host resistance, 
different syndromes based on the immune complex pathomechanisms and may 
result indirectly in a poorer prognosis by itself.
The measurement of solubilization and precipitation inhibition capacity 
are simple, reliable, reproducible and does not require expensive complement 
technology. These two methods were worked out earlier as diagnostic methods 
in the search for autoimmune diseases [10, 14, 17]. It was found that these assays 
appeared to be better methods for the early indication of disease activity than 
the measurement of CIC levels [8, 14, 17].
Our recent results indicate that the acquired deficiency of complement 
functions can be established by CMSC and IPIC measurement in the sera of 
patients with high-grade non-Hodgkin’s lymphomas even in time of remission. 
These defects were found to be milder in the group of low-grade lymphomas and 
were not detectable in the group of patients with CLL. The defective complement 
functions or decreased levels of early complement components were reported 
by the authors on close to half of the patients with CLL [18, 23, 24], but our 
results did not show the same frequency as theirs. The difference appeared 
because our CLL group was selected under strict criteria: they were in the 0 and 
1 Rye stage. We have not yet measured the levels of those components, but in 
the functional tests like CH50 or IPIC the smaller decreases of the components 
are moderately balanced. Our results indicate that these defects may be more 
frequent in the types of lymphoma which show higher malignancy. The change
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of CH50 levels was found to be similar to that of IPIC values, and the decrease 
in C3 levels was detectable in the high-grade and low grade lymphomas, too. 
Elevated CIC levels were observable in those cases in which both CMSC and 
IPIC were decreased. The causes of decreased solubilization and precipitation 
inhibition capacity are more complicated in lymphomas than they are in auto­
immune diseases. The depressed protein synthesis and toxic effects of the tumor 
or the treatment are associated with complement consumption which can appear 
during the immune complex formation and the elimination of infective agents.
These recent examinations were carried out in the remission period of the 
disease. These results would serve as a basis for our following investigations in 
time of disease activity and for measurement of therapeutic effect on these param­
eters. Our conclusion is that the solubilization and precipitation inhibition 
capacity can be used as prognostic factors during the course of malignant lympho­
mas. There is another important aspect of determining the impaired complement 
function: it could be substituted by using fresh, active complement containing 
plasma at the time of infection and to prevent serious acute inflammations due 
to immune complexes.
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Haemolytic Disease of Two Newborns in a Rhesus Anti-e 
Alloimmunized Woman. Review of Literature
P. M oncharmont*, F. J uron-D upraz, D. R igal, M. Vígnál,
F. M eyer
Centre Régional de Transfusion Sanguine de Lyon, Pavilion H, Hôpital E. 
Herriot, Place d’Arsonval, 69374 Lyon, France
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Haemolytic disease of the newborn (HDN) due to Rhesus anti-e alone is 
rarely observed in the Caucasian population. We report here a case of an R2R2 
mother who had never been transfused and whose two children had a mild HDN 
without transfusion or blood exchange transfusion (BE) after delivery.
Keywords: anti-e, pregnancy, haemolytic disease, newborn infants
Introduction
In 1944, Mclvor and Lucia [1] described the first case of HDN due to 
Rhesus anti-e antibody. Since then, few cases of HDN with anti-e antibody have 
been reported (Table 1). HDN with anti-e antibody is rarely encountered. In fact,
Table 1
Cases of anti-e alloimmunization alone observed in pregnant women with 
haemolytic disease of the newborn
A uthors Sex
A ssum ed
g eno type D A T BE
Clinical
ou tcom e
Pettenkofer et al. 
(1953)
female CDE/cde + No good
Von Bresgen et al. 
(1956)
male cDE/cde + Yes death
Pepperel et al. 
(1977)
Hanzlick and
+ No good
Senhauser (1979) 
Chapman and
male CDe/cDE + No good
Waters (1981) female cDE/cde + No good
* Correspondence: P. Moncharmont, CRTS-Lyon, B. P 401 Beynost, F-01700 Miribel,
France
3 * VSP, U trecht, T okyo
A kadém ia i K iadó, Budapest
98 P. Moncharmont et al.: Anti-e haemolytic disease o f  the newborn
in their study of 72,138 mothers, Pepperell et al. [2] found only one pregnancy 
with anti-e alloimmunized patient and positive direct anti-human globulin test 
(DAT) on cord blood of the baby. One case of mild HDN was observed by 
Hanzlick and Senhauser [3] and recently by Chapman and Waters [4].
We report here two cases of HDN due to anti-e in a family where the mother 
had not been transfused previously.
Materials and Methods
Standard methods (enzyme treated red blood cells (papain), anti-human 
globulin test in low ionic strength saline and polybrene autoanalyzer), according 
to AABB methods [5] were used for detection and titration of the alloantibodies 
in maternal serum and cord blood. Haemoglobin, bilirubin and the Liley index 
were evaluated by spectrophotometry.
Case Report
A Caucasian woman, Mrs. ROD . . .  born in 1946 in Poland whose blood 
group was AB Rhesus positive (cDE/cDE) has never been transfused. The hus­
band’s blood group was 0 Rhesus positive (CDe/CDe). In 1967, she became pregnant 
and a boy was born at 38 weeks of pregnancy. Seven years later, after a second 
pregnancy without complications, a girl was born at 37 weeks of pregnancy. No HDN 
was observed in these two newborn infants. Furthermore, no transfusion or BE 
was required after delivery. In 1977, during the third pregnancy, she had a
Tabic 2
Detection of anti-e with three methods and evolution of titre during the fifth
pregnancy
W eeks o f 
p regnancy
M ethods
P apain  trea ted  
red  b lood  
cells
A nti-hum an  
globulin  test
P o lybrene
au to an a ly zer
10 + ( і б ) — +
17 +  (3 2 ) - +
2 3 +  0 6 ) +  ( і б ) +
2 7 +  (3 2 ) +  ( і б ) +
3 2 +  ( N D ) +  (6 4 ) +
35 +  ( 1 2 8 ) +  ( 1 2 8 ) +
( ) =  titre; ND =  not determined
H aem ato log ia  23, 1990
P. Moncharmont et al.: Anti-e haemolytic disease o f  the newborn 99
Table 3
Evolution of bilirubin concentration in serum after delivery of the fourth child
Time after 
delivery (h r)
C oncen tra tion
Gumol/l)
0 48
4 75
20 115
28 140
48 158
72 225
96 182
spontaneous abortion at 8 weeks of gestation. In 1978, during the fourth preg­
nancy, by the 27th week of gestation, an alloantibody anti-e was detected with 
the three methods, and its titer was 32 in anti-human globulin test. At 32 weeks 
of pregnancy, the anti-e alloantibody was again found with the three methods 
and its titre rose weakly to 64 in anti-human globulin test. Examination of the 
amniotic fluid showed that the Liley index values were 0.02 and 0.01 at 32 and
35 weeks of pregnancy, respectively. At 38 weeks of pregnancy, after spontaneous 
delivery, a girl was born and her blood group was A Rhesus positive (CDe/cDE. 
On cord blood, the DAT was positive( + ), bilirubin and haemoglobin were
36 /miol/1 and 165 g/1 respectively. The outcome of this HDN was good and 
no BE or transfusion was needed. In 1981, during the fifth pregnancy, the anti-e 
was still detected in maternal serum. The variations of anti-e titre are shown in 
Table 2. The Liley index was determined three times during this pregnancy and 
their values were 0.022, 0.014 and 0.01 at 32, 35 and 38 weeks, respectively. In 
December 1981, a girl was born and her blood group was found to be B Rhesus 
positive (CDe/cDE). On cord blood, DAT was positive( +  ), bilirubin and haemo­
globin were 48 /unol/1 and 190 g/1 respectively. The evolution of bilirubin con­
centration is reported in Table 3. No BE or transfusion was required.
Discussion
This report describes a case of an alloimmunized mother with anti-e anti­
body alone and whose two babies presented a positive DAT on cord blood and 
a mild HDN. The mother had never been transfused and the only immunizing 
stimulus was previous pregnancies. HDN due to anti-e antibody alone is rarely 
observed in the Caucasian population. This phenomenon can be explained partly 
by the high incidence of the Rhesus-e antigen in this population and partly by
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the relatively low potency immunogenicity of this antigen [6]. In fact, Hanzlick 
and Senhauser [3] reported a case of a newborn infant with a haemolytic disease 
due to an anti-e antibody with good outcome. Similar data are given by Chapman 
and Waters [4] and Pepperell et al. [2]. Nevertheless, Bresgen et al. [7] have 
observed an HDN due to anti-e antibody with the death of the child despite BE. 
In the present case, the anti-e antibody titre rose slightly during the fourth preg­
nancy and markedly during the fifth pregnancy (Table 2). Despite this increase, 
the Liley index values did not suggest foetal damage. Further, no BE or trans­
fusion was required for these two newborn infants after delivery. This observation 
agrees with the data of Hanzlick and Senhauser [3] who have observed a HDN 
in a first baby and probably in a second without transfusion or BE in an anti-e 
alloimmunized woman.
In conclusion, this report confirms that HDN due to anti-e antibody alone 
remains generally mild even after some pregnancies with antigenic stimulus and 
after a first case of HDN in the family.
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Defective CS А-Dependent Granulopoiesis in Patients with 
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Colony stimulating activity (CSA) and granulocyte-macrophage progenitor 
cells (GM-CFC) were assayed in the bone marrow and peripheral blood of 17 patients 
with drug-induced chronic neutropenia. Leukocyte-derived and monocyte/macrophage- 
derived CSA from the neutropenic patients was found to be singnificantly decreased 
compared to normal control. However, bone marrow and peripheral blood GM-CFC 
were within normal limits. These data suggest that in neutropenic patients monocyte/ 
macrophages exhibit most likely a qualitative defect in CSA production, which may 
account at least in part, for the impaired granulopoiesis observed in drug-induced neu­
tropenia.
Keywords: GM-CFC, CSA, neutropenia, granulopoiesis
Introduction
Chronic neutropenia is a term used to describe a heterogeneous group of 
disorders with reduced numbers of circulating neutrophils for prolonged periods 
of time, without any evidence of an underlying disease known to be associated 
with granulocytopenia. Infantile genetic agranulocytosis, chronic idiopathic 
neutropenia, autoimmune neutropenia, chronic hypoplastic neutropenia and 
drug-induced chronic neutropenia, are included in this group of disorders [1 — 5]. 
Efforts to clarify the mechanism of granulocytopenia in these disorders have 
yielded very limited information so far.
In the present study we summarize our observations on some parameters 
of granulopoiesis in a group of patients with drug-induced chronic neutropenia.
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Materials and Methods
Seventeen neutropenic patients (4 males and 13 females) aged 15 to 68 
years were included in this study (Table 1). The patients fullfilled the following 
criteria: 1) Circulating neutrophils <1.700/^1 of blood; 2) No concomittant 
monocytosis; 3) Bone marrow myeloid : erythroid ratio equal or <3 : 1; 4) Per­
centage of morphologically recognized proliferating granulocytic cells (prolif­
erating pool) <25% of the total number of nucleated marrow cells; 5) Per­
centage of marrow non-proliferating granulocytic cells (maturation pool) <35%; 
6) Absence of splenomegaly; 7) No evidence of any underlying disease known 
to be associated with neutropenia; 8) No previous exposure to irradiation or use 
of cytotoxic drugs; 9) Negative leuko-agglutination test; 10) No evidence of 
familial or cyclic neutropenia, and 11) Absence of increased sensitivity to bacterial 
infections.
Table 1
Clinical data of the 17 neutropenic patients
C ase
« A ge/sex D ru g s  received
D u ra tio n
(m o n th s)
l 49, M Dipyrone, aminopyrine 4
2 62, F Ibuprofen 3
3 34, F Indomethacine, sulindac, meprobamate, 
diazepam
6
4 50, F Carbimazole, diazepam, dipyrone, 
insecticides
3
5 62, F Indomethacine, phenylbutazone 4
6 50, F Lorazépam, diazepam 10
7 23, F Oxyphenbutazone 4
8 68, M Phenylbutazone, dipyrone, ampicillin, 
insecticides
18
9 48, M Ergoloid mesylates, dipyrone 6
10 47, F Trimethoprim-sulfasoxazole, dipyrone 10
11 56, F Ibuprofen, diazepam 10
12 50, F Diazepam, dipyrone 2
13 54, F Carbimazole 5
14 55, F Diazepam 8
15 15, M Carbamazepin 11
16 60, F Sulindac 7
17 40, F Diazepam, dipyrone 2
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Table 2
Distribution of bone marrow granulocytic cells in neutropenic patients and
normal controls
P ro life ra tin g  M a tu ra tio n  M ean
p o o l1 p o o l2 M yeloid/
------ — - E ry th ro id
( %) ratio
Patients 19.2+ 1.2 31.7+2.2 1.93
(n =  17) (n =  17)
Controls 17.0-28.0 35.0-50.0 3.00
1 Blast cells, Promyelocytes and Myelocytes
2 Metamyelocytes, Stab cells and PMNs
All patients had previously received one or more non-cytotoxic drugs 
and/or had been exposed to insecticides, as shown in Table 1. In most cases 
these compounds had been used for a period ranging between a few days 
and several months. The use of drugs and the contact with the insecticides had 
been discontinued at least two months before the study. Based on the above 
criteria and the previous history of the patients (Table 2), we classified their 
neutropenic state as drug-induced, although the causes of neutropenia might 
not have been necessarily uniform.
Preparations o f Cell Suspensions
Unfractionated peripheral blood leukocytes (UF PBL) were obtained by 
allowing heparinized venous blood to settle at room temperature for 1—2 hours. 
The separated leukocyte-rich plasma was then removed and the leukocytes were 
used either for preparation of stimulating soft-agar underlayers (see below), 
or as target cells for colony formation.
Unfractionated bone marrow cell suspensions (UF BMC) were obtained 
as above. Following centrifugation, the buffy coat was removed and the marrow 
cells were suspended in supplemented MacCoy’s 5A medium containing 5% 
fetal calf serum (FCS).
Suspensions of non-adherent light density cells (LDNA) were prepared 
from peripheral blood or bone marrow light density mononuclsar cells (LD) 
isolated by the Ficoll/Hypaque method. 5 x 106 peripheral blood or bone marrow 
LD cells were placed into Petri dishes (Falcon Plastics, Los Angeles Ca.) with 
2 ml of supplemented MacCoy’s 5A medium-5 % FCS and were incubated for 
two hours in a fully humidified incubator of 37 °C and 7.5% C 02 in the air. 
The non-adherent LD cells were collected by washing the plates twice, cen­
trifuged, tested for viability and resuspended in medium. Approximately 95% of 
LDNA cells obtained by this procedure, were small lymphocytes.
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Preparation o f Monocyte/Macrophage Conditioned Medium
One ml of supplemented MacCoy’s 5A medium containing 15% FCS [6] 
was added to each Petri dish, immediately after the removal of LDNA cells. 
Light density cells (LDAC) adhering to the bottom of the plates were then sub­
mitted to a further incubation for 5 days in the humidified incubator. Afterwards, 
the supernatant fluid, called monocyte/macrophage conditioned medium (MoCM) 
was collected, centrifuged, filtered and stored at — 20 °C until used. The number 
of LDAC per plate was determined by the difference between LD cells initially 
plated and LDNA cells recovered after washing of the dishes. Approximately 
98 % of LDACs obtained by this method were esterase positive and were either 
monocytes or macrophages.
Assays for Colony Formation
All assays for colony formation by UF BMC, UF PBL or LDNA cells 
were performed in triplicate in 35 x 10 mm Petri dishes (Falcon) according to 
the method of Pike and Robinson [6]. 106 normal UF PBL in underlayers were 
used as source of exogenous colony-stimulating activity (CSA). After 10-12 
days of incubation all clusters containing over 50 cells were counted as colonies. 
Cellular composition of picked-olf colonies was determined after staining with 
0.6% orcein in 60% acetic acid.
Assays for Colony-Stimulating Activity (CSA)
Leukocyte-derived CSA was assayed by incorporating 10e UF PBL in 
underlayers of 1 ml of 0.5% agar in supplemented MacCoy’s 5A medium con­
taining 15% FCS into Petri dishes. These underlayers were tested for CSA against 
10° normal UF PBL suspended in 1 ml of 0.3% agar-medium overlayers. Colonies 
were counted after 10 — 12 days of incubation.
Monocyte/macrophage-derived CSA in conditioned medium was deter­
mined by the method of Pike and Robinson [6], slightly modified. 0.15 ml of 
MoCM were placed into Petri dishes and were tested for CSA against normal 
GM-CFC.
Results
Bone marrow granulocyte/monocyte colony forming cells (GM-CFC) of 
the neutropenic patients are shown in Table 3. In cultures stimulated with exo­
genous CSA, no statistically significant differences were observed between the 
neutropenic and the control group. In unstimulated cultures, colony formation 
was noted in 1 out of 7 patients and in 5 out of 9 normal subjects, when 
UF BMC were tested for autostimulation. These distributions were not statis­
tically significant. Autostimulation was not observed in either group, when LDNA 
BMC were cultured in vitro.
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G M -C F C /1 0 5 U F  B M C 1 G M -C F C /0 .2 5 X  105 L D N A  B M C 1
W ithou t W ith W ith o u t W ith
exogenous exogenous exogenous exogenous
CSA CSA 2 CSA C S A 2
Patients 0. 2 +  0 .2 35.5+3.1 0 49.8+4.6
(n =  7) (n =  17) (n =  8) (n =  9)
Controls 1.7+0.7 31.7+4.3 0 44.3+5.3
(n =  9) (n =  11) (n =  6) (n =  6)
1 Values expressed as means +  1 SEM.
2 10° UF PBL taken always from the same normal donor were used as source of 
exogenous CSA.
Table 4 shows the numbers of GM-CFC in patients’ peripheral blood. 
In cultures stimulated with exogenous CSA, a statistically significant difference 
(p < 0.05) was found between GM-CFC values of the two groups, when UF 
PBL were tested. However, this difference was not observed when LDNA PBL 
were cultured in vitro, under the same experimental conditions. In unstimulated 
cultures, colony formation was noted in 2 out of 9 patients and in 5 out of 19 
normal subjects when UF PBL were tested for autostimulation (data not shown). 
These distributions tare not statistically significant at the level of 5%.
Analysis of the type of colonies which were formed in vitro by patients’ 
GM-CFC, did not reveal any statistically significant differences compared to 
those of the controls.
The capacity of patients’ UF PBL to stimulate colony formation by normal 
GM-CFC was found to be significantly impaired compared to the control group
G M -C F C /1 0 8 U F  P B L 1 G M -C F C /0 .25І ХІ 0 8 L D N A  P B L 1
W ithou t
exogenous
CSA
W ith
exogenous
CSA 2
W ithou t
exogenous
CSA
W ith
exogenous
C S A 2
Patients 0.2 + 0.1
(n =  9)
34.2+2.9 
(n =  17)
0
(n =  9)
60.1+5.6 
(n =  11)
Controls 0.5+0.2 
(n =  19)
27.9+ 1.6 
(n =  47)
0
(n =  21)
49.7+4.5 
(n =  21)
1 Values expressed as means +  1 SEM.
2 10® UF obtained always from the same normal donor, were used as source of exoge­
nous CSA.
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Peripheral blood GM-CFC in neutropenic patients and normal controls
Table 3
Bone marrow GM-CFC in neutropenic patients and normal controls
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Table 5
CSA capacity of UF PBL in neutropenic patients and normal controls
C olonies . j D egree o f
p e r  10e U F  P B L 1 a UC Significance
Patients 21.1+2.5 2.73 p<0.01
(n =  15)
Controls 28.4+1.4 -  -
(n =  31)
1 10e normal UF PBL were used as target cells. Values are expressed as means +  1 SE.
Table 6
Monocyte/macrophage-derived CSA in conditioned medium in neutropenic 
patients and normal controls
N um ber o f  
LD  cells 
p la ted 1
M ean  num ber 
o f  L D A C
(X  10e)
C o lon ies2
P er 0.15 ml 
o f  CM
P er 10e L D A C  
in  1 m l CM
Patients 5x 10° 1.4+0.1 15.6+2.9 59.7+ 12.03
(n =  11) (n =  13) (n =  11)
Controls 5x 10° 1.6+0.3 28.0+3.1 116.8+ 11.33
(n =  6) (n =  7) (n =  6)
1 In each case, 3 to 5 Petri dishes were used.
2 10° normal LD PBL obtained always from the same donor, were used as target cells. 
The values are expressed as means +  1 SE.
3 Statistically significant difference between patients’ and controls’ values at the level 
of 1%.
(p < 0.01) as shown in Table 5. Additionally, a statistically significant decrease 
(p < 0.01) in patients’ LDAC-derived CSA in conditioned medium was docu­
mented, as shown in Table 6. The latter finding is not due to a subnormal number 
of adherent cells of the patient group, since the mean numbers of LDAC that 
remained at the bottom of Petri dishes, after the removal of LDNA cells, did not 
differ significantly from the control.
Finally, attempts to establish any correlation between patients’ GM-CFC 
or CSA to some of the hematologic parameters, failed to demonstrate a statis­
tically significant dependence of leukocyte-derived CSA from the number of 
circulating monocytes (r =  0.165) or the number of leukocytes (r =  0.025). 
Similarly, no statistical significant relationship was found between bone marrow 
GM-CFC and the marrow granulocyte proliferating pool (r = 0.48) or the 
number of stab cells and mature neutrophils (r = —0.06).
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Discussion
It is well established that granulopoiesis involves interactions between 
non-proliferating cells producing regulatory factors and proliferating cells which 
respond to these factors [7]. In humans, monocytes/macrophages [6, 8 — 11], 
lymphocytes [10, 12], endothelial cells [13] and some other stromal cells [14] 
have already been recognised as the most important microenvironmental com­
ponents producing stimulatory factors, i.e. CSA. Granulocyte/macrophage pro­
genitor cells (GM-CFC) and morphologically identifiable granulocytic precursor 
cells are capable of responding to CSA and enhance their proliferation and 
maturation rate [14—15]. The system is under the control of several inhibitors 
of granulopoiesis, such as prostaglandins [16—17], interferons [18 — 19] or 
lactoferrins [20].
The data presented here indicate that CSA production by monocyte/macro- 
phages is defective in patients with drug-induced chronic neutropenia. Both 
UF PBL in underlayers and monocyte/macrophage-derived CSA in conditioned 
medium from the neutropenic patients, were less capable of stimulating colony 
formation on normal GM-CFC compared to the normal control group. These 
findings are not due to quantitative differences in monocytes in the underlayers, 
since the absolute number of patients’ monocytes in 10° UF PBL seeded in under­
layers was equal to or higher than that of the control underlayers. Additionally, 
the number of monocyte/macrophages (LDAC) was adjusted when CSA in 
conditioned medium was studied (Table 6). It is conceivable that the low CSA 
values in our patients should be related to some qualitative abnormality of CSA- 
producing cells. Whether this abnormality is a result of a direct effect of the drug 
on the intracellular CSA-producing system of monocyte/macrophages or related 
to some alterations on CSA production directly [21] or indirectly [17, 22 — 23] 
remains unclear. It is noteworthy that the levels of serum CSA and of several 
inhibitors of granulopoiesis in the group of neutropenic patients were within 
normal limits (data not shown). Decreased CSA values in leukocyte-derived and 
in LDAC-derived MoCM were observed in 2 out of 6 patients with various types 
of chronic neutropenia [24]. Decreased CSA concentrations in bone marrow 
LDAC-derived MoCM have been also documented in 41 patients with chronic 
idiopatic neutropenia [25].
Colony-forming capacity of patients’ BMC and PBL was within normal 
limits. Randomly selected colonies from patients’ cultures showed a normal 
pattern of differentiation of GM-CFC to mature granulocytic forms. These 
observations indicate that neutropenia in patients with drug-induced chronic 
neutropenia is not associated to an inherent abnormality of GM-CFC for prolif­
eration or differentiation. Normal levels of GM-CFC in peripheral blood and 
bone marrow have been found in 9 patients with chronic neutropenia due to non- 
cytotoxic drugs as in our group [5]. Furthermore, in cases of chronic idiopathic 
neutropenia, marrow and peripheral blood GM-CFC were either normal or 
slightly increased [25—26].
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Although the mechanism of overall regulation of granulopoiesis has not 
been elucidated entirely yet, it is conceivable that patients with macrophages 
defective for production of CSA in sufficient amounts, might potentially become 
neutropenic [24]. It has been shown that little triggering is enough to stimulate 
stem cell proliferation and differentiation [27], while proliferation, differentiation 
and maturation of morphologically recognizable granulocytic precursor cells 
requires higher concentrations of the inducer stimulus [15]. If this is the case, 
it is possible that in low concentrations of CSA, the bone marrow maturation 
pool of granulocytic series would be decreased e.g. ‘maturation arrest’. In our 
patients with low CSA values, the maturation pool was below the lower level of 
the normal range (Table 2), while the proliferating pool and GM-CFC values 
were within normal limits (Tables 2 and 3). Thus, one could postulate that in 
patients with drug-induced chronic neutropenia, granulopoiesis is regulated at 
a lower level compared to normal, most probably as a result of inadequate amounts 
of functional CSA liberated by macrophages into the hematopoietic micro­
environment.
References
1. Kostmann, R.: Infantile genetic agranulocytosis. Acta Paediatr. Scand. 45, (Suppl. 105)
1 (1956).
2. Butler, J. J.: Chronic idiopathic immunoneutropenia. Am. J. Med. 24, 145 (1958).
3. Kyle, R. A., Linman, J. W.: Chronic idiopathic neutropenia. N. Eng. J. Med. 279, 1015
(1968).
4. Boxer, L. A., Greenberg M. S., Boxer, G. J., Stossel A. P. : Autoimmune neutropenia.
N. Engl. J. Med. 293, 748 (1975).
5. Dale, D., Guerry, D., Wewerka, J., Bull, J., Chusid, M.: Chronic neutropenia. Medicine
58, 128 (1979).
6. Pike B., Robinson W. A. : Human bone marrow colony growth in agar gel. J. Ceil Physiol.
76, 77 (1970).
7. Metcalf, D. : The molecular biology and functions of the granulocyte-macrophage colony-
stimulating factors. Blood 67, 257 (1986).
8. Chervenik, P. A., LoBuglio, A. F. : Human blood monocytes: stimulation of granulocyte
and mononuclear colony formation in vitro. Science 178, 164 (1972).
9. Moore, M. A. S., Williams, N., Metcalf, D.: In vitro colony formation by normal and
leukemic hematopoietic cells. Interaction between colony-forming and colony-stimulat­
ing cells. J. Nat. Cancer Inst. 50, 591 (1973).
10. Shah, R. G., Caporale, L. H., Moore, M. A. S.: Characterization of colony-stimulating
activity produced by human monocytes and phytohemagglutinin-stimulated lympho­
cytes. Blood 50, 811 (1977).
11. Mahmood, T., Robinson, W. A.: Granulocyte modulation of endotoxin-stimulated
colony-stimulating activity (CSA) production. Blood 51, 879 (1978).
12. Privai, J. T., Paran, M., Gallo, R. C., Wu, A. M.: Colony-stimulating factors in cultures
of human peripheral blood cells. J. Nat. Cancer. Inst. 53, 1583 (1974).
13. Knudtzon, S., Mortensen, B. T. : Growth stimulation of human bone marrow cells in
agar culture by vascular cells. Blood 46, 937 (1975).
14. Metcalf, D., Foster, R.: Bone marrow stimulating activity of serum from mice with viral-
induced leukemia. J. Nat. Cancer Inst. 39, 1235 (1967).
15. Metcalf, D.: “Hemopoietic colonies” Berlin: Springer-Verlag, 1977, p. 70.
H aem ato log ia  23, 1990
G. Eliopoiilos et al.: CSA defect in drug-induced chronic neutropenia 109
16. Snyder, D., Beller, D., Unanue, E. : Prostaglandins modulate macrophage la expression.
Nature 299, 163 (1982).
17. Kurland, J. I., Broxmeyer, H. E., Peius, L. M., Bookman, R. S., Moore, M. A. S.: Role
for monocyte-macrophage derived colony stimulating factor and prostaglandin E in 
the positive and negative feedback control of myeloid stem cell proliferation. Blood 52, 
388 (1978).
18. Broxmeyer, H. E., Lu, L., Platzer, E., Feit, C., Juliano, L., Rubin, B.: Comparative
analysis of the influences of human gamma, alpha and beta interferons on human 
multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage 
(CFU-GM) progenitor cells. J. Immunol. 131, 1300 (1983).
19. Greenberg, P. L., Mosny, S. A.: Cytotoxic effects of interferon in vitro on granulocytic
progenitor cells. Cancer Res. 37, 1794 (1977).
20. Broxmeyer, H. E., Ralph, P., Bognacki, J., Kincade, P., Dedousa, M.: A subpopulation
of human polymorphonuclear neutrophils contains an active form of lactoferrin 
capable of binding to human monocytes and inhibiting production of granulocyte- 
macrophage colony stimulatory activities. J. Immunol. 124, 903 (1980).
21. Keltőn, J. G., Huang, A. T., Mold, N., Logue, A., Rosse, W. F.: The use of in vitro
techniques to study drug-induced pancytopenia. N. Engl. J. Med. 301, 621 (1979).
22. Nelson, J., Lutton, J., Fass, A.: Procainamide-induced agranulocytosis with reversible
myeloid sensitivity. Am. J. Hematol. 17, 427 (1984)
23. Heit, W., Kern, P., Heimpel, H., Kubanek, B.: Granulocyte colony forming cells in vitro:
I. Patients with drug-induced agranulocytos. Blut 34, 403 (1977).
24. Senn, J., Messner, H., Stanley, R.: Analysis of interacting cell populations in culture of
marrow from patients with neutropenia. Blood 44, 33 (1974).
25. Greenberg, P. L., Mara, B., Steed, S., Boxer, L. : The chronic idiopathic neutropenia
syndrome. Correlation of clinical features with in vitro parameters of granulopoiesis. 
Blood 44, 915 (1980).
26. Rickard, K. A., Brown, R., Yuen, E., Kronenberg, H.: Chronic idiopathic neutropenia.
Granulopoietic assessment by bone marrow culture and granulocyte kinetics. Am. J. 
Hematol. 9, 193 (1980).
27. Lahiri, S. K. : Kinetics of hemopoietic recovery in endotoxin-treated mice. Cell Tissue
Kinet. 9, 31 (1976).
H aem ato lo g ia  23, 1990

Haematolog іа 23 (2), pp. ! II — 120 (1990)
Comparison of Some Lymphocyte Markers 
in B-cell Chronic Lymphocytic Leukaemia 
and Systemic Lupus Erythematosus 
(The B Lymphocyte Subset)
T. Magyarlaki, H. Losonczy, A. Pár
Department of Pathology, 1st Department of Medicine, University Medical School
of Pécs, Szigeti u. 12,
H-7643 Pécs, Hungary
(Received 18 July, 1988; accepted 17 March, 1989)
Spontaneous mouse red-cell rosette formation (M-rosette), Leu 1 (CD 5) mono­
clonal antibody binding, ecto-nucleotidase enzyme reactions and mitogen responses 
of peripheral blood lymphocytes in 10 patients with B-cell chronic lymphocytic leu­
kaemia (CLL), in 8 with systemic lupus erythematosus (SLE) and in 10 controls were 
studied.
The numbers of Leu 1 (CD 5) positive B lymphocytes in CLL and SLE were 
higher than in controls. These are called ’’autoregulatory” B lymphocytes, which are 
thought to be independent of T-cell regulatory effects. A significant increase of mouse 
rosette forming cells (MRFCs) was found in CLL, while in SLE and in controls their 
number was low.
Compared to the B lymphocytes of SLE patients and controls, those of CLL 
patients showed diminished responses to pokeweed mitogen stimulation parallel to 
their decreased level of 5’-nucleotidase.
Correlations between these markers and the features of isolated M-rosette 
positive CLL B lymphocytes are discussed.
Keywords: B-cell chronic lymphocytic leukaemia, systemic lupus erythemato­
sus, M-rosette, Leu 1 (CD 5), 5’-nucleotidase, pokeweed mitogen responses, auto­
regulatory B lymphocytes
Introduction
Cells forming mouse red-cell rosettes spontaneously (MRFCs) represent a dis­
tinct population of B lymphocytes in the peripheral blood of CLL patients [5, 10]. 
MRFCs show diminished pokeweed mitogen responses and secrete autoanti­
bodies of the IgM type characteristic of autoimmune disorders [8, 18, 29]. This 
explains similarities between MRFCs and the so-called “autoregulatory” B 
lymphocytes described by some authors [18, 32].
Leu 1 (CD 5) monoclonal antibody detects a lymphocyte membrane glyco­
protein originally thought to be specific to mature T lymphocytes. Leu 1 (CD 5) 
can also be expressed by foetal spleen B lymphocytes and some B-cell lymphomas,
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especially by CLL B lymphocytes [1, 2, 16]. Leu 1 (CD 5) positivity indicates 
either immaturity of the B lymphocytes or the presence of a distinct subpopula­
tion equivalent to “autoregulatory” B lymphocytes [6, 19].
5’-nucleotidase (5’-NU-ase) and adenosine triphosphatase (ATP-ase) are 
lymphocyte surface enzymes (ectoenzymes) of purine nucleotide metabolism [7, 
9]. 5’-NU-ase activity is lower and ATP-ase activity is higher in CLL patients 
than in controls [11, 17]. The expression of 5’-NU-ase shows some correlation 
with cell maturation, i.e. in mitogen stimulated lymphocytes and myeloma cells 
5’-NU-ase activity is higher than in immunodeficiencies and CLL [20, 23, 25, 28].
Pokeweed mitogen stimulation (PWM) results in polyclonal activation of 
B lymphocytes dependent on T-cell regulatory effects [15, 30]. Decreased PWM 
responses can be detected in CLL and in isolated MRFCs [18, 26]. Results of 
PWM responses in SLE are contradictory as both hyporeactivity and hyper­
reactivity of B lymphocytes have been reported [8, 30]. Above markers are widely 
studied in haematological disorders and in autoimmune diseases, especially in 
CLL and SLE.
B-cell chronic lymphocytic leukaemia (CLL) as a clonal proliferation of 
B lymphocytes is known to be a relatively slowly progressing lymphoproliférative 
disorder. The immature CLL B lymphocytes fail to develop into mature immuno­
globulin secreting plasma cells. The exact mechanism of this maturation defect, 
the role of B-T-cell interactions, the immunoregulatory role of T lymphocytes 
in this condition has been widely discussed by several authors [4, 6, 14, 21, 22]. 
Primary immunoregulatory anomalies of B lymphocytes independent of T-cell 
regulatory effects have also been suggested. B lymphocytes in CLL expressed 
Leu 1 (CD 5) and M-rosette positivity [4, 9, 11, 26]. 5’-NU-ase and PWM re­
sponses are diminished in CLL [11, 17, 26].
Systemic lupus erythematosus (SLE) is a polysystemic autoimmune disease 
associated with autoantibodies secreted by polyclonally activated B lympho­
cytes [27, 30]. The role of regulatory T lymphocyte subsets in SLE is well estab­
lished (decreased level of suppressor T cells, T helper cell hyperreactivity) [12, 13, 
24]. It is known that in SLE B lymphocytes may be expressed by Leu 1 (CD 5), 
M-rosette positivity [8, 19] and anomalous functions [32] characteristic of “auto­
regulatory” B cells.
In the present study we compared some markers of peripheral blood lympho­
cytes in 10 patients with CLL, in 8 with SLE and in 10 controls. Correlation 
between the markers, co-expression and disease specificity are discussed.
Materials and Methods
Patients: The diagnosis of CLL in 8 males and 2 females was based on 
lymph node biopsies, bone marrow and blood studies in 9 cases (7 pseudofol- 
licular, 2 of diffuse type) and in one case on bone marrow and blood tests. The 
white blood cell count (WBC) was 11.0-45.0 G/l, the ages of the patients ranged
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between 43 and 81 years (median age 66.8). At the time of the study 3 of the 
patients were in stage Rai I, and 7 in Rai II. None of them had received treatment 
during the last six months. The diagnosis of SLE in 2 males and 6 females was 
based on the ARA (American Rheumatic Association) criteria [29]. Four patients 
had been treated with 10-15 mg Prednisolone daily, but not in the last six months. 
Their ages varied between 35 and 65 years (median age 39.5). The WBC was 
3.0-7.0 G/l. The ages of the 10 controls varied between 26 and 40 years (median 
age 31.5). Both sexes were represented in controls (6 males, 4 females). These 
patient groups were not age- and sex matched because of the clinical nature of 
these diseases.
Isolation of the cells: Lymphocytes were isolated from heparinized venous 
blood of CLL, SLE patients and controls by Ficoll-PaqueR (Pharmacia) gradient 
centrifugation. After removing monocytes by their plastic adherence, T and non- 
-T lymphocytes were separated from each other on a Ficoll gradient based on 
their rosette forming capacity with 2-aminoethyl-isothiuroniumbromide (AET) 
pretreated sheep erythrocytes (E-rosette). After removing attached sheep ery­
throcytes by 0.83% ammonium-chloride lysis, the E-rosette positive cells 
(“T lymphocytes”) were further separated into TG-positive and TG-negative 
cells (“T suppressor” and “T helper lymphocytes”) by the anti-ox-IgG antibody- 
-rosette (TG-rosette) method [22]. The E-rosette negative cells (“ B lymphocytes”) 
were further separated into M-rosette positive and M-rosette negative subsets 
using CBA mouse erythrocytes [18].
Cell cultures: Isolated subsets (E+, E~, TG+, TG_, MRFCs and M-rosette 
negative cells) were cultured ( 2x l 06 cell/ml in RPMI 1640, Wellcome) with 
5 pi pokeweed mitogen (Gibco Lab.) in 100 pi microtitre plates(Nuch) ina CO.,- 
-thermostat for 120 hours [14, 22]. Co-cultures were made by mixing 50-50 pi 
of cells from the isolated subpopulations stimulated with PWM [18]. Cell pro­
liferation was determined by Romanowsky Giemsa staining and in the co- 
-cultures by immunofluorescence analysis of intracytoplasmic immunoglobulins 
of the B cells [30].
lmmunocytochemical reactions: The binding of monoclonal antibodies 
(MoAbs) Leu 1 (CD 5, Becton-Dickinson), OKT3 (CD:i, Ortho) and Bx (CD 20, 
Coulter) were studied on cytospin preparations (Shandon) by the indirect im­
munoperoxidase method [21]. As a second antibody, peroxidase-conjugated rab­
bit immunoglobulin to mouse immunoglobulins (DAKO) and 3-amino-9-ethyl- 
carbazole (Ortho, kit chromogen) were used. Each incubation was carried out 
at room temperature for 60 minutes, and the cytospin preparations were counter- 
stained with Mayer’s haematoxylin. The enzyme reactions (5’-nucleotidase and 
adenosine triphosphatase) used in cryostat sections [31] were adapted to cytospin 
preparations. Adenosine-5’-monophosphoric acid disodium salt (AMP) or adeno- 
sine-5’-triphosphoric acid disodium salt (ATP) (Reanal) was used in Tris-maleat 
buffer (pH 7.2) supplemented with magnesium sulphate and lead nitrate.
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Results
Figure 1 shows the labelling of lymphocytes of 10 patients with CLL, 
8 with SLE and 10 controls. The WBC of CLL patients were significantly higher 
than those of SLE patients and controls (see Materials and Methods). The per­
centage of T cells determined by OKT3 (CD 3) monoclonal antibody was lower 
in CLL (18-32%) than in SLE patients and controls (52-78%) (Fig. la, “panB-F 
panT”). The percentage of Leu 1 (CD 5) positive lymphocytes in controls and 
T cells determined by E-rosettes or OKT3/CD 3 were equal. In CLL and SLE 
the percentage of Leu 1 (CD 5) positive cells was similar, but it was higher than 
the percentage of E-rosette positive or OKT3 (CD 3) positive T cells (p <  0.001- 
-0.05). This means that some of the Leu 1 (CD 5) positive cells were B cells in 
both CLL and SLE (Fig. la, “Leu 1”). The percentage of mouse rosette forming 
cells (Fig. la, “M-rosette”) was high in CLL (42-57%) and very low in SLE 
patients and controls (4-9%). The percentage of M-rosettes and Leu 1 (CD 5) 
positivity among non-E-rosette forming cells (Fig. lb, “isolated B”) was signifi­
cantly higher in CLL (average 73%) than in SLE (average 14%). Leu 1 (CD 5) 
positivity of B cells in SLE patients was higher than in controls; this latter differ­
ence was, however, not significant (Fig. lb, “ M-ros.” and “ Leu-1”). No corre­
lation between the absolute lymphocyte counts and the markers of lymphocyte 
subpopulations in individual cases were found (data not shown in Figures).
Figure 2a presents a MRFC (M-rosette). Figure 2b shows MRFCs of the 
same patient, one of them (arrow) reacting with Leu 1 (CD 5), the other being 
negative (arrow head). Figure 2c demonstrates isolated MRFCs from CLL. Three 
of the cells reacted with Leu 1 (CD 5) (open arrows), the others were negative.
Fig. 1. B-lymphocyte markers in 10 cases of CLL, 8 cases of SLE and 10 controls. Distribu­
tion of T- and B-lymphocytes (“panT + panB”), Leu 1 and M-rosette positivity in peripheral 
blood lymphocytes (left side of diagram, la). M-rosette and Leu 1 positivity in isolated 
B-lymphocytes (insert, lb). Standard deviations are shown at the top of the columns
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Fig. 2. A) M-rosette positive lymphocyte (cell with dark nucleus) forming rosette with CBA 
mouse erythrocytes (smaller gray anuclear cells attached). Romanowsky Giemsa staining.
X 2 0 0 0
B) M-rosette positive cells (two larger cells each with 3 attached erythrocytes), one 
of them showing Leu 1 positivity (cell at bottom with intense dark membrane positivity, 
arrow), the upper rosette forming cell is negative (gray, arrow head). Immunoperoxidase
reaction, x 2000
C) Isolated M-rosette forming CLL B lymphocytes, three of them showing intense 
dark membrane positivity with Leu 1 monoclonal antibody (open arrows). The other cells
(light gray) are negative lymphocytes, x 2000
Fig. 3. B-lymphocyte function in 8 cases of CLL, 6 of SLE and 6 controls. Distribution of 
B- and T-Iymphocytes (“panB +  panT”), ATP-ase, 5’-NU-ase reaction and PWM stimula­
tion in peripheral blood lymphocytes (left side of diagram, 3a). Co-cultures with B- and T- 
(helper)-cells in the course of PWM stimulation (insert, 3b). Standard deviation as in Fig. 1
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In Fig. 3a, 8 patients with CLL, 6 with SLE and 6 controls are presented. 
The “panB + panT” values are similar to those shown in Fig. la. No significant 
differences were observed between the numbers of adenosine triphosphatase 
(ATP-ase) positive cells in CLL, SLE patients and controls (63-78 %). The 5’-NU- 
-ase and pokeweed mitogen (PWM) responses were significantly decreased in 
patients with CLL (p <  0.001), compared to SLE and controls (Fig. 3a). Co- 
-cultures (Fig. 3b) were grown with PWM stimulated “B-cells” (non-E-rosette 
forming cells) mixed with “T-helper cells” (IgG-Fc-receptor negative E-rosette 
forming cells). Normal T-helper lymphocytes (second column, Fig. 3b) had 
a greater stimulatory effect on CLL B lymphocytes than autologous T helper 
lymphocytes of CLL patients (first column, Fig. 3b) (p < 0.01). However, the 
values of normal B cells (third column, Fig. 3b) were not reached (p < 0.02).
Figure 4a shows PWM treated lymphocytes isolated from the peripheral 
blood of an SLE patient. The two larger cells (arrows) are blasts, the others are 
small lymphocytes. Figure 4b: In one of the PWM induced blasts from the same 
cell culture (open arrow) intense 5’-nucleotidase positivity is visible, while a small, 
non-stimulable lymphocyte is negative (black arrow). Figure 4c shows M-rosette 
positive B lymphocytes of a CLL patient. No blasts are visible after PWM stimu-
Fig. 4 A) Pokeweed mitogen (PWM) induced lymphocytes isolated from peripheral blood of 
SLE patient. Two larger cells show blastic transformation (arrow), the others are unrespon­
sive small lymphocytes (smaller cells). Romanowsky Giemsa staining, x 2000
B) Pokeweed mitogen (PWM) induced lymphocytes from peripheral blood of SLE 
patient. Intense membrane enzyme positivity of a blast cell with 5’NU-ase (large cell with 
surface dark positivity, open arrow) and a negative, unresponsive small lymphocyte (black 
arrow) can be seen. Ecto-5’-nucleotidase reaction +  pokeweed mitogen stimulation, x 2000
C) Isolated M-rosette forming CLL B lymphocytes. Unresponsiveness to PWM stimu­
lation (no large blast cells, only small lymphocytes are present). Low 5’NU-ase reaction, 
(only one cell in top right corner shows granular dark membrane staining (double arrow).
Ecto-5’-nucleotidase reaction +  pokeweed mitogen stimulation, x 2000
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Fig. 5. M-rosette forming CLL B lymphocytes from 6 cases of B-CLL (isolated M+ and 
M -  cells). Percentage of M+ and М -  cells in isolated B-lymphocytes (left side of diagram, 
5a). Leu 1, ATP-ase, 5’-NU-ase activity and PWM stimulation in isolated M+ and M~ 
lymphocytes (right side of diagram, 5b). The deviation from standard values shown as in
Fig. 1
lation, and except for one cell (double arrow) no 5’-nucleotidase positivity was 
observed.
In Fig. 5a isolated B lymphocytes (non-E-rosetting cells) from 6 patients 
with CLL were further isolated into M-rosette positive (52-76% of B cells) and 
negative cells. The Leu 1 (CD 5), ATP-ase, 5’-NU-ase positivity and PWM 
responses of isolated M-rosette forming and M-rosette negative cells are shown 
in Fig. 5b. The Leu 1 (CD 5) positivity is significantly higher (p <  0.001), while 
the 5’-NU-ase and PWM responses are diminished (p < 0.01) in M-rosette 
positive CLL B lymphocytes. Figure 5b shows no significant differences in ATP- 
-ase activity.
Discussion
In the present study the expression of Leu 1 (CD 5), the number of MRFCs, 
purine-nucleotidase enzyme (5’-nucleotidase and adenosine triphosphatase) 
activities and pokeweed mitogen responses of lymphocytes from peripheral blood 
in CLL and SLE patients and in controls were measured. The reproducibility 
of these markers in the 10 cases of CLL was tested repeatedly in two-three months 
periods for two years (average positivity was 83-112%). The reported differences 
between T- and B lymphocyte markers and functions in older age groups [19, 
25, 32] are not compatible with the significant changes we observed between CLL 
and SLE patient groups.
Leu 1 (CD 5) is a monoclonal antibody detecting a 67 kD membrane 
glycoprotein of peripheral T lymphocytes and a rather small number of B lymph­
ocytes (autoregulatory B cells) [19]. Leu 1 (CD 5) positive B lymphocytes are 
present in the follicules of foetal lymph nodes and spleen and cord blood [1, 6, 
16], in low grade malignant lymphomas (B-CLL and centrocytic ml) and in auto-
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immune diseases [2, 6, 19]. Accordingly, our examination showed Leu 1 (CD 5) 
positivity of B lymphocytes in both CLL and SLE but not in controls (Fig. 1).
M-rosette (Fig. 2a) positivity, the spontaneous rosette formation of peri­
pheral B lymphocytes with CBA mouse erythrocytes (mouse rosette forming cells, 
MRFCs) can be detected as a distinct minor subpopulation of normal peripheral 
B lymphocytes [18]. MRFCs are also present in cord blood and in peripheral 
blood after bone marrow transplantation [19]. High numbers of MRFCs can be 
observed in the peripheral blood of B-CLL patients [3, 5, 10]. Some authors 
suggest that autoregulatory B lymphocytes express Leu 1 (CD 5) and they are 
MRFCs [19, 32]. In this study SLE B lymphocytes expressed Leu 1 (CD 5) but 
did not form M-rosettes, while CLL B lymphocytes were positive for Leu 1 
(CD 5) and formed M-rosettes (Fig. 1). Double labelling showed that not all 
MRFCs (Fig. 2b) were Leu 1 positive. However, isolated MRFCs in a CLL B 
lymphocyte population expressed significantly higher Leu 1 positivity (average 
73%) (Fig. 2c) than did mouse rosette negative cells (average 9%) (p <  0.001).
Purine degradative enzymes, such as ecto-5’-nucleotidase (5’-NU-ase) and 
ecto-5’-adenosine-triphosphatase (ATP-ase) are present predominantly on normal 
B lymphocytes (but present at lower levels also on normal T lymphocytes), and 
can be observed in B cell malignancies [7, 23, 25]. The enzyme of 5’-NU-ase is 
deficient in B-CLL lymphocytes, and the activity of ATP-ase is higher [9, 11]. 
A reversal of this pattern (i.e. higher 5’-NU-ase and low ATP-ase activity) can 
be observed in malignant lymphoma cases showing plasmocytoid or plasmocytic 
differentiation [17, 23]. The lower 5’-NU-ase activity, as a differentiation marker 
might be a sign of immaturity in cases of infectious mononucleosis and in T sup­
pressor lymphocytes of AIDS patients [25, 28]. Our results suggest that the sig­
nificantly lower number of 5’-NU-ase positive B lymphocytes (Figs 3 and 5) are 
characteristic of CLL patients (p < 0.001). No alterations in 5’-NU-ase positive 
cells were seen in SLE patients compared to controls (41-53%). There were no 
significant alterations in ATP-ase activity of lymphocytes of either B-CLL or 
SLE patients compared to controls (63-73%).
Pokeweed mitogen response (PWM), a polyclonal activation of B lympho­
cytes dependent on T cell regulation, is characteristically diminished in B-CLL [14, 
26] and in isolated MRFCs of controls [18]. The PWM response is in correlation 
with the functional immaturity of B cells in CLL [6, 15]. SLE B lymphocytes are 
polyclonally activated (the number of circulating immunoglobulin secreting cells 
is higher), while the responsiveness to PWM (and to T helper effects) may be 
defective [8, 30]. In the present study peripheral blood lymphocytes (Fig. 3) and 
isolated M-rosette positive CLL B lymphocytes (Fig. 5) had significantly de­
creased PWM responses (p < 0.001 and p <  0.01). SLE lymphocytes responded 
normally to PWM. In co-cultures (Fig. 3b) abnormalities of both T- and B-cell- 
-responses were detected in the course of PWM stimulation in CLL patients. The 
blast cell response to PWM (Fig. 4a) and 5’-NU-ase positivity (Fig. 4b) showed 
parallelism, i.e. in SLE patients and controls both markers were normal, while 
CLL patients had decreased 5’-NU-ase activities and PWM responses (Fig. 3).
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In isolated M-rosette positive CLL B lymphocytes (Fig. 4c) both 5’-NU-ase 
activity and PWM responses were diminished (Fig. 5).
Further studies of B lymphocyte markers are needed to understand the 
B cell differentiation and the pathogenesis of B cell lymphoproliférative and auto­
immune disorders. Besides the general interest in using markers and functional 
studies of B lymphocytes in immuno-haemopoietic disorders, these observations 
also have a diagnostic significance.
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Does Human Bladder Carcinoma Cell Line 5637-Conditioned 
Medium Supplement the Growth of Megakaryocyte Colonies 
(CFU-Mk) in Cultures of Human Bone Marrow?
Maria Podolak-Dawidziak
Dept, of Haematology, Medical Academy, Pasteura 4, 50-367 Wroclaw, Poland 
(Received 20 June, 1989; accepted 22 September, 1989)
Growth conditions of human megakaryocyte colony forming units (CFU- 
Mk) in vitro are still not clearly defined. Elaboration of reproducible culture 
conditions to promote growth of megakaryocyte colonies is important for the 
study of their development and differentiation in various diseases, and this must 
include a standard source of growth factors for CFU-Mk to replace plasma and 
medium conditioned by phytohaemagglutinin stimulated leukocytes (PF1A-LCM) 
from donors.
The aim of this study was to compare the effect of human bladder carcinoma 
cell line 5637-conditioned medium (5637-CM) on megakaryocytopoiesis in 
healthy subjects with other stimulators such as: PHA-LCM, erythropoietin 
(EPO) and plasma from patients with aplastic anaemia (AA). The study was 
performed at the Dept, of Haematology University of Wales College of Medicine, 
Cardiff, U. K. Bone marrow samples were obtained with informed consent from 
haematologically healthy patients undergoing cardiac or orthopedic surgery. 
The CFU-Mk assay was as described by Messner et al. (1982) [1]. Plasma from 
healthy volunteers was added to PHA-LCM and EPO stimulated cultures. 
AA plasma was obtained from 11 patients and pooled. The effectiveness of 
conditioned media of CFU-Mk growth was assessed by the paired t-test. Table 1 
shows a summary of actions of different stimulators on megakaryocyte colony 
formation in vitro. PHA-LCM promoted growth of CFU-Mk derived colonies 
to a greater extent after addition of EPO (lU/ml) (p < 0.05), but further increase 
of EPO to 2U/m! did not enhance this effect. 5637-CM alone stimulated CFU-Mk 
colony growth more effectively than PHA-LCM (p < 0.005). The CFU-Mk 
colony growth with 5637-CM was not statistically different from that in cultures
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Table 1
Effect of different stimulators on CFU-Mk derived colony formation in bone 
marrow from healthy subjects (n =  11)
C F U -M k colon ies per 2 x 105 cell cu ltu re
m ean SEM range
Normal human plasma 
+  PHA-LCM 16.1 6.9 9 -35
Normal human plasma 
+  PHA-LCM 
+ EPO (lU/ml) 20.0* 11.0 11-48
Normal human plasma 
+  PHA-LCM 
+  EPO (2U/ml) 17.9 8.7 9 -4 0
Normal human plasma 
+  EPO (lU/ml) 19.3* 10.4 10-43
Normal human plasma 
+  EPO (2U/ml) 14.6 8.9 7 -36
5637-CM 22.9* 9.9 12-47
5637-CM
+  EPO (lU/ml) 21.9* 9.7 10-40
5637-CM
+  EPO (2U/ml) 18.2 7.3 10-37
AA plasma 26.6* 13.5 13-44
* p <  0.05 vs controls (Normal human plasma +  PHA-LCM)
supplemented with AA plasma. The addition of EPO (lU/ml) to 5637-CM did 
not further stimulate CFU-Mk growth. A number of haemopoietic growth 
factors including megakaryocyte colony stimulating factor (Meg-CSF), recom­
binant (r) EPO and granulocyte/macrophage colony stimulating factor (GM-CSF) 
are capable of the stimulating cloning efficiency of human megakaryocyte progeni­
tors [2]. Result of this preliminary study indicate that the bladder carcinoma 
cell line 5637-CM promotes the growth of CFU-Mk derived colonies to a similar 
extent as aplastic anaemia plasma. It was shown recently that 5637-CM contain 
factors which support the growth of erythroid, eoxinophil and granulocyte/macro­
phage progenitors, and also the growth of mixed pluripotent progenitors, all 
from normal human bone marrow [3]. Pluripotent CSF (pluripoietin alpha), 
one of two factors purified from human bladder carcinoma 5637 cell line-condi­
tioned medium, might be responsible for this action [4]. Further study is required 
to elucidate the role of this factor in megakaryocytopoiesis and its interaction 
with other growth factors.
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Stimulation o f human erythrocyte 2,3-bisphos- 
phoglycerate phosphatase by vanadate. G. L. 
Mendz, S. J. Hyslop and P. W. Kuchel 
(Department of Biochemistry, The Uni­
versity of Sydney, New South Wales, 
Australia). Arch. Biochem. Biophys. 276, 
160 (1990).
The rates of vanadate-stimulated hydro­
lysis of 2,3-bisphosphoglycerate in meta- 
bolically competent erythrocytes and in 
hemolysates were determined from data on 
time courses up to 35 min employing 31P 
nuclear magnetic resonance spectroscopy. 
The enhanced rate of hydrolysis of the 
bisphosphate was attributed principally to 
the activation of the phosphatase activity 
of 2,3-bisphosphoglycerate synthetase both 
in cell suspensions and in hemolysates. 
Information on the concentrations of vana­
date and vanadyl present in the preparations 
was obtained employing 5lV nuclear mag­
netic resonance spectroscopy and electron 
paramagnetic resonance spectroscopy. Redox 
reactions involving vanadium ions appeared 
to be important in establishing the final 
equilibrium concentrations of the oxy- and 
oxo-ions (vanadate and vanadyl, respec­
tively), but the data suggested that the activa­
tion of the enzyme resulted from direct 
action of the vanadium ions on the enzyme 
and not as a consequence of the alteration 
in the equilibrium of intracellular oxidants 
and reductants.
Agnes Enyedi
Fatty acid acylation o f membrane skeletal 
proteins in human erythrocytes. D. Maretzki, 
M. Mariani and H. U. Lutz (Laboratory 
for Biochemistry, Swiss Federal Institute of 
Technology, ETH-Zentrum, Zurich, Switzer­
land). FEBS Letters 259, 305 (1990).
Fatty acid acylation of membrane 
proteins was studied on human erythrocytes 
by measuring incorporation of [3H]palmitate 
at different specific radioactivities. A 55 kDa 
polypeptide within the band 4.5 region was 
the main acceptor protein for acylation by 
fatty acids (palmitate, stearate, oleate), 
while other polypeptides (80, 65, 48, 30 kDa) 
incorporated [3H]palmitate slowly, in sub- 
stoichiometric amounts. Integral membrane 
proteins were preferentially fatty acid 
acylated. Skeletal membrane proteins were, 
however, poorly labeled. Neither purified 
ankyrin nor band 4.1 protein were fatty acid 
acylated in human erythrocytes. On the other 
hand, label associated with high molecular 
weight skeletal proteins resisted low and 
high ionic strength extractions, and was 
extracted selectively by urea along with a 
small subpopulation of spectrin which was 
also tightly associated with the membrane.
Agnes Enyedi
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Age-related changes o f erythrocyte membrane 
in the senescence-accelerated mouse. H. Abe 
and M. Orita (Research Institute of Oriental 
Medicine, Kinki University, Ohnohigashi, 
Osakasayamashi, Osaka, Japan). Mechanisms 
o f  Ageing and Development 51, 215 (1990).
Age-related changes in erythrocytes in 
senescence-accelerated mice (SAM-P) and 
control mice with normal aging characteris­
tics (SAM-R) were examined. A significant 
decrease in the number of erythrocytes and 
significant increases in MCV and ATP levels 
were observed with aging in SAM-P, while 
no significant changes were seen in SAM-R. 
Erythrocytes in aged SAM-P were less 
fragile than those in aged SAM-R. The 
contents of cholesterol and phospholipids 
in erythrocyte membranes increased signif­
icantly in aged SAM-P, but the molar ratio 
of cholesterol,/phospholipid decreased. The 
plasma cholesterol level of SAM-P decreased 
with aging. Changes such as those observed 
in SAM-P were not seen in SAM-R during 
the period of observation.
Agnes Enyedi
Carriers o f ataxia-telangiectasia gene display 
additional protein fraction and changes in the 
environment o f SH groups in erythrocyte 
membrane. M. Rybczynska, A. L. Pawlak,
S. K. Hoffmann and R. Ignatowicz (Depart­
ment of Biochemistry, Medical Academy, 
Poznan, Poland). Biochim. Biophys. Acta 
1022, 260 (1990).
Additional protein fraction migrating 
slower than spectrin has been detected in 
erythrocyte membranes from an ataxia- 
telangiectasia (А-T) patient and from his 
mother (А-T heterozygote). In erythrocyte 
membranes labelled with maleimide spin 
label changes in signal of the weakly im­
mobilized spin label as related to that of 
strongly immobilized one (w/s) were noted. 
In comparison to age-matched control 
groups the values of w/s were lower in A-T 
heterozygotes (ten persons) and higher in 
А-T homozygotes (four persons). In control 
persons the values of w/s increased with age,
whereas in families with А-T no significant 
differences in this parameters were noted 
between children and parents. The presence 
of additional protein fraction in erythrocytes 
membranes of А-T patient and А-T hetero­
zygote indicates that these phenotypes can be 
differentiated from the healthy control 
persons for the first time on the basis of 
changes detected in the erythrocytes. This 
change in erythrocyte membrane may 
explain the decrease in the w/s parameter of 
electron spin resonance in А-T heterozygotes. 
On the other hand increased values of w/s in 
А-T patients may be caused by disease 
process.
G. Gárdos
Reduced intracellular pH in lymphocytes 
from the spontaneously hypertensive rat. 
D. C. Battle, A. Saleh and G. Rombola 
(Northwestern University Medical School 
and the Lakeside Veterans Administration 
Medical Center, Chicago, Illinois, USA). 
Hypertension 15, 97 (1990).
This study was designed to determine the 
cytoplasmic pH (pH) profile of lymphocytes 
from a rat model of genetic hypertension 
that is well suited for study before and after 
the development of spontaneous hyperten­
sion. For this purpose, pH, was measured 
in thymic lymphocytes obtained from 
spontaneously hypertensive rats (SHR) and 
from age-matched Wistar-Kyoto (WRY) 
control rats using 2’,7’-bis carboxyethyl-5,6- 
carboxyfluorescein (BCECF), a pH-sensitive 
fluorescence probe. At the age of 16—20 
weeks, pH, of lymphocytes suspended in a 
HC03-free HEPES-buffered solution, was 
markedly lower in the SHR than in the 
WKY rats (7.07 +  0.02, n =  16 and 7.22 ±  
0.01, n =  15, respectively, p <  0.001), where­
as systolic blood pressure was higher in 
SHR than in WKY rats (175 +  5.0 and 
105 +  3.0 mm Hg, respectively, p <  0.001). 
In rats less than 5 weeks of age, pH, was also 
lower in SHR than in WKY rat lymphocytes 
(7.12+ 0.04, n =  11 and7.23± 0.04, n =  11, 
respectively, p <  0.05), although at this 
age systolic blood pressure was not different
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between the two groups (87 +  4.0 and 
85 +  3.0 mmHg, respectively). In lympho­
cytes suspended in a more physiological 
H C 03/C 02-buffered solution, pH, was again 
lower in the adult SHR than in the WKY rat 
(7.18 ±  0.02, n =  16 and 7.31 ±  0.02, n =  
16, respectively, p <  0.001). Under this 
condition, blockade of Na+— H+ exchange 
by a specific inhibitor, ethyl-isopropyl- 
amiloride (EIPA), or by exposure to Na+- 
free media resulted in intracellular acidifica­
tion in both SHR and WKY rat lympho­
cytes. The difference in pH( between SHR 
and WKY rat lymphocytes persisted after 
blockade of the Na+— H+ exchanger by 
either EIPA (7.09 ±  0.04 vs. 7.20 ±  0.03, 
p <  0.05) or by removal of external Na+ 
(7.04+ 0.05 vs. 7.19+0.02, p <  0.005). 
These data show that reduced pH! is a 
feature of lymphocytes from the SHR that 
is apparent before and after the development 
of hypertension. Persistence of reduced pHj 
in SHR cells, as compared with WKY rat 
cells, after Na+— H+ blockade suggests that 
a primary abnormality in the activity of the 
Na+—H+ exchanger is unlikely to account 
for the observed reduction in steady-state 
pH( of SHR cells. This alteration in pH, 
regulation persisted after removal of external 
Na+ and was seen in the presence and in the 
absence of external H C 03, indicating that 
a sodium-independent, bicarbonate-indepen- 
dent mechanism of cytoplasmic acid accu­
mulation accounts for the observed differ­
ence in pH|.
B. Sarkadi
Antibodies against membrane interleukin la 
activate accessory cells to stimulate prolifera­
tion o fT  lymphocytes. E. M. Eugui and S. J. 
Almquist (Department of Immunology, 
Syntex Research, Palo Alto, CA., USA). 
Proc. Nat. Acad. Sei. USA. 87, 1305 (1990).
Some monoclonal antibodies (mAbs) 
against interleukin (IL) la have been found 
to activate antigen-presenting cells (APC, 
human peripheral blood monocytes and B 
lymphocytes), so that unstimulated T lym­
phocytes cultured with them are induced to 
proliferate and secrete IL-2. Control mAbs of 
the same isotypes and mAbs against iL-\ß  
do not activate APC. In the absence of APC, 
mAbs against IL-lx do not induce prolifera­
tion of T lymphocytes. Mitomycin C-treated 
activated APC still induce T-cell prolifera­
tion. Proliferation of T lymphocytes cannot 
be induced by culture supernatants and 
requires contact with APC activated by 
mAbs against IL-lx. The observations 
imply that surface membrane IL-lx can 
function as a triggering molecule on APC, 
which could play an important role in the 
initiation of immune responses by T lympho­
cytes.
B. Sarkadi
Patch-clump profile o f ion channels investing 
murine B lymphocytes. F. V. McCann, D. C. 
McCarthy and R. J. Noelle (Department of 
Physiology and Microbiology, Dartmouth 
Medical School, Hanover, New Hampshire, 
USA). J. Memb. Biol. 114, 175 (1990).
Patch-clamp studies of single ion channel 
currents in freshly isolated murine B lympho­
cytes are characterized here according to 
their respective unitary conductances, ion 
selectivities, regulatory factors, distributions 
and kinetic behavior. The most prevalent 
ion channel in murine B lymphocytes is a 
large conductance (348 pS) nonselective 
anion channel. This report characterizes 
additional conductances including: two 
chloride channels (40 and 128 pS), a calcium- 
activated potassium channel (93 pS), and an 
outwardly rectifying potassium channel 
which displays two distinct conductances 
(18 and 30 pS). Like the anion channel, both 
chloride channels exhibit little activity in the 
cell-attached patch configuration. The kinetic 
behavior of all of these channels is complex, 
with variable periods of bursting and 
flickering activity interspersed between pro­
longed closed/open intervals (dwell times). 
It is likely that some of these channels play 
an important role in the signal transduction 
of B cell activation.
B. Sarkadi
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ADP evokes biphasic Ca2+ influx in fura-2- 
loaded human platelets. Evidence for Ca2+ 
entry regulated by the intracellular Ca2+ 
store. S. O. Sage, R. Reast and T. J. Rink 
(The Physiological Laboratory, University of 
Cambridge, Cambridge, UK). Biochem. J. 
265, 675 (1990).
Stopped-flow fluorimetric studies at 37 °C 
have shown that ADP, at optimal concentra­
tions, can evoke Ca2+ or Mn2+ influx in 
fura-2-loaded human platelets without mea­
surable delay. In contrast, the release of 
Ca2+ from intracellular stores is delayed in 
onset by about 200 ms. By working at a 
lower temperature, 17 °C, the rise in cytosolic 
calcium concentraton ([Ca2+],) evoked by 
ADP in the presence of external Ca2+ is 
biphasic. The use of Mn2+ as a tracer for 
bivalent-cation entry indicates that both 
phases of the ADP-evoked response are 
associated with influx. The fast phase of the 
ADP-evoked rise in [Ca2+]i, which occurs 
without measurable delay at both 17°C and 
37 °C, is consistent with Ca2+ entry mediated 
by receptor-operated channels in the plasma 
membrane. The delayed phase, indicated by 
M n2+ quench, is coincident with the discharge 
of the intracellular Ca2+ stores. For- 
skolin did not inhibit the fast phases of ADP- 
evoked rise in [Ca2+]j or Mn2+ quench, but 
completely abolished ADP-evoked discharge 
of the intracellular stores, the delayed phase 
of the rise in [Ca2+]| observed in the presence 
of external Ca2+ and the second phase of 
Mn2+ quench. The timing of the delayed 
event appears to be modulated by [Ca2+],: 
the delayed phase of Mn2+ quench coincides 
with discharge of the intracellular stores in 
the absence of added Ca2+, but with the 
second phase of the ADP-evoked rise in 
[Ca2+]| in the presence of extracellular Ca2+. 
Similarly, blockade of the early phase of 
Ca2+ entry by SK&F 96365 further delays 
the second phase. It is suggested that a
pathway for Ca2+ entry which is regulated 
by the intracellular Ca2+ store exists in 
platelets. This pathway operates alongside, 
and appears to be modulated by the activity 
of, other routes for Ca2+ entry into the 
cytosol.
G. Gár dos
How does fluoroaluminate activate human 
platelets? F. Rendu, M. Lebret, D. Tenza 
and S. Levy-Toledano (U 150 Inserm, URA 
334 CNRS, Hôpital Lariboisière, 75010 
Paris, France). Biochem. J. 265, 343 (1990).
Platelet activation induced by NaF or 
fluoroaluminate (A1F4_) was studied. The 
latter has been described to substitute for the 
y-phosphate group of the GTP molecule. 
With 10 mM-NaF, a concentration unable to 
induce any measurable Ca2+ mobilization 
(as measured with Indo 1), addition of 
AlClj, potentiated platelet aggregation, throm­
boxane synthesis, diacylglycérol formation 
and p43 phosphorylation, without any 
increase in intracellular Ca2+. Neither 
phosphoinositide hydrolysis nor phosphatidic 
acid formation could be detected. A1F4~ 
induced the release through a granule centra­
lization within a microtubule bundle, although 
no myosin light-chain phosphorylation could 
be detected. Addition of flurbiprofen (10 /íM) 
resulted in only partial inhibition of diacyl­
glycérol formation, with no effect on the 
release reaction or on p43 phosphorylation. 
The present results suggest that A1F4~ does 
not stimulate a G-protein governing the 
phosphoinositide-specific phospholipase C. 
The A1F4_ -induced diacylglycérol formation 
is discussed. Moreover, these results bring 
evidence that there is no correlation between 
granule centralization and myosin light- 
chain phosphorylation.
G. Gárdos
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T cell defects are very often involved in baematological diseases and occur even 
more frequently as a consequence of our therapeutic interventions. T cells play a central 
role in the immune defence of the organism. To perform this function, they move 
around the body to achieve a particular stage of development and in search for anti­
genic insult. In the course of this, they have to communicate and cooperate with various 
cells. T cells carry a high number of structurally and functionally defined and even 
more as yet undefined surface structures. The variability and functional pleitropism 
of these molecules and as a consequence that of their interactions with surface struc­
tures of other cells is infinite. This paper will be limited to discuss briefly the following 
subjects:
— the presentation of antigens to T cells
— structure and function of the T cell receptor (TCR) and its interactions with the antigen 
presenting major histocompatibility complex (MHC) molecule
— accessory molecules and other modulating surface structures
— the role of carbohydrates
— pitfalls of inferences on interacting cell surface structures
Keywords: T cells, target cells, major histocompatibility complex, carbohydrates, T cell
receptor, antigens
The Presentation of Antigens to T Cells
Whereas immunoglobulins (Ig) have both soluble and membrane forms 
that can bind to antigen alone, antigens have to be presented in an attractive 
form to T cells (Fig. 1). The specific antigen receptor of T cells exists only on cell 
surfaces and recognizes only processed antigen fragments embedded in the MHC 
class I or class II antigens. The antigen presenting cell (APC) for regulatory 
cells may be a MHC class II positive interdigitating cell, a B cell or a professional 
macrophage. Any MHC class I positive cell can function as an APC for cytolytic 
T cells (CTL). The presented antigenic fragments are short peptides. The fact 
that amino acid substitutions far from the antigenic determinant can modulate 
T cell recognition, points to the conformational recognition of a large peptide.
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Fig. 1. Antigens have to be presented in an attractive manner
The complete steric structure of the MHC class I HLA-A2 molecule had 
been disclosed by the X-ray crystallographic studies of Björkman et al. (1987). 
The HLA-A2 molecule consists of two pairs of structurally similar domains:
1) the membrane-distal а-l and a-2 domains and
2) the membrane-distal a-3 and ß2 microglobulin and a-3 domains.
The а-l and a-2 polypeptide chains form a deep groove on the top of the 
HLA-molecule (Fig. 2), the bottom of which is lined by anti-parallel /J-pleated 
sheets spanned by the two long a-helices (Fig. 3). This is in fact the specific antigen 
binding site of the MHC molecule. Most of the non-conserved residues are located 
in this site, selected to generate an ability to present many different peptides. 
Conserved residues pointing into the recognition site serve probably as binding 
sites for TCR and other T cell epitopes. Björkman et al. found processed antigenic 
peptides bound to the antigen recognition site. The fact that these remained 
bound to HLA during the entire purification and crystallization procedure
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Fig. 2. The two pairs of structurally similar domains of the HLA-A2 molecule 
(P. J. Björkman et al.: Structure o f the human class 1 histocompatibility antigen. HLA— A2. 
Reprinted by permission from NATURE Vol. 329, p. 508, Copyright ©  1987 Macmillan
Magazines Ltd.)
argues for a very slow kinetic rate off for peptides bound to HLA molecules. 
It is surmized that in the absence of foreign antigens, processed peptides of self 
antigens occupy the binding site.
Structure and Function of the TCR and Its Interactions with the 
Antigen Presenting MHC Molecule
In contrast to the precise steric structure of the MHC-Ag complex, very 
little is known at the molecular level on how the TCR recognizes this complex.
The TCR-s perform the complex function of 1) recognition of specific 
antigens and 2) the translation of antigen binding into biochemical signals that 
activate the immune response of T cells. This multi-unit receptor is present on 
all mature and many developing T cells. The TCR is comprised of the antigen 
recognition part Ti, which is stoichiometrically but non-covalently associated 
with the invariant proteins of the CD3 complex (Fig. 4). The Ti is built up by 
polymorhic ot/ß or y/ô chains, the ct/ß heterodimer being far more common. In 
normal individuals TCR y/ô is found on 1 to 10% of mature CD3 pos. peripheral 
blood T cells, on the majority of dendritic T cells of the skin and on 0.1 to 1.0%
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Fig. 3. The antigen binding site of the MHC molecule 
(P. J. Björkman et al.: Structure o f  the human class l  histocompatibility antigen. HLA — A2. 
Reprinted by permission from NATURE Vol. 329, p. 509, Copyright ©  1987 Macmillan
Magazines Ltd.)
of the most immature CD3 pos. thymocytes. The human CD3 is comprised of y, 
ô, E and disulfide-linked ^-chains. The large intracellular portion of CD3 chains 
as compared to Ti chains (which have large extracellular domains and only 5 
to 12 intracellular amino acids) points to the transmembrane signalling function 
of the CD3 complex. This is especially true for the ^-chain which has an ex­
tremely small extracellular and a very large intracellular domain with 6 potential 
sites for tyrosine phosphorylation. The tyrosine-phosphorylated ^-chain is the 
previously described p21, the protein known to become tyrosine-phosphorylated 
in response to Ag binding. The recently described »/-chains, are linked to approxi­
mately 10% of the ^-chains. The lack of »/-chains has been described to result in 
inefficient coupling of receptor occupancy to phosphoinositide (PI) hydrolysis 
(Marcep et al. 1988).
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Fig. 4. The TCR (Ti +  CD3) complex
The transmembrane region of all CD3 components have a charged residue 
in their completely hydrophobic transmembrane sequence: y-, <5- and e-chains 
have a positively charged, while the < -^chain a negatively charged residue. This 
very exceptional feature — to have non-covalent interactions within the trans­
membrane domain of each CD3 subunit — may enable the complex CD3 struc­
ture to react on binding of even small doses of antigen to Ti with an allosteric 
shift, that is magnified through the complex, ending up in a second stable con­
formation in which multiple contacts with the second messenger system are 
activated.
To get a better insight into details of TCR/Ag/MHC interactions, Davis 
and Björkman (1988) summarized current structural information on TCR genes 
and their products and offered a hypothetical structural model, while Claverie 
et al. (1989) constructed a complete steric model of the TCR molecule and investi­
gated the putative organization of the TCR/peptide/HLA-A2 complex. Both 
models are based on the significant homology between the antigen-contacting 
variable domains of the Ig heavy and light chains (Vh and Vl) and the variable 
domains of the TCR (V„ and Vp) with an average of 25 — 40 % amino acid identity. 
TCR-s are thus suggested to have similar spatial organization to the Ig Fab 
moiety. The TCR Va and regions have just like VH and VL, three variable 
loops designed to make contact with the antigen and are thus referred to as 
complementarity-determining regions, CDR1, CDR2 and CDR3 in both mole-
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Fig. 5. A speculative model of the TCR/peptide/HLA-A2 interaction 
( J.-M. Claverie et al.: Implications o f a Fab-like structure for the T-cell receptor. Reprinted by 
permission from IMMUNOLOGY TODAY Vol. 10, p. 12. Copyright ©  1989 Elsevier Trends
Journals )
cules. The respective geometries of a Fab-like TCR structure and of the HLA-A2 
binding site suggest a model where both variable CD3 chains of TCR interact 
with the peptide antigen presented at the antigen binding site of the MHC mole­
cule. The first and the second less variable regions (CDR1 and CDR2) of the 
TCR molecule are in a position for making contact with both polymorphic and 
conserved residues pointing up from the а-l and a-2 helical regions of the antigen 
presenting HLA molecule (Fig. 5). If the peptide can fit deep inside the groove, 
the interactions between the TCR CDR1/CDR2 and the HLA-A2 can be realized. 
If the peptide protrudes into the interface of the contacting molecules, steric 
constraints could preclude the interactions between the MHC and TCR mole­
cules. This is the molecular basis of the MHC restriction that cannot be easily 
reconciled with totally antigen-independent МНС-restriction schemes as that i.e. 
of the self-“ learning” hypothesis.
Accessory Molecules and Other Modulating Surface Structures
The presentation of peptides by MHC class I or class II molecules seems 
to correlate with the endogenous (live virus, self-proteins) versus exogenous 
(and thus first endocytosed) nature of the native antigen. There are no essential
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Fig. 6. Molecules crucial to the activation of T cells are all members of the immunoglobulin
superfamily of adhesive proteins
features distinguishing these two pathways at the level of peptide binding or for 
the type of TCR involved in antigen recognition. The basic differences between 
helper T cells (mostly reacting with MHC class II presented antigen) and CTL-s 
(mostly reactive to MHC class I presented antigen) is thought to depend on the 
interaction with the surface molecules CD4 and CD8.
CD4 and CD8 molecules, just like all other surface molecules crucial to 
T lymphocyte activation (subunits of TCR, class I and class 11 MHC, CD2, 
leukocyte function associated molecules LFA-1 and LFA-IH), are all members 
of the Ig superfamily. All these molecules share not only structural similarities 
between their disulphide bonded extracellular domains but have also a common 
adhesive function (Fig. 6). The regulatory interactions between cell adhesion 
molecules concentrate actions to restricted areas of the lymphocyte membrane 
amplifying in this manner weak reactions. T cells reorient their microtubule­
organizing centres and Golgi apparatus towards the site of interaction with APC-s 
(Poo et al. 1988). T cells and APC-s can thus form transient mobile synapses for 
the bidirectional exchange of critical information. Lymphokines and other cyto­
kines are secreted into these synaptic spaces via directional exocytosis.
Both the induction of T helper cells by APC-s and the delivery of help to 
B cells need direct contact (Fig. 7). Similarly, the cytotoxic activity of T cells is 
dependent on an appropriate contact between the CTL and its target cell. The 
initial adhesions are mediated via LFA-1 and CD2 molecules (Fig. 8). These
H aem ato lo g ia  23, 1990
136 5 .  Hollán: How T  cells talk to target cells
Fig. 7. Direct cell to cell contact is needed for interactions of T cells with antigen presenting
cells
Fig. 8. Antigen-dependent and antigen-independent pathways of T cell activation
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antigen non-specific interactions and the resulting antigen-independent activation 
of the T cells were shown to precede the recognition of Ag by TCR. The strong 
association between CD2 and LFA-3 (binding constant 1.7 x 10~' M) may be 
necessary to stabilize adhesions between motile cells. Similarly LFA-1 can interact 
(among other ligands) with the intercellular adhesion molecule (ICAM-1) which 
like LFA-3 has a broad tissue distribution. CD 2—LFA-3 and LFA-1 — ICAM-I 
binding provide the T cell with two different adhesion pathways which differ 
in their temperature dependence and Mg2+ requirements (de Vries et al. 1989). 
The use of a certain adhesion pathway may result in different physiological 
responses of T cells. Apart of CD2 and LFA-1 some other surface structures 
of human T cells (CD28 and Tp 103) are claimed to have the capacity to activate 
in a non-specific way. In mature T cells the antigen-dependent and independent 
pathways are able to interact, which may reflect a system of checks and balances 
necessary to maintain homeostasis in the immune system.
CD4 and CD8 are also involved in adhesions between T cells and APC-s 
and in adhesions between CTL-s and target cells, respectively. CD8 and CD4 are 
considered as minor adhesion molecules as compared to CD2 and LFA-1 (de 
Vries et al. 1989). CD4/CD8 molecules are needed to TCR antigen interactions 
in situations where the intrinsic affinity of the TCR for its antigen is low, or in 
cases where only low concentrations of antigen are accessible for the TCR. 
Biddison and Shaw (1989) point out that surface molecules situated in such 
a manner as to mediate adhesion are also ideally suited for transducing informa­
tion. CD4 and CD8 molecules not only serve to enhance the avidity of T cells 
by binding to class 11 and class I MHC antigens, but are also involved in the post 
binding events of CTL activation. Recent studies suggest that CD4 and CD8 
play a critical role in the intrathymic development of T cells as well. CD4 and 
CD8 are proposed to be bifunctional molecules capable of interacting with MHC 
class I and class II molecules on stimulator and target cells, and with the TCR-s 
on the same cell. Depending on the state of differentiation, one or the other bind­
ing function is more important (Eichmann et al. 1989).
Veilette et al. (1988) have shown that a src-related tyrosine-kinase, the p56 
is associated with the cytoplasmic parts of CD4/CD8. Through activation of 
the Ti —CD3 complex, the adhesion of CD4/CD8 to TCR may bring p56k,~ 
to direct contact with the £-chain resulting in its tyrosine phosphorylation (Fig. 9). 
This is how the physical association of CD4/CD8 with an intracellular kinase is 
involved in transmembrane signalling of T lymphocytes. Mustelin and Altman 
(1989) suggested that CD4/CD8 may control the mobility and hence the acces­
sibility of p56Tck to the ij-chain in the T cell membrane.
It is still a wide-spread dogma that CD4 expression is strictly correlated 
with helper function and that CD4 reacts restrictedly with MHC class II antigen, 
while CD8 positive cells are strictly suppressor or cytotoxic cells reacting selec­
tively with MHC class I antigens. The initially oversimplified categorization of 
suppressor T cells became recently one of the most controversial topics in immu­
nology. The inability to correctly identify suppressor cells as a distinct T cell
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Fig. 9. Model of MHcl/Ag/TCR, CD4 or CD8 and p56Ick aggregate.
(T. Mustelin and A. Altman: Do CD4 and CD8 control T-cell activation via a specific tyrosine 
protein kinase? Reprinted by permission from IMMUNOLOGY TODAY Vol. 10, p. 190, 
Copyright ©  1989 Elsevier Trends Journals)
subset has led to the conclusion that they simply may not exist (Möller 1988). 
It is now accepted that class II restricted T cells are heterogenous at the functional 
level (helper and cytotoxic) and they are also — albeit rarely — heterogenous at 
the phenotypic level (CD4 and CD8). The basis of this heterogeneity is as yet 
unresolved. There are different possibilities: 1) two separate MHC class II 
restricted T cell lineages may exist which may only differ in their requirements 
for lymphokines and/or accessory signals, 2) the intensity of the triggering stimu­
lus may determine the effector function, or 3) the two functions may be per­
formed by T cells at different stages of development. Lanzavecchia (1989) raises 
the hypothesis that the МНС-class II restricted CTL-s might be the endlessly 
elusive T suppressor cells. De Vries et al. (1989) have described that interleukin-4 
(IL-4) can induce the expression of CD8+ protein on CD 4+ cells, illustrating 
that the phenotype of mature functional CD4+ cells is not irreversibly fixed. 
IL-4 may also be associated with the induction of CD8 expression during the 
transition of CD4 CD8 to CD4 + CD8+ thymocytes during thymic maturation.
Whereas migration of non-activated lymphocytes is widespread through 
the body, effector cells and memory cells exhibit remarkable selective migratory
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behaviour, moving mainly to tissues originally involved in antigen exposure and 
cell activation. The extravasation of blood-borne lymphocytes is regulated by 
interactions of the address-dependent expression of homing receptors with the 
endothelium of specialized organ venules, the so-called high endothelial venules 
(HEV). At least three independent homing receptor systems are responsible for 
controlling traffic of the lymphocytes to different areas of the lymphoid system 
and to inflamed synovia. Homing receptors are also expressed by many human 
lymphoid neoplasms and appear to play a role in lymphoma metastasis.
A superfamily of endothelial surface molecules selectively expressed on 
mucosal organs are the ligands for lymphocyte homing receptors. These ‘vascular 
addressins’ appear to function as tissue specific address signals for recognition by 
lymphocytes in the circulating blood (Streeter et al. 1988). Rosen et al. (1985) 
suggested that sialic acids on endothelial cells may be organ specific recognition 
determinants for lymphocyte attachment. Lymphocytes bear also receptors which 
recognize fibronectin, collagen, laminin, fibrinogen and von Willebrand factor. 
The fibronectin receptors appear to be essential in the colonization of the thymus 
by T cell precursors. Adhesion capability of more differentiated T cells is dim­
inished or absent. Fibronectin receptors are thought to anchor the developing 
cells until they are ready to emigrate. The difference between the expression of 
various adhesive protein receptors also reflects the different matrix adhesion 
requirements of mobile, stimulated cells versus quiescent cells (Hemler 
1988).
Six molecules (CD2, LFA-3, LFA-1, UCHL1, Pgp-1, CD44 and CDw29) 
are all either newly expressed or increased in expression on memory T cells. Since 
Pgp-1 in man is the Hermes-homing receptor, homing receptors as well as ICAM-1 
and VLA molecules are also increased on memory cells. The heightened level 
of many adhesion molecules on memory T cells suggest that facilitated cell inter­
actions may account for at least some of the features of secondary immune re­
sponses (Hogg 1989).
Activated T cells are characterized by the expression of 1L-2R (CD 2R 
and CD25) and a number of other newly expressed surface structures, the CD26 
(dipeptidyl-peptidase IV), CD30, CD69, CDw70, CD71 (transferrin receptor). 
The insulin receptor is also absent on resting T cells and synthetized de novo 
by stimulated cells.
The surface of T cells possess a multitude of other receptors that interact 
with hormones, carrier proteins, pharmacoactive substances, neuropeptides and 
drugs. Immature T cells bear receptors for respective classes of thymic hormones.
We have shown that the AchE activity of peripheral blood lymphocytes 
is restricted to the T cells, especially to a low density fraction which represents 
an activated T cell population (Szelényi et al. 1982). In another series of experi­
ments we have found a significant increase in acetylcholinesterase (AchE) activity 
and in muscarinic acethylcholin receptor (mAchR) expression in normal human 
peripheral blood lymphocytes as an early response to stimulation by mitogens, 
phorbol-myristylacetate (PMA), anti-CD3 mAb and the CA ionophor A23187.
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Fig. 10. The carbohydrate moieties of glycoproteins and glycolipids protrude into the extra­
cellular space like antennas and interact with proteoglycans
In contrast to this, T-ALL cells showed a markedly decreased AchE activity, 
normal expression of mAchR, weak response to mitogens with no significant 
change in their initially higher cGMP values (Szelényi et al. 1987).
The Role of Carbohydrates
Studies with mAbs have shown that antigenic determinants of biologically 
important receptors and other surface molecules involved in cell to cell communi­
cation are carbohydrate antigens which, according to their carrier structures, 
are either glycoproteins or glycolipids (Fig. 10). Glycoproteins span the cell 
membrane. Glycolipids are much smaller and more cryptic. The sugar residues 
of both protrude like antennas from the external surface of the lipid bilayer and 
interact with the cloud of proteoglycans surrounding the cells. Biological role of 
carbohydrate groups received renewed attention, since the sequence diversity 
and the infinite variability of the carbohydrate code provides signals for protein 
targeting and cell-cell interactions. Carbohydrate recognition signals render the 
possibility for ‘social’ interactions of cells. These signals are the language by 
which cells can talk to each other. I have already mentioned that the tissue specific 
recognition of lymphocytes by endothelial cells is highly dependent on the specific
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glycosylation of the cells. The anti-carbohydrate monoclonal antibody (HNK.-1) 
originally raised against a human NK cell-line recognizes cell adhesion molecules 
distributed on both the nervous system and the immune system. These neural 
adhesion molecules seem to be important for the entry of lymphocytes into the 
brain. I would even surmise an eventual role of these structures in the develop­
ment of ‘sanctuaries’ for malignant cells in the central nervous system. Dramatic 
changes of the oligosaccharide moiety of glycoconjugates are often associated 
with ontogénie and oncogenic events without affecting cell viability. In different 
stages of cell development, a repertoire of different glycoforms of proteins may 
have a unique spectrum of biological activities. Besides species specific and tissue 
specific glycoslyation, the glycotype of a cell is defined by its unique glycosylation 
capacity. This depends on differences in the level, activity and expression of 
individual intracellular glycosidases and glycosyl-transferases, as well as on intra­
cellular routing, topography and exposure to these enzymes, availability of 
necessary metabolites and the activities of ecto- and extracellular enzymes. Tissues 
appear to create markedly few glycoforms in common.
The posttranslational glycosylation of polypeptides serves to generate 
discrete subsets of glycoproteins leading to finely tuned functional diversity. 
The glycotype defines the cellular identity. The recognition of this by other cells 
requires a complementary array of lectins. The carbohydrate moiety confers 
also important physical properties on the carrier proteins and lipids, such as 
conformational stability, protease resistance, charge and water binding capacity. 
Water molecules influence molecular interactions in all biological systems. Ordered 
water molecules can contribute directly to the properties of proteins by influencing 
their interactions with ligands.
Pitfalls of Inferences on Interacting Cell Surface Structures
Taking into account all aforementioned variability of factors influencing 
cell to cell interactions, we cannot wonder about a number of contradictions 
arising between the results of in vitro and in vivo investigations. Structural studies 
of the interaction in antigen-antibody complexes focus purely on spatial arrange­
ment of atoms. The functional approach has to introduce, however, the fourth 
dimension, time. Methods, which operate within a functional perspective actually 
analyze cross-reactivity, since the hydrogen bonds at the epitope-paratope inter­
face have dynamics of binding and breaking in the course of interactions. It is, 
however, a serious pitfall that experimental conditions of binding assays influence 
the conformation of the antigenic peptide. Assay conditions will, in fact, deter­
mine whether binding is observed or not, and thus whether certain residues are 
scored as belonging to the functional epitope (Regenmortel, 1989).
Anti-peptide antibodies are extremely useful for isolating and characterizing 
gene products. The high success rate in this case is partly due to the fact that 
cross-reactive antibodies need not necessarily be specific for the native confor-
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Fig. 11. Quite often a conceptual jump is needed
mation of the protein to detect the antigen in many of the currently used immuno­
assays. This does not diminish their practical value, but we simply have to keep 
in mind that in an attempt to understand the real structural basis of protein 
antigenicity in addition to the aminoacid sequence and the tertiary structure, 
accessibility, protrusion, mobility and hydrophilicity also have to be taken into 
account.
It is now generally recognized that the systems under investigations in 
biological sciences exhibit such a high degree of complexity that traditional 
notions of linear casuality do not apply. In discerning the highly important 
epitope-paratope interactions in cell to cell conversation, the more analytical 
framework of network casuality has to be applied, since a large number of inter­
acting factors and variables seem to influence a particular feature of the system 
instead o f causing it. Quite often a conceptual jump is needed to go from structure 
to function and vice-versa (Fig. 11). It is, however, extremely important to dif­
ferentiate between observation and inference. It happens quite often that conclu­
sions and categorizations based on inferences are being too quickly and uncriti­
cally applied in clinical practice.
We cannot dispense with the molecular structure and the physicochemistry 
of cell to cell interactions if we want to understand the real language of conver­
sation between the cells of our organism.
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Conclusion
1. Direct cell to cell contact is needed for conversation between T cells 
and antigen presenting cells:
— strong bonds are needed for stabilizing interactions between motile cells,
— for concentration of action to the area of cell to cell contact,
— for bidirectional exchange of crucial information via transient mobile synapses 
and
— for the regulation of lymphocyte traffic.
2. The recognition of the MHC presented peptides is conformational. 
Protrusions, accessibility, mobility and hydrophilicity of the interacting struc­
tures as well as the dynamics of bonding at the interface have to be taken into 
account.
Steric models of the TCR/antigen/MHC complex point to the antigen depen­
dent molecular basis of MHC restriction.
3. A broad spectrum of T cell surface molecules modulate the immune 
response.
4. Carbohydrate recognition signals form the finely tuned language for 
“ social interactions” between cells.
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Policies on iron in Denmark
V. Thambypillai, K . Staehr-Johansen
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The mounting evidence on the adverse effects of increasing iron stores raises 
the question of the appropriateness of existing national policies on iron fortification 
of foods and iron supplementation in the development countries. A pilot study on the 
pattern of iron supplementation during pregnancy was implemented in one county of 
Denmark. The results of the study suggest that there is inappropriate use of iron and 
laboratory investigation for haemoglobin during pregnancy. For recommendations to 
be made at national level similar studies should be performed in other counties of 
Denmark.
Keywords: iron, iron policies, iron supplementation, iron fortification
Iron deficiency anaemia (IDA) is basically a health problem associated 
with poverty and ignorance. The most vulnerable groups are pregnant women, 
infants and children, who all have increased demands for iron due to the rapid 
growth and the physiological changes they undergo.
Denmark, like most other countries in the European region, realising the 
magnitude of the problem of IDA and the serious consequences that it can have, 
introduced supplementation and fortification programmes. These were introduced 
in the post-war years, about 30 — 40 years ago, when IDA was a public health 
problem and when it was a cause of morbidity and mortality.
The situation in Denmark today is different. Socioeconomic conditions 
have improved tremendously, education level is high, eating habits and patterns 
have changed, food is abundantly available, vitamins and minerals are within 
easy reach of the people, and in general infections are well under control. All 
these factors have lead to the virtual disappearance of IDA, with the exception 
of a small percentage of women. There is, on the other hand, an increasing con­
cern and interest on the hazards associated with increased iron intake and iron 
stores, and the judiciousness of continuing old and established supplementation 
and fortification programmes without proper objective assessment.
Haemochromatosis, which was previously considered a relatively rare 
condition, is now occuring more commonly in countries like Sweden, which has 
been one of the strong promoters and implementers of food fortification pro­
grammes over the last 30 — 40 years [1,2]. Fortification programmes could have also
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contributed to accelerating the course of the disease in persons with preclinical 
haemochromatosis, thus causing them to present themselves with clinical signs 
and symptoms at an earlier age [3].
High haemoglobin levels and increased iron stores have also been regarded 
as “risk factors” for the development of myocardial infarction, which is one of 
the major killers in affluent societies; and that in fact, mild anaemia and lower 
iron stores protects one from heart disease [4, 5, 6].
High body iron stores have also been linked to increased risk of cancer [7]. 
The iron and protein, traditionally associated with the metabolism of iron, have 
shown to suppress immune function. Of these the most extensively documented 
is ferritin which has been shown to suppress T cell functions and to be associated 
with causing cancer [8]. Further, the role of iron and its importance in the etiology 
of rheumatoid disease has also been suggested [8, 9].
In the association of iron with infection, the critical question is not whether 
iron deficiency is associated with fewer infectious complications, but whether 
correcting the hypoferraemia of inflammation may deleteriously affect existing 
infection [10].
An average Danish diet today contains 10 — 20 mgs of iron per day, this 
is 10 times more than the amount required to replace the iron lost daily through 
the normal physiological processes [11]. It has been pointed out by the National 
Food Agency (Levnedsmiddelstyrelsen) that the low iron stores in the Danish 
women is not caused by low intake of iron in their diet, but by a low total intake 
of energy. Therefore, iron fortification of foods, if it is aimed to help alleviate 
or present low iron stores in these women, will not help them at all [12]. Recognis­
ing this fact, it has been decided that iron fortification is not an absolute necessity 
in a population that is not iron deficient. Denmark has, since early 1987, made 
iron fortification of flour and cereals voluntary, but none of the producers have 
wanted to fortify these foods. It is, however, statutory to fortify infant formulae 
with iron [13, 14].
As women during pregnancy are at higher risk of developing IDA, iron 
supplementation has been one of the chief activities of antenatal care, and iron 
supplements are prescribed widely, starting from the first trimester of pregnancy, 
without any regard to the individual partient’s needs. This uncritical prescription, 
without taking into account that it produces unnecessary and unpleasant gastro­
intestinal side effects, is usually justified on the basis that dietary intake is pre­
carious in relation to needs, the preparations used are without harm, and defi­
ciencies are so common as to justify supplementing the whole population [15]. 
Routine iron supplementation, if recommended, can be delayed until after 28 weeks 
of pregnancy [16]. A review of 17 controlled clinical trials, on iron and vitamin 
supplementation during pregnancy in developed countries, found that there was 
little or no evidence of obvious benefit from iron to either the mother or the 
foetus [17]. Also, low iron stores do not have the same importance in pregnant 
women as in the non-gravidae, and in practice half have restored their iron stores 
within two months of delivery [15]. Further, maternal iron deficiency does not
H aem ato lo g ia  23, 1990
V. Thambypillai & K. Staehr- Johansen : Policies on iron in Denmark 147
lead to complications during delivery and does not cause neonatal iron deficiency 
[18, 19]. All this evidence questions the value of iron supplementation to those 
with mild and moderate IDA during pregnancy.
For a long time it was believed that higher maternal haemoglobin was an 
indicator of good prognosis or outcome for the pregnancy. But now, studies have 
found that high haemoglobin levels are associated with foetal disorders, both 
growth retardation and intra-uterine death of unknown cause, before the beginning 
of labour [20] and low birth weight [21]. is it then justified for non-anaemic 
women to receive iron supplementation during pregnancy?
Blanket administration of iron in areas where there are no obvious indica­
tions has been questioned by the WFIO. The WHO recommendation for iron 
supplementation during pregnancy is that it should be practised primarily in the 
second half of pregnancy when the iron requirement is greatest [22]. As the 
maintenance of haemoglobin concentrations at non-pregnant levels does not 
seem necessary, the need for prophylactic iron should then be reassessed in the 
light of improvements in the nations health, and newly applied strategies suited 
to the real needs of the people need to be developed. In Denmark the policy on 
iron supplementation during pregnancy has remained unchanged until now.
Target 38 of the Health for All by the Year 2000 policy states: “ Before 
1990, all Member States should have established a formal mechanism for the 
systemic assessment of the appropriate use of health technologies and of their 
effectiveness, efficacy, safety and acceptability, as well as reflecting national 
health policies and economic restraints.” Realising that iron is not being given 
enough attention in the right perspective by health planners and policy makers, 
the Quality of Care and Technologies (QCT) programme of the World Health 
Organisation Regional Office for Europe, selected it as on of its key areas of 
activities.
In 1986, QCT, WHO in collaboration with the International Society of 
Haematology and the International Committee for Standardization in Haema­
tology, held an International Workshop on Appropriate Iron stores in Pilisszent- 
kereszt, Hungary [23]. During this workshop it became clear that the optimal 
iron state is still unknown and that extensive biochemical, clinical and epidemiolog­
ical investigations are needed to determine where this optimum should be placed. 
On the specific area of supplementation and fortification, it was recognised that 
there was a need for the review of national policies since there is a wide variation 
between different countries. These expected variations could be helpful for 
targeting further research on health consequences and policy decisions.
This Workshop resulted in further studies that are in various stages of 
development. A study on iron supplementation during pregnancy — a randomized 
controlled trial, on a sample of 2912 women in Finland — has been completed, 
and preliminary results show that there is no benefit of iron supplementation 
during pregnancy (verbal communication). Another study which examines the 
effect of iron quantity in milk formulae on child growth and health in Hungary 
is still in progress.
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A pilot study on the appropriate utilization of iron — through the review 
of national policies on supplementation and fortification — and the study of 
supplementation patterns during pregnancy in Storstroems County, Denmark is 
now nearing completion. Preliminary results show that three of the 185 pregnant 
women had haemoglobin levels below 11 gm % at the beginning of their pregnancy 
(between 8 — 12 weeks), 122 (66%) of them were started on iron supplementation 
during the first trimester. The prescription of iron appears to be unrelated to the 
haemoglobin levels. Six women decided not to take iron because they felt that 
they had no need for it. 49 of the 179 (27 %) women who took iron supplementation 
suffered side-effects. A majority (75%) of them did not pay attention to their 
diet, and did not increase intake of foods rich in iron during their pregnancy. 
In Denmark, the National Board of Health is in the transition phase of revising 
its policy on iron supplementation during pregnancy. The new policy will recom­
mend that supplementation be given only to those needing it. The earlier policy 
was that all women should receive iron supplementation from the first trimester. 
The results of the pilot study show that:
1. diet, which is the basic cause of IDA, needs to be given more attention during 
pregnancy,
2. the side-effects suffered could have been minimised if supplementation, in 
those not anaemic, had been postponed to the second trimester of pregnancy,
3. results of the haemoglobin tests were not influencing treatment patterns,
4. the practice of supplementation during pregnancy conforms with the earlier 
national policy, but not with the proposed one.
The above indicates that there may be inappropriate use of iron during 
pregnancy, and the laboratory investigations for the diagnosis of anaemia. 
This assumption, however, is based on the practice in one county only. For 
recommendations to be made at a national level, studies need to be done in 
other counties of Denmark as well. The experience gained may not only be of 
national value but may serve as a model for other countries in investigating and 
promoting the appropriate use of iron internationally.
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A comparative investigation has been carried out on the effect of plasma 
fibronectin (Fn) on the adhesive properties of normal rat lymphocytes obtained from 
different lymphoid tissues: blood, spleen, mesenteric and tonsillar lymph nodes. Fn 
was immobilized on the basis of its ability to bind to gelatin. We established that 
concentrations of 40— 50 fxg/ml are sufficient for a saturation effect on Fn coating. For 
spleen cells an adhesion of 55.7 +  9.3%, for mesenteric lymph nodes 34.5+ 8.7% 
and for tonsillar cells 33.8 +  3.2% was observed. Blood lymphocytes showed the 
lowest adhesion, 21.3+ 4.2%. Compared to the other lymphoid tissues, the spleen 
cells exhibited a “basal” adherence to surfaces coated with gelatine only: 19.2+ 4.1%. 
T lymphocytes participate to a greater extent in the process, since their number 
was significantly reduced in cell suspensions after adhesion to both gelatin and 
gelatin-Fn coated surfaces. The addition of soluble Fn leads to a competitive inhibition 
of the lymphocyte adhesion to gelatin-Fn coated surfaces.
The data demonstrated the important role of Fn for the adhesive interactions of 
lymphocytes during their functional distribution in the tissues.
Keywords: lymphocyte adhesion, fibronectin, lymphoid tissues
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Introduction
Fibronectin (Fn) is a major component of the extracellular matrix (ECM). 
It is known to promote cell adhesion and to affect growth and differentiation of 
various cells [1]. The mechanism by which lymphoid cells recognize and adhere 
to Fn or to other components of ECM has been intensively investigated during 
the past few years [2, 3]. Recent studies [4, 5] showed that these cells have adhesive 
receptors, which can mediate cell-to-cell or cell-to-matrix interactions. They 
seem to play an important role in the migration of lymphocytes into extravascular 
tissues, in complex formation with antigenic target cells and in the recirculation 
to lymphoid organs [4]. The results published in our previous communication 
suggest the presence of a lymphocyte subpopulation in human peripheral blood, 
showing an ability to interact with both immobilized and soluble Fn [8].
In the present study we continued our experiments in a rat’s lymphocyte 
system, making a comparative investigation on the effect of plasma Fn on the
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adhesive properties of lymphocytes obtained from different peripheral lymphoid 
tissues, such as spleen, mesenteric and tonsillar lymph nodes and blood. This 
was done to answer the question whether the adhesive behaviour of lympho­
cytes, especially the interaction with Fn, is connected with their functional 
distribution and migration in the organism.
Materials and Methods
Preparation of lymphocyte suspensions
Rat lymphocytes were obtained from various peripheral lymphoid organs 
according to Hudson and Hay [8]. Sodium citrate (3.8%) in 9 : 1 ratio was used 
as an anticoagulant. The blood was drawn from v. cava inferior and after the 
animals were killed the spleen, mesenteric and tonsillar lymph nodes were removed. 
Single cell suspensions were made by gentle stimulation of the organs with a 
needle, washing with PBS and filtering through a nylon mesh. The cells were 
further purified by differential gradient centrifugation on Lymphoprep (Niegaard 
& Co. A/S Oslo, Norway, r.w. 1,077) and resuspended in Eagle medium to a 
final concentration of 5 x 10° cells/ml. The purity of the lymphocyte suspensions 
was higher than 95%, contaminated with a small amount of red blood cells 
(1—3%) and macrophages (2 — 4%). Viability was determined by trypan blue 
exclusion test and was higher than 90%.
In some experiments we measured the amount of T lymphocytes with 
T-rosette determination, using fresh rabbit erythrocytes, according to Taswell [9].
Determination of the lymphocyte adhesion
The adhesion assay was carried out in 96 ELISA plates with flat bottomed 
wells (Type Novogen, Czechoslovakia) as previously described [7]. Briefly, 
5 x 10° cells in 0.1 ml medium were pipetted into each well and the plates were 
incubated at 37 °C for 60 min in a humidified 5% C 0 2 air incubator. At the 
end of the incubation, the nonadherent cells were removed by washing twice 
with PBS. The cells that adhered to the bottom of the wells were fixed with 2.5% 
glutaraldehyde for 15 min, stained with 1% methylene blue in PBS for 1 hour, 
and washed twice again. In some cases, the supernatant from each well was 
resuspended gently and collected in order to estimate the concentration of unat­
tached cells.
The degree of adherence was assayed in two ways: (a) by counting the 
unattached cells and calculating the percentage of adhesion, and (b) photometri­
cally, by measuring the optical density of the dye bound to the attached cells. 
In the assay (a) the supernatant from each well was gently collected and counted
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in a haemocytometer. The percentage of adhesion was calculated by the following 
formula:
Adhesion (%) =
Number of viable cells after incubation 
Number of viable cells before incubation
In assay (b), after staining the attached cells (see above), 100 p.1 of 70% 
ethanol was pipetted into each well and absorbance was estimated after 30 min 
at 650 nm in an ELISA processor (Sumal, Zeiss, DDR). The results obtained 
using method (b) showed a satisfactory correlation when compared to method (a).
Purification o f fibronectin
Acid citrate dextrose plasma (ACD-plasma) was collected from healthy 
donors. The fibronectin was prepared by affinity chromatography on gelatin- 
Sepharose 4B according to the method of Engval and Ruoslahty [10] and stored 
in 4 M urea. Before utilization the Fn was transferred to 120 mM NaCl and 
50 mM Tris, pH 7.3 by gel filtration with Sephadex G-25. The purity of the Fn 
was assayed by SDS polyacrilamide electrophoresis (7.5% slab gel). A single 
band was observed at 220 kDa.
Preparation o f gelatin and gelatin-fibronectin coated surface
The gelatin coated surface were prepared by addition of 100 jxl gelatin 
(Sigma, 300 bloom) solution at a concentration of 50 pg/ml in PBS to wells, 
incubating the plates overnight in a humidified thermostat at 37 °C, and sub­
sequently washing them three times with PBS. Immobilization of Fn was carried 
out on the basis of its ability to bind to gelatin. For this purpose some of the 
gelatin coated wells were additionally exposed to various concentrations of Fn 
(2.5 — 80.0 [xg/ml) in PBS for 30 min at room temperature.
Results
The adhesion of rat lymphocytes to Fn coated surface was investigated. 
The target of this study were normal lymphocytes isolated from blood, spleen, 
mesenteric and tonsillar lymph nodes. The ability of Fn to interact with denatured 
collagen (i.e. gelatin) [10] was used in order to model a binding of this protein 
as similarly as possible to physiological conditions.
Typical experimental data concerning the adherence of different lymphocytes 
on gelatin coated and gelatin — Fn coated wells are shown in Fig. 1. A marked 
increase is apparent in the lymphocyte adherence to Fn coated wells. Counting 
the concentration of unattached cells, the following percentages of adhesion 
were found: spleen cells 55.7 +  9.3%, mesenteric cells 34.5 +  8.7%, tonsillar 
lymph node cells 33.8 + 3.2%, blood lymphocytes 21.3 +  4.2% (see Table 1).
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Table 1
Adhesion of rat lymphocytes obtained from different peripheral lymphoid tissues 
to gelatin and gelatin-fibronectin coated surfaces
Lym p h o cy te
A d h es io n  in 
( m e a n  +  S.E.
%
M.)
source
gelatin co a te d  
a lo n e
gelat in-Fn
coated
Blood 11.2+0 7 21.3+4.2
Spleen 19.2+4.1 55.7+0.3
Mesenter. lymph 
nodes 12.0+ 1.0 34.5+8.7
Tonsillar lymph 
node 14.7+0.9 33.8+ 3.2
A certain augmentation in the basal adherence to wells coated with gelatin only 
was observed for spleen cells (19.2 ± 4.1 %), when compared to the other lym­
phoid tissues (Table 1).
The curves for the lymphocyte adhesion induction (measured photo­
metrically) as a function of the coating concentration of Fn are shown in Fig. 2. 
It is evident that concentrations of 40—50 jag/ml are necessary for achievement 
of maximal effect of Fn coating. Independently of the quantitative differences, 
the curves for lymphocytes from various tissues were similar and a plateau was 
reached at almost equal concentrations of Fn.
In Fig. 3, the adhesion to Fn is presented as Adherent Index (AI) (indicating 
the mean ratio between adhesion to Fn and corresponding gelatin (control) 
surface. The results from 11 separate experiments (using different animals) showed 
that the spleen lymphocyte population exhibits a maximal ability to interact 
with Fn, where AI = 2.7 + 0.2 (p < 0.05), followed by lymphocytes from 
mesenteric and tonsillar lymph nodes (which were not distinguishable from each 
other) AI = 2.4 +  0.1 and 2.5 +  0.2, respectively (p > 0.05). The lowest AI is 
characteristic of blood lymphocytes — 2.0 +  0.1 (p < 0.05).
In this system, the effect of soluble Fn was tested, since this protein is 
a normal component of the blood plasma (as well as other biological fluids) and 
could compete with immobilized Fn in cell receptor binding [7]. A significant
Fig. 1. Morphology of different rat lymphocytes adhered to gelatin coated (a, c, e, g) and 
gelatin-Fn coated wells (b, d, f, h). (a, b)-blood lymphocytes; (c, d)-spleen; (e, f)-mesenteric 
lymph node; (g, f)-tonsillar lymph node. Rat lymphocytes were obtained from different 
peripheral lymphoid organs (see Materials and Methods) and were incubated for 1 hour at 
37 °C in polystyrol plates precoated with gelatin or gelatin-Fn (50 gg per ml for 30 min). At 
the end of incubation nonadherent cells were removed by washing twice with PBS. The cells 
adhered to the bottom of the wells were fixed with 2.5 % glutaraldehyde and stained with 1 %
methylene blue
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Fig. 2. Lymphocyte adhesion induction as a function of the coating concentration of Fn. 
Different concentrations of Fn in 50 mM this 120 mM NaCl, pH 7.4, were used for a second 
coating of gelatin precoated wells. The degree of adherence was assayed photometrically 
(r.p.m.-relative photometrical units) as described under Material and Methods. Each point
is the mean of four experiments
Fig. 3. Effect of Fn on the adhesive properties of lymphocytes from different peripheral 
lymphoid tissues. The adhesion to immobilized Fn is presented as Adherent index (mean ratio 
between lymphocyte adhesion to gelatin-Fn and gelatin coated wells). The inhibitory effect of 
soluble Fn (in concentration 200 fjtg/ml) on the lymphocyte adhesion to Fn coated surface 
(gelatin-Fn wells) was also tested. The degree of adherence was assayed photometrically (see 
Material and Methods). Each value is mean +  Confidence Limit (p =  0.05) from 11 different 
experiments. The measurements were performed in triplicate
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Table 2
T (B) lymphocyte content
B efore adh esio n  A fte r  ad h e sio n
Lym phocyte
non T  (B) 
(%)
gelatin gelatin'-Fn
(%) T
(%)
non T (B)
(%)
T  n o n  T  (B)
(%) (%)
Blood 56 44 39 6i 35 65
Spleen 51 49 37 63 25 75
Mesenter. 
lymph node 45 55 23 77 31 69
Tonsillar lymph 
node 58 42 45 55 43 57
decrease of lymphocyte adhesion to gelatin-Fn coated surfaces was observed 
and this effect was similar for cells prepared from various lymphoid tissues 
(Fig. 3).
Гп some experiments, the amount of T lymphocytes in the suspension 
(respectively non T (B) lymphocytes) before and after adhesion was evaluated, 
in order to find out which cells are involved in the adhesive process. The data 
are presented in Table 2. A definite tendency for a reduction of T cells after 
adhesion to both gelatin and gelatin-Fn coated surfaces was measured.
Discussion
Our data indicate that there exists a subpopulation of lymphocytes, which 
is able to interact with Fn. This fact is in good accordance with our previous 
study [8], and also some recent investigations concerning the human lymphocytes 
[4, 5, 6, 7].
In the present work we showed that there are significant differences in the 
lymphocyte adhesion to Fn, depending on the lymphoid tissues they originate 
from. The highest adhesion was exhibited by spleen lymphocytes where more 
than 50% of the cells adhered, followed by lymphocytes from tonsillar and 
abdominal pools (35% and 33%, respectively). The lowest adhesivity was shown 
by blood lymphocytes (approx. 21 %). It should be noted that the values observed 
for blood lymphocyte adhesion are in good accordance with our previous data 
concerning the effect of Fn on human peripheral lymphocytes [7]. It seems that 
T lymphocytes participate to a greater extent, since their number was reduced 
by about 15 — 20% after adhesion. This, however, is valid for both lymphocyte 
adhesion to gelatin and gelatin-Fn coated surfaces. Kurki et al. [4] reported 
that mitogen stimulation promotes human T lymphocyte adhesion to Fn, indicat-
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ing that the attachment of lymphocytes depends also on their functional state. 
However, not only the T cells are sensitive towards Fn. Liao et al. [5] showed 
that some B lymphoid cell lines adhere predominantly to Fn. We suggest that 
both T and B lymphocytes participate in adhesion (probably to a different degree). 
Otherwise, it is hard to explain the significant difference in adhesion, for example 
between spleen and blood lymphocytes, in spite of the fact that T cell diminution 
(Table 1) was similar. Obviously a more universal mechanism of attachment 
to Fn, which is not related to their subpopulation characteristics, might be valid 
in the case. In this respect, the differences in the lymphocyte adhesion to Fn 
which we observed are probably a result of the accumulation of these cells in 
organs, where lymphocytes exist mainly in an immobilized state. It is difficult 
to explain, however, why of all lymphoid cells spleen lymphocytes showed the 
highest adhesiveness to Fn. One possibility is that it may be due to the functional 
storage of a certain part of “adhesive” blood cells (including lymphocytes) in 
sinusoidal vessels [11].
In a previous paper we reported the inhibition of lymphocyte adhesion on 
Fn coated surfaces in the presence of soluble Fn in the medium [7]. This effect 
was confirmed in the present experiments, indicating that the lymphocytes could 
apparently interact with both immobilized and soluble Fn. According to our 
concept, the interaction of Fn receptor with solid phase-immobilized Fn leads 
to cell adhesion, while preliminary saturation of the receptor with soluble Fn 
induces a competitive inhibition of the process. It is noteworthy, however, that 
this is not typical of other cell systems, for example in fibroblast or hepatocyte 
adhesion [5]. This suggests the existence of some differences between the Fn 
receptor in lymphocytes and in other cells. A specific 140 KDa receptor for Fn 
was recently isolated from the MOPS 315 lymphoid cell line, which exhibits 
a cross immunoprécipitation with the BHK fibroblast Fn receptor [5]. A similar, 
but 190 KDa Fn receptor protein was also isolated from activated T lympho­
cytes [4]. The problem of the type of interaction of the soluble Fn and the cor­
responding lymphocyte membrane receptor (which occurs for example in blood 
or other biological fluids) also remains unsolved. Most likely this interaction is 
comparatively weak, since Fn could be washed away in the course of lymphocyte 
preparation. Otherwise it would not be possible to monitor any effect of Fn in 
these experiments.
In the present work we also established certain differences in the adhesion 
of lymphocytes on denatured collagen (i.e. gelatin). In general, the spleen cells 
exhibited a definitely higher tendency for attachment on this material, whereas 
blood or lymph node lymphocytes did not show any significant differences. Such 
results could be explained by the existence of some bound Fn on the lymphocyte 
surface, which could not be washed off during cell preparation, and which 
interacts with gelatin. Nevertheless, the direct interaction of lymphocytes with 
collagen (gelatin) should not be ruled out, since there is certain evidence in liter­
ature [6, 12] for the existence of a collagen binding protein (VLA 2), which is 
a component of the integrin complex [13].
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the Presence of Fibrinogen and a2-Macroglobulin
I. Léránt,1* T. K ovács,1 B. Papp,1 J. M a ndl ,2 P. Lambin,3 R . M achovich1
12nd and 21st Institute of Biochemistry, Semmelweis University Medical School,
Р.О. Box 260, Budapest, H-1444, Hungary 
3Centre National de Transfusion Sanguine, Paris, France
(Received 7 June, 1988; accepted 11 October, 1989)
Binding of thrombin to cultured endothelial cells has been studied in the 
presence of fibrinogen and or2-macroglobulin. Both fibrinogen and <x2-macroglobulin 
inhibit the interaction of thrombin with endothelial cells. Whereas fibrinogen decreases 
the rate of activation by the thrombin-thrombomodulin complex of protein C, throm­
bomodulin inhibits the rate of inactivation by a2-macroglobuIm thrombin, ^-macro- 
globulin also binds to endothelial cells; (Kd =  3x 10_7 M with 3x 105 binding 
sites/cell), and the rate of binding of the «2- macroglobulin to endothelial cells is faster 
than its complex formation with the thrombin. The data suggest that essentially the 
cell-bound form of fibrinogen and a2-macroglobulin influences thrombin binding 
and functions.
Keywords: aortic endothelial cells, fibrinogen, or2-macroglobulin, protein C, 
thrombin, thrombomodulin
Introduction
Thrombin interacts with both molecular and cellular components of hemo­
stasis [1, and references therein]. Its function is highly controlled by endothelial 
cells [2, and references therein]. The in vivo interaction of thrombin with endo­
thelial cells occurs in the presence of high concentration of plasma proteinase 
inhibitors and fibrinogen. These proteins, besides being substrates of thrombin, 
can also bind to endothelial cells directly, with different affinities and at various 
rates [3 — 6]. The interaction of endothelial cell with thrombin may be modified 
by either free or cell-bound form of these plasma components.
In the present work, we examined the effect of fibrinogen and oc2-macro- 
globulin on the binding of thrombin to endothelial cells. We have found that 
a2-macroglobulin binds rapidly to endothelial cells. The cell-bound form of the 
inhibitor or fibrinogen interferes primarily with the binding of thrombin to 
endothelial cells.
* To whom correspondence should be addressed.
3* VSP, Utrecht, Tokyo 
Akadémiai Kiadó, Budapest
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Materials and Methods
Sepharose 4B, Sephadex G-25 and Sulphopropyl Sephadex C-50 Sephacryl 
S-300 were purchased from Pharmacia Fine Chemicals, Uppsala, Sweden. 
Fibrinogen (human, grade L) and the chromogenic peptide substrate, H-D-Phe- 
Pip-Arg-pNA x2HCl (S-2238) were the products of KAB1 AB and KABI Diag- 
nostica, Stockholm, Sweden, respectively. 125I (as Nal, tracer free) was purchased 
from the Isotope Institute of the Hungarian Academy of Sciences, Budapest, 
Hungary. Lactoperoxidase (B grade, 42 l.U./mg) was from Calbiochem. Other 
chemicals were obtained from the Factory of Laboratory Chemicals (Reanal) 
Budapest, Hungary.
Human a-thrombin was prepared as published earlier [7, 8]. Protein C 
was prepared from human plasma [9]. Thrombomodulin was isolated from rabbit 
lung according to the method of Esmon et al. [10]. Human a2-macroglobulin 
was prepared as described earlier [11, 12]. Antithrombin III was isolated from 
human plasma [13].
For the activation of protein C, thrombin and thrombomodulin was incu­
bated for 5 min at 37 °C, thereafter protein C was activated with the thrombin- 
thrombomodulin complex (25 nM) for 10 min at 37 °C in 20 niM TRIS HCl 
0.1 M NaCl buffer, pH 7.4, containing 10 mM CaCL as described in [14]. Throm­
bin activity was neutralised by the addition of antithrombin HI (2 jaM) and 
heparin (0.5 mU/ml). Neither the thrombomodulin nor antithrombin III inhibited 
the amydolytic activity of the activated protein C on S-2238 substrate.
The activity of thrombin was blocked by a 100-fold molar excess of di­
isopropyl fluorophosphate (DFP) at 4 °C for 1 hour. Excess amount of DFP 
was removed by gel filtration on a Sephadex G-25 column. Chemical modification 
of lysine side chains of fibrinogen was carried out with pyridoxal 5’-phosphate 
(PLP) as described in [5]. PLP and NaBH4 were used in a 100-fold molar excess.
Protein concentrations were determined by the method of Lowry et al. [15]. 
Molar concentrations were calculated using molecular masses 36 KD; 720 KD; 
62 KD; 75 KD; and 65 KD for thrombin [7], a2-macroglobulin [11 ], protein C [9], 
thrombomodulin [10] and antithrombin III [13], respectively.
SDS gel electrophoresis was carried out in 7% polyacrylamide slabs [16]. 
Proteins were iodinated by lactoperoxidase [17].
To prepare thrombin-a2-macroglobulin complex, 2.8 jj.m 12°I-thrombin and 
2.8 jxM or.2-macroglobulin were incubated at 22 °C for various times. Thereafter 
125I-thrombin and 125I-thrombin-a2-macroglobulin complex was separated on 
Sephacryl S-300 column (0.8x5 cm), equilibrated with 0.1 M phosphate buffer 
pH 7.4.
Bovine aortic endothelial cell (BAEC) were obtained as described previ­
ously [18]. The vials contained approximately 2 x 10s BAECs. For binding 
studies they were washed three times with phosphate buffered saline, pFI 7.4 
containing 1 mg/ml bovine serum albumin. The 12oI-labelled ligands were added 
in 0.5 ml serum deficient Dulbecco’s medium containing 2 mg/ml albumin, 10
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mM HEPES, pH 7.4, and incubated. After incubation the cells were washed 
three times within 15 sec with PBS-albumin, and finally 5 ml of liquid-scintillation 
cocktail (Triton X-lOO-toluene-PPO-POPOP) was added for determination of 
radioactivity bound to the cells. For dissociation experiments, cells were incubated 
in the presence of 12oI-ligands as described above, and thereafter they were washed 
three times with fresh medium used for binding experiments. Finally, 0.5 ml 
of this medium was added. At various times the medium was changed and the 
radioactivity of the medium and of the cell fraction was determined.
Results and Discussion
The interaction and the functions of thrombin with and on the endothelial 
cells can be influenced by various factors. Among them, a possible role of fibri­
nogen and a2-macroglobulin has been examined. Both proteins interact directly 
with thrombin and also with endothelial cells [6]. Thus, the question arose how 
fibrinogen and a2-macroglobulin can affect the binding of thrombin to endo­
thelial cells.
Fig. 1. Effect of fibrinogen on the interaction between thrombin and endothelial cells.
A. Binding of thrombin to endothelial cells in the presence of fibrinogen. 
Endothelial cells (2xl03 cells per vial) were preincubated with various concentrations of 
fibrinogen at 22 °C for 20 min. Thereafter, free fibrinogen was removed by washing and the 
cells were further incubated for 10 min in the presence of either 100 nM 123I-thrombin-DIP (o) 
or 100 nM 123I-thrombin-native ( • ). The amount of radioactivity bound to cells was
determined.
B. Binding of active center blocked thrombin to endothelial cells in the presence of
fibrinogen.
100 nM 123I-thrombin-DlP was incubated with 2x 105 endothelial cells in the presence of 
indicated concentrations of fibrinogen. After 10 min incubation at 22 °C, the cell bound
radioactivity was determined.
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Fig. 2. Effect of fibrinogen on the rate of activation of protein C by 
thrombin-thrombomodulin complex.
Protein C was activated by thrombin-thrombomodulin complex in the absence or presence of 
various concentrations of PLP modified fibrinogen at 37 °C for 10 min as described in the 
Materials and Methods section. 100% activity represents the activity of activated protein C 
formed without the addition of PLP-fibrinogen
The binding of both native and DIP-thrombin was decreased by the pre­
incubation of endothelial cells with fibrinogen (Fig. la). Similar results were 
obtained, when endothelial cells were incubated in the presence of 125-I-DIP- 
thrombin and varipus concentrations of fibrinogen (Fig. lb). These data indicate 
that the cell-bound fibrinogen cannot serve as an alternative binding site of 
endothelial cells for thrombin; it is rather inhibitory.
On the other hand, the cell-bound fibrinogen may modify some functions 
of thrombin on the cell surface. As it can be seen from Fig. 2, fibrinogen, modified 
by pyridoxal 5'-phosphate (PLP) to prevent clot formation, decreased the rate 
of activation by thrombin/thrombomodulin complex of protein C in a concentra­
tion dependent manner. Control experiments show that fibrinogen did not inhibit 
the activity of activated protein C on the synthetic peptide substrate S-2238 
(not shown). All these effects of fibrinogen seem to provoke thrombus formation.
a2-macroglobulin may also contribute to the regulation of thrombin activity. 
This inhibitor forms a complex with thrombin, in which the enzyme loses its 
capacity to clot fibrinogen. Furthermore, some data [19] suggest that oe2-macro- 
globulin interacts directly with endothelial cells, although no quantitative data 
are available in the literature. Therefore first we determined the kinetical param­
eters for the binding of a2-macroglobulin to these cells. Our results show that 
a2-macroglobulin binds to endothelial cells in a time and concentration dependent 
manner (Fig. 3 and Table 1). To attain equilibrium between free and cell-bound
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Fig. 3. The binding of a-,macrogIobulin to endothelial cells.
Endothelial cells (2xl05 cells per vial) were incubated for 2 min in the presence of various 
concentrations of 125I-a2-macroglobulin (between 10 and 200 nM) at 22 °C. The ratio of bound 
(B) and free (F) or2-macroglobulin is plotted as a function of bound inhibitor.
In inset: Time dependence of binding of a-2-macroglobulin to endothelial cells at an inhibitor
concentration of 50 nM
a.2-macroglobulin about 30 seconds are necessary. A 10-fold molar excess of 
unlabelled a2-macroglobulin resulted in a 30% decrease in the binding of 125I- 
labelled a2-macroglobulin (data not shown). After the binding of a2-macroglobulin
Table 1
Binding parameters for thrombin and a2-macroglobulin
B inding
sites/cell
Thrombin"1" 3x 10~8 M 3x 104
a2-macroglobulin 3x 10-7 M 3x 105
+ Data are taken from Ref. 5. Binding parameters for a2-macrogIobulin are calculated 
from Fig. 3.
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Fig. 4. Dissociaton of o^'macroglobulin from endothelial cells.
Endothelial cells (2xl03 cells per vial) were preincubated with 100 nM 12T-:í2-macroglobulin 
for 2 min at 22 °C. Thereafter, free ligands were removed by washing, and the cells were further 
incubated in fresh media as indicated in Figure. After 6 min incubation, endothelial cells were 
treated with trypsin (100 gg/ml) for 8 min, and the cell-bound radioactivity was determined. 
Radioactivity bound to cells is expressed as a percent of the amount of a2"macroglobulin 
bound at the end of the 2 min preincubation period
to endothelial cells a rapid dissociation occurred; 50% of the bound inhibitor 
was released in 3 min (Fig. 4). The remaining 50% radioactivity bound to the 
cells was releasable by trypsin treatment, indicating that oc2-macroglobulin is not 
taken up by endothelial cells at 22 °C. Since the concentration of a2-macroglobulin 
in the circulation is high (about 3.5 ;лМ), our results suggest that the endothelial 
cells are saturated with tx2-macroglobulin in vivo.
To study how a2-macroglobulin influences the interaction of thrombin with 
endothelial cells, the cells were preincubated with the inhibitor and, thereafter 
the binding of 125I-thrombin was determined. ot2-macroglobulin decreased the 
binding of thrombin to endothelial cells; a 20-fold molar excess of the inhibitor 
resulted in 36% decrease of binding of thrombin to endothelial cells (Table 2). 
Since thrombin could form a complex with oc2-macroglobulin, the binding of the 
inhibitor-enzyme complex to the endothelial cells was also studied. 125I-thrombin 
was preincubated with molar excess of a2-macroglobulin for 30 min. At various 
periods samples were taken and used for binding experiments. After 30 min 
incubation, the reaction mixture was applied to a column to isolate 125I-thrombin- 
a2-macroglobulin complex. The binding of the separated complex to endothelial 
cells was also determined. The results show the more complex formed the less 
radioactivity was bound to the endothelial cells (Fig. 5 and Table 2). The amount 
of 125I-thrombin-a2-macroglobulin complex bound to the endothelial cells was
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Fig. 5. Effect of a2-macroglobuIin on the binding of thrombin to endothelial cells. 
For direct binding studies 125I-thrombin (100 nM) was preincubated with a2-macroglobulin 
(125 nM) at 22 °C for 30 min. At various periods, as indicated, aliquots of reaction mixture 
were taken and added to endothelial cells. After 30 min incubation, the reaction mixture was 
gel-filtered as described in Materials and Methods, and the binding of the separated throm- 
bin-x,-macroglobulin complex to endothelial cells was also determined. The amount of 
radioactive ligands bound to endothelial cells (2x 104 cells per vial) in a 5 min incubation 
period was determined. Binding of separated thrombin-a2-macroglobulin complex is shown
by the column
Table 2
Binding of thrombin to endothelial cells in the presence of a-macroglobulin
Concentration of ot-macroglobulin 
none 250 nM 1000 nM 
100% 84% 64%
Endothelial cells (2x 105 cells per vial) were preincubated with indicated concentrations 
of «2-macroglobulin at 22 °C for 1 min. Thereafter, 50 nM 125I-thrombin was added and the 
reaction mixture further incubated for 1 min. The amount of cell-bound enzyme was deter­
mined as detailed in Materials and Methods. Results are expressed as percent of the thrombin 
bound without the addition of a2-macroglobulin.
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Table 3
Formation of thrombin-or2-macroglobulin complex in the presence of 
thrombomodulin
Tim e of  the in c u b a t io n  (min)
1 2 3 5 10 20
Absence of thrombomodulin 10 15 20 40 50 70
Presence of thrombomodulin 9 10 10 15 15 20
l23I-thrombin (0.38 [iM) was preincubated either in the absence or in the presence of 
thrombomodulin (2.1 p,M) for 1 min. Thereafter *2-macrogIobulin 0.93 ,uM) was added and 
further incubated at 22°C for times indicated in Table 3. Samples of reaction mixture were 
taken, applied to SDS gel electrophoresis for determination of the free enzyme and the enzyme- 
inhibitor complex formed. The gels were sliced and measured for radioactivity. Results are 
expressed as the percent of radioactivity in the thrombin-a2-macroglobulin complex related to 
the total radioactivity (free thrombin plus thrombin-«2_macroglobulin complex).
less than the amount of bound radioactivity of the samples, containing both 
12oI-thrombin and 125I-thrombin-a2-macroglobulin complex. The data of Fig. 5 
suggest, that the affinity of the inhibitor-enzyme complex to endothelial cells is 
less than that of the free enzyme. From these results we conclude, that the inhi­
bitory effect of a2-macroglobulin on the thrombin-endothelium interaction is the 
consequence of a complex formation between enzyme and inhibitor and it cannot 
be excluded that there is a competition between a2-macroglobulin and thrombin 
for their binding to endothelial cells. However, observation concerning the effect 
of thrombomodulin on the a2-macroglobulin thrombin complex formation (see 
later) in cell free system do not seem to support this assumption.
Since the rate of binding of both thrombin and a2-macroglobulin is very 
rapid [5] (Fig. 3) while the reaction between thrombin and the inhibitor is slow 
(Table 3), we assume that the free a2-macroglobulin may not play important role 
in the control of thrombin action on endothelium.
The possible influence of thrombomodulin on complex formation between 
thrombin and a2-macroglobulin was also determined. 125I-thrombin was incu­
bated with a2-macroglobulin either in the absence or in the presence of molar 
excess of thrombomodulin, and the amount of inhibitor-enzyme complex formed 
was determined by SDS gel electrophoresis. As shown in Table 3, thrombo­
modulin inhibits the reaction between thrombin and a2-macroglobulin, similarly 
as heparin [20]. These data suggest that, the endothelium-bound thrombin can 
be quasi protected against a.2-macroglobulin.
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The Effect of Gamma-hexachlorocyclohexane (Lindane) 
on Blood Cells, Kidney and Liver Tissues in Rabbits
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The effect of intragastric administration of gamma-hexachlorocyclohexane 
(lindane) on peripheral blood cells, kindey and liver was studied in rabbits. White 
blood cells were found to be most affected by lindane, as was shown by the reduced 
phagocytic activity of neutrophils and the increased number of lymphocytes with 
inactive nucleoli.
The changes in the characteristics of erythrocyte cell membranes dependend on 
the length of time lindane was administered and on its withdrawal. Histological 
examination of the liver and kidney showed focal degeneration of tissue and cell 
structure.
Keywords: gamma-hexachlorocyclohexane, leucocytes, erythrocytes, kidney’
liver
Introduction
Lindane is a hematotoxic compound that
— acts directly on bone marrow stem cells [1, 2]
— impaires blood cells in the course of immune mechanism [3], and
— changes the cell membrane [4, 5].
A relationship exists between exposure to organochlorine pesticides and 
their cumulation in adipose tissue, liver and bone marow on the one hand, and 
the development of the hemopoietic system disease on the other [6].
This paper describes the effect of lindane on blood cells, kidney and liver 
tissues after exposures of varying length of time.
Materials and Methods
Animals and animal exposure
Gamma-hexachlorocyclohexane (lindane) was synthetized by the Institute 
of Organic Industry in Warsaw (99.2% purity). Twenty-seven male rabbits 
chosen at random (mean body weight 2800 g) were administered lindane intra-
VSP, Utrecht, Tokyo 
Akadémiai Kiadó, Budapest
gastrically every 24 hours. Lindane was dissolved in 1.5 ml of soyabean oil; 
the daily dose per rabbit was 7 mg/kg (0.1 LD50) [7]. The control animals received 
the same volume of the solvent. Similar doses are used in the examination of 
chronic toxicological effects in experimental animals [8].
The experiments were performed in three different time series. The rabbits 
were administered:
1) a total of 0.5 LD5n lindane during one week, in equal doses,
2) a total of 0.5 LD50 lindane during one week, in equal doses; the rabbits were 
examined one week after the withdrawal of the pesticide,
3) a total of 2.0 LD5() lindane during 4 weeks, in equal doses (after one week 
— 0.5 LD50, after two weeks —1.0 LDS0, after three weeks 1.5 LD50 and after 
four weeks 2.0 LD50).
Blood samples were taken once a week.
172 M. Grabarczyk et al.: Lindane’s effect on rabbit blood cells
Cytotoxic effect
Erythrocyte, reticulocyte, leucocyte and differential white blood cell counts, 
haemoglobin level and haematocrite index were determined by routine methods 
in the rabbits’ peripheral blood.
The physicochemical paraméteres used for the characterization of erythro­
cytes were: osmotic fragility [9], and the degree of erythrocyte damage under 
conditions of “oxidative shock” measured by the spectrophotometric method. 
“Oxidative shock” was induced with 2.5 mg/ml of acetylphenylhydrazine (APH) 
at an incubation time of 3 hours. The levels of the methemoglobin and of dena- 
turated haemoglobin were measured at the 630 nm wave and 700 nm wave, 
respectively.
The index of phagocytic activity and the percentage of non-phagocytizing 
neutrophils were calculated as described previously [10]. The nucleolar activity 
in the lymphocytes was determined according to Smetana [11 ].
The examined parameters of erythrocytes, neutrophils and lymphocytes 
are an important characteristic of these blood cell functions.
Prior to taking the liver and kidney sections, the animals were injected 
with pentobarbital, 100 mg per kg weight. The small fragments of liver and kidney 
were fixed in aceton at 4 °C, and embedded in paraffin. The tissues were cut 
into 7 /mt thick sections and were stained by haematoxylin and eosin.
Statistical analysis
The statistical analysis was based on Student’s t test, the calculation of 
+ SD and +SEM and confidence extended to the difference between the average 
of two normal distributions at the confidence level of 5% [12]. The rise or fall 
of the mean values of the determined parameters was calculated as the per cent 
of mean control values {A %).
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Results
In the course of the series of experiments, the weight of the experimental 
rabbits did not change as compared to the group of control animals. No changes 
were observed either in the haemoglobin level or in the haematocrit value.
After the administration of 2.0 LD30 lindane, the reticulocyte count rose 
by 25 % in relation to the control group.
Fig. 1. Changes in the osmotic resistance (% hemolysis) of peripheral blood erythrocytes in 
rabbits (confidence extent at 5% level):
A — during four weeks of lindane administration, □  -  Lindane, II! -  Control;
B — after one week of lindane administration (1) and one week after lindane withdrawal (2); 
(C — control, L lindane). Each bar represent mean +  SEM of five animals. 
Asterisks indicate statistically significant treatment effects
Fig. 2. Methemoglobin level (A) and denatured hemoglobin level (B) in peripheral blood 
rabbits’ erythrocytes (C — control, L — lindane) after one week of lindane administration 
(1), and one week after lindane withdrawal (2), (x +  SEM)
I— A and B values in relation to oxyhemoglobin accepted as 1
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Some erythrocyte functions were changed, e.g. osmotic fragility (Fig. 1) 
and the sensitivity of the cells exposed to the “oxidative shock” (Fig. 2). After 
the administration of 1.0 LD5n lindane (two weeks), the osmotic fragility increased 
by about 10 % over the control value, without changed sensitivity to the “oxidative 
shock” . One week after the withdrawal of lindane, a significant decrease of 
osmotic fragility was observed, as evidenced by a 32% increase of haemolysis 
in relation to controls (Fig. lb).
At the same time, the increased sensitivity of the erythrocytes to “oxidative 
shock” was expressed as a 42% rise (control 1 = 3.25, lindane I = 4.62) of the 
methaemoglobinlevel (Fig. 2a) and a 32% rise (control I =  1.63, lindane I =  2.16) 
of denaturated haemoglobin (Fig. 2b).
After the administration of 2.0 LD30 lindane, the leucocyte count decreased 
as compared to the control group.
The changes in leucocyte activity included a significant decrease in the 
phagocytosis index of the neutrophils (Fig. 3b), with an increase in the number 
of non-phagocytizing neutrophils after the administration of 0.5 LD50 lindane
Fig. 3. Changes of the phagocytic activity of peripheral blood neutrophils in rabbits during 
four weeks of lindane administration 
A — percentage of non-phygocytizing neutrophils,
B — phagocytosis index (IP) (confidence extent at 5% level)
И  — Lindane, ill — Control
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Fig. 4. Nucleoli in peripheral blood lymphocytes in rabbits after four weeks of lindane admin­
istration (3), (C — control, L — lindane). A — nucleolar coefficient (mean number of 
nucleoli in a lymphocyte x +  SEM), B — percentage of lymphocytes with micronucleoli
(X ±  SEM)
(Fig. 3a). The most significant decrease in phagocytosis was observed after the 
administration of 1.5 LD50 lindane (Fig. 3).
After the administration of 2.0 LD50 lindane, the lymphocyte population 
showed a significant rise in the percentage of lymphocytes with non-active nucleoli 
(micronucleoli) (Fig. 4b), which caused a significant increase in the lymphocyte 
nucleolar coefficient (Fig. 4a).
The administration of 2.0 LD50 lindane produced noticeable hepatocellular 
damage (Fig. 5), and frequent aggregation of erythrocytes in the hepatic lobules. 
In the renal cortex, the degeneration of glomeruli and tubular cells was observed 
(Fig. 6).
Discussion
The purpose of this paper was to explore the functional and structural 
changes in blood cells induced by lindane and to determine whether these alter­
ations are toxic responses.
The focal lesions resulting in the degeneration of cell structure observed 
in liver and kidney, and the accompanying changes in the morphotic elements 
of the peripheral blood suggest that lindane has a cytotoxic effect.
The increase of the number of reticulocytes in the total erythrocyte pool 
observed after 4 weeks of lindane administration (2.0 LD50) is a supplementation 
erythrocyte number reduction. This reduction is a result of increased phagocytosis 
of the erythrocytes by macrophages in the rabbits’ liver [13].
In many cases, the borderlines between physiologic limits (normal functions) 
and toxicity (functional impairment) are difficult to define.
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Fig. 5. The rabbit’s liver after four weeks of lindane administration (2.0 LD30); C — control, 
L — lindane: hepatocellular damage is visible (arrows), (Hematoxylin and eosin, 200x )
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Fig. 6. Renal cortex of a rabbit after four weeks of lindane administration (2.0 LD50); C — 
control, L — lindane: cells destruction in renal tubules is visible, glomerulus with changed 
structure (arrow), (Hematoxylin and eosin, 200X )
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The impaired function of peripheral blood cells accompanying lindane 
administration was found to differ in red and in white blood cells. Changes in 
the physicochemical properties of the erythrocyte cell membrane varied during 
lindane administration and after its withdrawal, while the phagocytic activity 
of the neutrophils was decreased both during and after lindane administration. 
This observation can be connected to differences in the properties of the cell 
membrane structure of erythrocytes and neutrophils [14, 15]. It also depended 
on the similarity of lindane to inositol isomers, which are neutrophil cell membrane 
components [15].
The impairment of the neutrophils due to lindane is a cause of increased 
susceptibility to infections of the organisms exposed to this organochlorine 
pesticide [16].
The increased percentage of cells with non-active nucleoli observed after 
the administration of 2.0 LD50 lindane can be related to the inhibition of RNA- 
synthesis in the lymphocytes. A similar process was noted after the application 
of other pesticides [17] and cytostatic drugs [18].
The degenerative changes of renal tubules in the cortex observed after 
2.0 LD50 lindane were similar to the effect obtained in the investigations of 
another chloriated compound [19], and are also connected with the process of 
the renal elimination of lindane metabolites [20].
The results obtained in the designed experimental set-ups suggest that 
further investigations of the cytotoxic effect of lindane on internal organs and 
peripheral blood are desirable; the changes in blood cells will be the “indicator” 
of the cytotoxic effects of lindane.
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Mobilization o f iron from endocytic vesicles. 
The effects o f  acidification and reduction. 
M. T. Nunez, V. Gaete, J. A. Watkins 
and J. Glass (Departamento de Biológia, 
Facultad de Ciencias, Universidad de Chile, 
Santiago, Chile). J . Biol. Client. 265, 6688 
(1990).
The factors necessary to dissociate iron 
from transferrin in endocytic vesicles and to 
mobilize the iron across the vesicle mem­
brane were studied in a preparation of 
endocytic vesicles markedly enriched in 
transferrin-transferrin receptor complexes 
isolated from rabbit reticulocytes. Vesicles 
were prepared with essentially fully saturated 
transferrin by incubating the reticulocytes 
with the protonophore carbonyl cyanide 
4-(trifluoromethoxy)phenylhydrazone prior 
to incubation with 59Fe, 125I-transferrin with 
or without fluorescein isothiocyanate label­
ing. Initiation of acidification by the addition 
of ATP was sufficient to achieve dissociation 
of 59Fe from transferrin with a rate constant 
of 0.054+ 0.06 s“ 1. Mobilization of "Fe 
out of the vesicles required, besides ATP, the 
addition of a reductant with 1 mM ascorbate, 
allowing ~  60% mobilization at 10 min 
with a rate constant of 0.0038 +  0.0006 s_1. 
An NADU : ferricyanide reductase activity 
could be demonstrated in the vesicles with 
an activity of 7.lx  10_9 mol of NADH 
reduced per min/mg of vesicle protein. Both 
dissociation and mobilization were inhibi­
ted by N-ethylmaleimide, carbonyl cyanide 
4-(trifluoromethoxy)phenylhydrazone, and 
monensin. Mobilization, but not dissocia­
tion, was inhibited by the permeant Fe(II) 
chelator T.cP-dipyridyl. The Fe(lII) chelators 
deferoxamine, diethylenetriaminepentaacetic 
acid, and apotransferrin did not promote 
mobilization of dissociated iron in the
absence of a reductant. This study establishes 
the basis for the cellular incorporation of 
iron through the endocytic pathway in 
which the endocytic vesicle membrane 
utilizes, in a sequential way, an acidification 
system, an iron reduction system, and an 
Fe(II) transporter system.
A. Egyed
Kinetic study o f the Ca2+ pump in erythrocytes 
from essential hypertensive patients. A. De la 
Sierra, P. Hannaert, J. P. Ollivier, N. Senn 
and R. Garay (INSERM U7, Hôpital 
Necker, Paris 75015, France). J. Hyper­
tension 8, 285 (1990).
Ca2+ pump kinetics were investigated 
in erythrocytes from 22 essential hypertensive 
patients and 20 normotensive controls 
(under initial-rate and steady-state condi­
tions, using Sr2+ as a Ca2+ analogue). The 
mean value of the apparent dissociation 
constant for total internal Ca2+ (KCa) was 
slightly but significantly increased in the 
hypertensive population (73 +  7 versus 
5 5 + 3  jumol/l cells, mean +  s.e.m., P =  
0.042 Mann-Whitney U-test). The statistical 
analysis showed that this was due to six 
essential hypertensives who exhibited a 
dissociation constant for Ca2+ that was 
higher than the upper 95 % normal confidence 
limit (KCa =  1 16+7  /rmol/l cells), and 
abnormally high maximal pump rates 
(7.7 +  0.6 versus 5.0 +  0.2 mmol/1 cells 
per h in normotensives, P <  0.001). In 
addition, the apparent dissociation constant 
for Ca2+ was inversely correlated with plasma 
renin activity, although the correlation was 
only borderline (P =  0.076). In the remain­
ing 16 hypertensive patients, all kinetic 
parameters of the Ca2+ pump were within
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the normal range. Finally, a simultaneous 
study of Na+ transport kinetics suggested 
that erythrocyte Ca2+ and Na+ transport 
abnormalities were independent phenomena. 
These results do not support the concept 
that primary hypertension (as a whole 
entity) is associated with a ubiquitous defect 
in the plasma membrane Ca2+ pump. 
However, in some essential hypertensive 
patients (about 25 %) the erythrocyte Ca2+ 
pump exhibited an apparent decreased 
affinity for internal Ca2+. A similar defect 
in vascular smooth muscle may induce a 
delayed Ca2+ extrusion after the opening of 
Ca2+ channels, a disturbance likely to be 
translated into increased vascular reactivity.
B. Sarkadi
Peroxidation-induced perturbations o f eryth­
rocyte lipid organization. D. Pradhan, M. 
Weiser, K. Lumley-Sapanski, D. Frazier, 
S. Kemper, P. Williamson and R. A. Schlegel 
(Department of Molecular and Cell Biology, 
The Pennsylvania State University, Uni­
versity Park, PA, USA). Biochim. Biophys. 
Acta 1023, 398 (1990).
Peroxidation of erythrocyte membrane 
lipids by hydrogen peroxide perturbs the 
lipid bilayer and increases phagocytosis by 
macrophages. This study addresses the 
underlying mechanism of these processes, 
and in particular the role of malondialdehyde, 
a major byproduct of lipid peroxidation. 
When erythrocytes were treated with hydro­
gen peroxide or ascorbate/iron to generate 
malondialdehyde, on with malondialdehyde 
itself, only those cells treated with hydrogen 
peroxide showed increased phospholipid 
spacing and enhanced phagocytosis. This 
result indicates that the alterations observed 
are unique to hydrogen peroxide treatment, 
and that malondialdehyde does not play a 
role in inducing these changes in surface 
properties. Comparison of adherence to 
human umbilical vein endothelial cells and 
phagocytosis showed that increased phago­
cytosis was not mirrored by enhanced ad­
herence. This result suggests that two 
different signals may mediate recognition of 
erythrocytes by macrophages and by endothe­
lial cells.
G. Gwdos
The pH dependence o f  the hemolytic potency 
o f bile salts. A. Ilani and R. Granoth (De­
partment of Physiology, Hebrew University- 
Hadassah Medical School, Jerusalem, Israel). 
Biochim. Biophys. Acta 1027, 199 (1990).
The membrane damaging potential of 
dilute solutions of bile salts was evaluated by 
monitoring continuously the hemolysis of a 
small sample of red blood cells (RBC) 
introduced into a defined media containing 
the bile salts at various pH values. The 
strength of the hemolytic bile salt was 
characterized by the rate of the induced 
hemolysis and by the time that elapsed 
between the introduction of the RBC sample 
into the bile salt containing solution and the 
onset of hemolysis. The potency of the 
unconjugated bile acids was extremely 
sensitive to pH, e.g. the rate of hemolysis 
caused by a 7.5 mM cholate was 1.5%, 20% 
and 64% per min when the pH of the 
solution was 7.65, 7.3 and 6.85, respectively. 
At low pH values the membrane damaging 
effects of deoxycholate was clearly discerned 
at micromolar concentration range. The 
hemolytic potency of glycodeoxycholate was 
also enhanced significantly by lowering the 
pH. The taurine-conjugated cholate and 
deoxycholate were only slightly sensitive to 
variations in pH. Taurocholate at concentra­
tions that were not hemolytic greatly 
enhanced the injurious potency of deoxy­
cholate. These results imply that in acidic 
solutions the presence of bile acids can 
cause damage to cell membranes. It is 
suggested that the acidic environment in the 
proximal duodenum and acidosis developed 
during hypoxia in the liver are two situations 
in which the bile salts may constitute a 
pathogenic factor.
Ilma Szász
Mapping the binding sites o f human erythro­
cyte ankyrin for the anion exchanger and 
spectrin. L. H. Davis and V. Bennett (Ho­
ward Hughes Medical Institute and Depart­
ment of Biochemistry, Duke University 
Medical Center, Durham, North Carolina, 
USA). J. Biol. Chem. 265, 10589 (1990).
This report describes initial characteriza­
tion of the binding sites of ankyrin for
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spectrin and the anion exchanger using 
defined subfragnents isolated from purified 
ankyrin domains. The spectrin-binding do­
main of ankyrin is comprised of two sub- 
domains: an acidic, proline-rich region 
(pi =  4) involving the amino-terminal 80 
residues from 828 to 908 and a basic region 
(pi =  8.8) that extends from 898 to 1386. 
The amino-terminal 70 amino acids of the 
spectrin-binding domain are critical for 
association with spectrin, since a subfragment 
missing this region is only 5 % as active as the 
intact domain in displacing binding of 
spectrin to inside-out membrane vesicles, 
while deletion of the first 38 residues of the 
acidic domain results in a 10-fold reduction 
in activity. The anion exchanger-binding 
site is confined to an 89-kDa domain that 
was isolated and characterized as a globular 
molecule with approximately 30% «-helical 
configuration. A subfragment of the 89-kDa 
domain extending from residues 403 to 779 
(or possibly 740) retains ability to associate 
with the anion exchanger. The 89-kDa 
domain is comprised of a series of tandem 
repeats of 33 amino acids that extend from 
residues 35 to 778. The activity of residues 
403—779 demonstrates that the 33-amino 
acid repeats of the 89-kDa domain are 
responsible for association between ankyrin 
and the anion exchanger. The 33-amino acid 
repeating sequence of ankyrin represents an 
ancient motif also found in proteins of 
Drosophila, yeast, and Caenor habditis 
elegáns. The finding that the 33-amino acid 
repeating sequence is involved in interaction 
with the anion exchanger implies that this 
motif may perform a role in molecular 
recognition in diverse proteins.
B. Sarkadi
ESR analysis with long-chain alkyl spin 
labels in bovine blood platelets. Relationship 
between the increase in membrane fluidity 
by alcohols and phenolic compounds and 
their inhibitory effects on aggregation. Sh. 
Kitagawa, F. Kametani, K. Tsuchiya 
and H. Sakurai (Laboratory of Physical 
Chemistry, Faculty of Pharmaceutical Sci­
ences, University of Tokushima, Tokushima, 
Japan). Biochim. Biophys. Acta 1027, 123 
(1990).
Four spin-labeled probes (5-doxylstearic 
acid (5-NS), its methyl ester (5-NMS), 16- 
doxylmethylstearate (16-NMS) and 4-(N,N- 
dimethyl-N-pentadecyl)ammonium-2,2,6,6- 
tetramethylpiperidine-l-oxyl (CAT-15) were 
used to monitor membrane fluidity change 
in bovine platelets induced by three alkyl 
alcohols, benzyl alcohol and two phenolic 
compounds. The relationship between the 
inscrease in membrane fluidity induced by 
these compounds and their inhibitory effects 
on platelet aggregation was observed. 
Experiments with the four probes showed 
that n-hexyl alcohol induced decreases in the 
order parameter of 5-NS and apparent 
rotational correlation times of the other 
probes at the same minimal alcohol con­
centration. The decreases were observed in 
the concentration range that inhibited 
aggregation. n-Amyl alcohol and n-butyl 
alcohol decreased the values of the para­
meters of the above mentioned only at 
higher concentrations that were dependent 
on their hydrophobicities. Like alkyl alco­
hols, benzyl alcohol and phenolic compounds 
decreased the values of the parameters in the 
concentration ranges in which these com­
pounds inhibited platelet aggregation. The 
concentration of these compounds causing 
50% inhibition of platelet aggregation, the 
IC50 values, and data on 5-NS-labeled 
platelets indicated that they inhibited aggre­
gation and decreased the value of the order 
parameter at lower concentrations relative to 
their Poct values in comparison to the 
effective concentrations of alcohols. Phenolic 
compounds also decreased the values of the 
apparent rotational correlation times of 
5-NMS and 16-NMS. These results indicate 
that the inhibition of platelet aggregation by 
alcohols and phenolic compounds is due 
to membrane perturbation in wide range in 
depths within the lipid bilayer.
Ilma Szász
Divalent cation-dependent structure in the 
platelet membrane glycoprotein la— lia ( VLA- 
2) complex. W. D. Staatz, K. J. Peters and 
S. A. Santoro (Division of Laboratory 
Medicine, Departments of Pathology and 
Medicine, Washington University School of 
Medicine, St. Louis, MO, USA). Biochem. 
Biophys. Res. Comm. 168, 107 (1990).
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Recent studies have shown that the 
platelet membrane glycoprotein la —lia 
(VLA-2) complex mediates the Mg++- 
dependent adhesion of platelets to collagen 
and that this adhesion is inhibited by Ca+ + 
in a simple, linear, noncompetitive manner. 
These findings suggested that separate 
binding sites for Mg++ and Ca++ stabilize 
different divalent cation-dependent struc­
tures within the receptor complex. To 
provide evidence for the existence of such 
structures purified platelet Іа—Па complex 
was subjected to limited proteolytic digestion 
in the presence of Mg++, Ca++, Mg+ + and 
Ca++, or EDTA and the resulting peptides 
mapped by SDS-PAGE using both one- and 
two-dimensional techniques. Unique patterns 
of tryptic peptides were produced under each 
of the conditions. The results indicate that 
Mg++ and Ca++ stabilize different struc­
tures within the la— Ha (VLA-2) complex 
and that these structures influence both the 
collagen binding activity and proteolytic 
susceptibility of the complex.
G. Gár dos
Decorsin. A potent glycoprotein lib— Ilia 
antagonist and platelet aggregation inhibitor 
from the leech Macrobdella decora. J. L. 
Seymour, W. J. Henzel, B. Nevins, J. T. 
Stults and R. A. Lazarus (Departments of 
Biomolecular Chemistry and Protein Chem­
istry, Genentech, Inc., South San Francisco, 
California, USA). / . Biol. Chem. 265, 10143 
(1990).
The discovery, purification, and charac­
terization of decorsin, a protein isolated from 
the North American leech Macrobdella 
decora, are described. Decorsin acts as an 
antagonist of platelet glycoprotein lib — Ilia 
(GPIIb—Ilia), and is a potent inhibitor of 
platelet aggregation. The protein was purified 
to apparent homogeneity from crude whole 
leech extracts by treatment with trifluoro- 
acetic acid followed by GPIIb —Ilia affinity 
chromatography and C18 reverse-phase high 
performance liquid chromatography. Decor­
sin was also isolated from a solution of leech 
ingestate by treatment with trifluoroacetic 
acid followed by C18 reverse-phase high per­
formance liquid chromatography. The pri­
mary sequence of decorsin indicates that the 
protein is 39 amino acids long and contains 
6 cysteine and 6 proline residues, as well as 
the sequence Arg-Gly-Asp, (RGD), a 
proposed regognition site of many adhesion 
proteins. A molecular mass of 4379 was 
obtained by fast atom bombardment mass 
spectrometry and is consistent with the mass 
calculated from the observed sequence. 
Evidence for an N-3 isoform, lacking the 
first 3 amino-terminal residues is also 
presented. Both decorsin and the N-3 isoform 
inhibit GP lib— Ilia binding to immobilized 
fibrinogen with an IC50 of ~  1.5 nM. Human 
platelet aggregation induced by ADP is 
inhibited by decorsin with an IC50 of ~  500 
nM; complete inhibition was observed at 
<  1 ,uM. Based on overall sequence homo­
logy, decorsin does not belong to the family 
of GPIIb —Ilia protein antagonists that is 
found in snake venoms, however, the 
carboxyl-terminal RGD-containing region 
from residues 27 to 38 of decorsin is approxi­
mately 60% homologous with the correspond­
ing region of the snake venom proteins, 
suggesting that high affinity binding of these 
proteins to GPIIb—Ilia is defined by this 
epitope.
G. Gardas
Membrane depolarization selectively inhibits 
receptor-operated calcium channels in human 
T (Jurkat) lymphoblasts. B. Sarkadi, A. 
Tordai and G. Gárdos (National Institute 
of Haematology and Blood Transfusion, 
Budapest, Hungary). Biochim. Biophys. Acta 
1027, 130 (1990).
Jurkat lymphoblasts were stimulated by 
a monoclonal antibody against the CD3 
membrane antigen and the evoked calcium 
signal was followed by the intracellular 
fluorescent calcium indicator indo-1. The 
technique applied allowed us to separately 
investigate the stimulus-induced intracellular 
calcium release and the calcium-influx 
pathways, respectively. In the same cells 
membrane potential was estimated by the 
fluorescent dye diS-C3-(5). The resting 
membrane potential of surkat lymphoblasts 
under normal conditionJ was between — 55 
and — 60 mV. Membrane depolarization, 
obtained by increasing external K+ con-
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centration, removing external Cl , or by 
increasing the Na+/K+ leak permeability 
with gramicidin or PCMBS, did not induce 
calcium influx in the resting cells and did 
not influence the CD3 receptor-mediated 
internal calcium release, while strongly 
inhibited the receptor-mediated calcium 
influx pathway. Half-maximum inhibition of 
this calcium influx was observed at membrane 
potential values of about —35 to —40 mV 
and this inhibition did not depend on the
external calcium concentration varied be­
tween 5 and 2500 ^M. Membrane hyper­
polarization by valinomycin did not affect 
either component of the calcium signal. 
The observed selective inhibition of the 
receptor-operated calcium influx pathway 
by membrane depolarization is probably an 
important modulator of calcium-dependent 
cell stimulation.
Ilma Szász
H a e m ato lo g ia  23, 1990

Printed in Hungary
Akadémiai Kiadó és Nyomda Vállalat, Budapest



INSTRUCTIONS TO CONTRIBUTORS
HAEMATOLOGIA is designed for the publication of original papers, preliminary 
reports, and review which contribute to the advancement in all fields related to haematology 
and blood transfusion. Manuscripts should be submitted in correct English and are accepted 
on the condition that they have not been published or accepted for publication elsewhere. Case 
reports, technical notes, and Letters to the Editor are also welcomed and will be published if 
appropriate.
Manuscripts should be sent to the Editor-in-Chief:
Prof. Susan R. Hollán
National Institute of Haematology and Blood Transfusion
Daróczi út 24
H-1113 Budapest, Hungary
Three copies of the manuscript should be submitted. They should be typed double­
spaced on one side of a good quality paper with proper margins. The first page of the ma­
nuscript should contain the following information: (1) title of the paper; (2) authors’ names; 
(3) name of institution in which the work has been carried out; (4) name and full postal 
address of the author to whom communications regarding the manuscript should be direct­
ed; (5) a short title not to exceed 40 characters (including space) to be used as a running 
head. The second page should contain an abstract of 50— 100 words, summarizing the 
reasons for the study, the methods used, the results, and the major conclusions. This page 
should also contain 4— 8 keywords placed in alphabetical order. Original papers should not 
exceed 15 printed pages including tables, figures, and references. Case reports should not be 
more than four, technical notes and Letters to the Editor not more than two printed pages in 
length. In the manuscripts the approximate location of tables and figures should be indicated 
in the margin. The manuscript of original papers should be divided into summary, introduc­
tion, materials and methods, results, discussion, acknowledgements and references. Review 
articles should also be appropriately divided. SI units should be used in the manuscript, except 
that, for the time being, litre (1) may be used as a unit of volume.
References : Only papers closely related to the author’s work should be referred to. In 
the text citations should include the name of the authors and/or the reference number in 
brackets. A list of references, numbered according to the order of their occurrence in the 
text, should be compiled at the end of the paper. It should be typewritten, double-spaced, 
on a separate sheet.
References to periodicals should be typed double-spaced and mention: (1) name(s) 
and initials of all the authors; (2) title of the paper; (3) international abbreviation of the 
periodical; (4) volume; (5) firstpage number; (6) year of publication in parentheses. Thus: 
4. Liebermann, J. E., Gordon-Smith, E. C. : Red cell pyrimidine 5’-nucleotidase and gluta­
thione in myeloproliferative and lymphoproliférative disorders. Brit. J. Haemat. 44, 425 
(1980).
References to books should include: (1) author(s)’ name(s); (2) title; (3) editor(s); (4) 
publisher; (5) place and year of publication. Thus: 5. Guyton, A. C., Taylor, A. E., Granger,
H. J. : Circulatory Physiology. 11. Dynamics and Control o f  Body Fluids. Saunders, Phila­
delphia 1975. Or: 6. Rappaport, J. M.: Granulocyte transfusion. In: Haematology o f Infancy 
and Childhood. D. G. Nathan, F. A. Oski (eds). Saunders, Philadelphia 1974, p. 875.
Illustrations must be cited and numbered in the order they appear in the text. All line 
drawings should be submitted as clear, glossy, black and white originals or good quality 
photographs. The author’s name and the title of the paper together with the serial number of 
the figure should be written on the back of each print. Legends for illustrations should be 
typewritten, double-spaced, on a separate sheet, and included at the end of the manuscript. 
Tables, each bearing a title, should be self-explanatory and numbered consecutively.
Authors will receive one set of proofs which must be corrected and returned to the 
Editor-in Chief within three days o f receipt. Major alterations of the text cannot be accepted.
Authors are entitled to 50 reprints free of charge.
HAEMATOLOGIA 
VOLUME 23 • NUMBER 3 1990
Contents
Holláti, Susan: How T cells talk to target cells 129
Thambypillai, V., Staehr-Johansen, K.: Policies on iron in Denmark 145
Altankov, G., Kostadinov, A., Marinova, L. : Fibronectin and the adhesive properties of
rat lymphocytes obtained from different peripheral lymphoid tissues 151
Léránt, I., Kovács, T., Papp, B., Mandl, J., Lambin, P., Machovich, R. : Interaction of 
thrombin with endothelial cells in the presence of fibrinogen and a2-macroglobu- 
lin " 161
Grabarczyk, Maria, Kopec-Szlçzak, Joanna, Szczepahska, Izabella, Wozniak, Jolanta, 
Podstawka, Urszula: The effect of gamma-hexachlorocyclohexane (Lindane) on 
blood cells, kidney and liver tissues in rabbits 171
Abstracts 181
Index: 26.861
/n r  UME 23 • NUMBER 4 • 1990 HU ISSN 0017-6559
International Quarterly o f  Haematology
EDITOR-IN-CHIEF:
S. R. HOLLÁN
EDITOR:
I. BERNÂT
ASSOCIATE EDITOR:
K. VÁRADI
IIIVSPIII
UTRECHT, THE NETHERLANDS, 
TOKYO, JAPAN
AKADÉMIAI KIADÓ, BUDAPEST
[AEMATOLOGIA
HAEMATOLOGIA
Haematologia is an international journal publishing original papers on all clinical and 
theoretical aspects of haematology. In addition to regular papers, book reviews and abstracts 
of selected papers from other periodicals also are a special feature of the journal.
Haematologia, published at quarterly intervals, provides the reader with complex and up-to- 
date information.
Manuscripts should be sent to the Editor-in-Chief:
Prof. Susan R. Hollán
National Institute of Haematology and Blood Transfusion 
Daróczi út 24 
H-1113 Budapest 
Hungary
Copy Editor:
D. Keszthelyi
Distributor for
Albania, Bulgaria, China, Cuba, Czech and Slovak Federal Republic, Korean 
People’s Republic, Mongolia, Poland, Romania, U.S.S.R., Viet-Nam, and Yugo­
slavia :
K U L T U R A
Hungarian Foreign Trading Company 
P.O.B. 149, H-1389 Budapest 62, Hungary
For all other countries subscriptions should be sent to 
VSP
P.O.B. 346
3700 AH ZEIST, The Netherlands
Subscription price for volume 23:
DM 330,— (including postage and handling)
Haematologia is covered in Current Contents/Clinical Practice, ISI/Biomed an the SCI.
©  Akadémiai Kiadó, Budapest
VOLUME 23 • NUMBER 4
HAEMATOLOGIA
INTERNATIONAL QUARTERLY OF HAEMATOLOGY
E D IT O R -IN -C H IE F :
S. R. HOLLÁN
E D IT O R :
I. BERNÂT
A S S O C IA T E  E D IT O R :
K. VÁRADI
M E M B E R S  O F  T H E  E D I T O R I A L  B O A R D :
G. A. ALEXEIEFF (Moscow) • A. ANDRÉ (Liège) • A. ANTONINI (Rome) • V. 
APATEANU (Bucharest) • G. ASTALDI (Tortona) • G. BAST (Rostock) • H. BEGE- 
MANN (Munich) • J. BERNARD (Paris) • E. BEUTLER (La Jolla, California) • H. 
BRAUNSTEINER (Innsbruck) • T. BURGER (Pécs) • A. I. CHERNOFF (Bethesda, 
Maryland) • J. DAUSSET (Paris) • E. DEUTSCH (Vienna) • G. DISCOMBE (London) •
C. A. FINCH (Seattle, Washington) • O. K. GAVRILOV (Moscow) • G. GÁRDOS (Bu­
dapest) • J. GERGELY (Budapest) • G. GRÁF (Budapest) • A. GRAFFI (Berlin) • T. J. 
GREENWALT (Cincinnati, Ohio) • A. HÄSSIG (Bern) • M. HRUBÍSKO (Bratislava) • 
E. KELEMEN (Budapest) • S. M. LEWIS (London) • T. MASUYA (Naha, Japan) • P. L. 
MOLLISON (London) • B. P. L. MOORE (Toronto) • A. E. MOURANT (London) •
D. G. NATHAN (Boston, Mass.) • P. A. OWREN (Oslo) • K. RÁK (Debrecen) • S. 
RAPOPORT (Berlin) • W. RUDOWSKI (Warsaw) • S. SEIDL (Frankfurt/Main) • V. 
SERAFIMOV-DIMITROV (Sofia) • J. V. SIMONE (Memphis, Tenn.) • J. P. SOULIER 
(Paris) • S. STEFANOVIC (Belgrade) • H. STOBBE (Berlin) • E. STORTI (Pavia) • 
O. N. ULUTIN (Istanbul) • J. J. van LOGHEM (Amsterdam) • R. L. VERWILGHEN
(Leuven) • A. VIDEBAEK (Copenhagen) • H. D. WALLER (Tübingen)
VSP UTRECHT, THE NETHERLANDS, TOKYO, JAPAN 
AKADÉMIAI KIADÓ, BUDAPEST 
1990

Haematologia 23 (4), pp. 187—191 (1990)
Ethanol Decreases the Level of Sulfhydryl Compounds in Red 
Blood Cells and Changes Their Hematological Pattern in Rats
M. Chwiecko, D. Pawlowska, A. Holownia, R. Farbiszewski*
Department of Inorganic and Analytical Chemistry, Medical Academy, 15—230 Bialystok
8, Poland
(Received 25 October, 1989; accepted January 31, 1990)
The level of sulfhydryl compounds in red blood cells (RBCs) and plasma and 
some haematological parameters were investigated in rats treated with ethanol for 4 
weeks (daily dose of 6g/kg, 30% w/v, p.o.). After ethanol ingestion, the significant 
decrease of non-protein — SH groups were observed in RBCs and plasma. In treated 
rats, the mean corpuscular haemoglobin concentration (MCHC) was decreased and 
the mean corpuscular volume (MCV) was increased. There is a positive correlation 
between these two parameters and decreased content of sulfohydryl groups in RBCs.
Keywords: ethanol, haematological pattern of blood, plasma, rats, red blood 
cells, sulfhydryl compounds
Introduction
Sulfhydryl groups are constant constituents of all cells and necessary for 
their integrity and normal function. In erythrocytes, they are involved in reactions 
maintaining the native structure of haemoglobin, enzimes and membrane pro­
teins [1]. Furthermore, SH groups participate in the protection of cells against 
free radicals and toxic compounds of endogenous and exogenous origin [2].
Acute and chronic ethanol (Et-OH) administration was found to induce 
alteration in hepatic reduced glutathione (GS-H) [3 — 4] hepatic non-protein sulf­
hydryl compounds and plasma protein sulfhydryl compounds [5]. The significant 
decrease in the content of protein and non-protein SH groups in liver and plasma 
was observed after acetaldehyde ingestion [6].
The aim of the present study was to investigate the effect of Et-OH on the 
level of sulfhydryl compounds of the red blood cell nonprotein fraction and on 
haematological pattern of rat blood.
Materials and Methods
Male Wistar rats (approx. 200 g) fed the standard diet, were divided into 
two groups: (A) 15 rats were given a daily dose of 6 g/kg ethanol (30% w/v in 
isotonic NaCl) p.o. for 4 weeks, (B) 10 rats (control group) received an equivalent 
volume of 0.15 M NaCl.
* To whom correspondence should be addressed
l VSP Utrecht, Tokyo 
Akadémiai Kiadó, Budapest
M. Chwiecko et al. : Red blood cells and ethanol
Blood for haematological measurements was taken by cardiac puncture 
into heparinized containers. The erythrocytes were separated from the plasma by 
centrifugation. The level of SH groups was measured in plasma and in haemo- 
lysed and deproteinized erythrocytes using 5,5’-dithiobisnitrobenzoic acid [7].
The following investigations were carried out: total red cell count (RBCs) 
was determined by chamber method, haemoglobin level (Hb) — by the cyan- 
methaemoglobin method and haematocrit (HCT) — by the micromethod. The 
mean corpuscular volume (MCV) and corpuscular haemoglobin concentration 
(MCHC) were calculated.
In serum, the activities of aspartate aminitransaminase (AspAT) [8] and 
y-glutamyltranspeptidase (GGTP) [9] were estimated.
The obtained results were analysed statistically with Student’s f-test. The 
value of p <  0.05 was taken as a statistically significant difference.
Results
Sulfhydryl compound level in erythrocytes and plasma of rats given ethanol 
for 4 weeks and of control group are summarized in Table 1. The amount of SH 
groups was about 35.4% lower in the erythrocyte non-protein fraction of rats 
treated with ethanol than in the control group. The differences were statistically
Table I
The effect of ethanol on non-protein sulfhydryl groups 
in RBCs and in the blood plasma of rats
S ulfhydry l compounds in
RBCs p la sm a
д М /ml /t M /m l
Ethanol group 0.410+ 0.094* 0.187+ 0.077*
Control group 0.634+ 0.081 0.271 +  0.095
* p <  0.05 with respect to the control group
significant (p < 0.05). The total level of sulfhydryl compounds in the plasma 
of rats treated with ethanol was also significantly decreased (31%) (p <  0.05).
Table 2 summarizes the haematological parameters estimated in the rats 
treated with ethanol and in the control group. In rats treated with ethanol, the 
increase of MCV and decrease of MCHC were observed. The differences were 
statistically significant. The ethanol group showed the enhancement of haemato­
crit value. Nevertheless, the erythrocyte count and the haemoglobin level 
did not differ from the control values.
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Table 2
The effect of ethanol on the haematological parameters
Contro l
group
Ethanol
g roup
Erythrocyte 
count (mln/ul) 11.06+ 0.87 10.64+ 0.77
Hematocrit (%) 44.70+ 1.80 48.90+ 2.30*
Hemoglobin
(g/I) 146.60+ 4.30 125.30+ 22.50
MCV (//m3) 40.41 +  3.21 45.95 +  2.17*
MCHC 32.79+ 0.63 25.66+ 1.35*
* p <  0.05 with respect to the control group
Table 3
The effect of ethanol on rat serum aspartate 
aminotransferase and y-glutamyltranspeptidase
Contro l
group
Ethanol
g roup
AspAT (IU) 155.0+ 21.5 195.9+ 11.9*
GGTP (IU) 30.5+ 10.1 46.9+ 7.5*
* p <  0.05 with respect to the control group
In rats treated with ethanol, the activities of AspAT and of GGTP were 
significantly increased (Table 3).
Discussion
Erythrocytes subjected to various physical and chemical factors can be 
rapidly transformed into a broad spectrum of transitional shapes that may alter 
the haemodynamic properties of blood and decrease cell survival in the circula­
tion [10]. The lipid bilayer of the erythrocyte membrane [11], and/or its underly­
ing cytoskeletal protein network may be directly responsible for the control of 
cell shape and specific rheologic properties. As one of the world’s most widely 
used drugs, ethanol is known to have deleterious effects on many organs and also 
on the blood cells [11]. Experiments have shown that Et-OEI exerts its pharmaco­
logical effects mainly by changing the “fluidity” [13]. Recent studies have docu-
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mented that Et-OH induces alteration in the membrane lipid composition of red 
blood cells (RBCs), due to decreased cholesterol efflux [12]. Ethanol induced 
alterations in the shape of human RBCs were accompanied by an enhancement 
of agglutination mediated by ligands with high affinity for negative cell surface 
charge [14].
In our studies, the significant decreases in sulfhydryl compounds of erythro­
cyte non-protein fraction was observed in rats treated with Et-OH for 4 weeks. 
The non-protein sulfhydryl groups consist mainly of the naturally occurring tri­
peptide : glutathione (GSH), free amino acid cystein and other components con­
taining free SH groups. In RBCs, the level of tripeptide is about 1000 times greater 
than in plasma, however, in erythrocytes SH groups are present in their reduced 
form [15].
The diminution of erythrocyte SH groups results in oxidative damage of 
cell [16] and defective transport of some amino acid into the cell. Expression 
of amino acid transport deficiency was shown to precede the decrease in intra­
cellular SH groups. These groups participate in the degradation of hydrogen 
peroxide, which is continuously formed in little amounts in the course of metabolic 
pathway and also under the influence of some drugs. They also protect haemo­
globin against oxidative dénaturation of its protein.
Our results are in agreement with those obtained by Uysal et ah, who have 
studied erythrocyte glutathione level in chronic alcoholic patients [17].
The decrease in the level of sulfhydryl compounds content in non-protein 
fraction of RBCs was accompained by changes in other haematological para­
meters. Our studies show positive correlation between the decrease in SH groups 
and diminution of MCHC in rats treated with Et-OH.
It can be concluded that observed abnormalities in intracellular non-protein 
sulfhydryl compounds of RBCs are responsible for the morphological character­
istics of subsequently altered physico-chemical properties of these cells. It is 
possible that these observations may also be useful as markers of alcohol abuse.
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Activation Antigens in Patients with Sjogren's Syndrome
Margit Zeher1, Katalin Pálóczi2, Gy. Szegedi1
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We report findings of a study of two receptors on mononuclear cells from pa­
tients with Sjogren’s syndrome (SS). The two receptors, interleukin-2 receptor (1L-2), 
transferrin receptor (TfR), were identified using monoclonal antibodies anti-IL-2 and 
OKT9.
We found that the IL-2 and TfR positive cells were significantly higher on 
mononuclear cells (MC) from peripherial blood (PB) of patients with SS than in 
healthy controls.
The study revealed that the IL-2 and TfR positivity reflects systemic immune 
activation and correlates closely with the activity of SS.
Keywords: Sjogren’s syndrome, clinical activity, interieukin-2 receptor, transfer­
rin receptor
Introduction
Sjogren’s syndrome (SS) is a chronic autoimmune disease characterised by 
lymphoid cell infiltration of exocrine glands, especially lacrimal and salivary 
glands, resulting in xerostomia and xerophthalmia [14, 22, 24].
Patients with SS have features suggestive of B cell hyperreactivity: including 
polyclonal hypergammaglobulinaemia, the presence of various autoantibodies 
(such as rheumatoid factor and anti-nuclear antibodies) and circulating immune 
complexes [1,2, 11].
Data of previous studies suggest that the T lymphocytes are activated in 
patients with SS [12, 25]. Resting T cells do not express high-affinity IL-2 recep­
tors; however, after activation with an antigen or mitogen, T cells rapidly express 
receptors. The IL-2 receptor (IL-2R) is composed of at least two subunits, the p55 
(CD25-Tac) and the p75 glycoproteins. p55 and p75 both bind IL-2 independently 
with either low or intermediate affinity, whereas a heterodimeric receptor com­
posed of p55 and p75 binds IL-2 with high affinity.
Our standard approach for the identification of T cell activation depends 
on detecting CD25-Tac and the transferrin receptor (TfR-CD71).
We wanted to find a fast laboratory test to determine clinical activity of 
SS. We measured the IL-2R and TfR positivity on the PBMC and determined 
whether they correlated with disease activity.
VSP Utrecht, Tokyo 
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Materials and Methods
Patients
Twenty-one patients with SS were studied. 21 females, aged 39 to 68 years 
(average 52 years). SS was diagnosed according to previously established crite­
ria [5].
Keratoconjunctivitis sicca was diagnosed after complete ophthalmologic 
examination. Xerostomia was established on the basis of a reduction in the stim­
ulated or spontaneous parotid flow rate and a focus score of more than 1 on 
labial salivary gland biopsy [6]. Nineteen SS patients had only glandular (primary 
SS) and another two had SS with an associated connective tissue disease (rheu­
matoid arthritis: RA). RA was diagnosed by standard diagnostic criteria [20]. 
SS of ten patients were in active clinical stage [26].
The control group was age and sex matched.
Isolation o f lymphocytes
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized 
venous blood by density centrifugation on Ficoll-Hypaque as previously described 
by Miyasaka et al. [15]. The mononuclear cells were collected from the interface, 
washed three times, and resuspended in complete RPMI-1640 (GIBCO) contain­
ing 100 pg/ml penicillin, 100 pg/ml streptomycin, 2 mM L-glutamin, 10 mM 
Hepes supplemented with 1 % fetal calf serum.
Monoclonal antibodies, indirect immunofluorescence, PA CS analysis
Anti-Tac (Becton Dickinson) and anti-transferrin (OKT9, Ortho Diagnostic 
System) monoclonal antibodies were used to detect IL-2 (CD25) and TfR (CD71) 
human lymphocyte surface antigens. 100 pi PBS containing 5% rabbit serum and 
5 pi monoclonal antibodies were added to 100 pi 1 x 107/ml of PBMC suspension. 
It was incubated in an ice water bath, 4 °C, for 30 min, then washed in PBS three 
times. Cells were labelled by 100 pi FITC-conjugated-anti-mouse-IgG. The cells 
were rewashed three times and fixed by 0.04% formaldehyde. The marked cells 
were analysed on a FACS-star. After 10,000 cells had been counted, the number 
of fluorescent cells was given in percentage [9]. Anti-mouse immunglobulin 
(DAKO) produced in rabbit and marked with F1TC was applied as a second 
antibody for the indirect test.
Results
The mean (+  SE) positivity of IL-2R on PBMC from the 11 normal control 
subjects was 3.1 +  1.4. Table 1 shows that the TL-2R positivity were markedly 
elevated in patients with SS if the disease was in a clinically active stage (18.48 +
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Table I
Interleukin-2 receptor (IL-2R) and transferrin receptor (TfR) positivity 
on peripheral blood mononuclear cells from patients with Sjogren’s syndrome
l I I
S jo gren’s syndrome Sjogren 's  syndrome 
Examin ed  in ac tive clinical in inactive clinical 
markers  s tage (n =  10) stage (n =  11)
%  o f  posit ive cells % o f  positive cells 
(m e an  ±  SE) (m ean  ±  SE)
C o n tro l  
( m e a n  ±  SE)
I I I
P value
IL-2R 18.48+5.1 2.72+0.5
Pi-n =0.01
3.1 +  1.4 Pr_nl =0.01
Рн-Ш =  N.S.
TfR 25.81 +  9.68 2.61 +  0.55
P i - и = 0 . 0 2  
3.7+0.7 P,_IM =0.02 
Рц- ui =  N.S.
+ 5.1), p value v.s. control was <  0.01 (by Student’s f-test). The mean (+ SE) 
positivity of IL-2R was 2.72 + 0.55 if the SS was in an inactive clinical stage, 
and did not differ significantly from the positivity of the normal controls (Table 1). 
IL-2R positivity correlated with the clinical disease activity in patients with SS.
Markedly elevated TfR positivity was found on PBMC of patients with SS 
(patients in active clinical stage: 25.81 + 9.68; controls: 3.7 +  0.7). TfR posi­
tivity reflected the clinical activity.
SS is considered to be associated with immune system activation. Likewise, 
SS is considered to be a disease caused by unregulated immune system activation 
resulting from as yet unidentified antigen(s).
Activated T cells [19], B cells [23, 27], natural killer cells [13], and macro­
phages [7, 8] express 1L-2 receptors.
It is known that maximal expression of cell membrane IL-2 occurs after 
48 — 72 hours [4] and that levels of IL-2R peak after 72 hours of in vitro activa­
tion with mitogens [17, 18].
Previously reported studies of the TfR have suggested that the appearance 
of this receptor is a prerequisite for cells to proceed from G1 phase to S phase in a 
cells DNA cycle [10]. Neckers and Cossman reported that the IL-2R needed to 
be expressed on phytohaemagglutinin in assay stimulated lymphocytes before 
the TfR could be expressed [16]. Work by Bettens et al. on lymphocytes stimulated 
by phytohaemagglutinin in assay showed that IL-2R is required to convert Gla 
(medium RNA content) into Glb (high RNA content) [3]. There could, therefore, 
be an evolutionary link between the two receptors.
Discussion
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We report the findings of a study of two receptors on PBMC from patients 
with SS. IL-2R and TfR positive cells were found to be significantly increased 
in PBMC of patients with SS. The study revealed that the 1L-2R and TfR positiv­
ity reflects systemic immune system activation and correlates closely with the 
activity of SS.
The ESR (erythrocyte sedimentation rate) is generally considered to be the 
best available serologic marker for monitoring disease activity in patients with 
autoimmune disease [21]. In some patients whose SS is in full clinical remission, 
a persistently elevated ESR may be present, even though all other laboratory 
results are normal.
Our findings indicate that serum levels of IL-2R and TfR may serve as a 
reliable serologic indicator of disease activity in inflammatory diseases character­
ized by immune system activation.
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The valuability of immunophenotyping of acute myeloid and lymphoid leukae­
mias in comparison to morphological and cytochemical classification were approached 
in 56 cases. Гп the case of acute myeloid leukaemias the immunophenotyping by mo­
noclonal antibodies CD14, CD 13, CD33 was less informative concerning the subtypes 
of the disease. The clinical diagnosis can be achieved on the basis of cytochemical 
investigation alone. In contrast, the diagnosis of lymphoid leukaemias requires all 
information obtained by immunophenotyping by a series of monoclonal antibodies 
CD3, CD2, CD4, CD8, CDI, CD19, CD20, CD21 and CD 10. On the other hand, the 
monoclonal antibodies are essential in differentiation of the very immature myeloid 
and lymphoid leukaemias. This is of great importance from the clinical point of view 
for determining the therapy. Molecular genetic studies based on the characterisation 
of the state of gene rearrangement of immunoglobulin and T-cell receptor beta chains 
have basic importance in the confirmation of the result of immunophenotyping and 
in the determination of leukaemias of unknown origin.
Keywords: FAB classification, immunophenotyping, gene rearrangement
Introduction
Conventional classification of the acute leukaemias as defined by the French — 
American—British (FAB) cooperative group is based on the morphological 
and cytochemical characteristics of the blasts [1]. Using these criteria approx. 
70 — 90% of the acute leukaemias (ALs) are of myeloid-monocytic or lymphoid 
origin [2]. Over the last decade, however, major advances in the characterisation 
of leukaemic blasts have been made with the use of monoclonal antibodies specific 
to various stages of differentiation of the lymphoid and myeloid lineages [3, 4, 
5, 6]. Immunophenotypic analysis can be used successfully: 1) to classify most 
cases which cannot be differentiated by cytochemistry [7], 2) to subclassify the 
acute lymphoid leukaemias (ALLs) into prognostically important subgroups and
3) to identify myeloid, monocytic and other non-lymphoid blast cells [8, 9, 10, 
11, 12, 13, 14, 15]. However, the discrimination between B-cell and T-cell lineage 
may be inconclusive when the neoplastic cells are a mixture of blasts from different 
lineages or/and from biphenotypic leukaemias [16, 17]. For this reason, the 
analysis of immunoglobulin gene and T-cell receptor gene rearrangement be-
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came increasingly important in the study of leukaemic cell clonality and lineage 
[18, 19, 20].
In this work we examined the immunological phenotype of peripheral blood 
mononuclear cells in a group of acute lymphoid leukaemia (ALL) and acute 
myeloid leukaemia (AML) patients in respect of clinical benefit. Results were 
compared with data obtained by FAB classification and cytochemical stains and 
in a few cases with the rearrangement of immunoglobulin and T-cell receptor 
genes.
Patients: Fifty-six patients (33 males and 23 females) affected by AML or 
ALL were studied. Mean age was 35 yrs (range 14 — 73). All patients were studied 
before initiation of induction chemotherapy.
Diagnosis and classification: The preliminary diagnosis and classification 
were performed using the FAB criteria. The morphology of the leukaemic blasts 
was analysed in May —Grünwald —Giemsa stained smears. The following reac­
tions were performed: periodic acid Schiff (PAS), acid phosphatase (AP), Sudan 
black B (Sudan BB), naphthol-ASd-choloacetate esterase (NASDCA), deoxy­
ribonuclease (DN-ase), alpha-naphtyl-acetate-esterase (ANAE), myeloperoxidase 
(MPO) and muramidase. Smears obtained by bone marrow aspiration were used 
for each reaction.
Immunological analysis: Peripheral blood and in few cases also bone mar­
row were used for immunological analysis. Mononuclear cells obtained after 
Ficoll — Flypaque gradient centrifugation were tested with a commercially avail­
able monoclonal antibody panel by indirect immunofluorescence in flow cyto­
metry. T-cell associated antibodies were CD3(T3), CD2(T1 I), CD4(T4), CD8(T8), 
CD1(T6), from Ortho Diagn. System. The B-cell associated reagents were 
CD19(B4), CD20(B1), CD21(B2), CD10(J5) from Coulter Corporation,
CD22(RFB4) from the Royal Free Flospital. Myeloid associated reagents 
were CD13(My7), CD33(My9), CD14(M02) from Coulter Corp. Class II. an­
tigens were detected with HLA-DR from Becton —Dickinson. Anti-IgM anti­
body (Heintel) was used as directly conjugated with F1TC. In the indirect im­
munofluorescence FITC conjugated rabbit anti-mouse immunoglobulin was 
used as second antibody (DAKO). The cell surface marker determination was 
performed according to the method of Janossy et al. [21]. Analysis of all 
samples was done using FACSTAR flow cytometer (Becton —Dickinson). The 
different right and forward angle light-scattering of normal and blast cell was 
also used to separate the two cell fractions. The relative fluorescence intensity of 
10 000 cells per sample was determined. Intracytoplasmic CD3 and CD22 stains 
were used according to the method of Janossy et al. [11, 12, 21]. The diagnosis 
was confirmed by analysing the immunoglobulin (Ig) and T-cell receptor beta 
chain gene (TCR) rearrangement [22, 23]. The immunologic subclassification of 
leukaemias was performed according to the criteria of Foon and Todd [8].
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Table 1
Cytochemical and immunological results of patients with AML I
Patien ts M PO S U D A NBB
D N -ase N A S D C A A N A E FAB
CD14
M 0 2
C D I 3
M Y 7
CD 33
M Y 9
%
H L A - D R Tmmunol.
P henotype
1. +  +  + +  +  + +  - +  +  + +  + M4 и 12 21 nt. myeloid
2. +  + +  +  + + +  +  + +  + M5 6 16 44 nt. myeloid
3. — — — — — MO 4 32 0 61 myeloid
4. +  +  + +  +  + — +  +  + +  +  + M4 5 56 40 22 myeloid
5. +  +  + +  + +  +  + +  +  + +  +  + M4 17 12 8 50 myeloid
6. +  +  + +  +  + +  +  + +  + +  + M4 1 14 80 54 myeloid
7. — — — — + MO 1 4 100 1 myeloid
8. — — — — + MO 3 9 10 68 stem cell
9. +  +  + +  +  + +  +  +  ,+ +  +  +  ,+ +  + M4 23 87 15 71 myeloid
10. +  +  + +  + +  +  +  ,+ +  + + М2 8 75 nt. 73 myeloid
11. + + +  , +  +  + + + M4 5 34 98 5 myeloid
12. +  +  + +  +  + +  +  + +  +  + + М2 30 34 nt. 69 myeloid
13. +  + +  + +  + +  + + М2 42 37 nt. 20 myeloid
14. +  + +  + +  - + +  - Ml 22 86 46 17 myeloid
15. +  +  + +  + +  - +  + + M4 8 87 nt. 83 myeloid
16. +  +  + +  +  + +  +  + +  +  + +  - М2 8 25 nt. 63 myeloid
nt. =  not tested
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Table 2
Cytochemical and immunological results of patients with AML II
Patien ts MPO SUDANBB D N -ase NASDCA ANAE FAB
C014
M02
CDI 3 
MY7
CD33
MY9 HLA-DR Im m uno l.
Pheno type
17 . +  +  + +  +  + + +  +  + + M4 nt. nt. 2 2 7 2 myeloid
18 . — — + — +  - MO 4 14 1 1 41 stem cell
19 . — — — + — MO 8 9 nt. 5 0 stem cell
2 0 . + — — + — MO 1 6 2 nt. 6 2 myeloid
21. + +  + + +  + +  + M4 33 4 5 nt. 2 4 myeloid
2 2 . +  + +  + +  - +  + + Ml 3 2 2 8 6 2 6 0 myeloid
2 3 . +  + + +  - + + М 2 4 nt. 7 0 5 0 myeloid
2 4 . +  +  + + + + +  + +  + + М 2 3 53 8 9 7 0 myeloid
2 5 . +  +  + + + + + +  +  + +  +  + M4 5 6 9 nt. 47 myeloid
2 6 . — — — — + MO 13 21 nt. 6 7 myeloid
2 7 . — — — — + MO 1 1 85 3 2 myeloid
2 8 . +  + + + + +  + +  - M l 3 2 2 8 6 2 4 9 myeloid
2 9 . +  + + + + +  + + М 2 2 2 8 4 0 2 7 myeloid
3 0 . +  + + + + +  + +  , +  + M4 2 4 3 2 5 2 5 myeloid
3 1 . +  + + , + + +  + nt. +  +  , + M4 5 16 10 2 8 myeloid
nt. =  no t  tested
1
2
0
2
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Results
FAB classification: following the criteria of the FAB group, 56 patients 
were classified. 27 patients belonged to myeloid type: MO: 8, M l: 3, М2: 8, 
M4: 12, M5: 1, and 25 cases were of lymphoid origin: LI : 4, L2: 20, L3: 1.
The cytochemical reactions have made the differential diagnosis of the blast 
cell more accurate. Within the lymphoid cells the PAS positivity is characteristic 
of the B-lymphoblast, while the AP reaction serves the differential diagnosis of 
T-lymphoblasts. Myeloid and lymphoid cells could be differentiated from each 
other with the help of DN-ase, MPO and Sudan BB reactions. Over 70% of the 
myeloid leukaemia cases showed positive reactions by MPO, Sudan BB and 
NASDCA stains, while DN-ase reaction was positive in 16/31 cases (51.6%) 
(Tables 1 and 2).
The ANAE reaction was positive in 23 out of 31 cases (74.1 %) and dubious 
in 4 cases. The reaction was found to be strongest in the case of M4 leukaemias. 
The cellular muramidase reaction was performed to prove the monocytoid char­
acteristics as a supplement of the other reactions.
Immunological characterisation o f the myeloid leukaemias : With the help 
of the monoclonal antibody panel used in our laboratory we confirmed the myeloid 
characteristics in 28 cases of leukaemias. In three of the patients the HLA-DR 
antigen was the only marker that could be detected on the cell surface (case 8, 
18, 19). In these cases the B-cell characteristics could be excluded on the basis of a 
negative intracytoplasmic CD22 determination, thus we thought this leukaemia 
to be of stem cell origin. We tried to compare the results of the FAB classification 
and of immunological marker studies (Table 3). CD 13, DR, CD33 antigens 
were present in all of the Ml cases. In the М2 subgroup the leukaemic cells 
expressed CD 13, CD33 and HLA-DR antigens, while two cases were found to be 
CD14 positive, too. A variable presence of CD 14, CD13, CD33 and HLA-DR 
recognized antigens was observed in AML subtype M4. The one patient with M5 
subtype was characterised as a CD14, CD13, CD33 and HLA-DR positive case. All 
MO type AML were CD14 negative and HLA-DR positive, while myeloid spe­
cific antigen (CD13 or CD33) was found on the cells in five cases.
MO : 8 M l  : 3 М 2 : 8 M 4  : 12 M5 : 1
CRI4+ 0/8 0/3 2 /8 5/12 i/i
CR13 + 3/8 3/3 7/7 9/11 i/i
CR33 + 2 /8 3/3 5/6 6/9 i/i
HLA-DR+ 8 /8 2/3 7/8 9/12 i/i
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Table 3
Comparison of FAB subclasses and positivity of monoclonal 
antibodies in AML patients
N u m b ers  o f  P ati en ts
M o n o c . l o n a l s
20 4 K. Pálóczi et al.: Immunophenotyping in ALs
Cytochemical and immunological data of ALL patients are shown in Tables 
4 and 5. Using cytochemical stain, 7 cases marked as ALL B-cell type, and 9 
cases as acute undifferentiated leukaemia (AUL) (Table 4). Six non-T ALL cases 
were only HLA-DR positive by immunophenotyping (group-I = stem cell leu­
kaemia). In these cases the intracytoplasmic CD3 and CD22 also proved to be 
negative. HLA-DR, CD19 and CD10 antigens were simultaneously present in 
four cases, these were classified as group III. Group VI. represents the most 
mature type of non-T ALL. In these four cases the cells expressed surface im­
munoglobulin (slg) and other antigens, including CD20, CD19, and HLA-DR. 
CALLA antigen (CD 10) may also be present (Table 4). The immunophénotype 
of the leukaemic cells was questionable in two cases (No. 32, No. 36). The gene 
rearrangement was not tested in one of these two patients and it was germ line 
in the other case. The immunodiagnosis was confirmed by Ig heavy chain gene 
rearrangement in ten non-T ALL cases. In one case (No. 34) the results of im­
munophenotyping and gene rearrangement study were contradictory.
The simultaneous positivity of the AP and negativity of Sudan BB reac­
tions were used as cytochemical markes in T-cell ALL (Table 5). Using these 
criteria 9 cases were found to be T-cell by cytochemistry, while only 7 of these 
cases proved to be T-ALL by immunophenotyping. One of the two latter cases 
(No. 50) was a non-T ALL-111 type (shown CD10+ and HLA-DR+ as well as 
CD2 —, CD3 —, CD8 —, CD4 —), while the other patient (No. 51) was diagnosed 
as having AML (CD13 + ). The criteria of Foon and Todd [8] were used for the 
evaluation of the T-ALL case, too. CD3, CD2, CD4, CD8 and CD1 antigens 
were detected on the surface of cells in 3 cases (group-II), and CD3, CD2, CD4, 
CD8 positivity and CD1 negativity was found in 2 cases (group-III). In two cases 
(No. 48, No. 53) the subgroups were undeterminable. The origin of the leukaemic 
proliferation was proved by TCR beta chain gene rearrangement in the 5 thus 
investigated T-ALL cases.
The purpose of this study was to compare the morphological, cytochemical 
and immunological characteristics of acute leukaemias. It is important to dis­
tinguish lymphoid from myeloid blast cells from the point of view of prognosis 
and therapy.
Morphological and cytochemical studies do not lead to the correct diagnosis 
in all cases. We used four monoclonal antibodies described to be of myeloid 
lineage in our AML cases (Tables 1, 2, 3). In our patients this panel of antibodies 
provided no more information than the cytochemical stains. Drexler et al. [5] 
using a broader monoclonal antibody panel found a correlation between the 
expression of the cell surface markers and the FAB subgroups, but immuno- 
logically only 3 subgroups could be established. Even among these groups there 
was a correlation only between the immature cells FAB Ml and the immuno­
logical phenotype (group I, HLA-DR + , CD33 + ). The reason for this is not only 
that these diseases are extremely heterogenous [8, 24, 25], but also that myeloid 
reactive antibodies may react with subsets or differentiation stages of lymphoid
H aem ato lo g ia  23, 1990
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Table 4
Results of patients with ALL non-•T-cell type (n =  16)
Patients F A B PAS
Cytochemical
Classificat ion
CD 19 CD 20 CD21 H L A - D R C D  10 s lgM Imm unol.
Pheno ty pe G enoty pe
32. L2 + ALL-B? 20 26 12 nt. nt. 3 ? nt.
33. L2 + ALL-B? 14 4 2 62 16 13 B-l. nt.
34. L2 +  + ALL-B. 87 89 5 88 41 84 B-Vl. T
35. L2 + ALL-B ? 7 1 1 52 14 15 B-I. B
36. L2 — AUL 4 3 0 nt. 0 10 7 G
37. L2 — AUL nt. nt. nt. 75 92 5 В-Ш. nt.
38. L2 — AUL 54 6 10 82 73 8 B-IIL B
39. L3 — AUL 4 4 3 74 4 20 B-l. G
40. L2 — AUL 9 nt. nt. 55 15 nt. B-L? B
41. L2 — AUL 21 70 9 80 27 73 B-VI. B
42. Li + ALL-B? 12 9 14 31 41 30 B-I. B
43. L2 — AUL 63 37 30 83 80 80 B-VI. B
44. Li — AUL 74 55 nt. 72 13 97 В-ѴГ. B
45. L2 — AUL 96 94 nt. 84 90 3 B-l 11. B
46. L2 + ALL-B 7 4 8 6 54 21 24 B-l. B
47. L2 + ALL-B? 45 nt. nt. 49 42 8 B-l II. B
nt =  not tested; AUL =  acute undifferenciated leukaemia; G =  germ line
. Pálóczi et al.: Im
m
unophenotyping in ALs 
205
H
aem
atologia 23, 1990
Table 5
Results of patients with ALL T-cell type (n =  9)
P atien ts FAB A cid pH
CD3
%
CD2
%
CD4 CDS
Vo
CD1 CD10
%
HLA-DR Im m uno l.
P heno type G eno type
48. L2 60 80 nt. nt. nt. nt. 12 T-ALL** T
49. LI nt. 92 65 67 61 nt. nt. T-ALL-II. T
50. L2 + 10 20 5 3 nt. 42 85 non-T-ALL nt.
51. L2 + 2 2 nt. nt. nt. 10 20 Myeloid 
My 7 : 72%
germ line
52. L2 + 66 92 35 24 6 3 4 T-ALL-III. T
53. LI + 73 72 12 7 nt. 11 16 T-ALL** nt.
54. L2 nt. 63 55 70 62 11 13 T-ALL-II. T
55. L2 + 49 92 37 28 0 3 6 T-ALL-IIL? nt.
56. L2 + 91 87 89 81 91 0 3 T-ALL-II. T
n t  =  n o t  te s te d ** =  in t r a c y to p la s m ic  C D 3  w a s  p o s i t iv e
206 
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cells [7, 9, 10, 17]. Moreover, many myeloid antigens are not or only partially 
expressed on immature cells. Recently, the best immunological reagent for the 
recognition of AML seems to be a monoclonal antimyeloperoxidase antibody
[26] . Reactivity with this antibody certainly seems to be a better test for AML 
than standard cytochemistry and has the advantage of making quantification 
possible.
In ALL the cytochemistry could not exactly separate T- from B-lineage
[27] . The staining patterns of AP (Table 5) of immature T-cells is not always 
characteristic. The PAS positivity of non-T lymphoid cells (Table 4) is also un­
certain. In those patients who had non-T ALL according to FAB criteria, the 
panel of monoclonals CD19, CD20, CD21, CD10, HLA-DR helped us to provide 
a more accurate diagnosis. Immunophenotyping made it possible to divide the 
cases into prognostically important subgroups. The immunological study provided 
valuable additional information expecially in our AUL cases (Table 4). We found 
a very good correspondence between the results of immunophenotyping and Ig 
gene rearrangement in non-T ALL. Results of immunophenotyping and DNA 
study were contradictory only in one case (No. 34). This patient was found to 
have B-ALL, group VI, while the TCR beta chain gene was rearranged (RG/GG). 
The Ig heavy chain gene was in germ line configuration. The results of immuno­
logical investigation and T-cell receptor gene rearrangement in ALL of T-cell 
type are in agreement in all tested cases (Table 5).
In problematic ALL cases, intracytoplasmic CD3 and CD22 staining are 
of diagnostic value. These early T and B cell markers may help to discriminate 
between immature (thymic and bone marrow) and mature T and B cell leu- 
kaemias/lymphomas [28].
In conclusion: immunophenotyping based on the use of monoclonal anti­
bodies makes the objective and reproducible differentiation of acute lymphoid 
and myeloid leukaemias as well as lymphoid leukaemias of T and B origin pos­
sible. Based on our results it can be stated that immunophenotyping did not 
help in distinguishing the subtypes of AML. Cytochemical methods can be well 
applied for purposes of clinical diagnostics. On the other hand, the diagnosis of 
acute lymphoid leukaemias is not possible without use of monoclonal antibodies.
References
1. Bennett, J. M., Catovsky, D., Daniel, М-T., Flandrin, G., Galton, D. A. G., Gralnick, H.
R., Sultan, C. : Proposals for the classification of the acute leukaemias: French-Ameri- 
can-British (FAB) Cooperative Group. Hr. J. Haematol. 33, 451 (1976).
2. Kuriyama, K., Tomonaga, M., Nonaka, H., Jinnai, I., Matsuo, T., Yoshida, Y., Ame-
nomori, T., Tanaga, M., Ichimaru, M., Ohmiya, A., Tsuji, Y. : A comparative study 
of immunological and cytochemical profiles between adult and childhood acute ly­
mphoblastic leukaemias (ALLs): heterogeneity in adult common ALL. Leukaemia 
Res. 9, 1237 (1985).
H aem ato lo g ia  23, 1990
208 K. Pálóczi et al.: Immunophenotyping in ALs
3. Wain, S. L., Borowitz, M. J.: Practical application of monoclonal antibodies to the diag­
nosis and classification of acute leukaemias. Clin. Lab. Haemat. 9, 221 (1987).
4. Janossy, G., Bollum, F. J., Bradstock, K. E. : Cellular phenotypes of normal and leukaemic
hemopoietic cells determined by analysis with selected antibody combinations. Blood 
56, 430 (1980).
5. Drexler, H. G., Minowada, J. : The use of monoclonal antibodies for the identification of
acute myeloid leukaemias. Leukaemia Res. 10, 279 (1986).
6. van der Reijden, H. J., Van Rhenen, D. J., Lansdorp, P. M., van’t Veer, M. B., Langen-
huijsen, M. M. A. C., Engelfriet, C. P., von de, Borne, A. E. G. K. : A comparison of 
surface marker analysis and FAB classification in acute myeloid leukaemia. Blood 61, 
443 (1983).
7. Greaves, M. F., Rao, J., Hariri, G., Verbi, W., Catovsky, D., Rung, P., Goldstein, G.:
Phenotypic heterogeneity and cellular origins of T-cell malignancies. Leukaemia Res. 5, 
281 (1981).
8. Foon, K. A., Todd, R. F. : Immunologic classification of leukaemia and lymphoma.
Blood 68, 1 (1986).
9. Drexler, H. G.: Classification of acute myeloid leukaemias-a comparison of FAB and
immunophenotyping. Leukaemia 1, 697 (1987).
10. Drexler, H. G., Gignac, S. M., Minowada, J. : Routine immunophenotyping of acute
leukaemias. Blut 57, 327 (1988).
11. Сатрапа, D., Janossy, G., Bofill, M., Trejdosiewitz, K., Ma, D., Hoffbrand, A. V.,
Mason, D. Y., Lebacq, A.-M., Forster, H.: Human B cell development. I. Phenotypic 
differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue. J. 
Immunol. 134, 1524 (1985).
12. Сатрапа, D., Thompson, J. S., Amlot, P., Brown, S., Janossy, G.: The cytoplasmic
expression of CD3 antigens in normal and malignant cells of the T lymphoid lineage. 
J. Immunol. 138, 648 (1987).
13. Hayhoe, F. G. J.: Classification of acute leukaemias. Blood Reviews 2, 186 (1988).
14. Majdik, O., Liszka, K., Lutz, D., Knapp, W. : Myeloid differentiation antigen defined by
a monoclonal antibody. Blood 58, 1127 (1989).
15. Stashenko, P., Nadler L. M., Hardy, R., Schlossmann S. F. : Characterisation of human
B lymphocyte specific antigen. J. Immunol. 125, 1678 (1980).
16. Greaves, M. F.: Differentation-linked leukaemogenesis in lymphocytes. Science 234, 697
(1986).
17. Greaves, M. F., Chan, L. C., Furley, A. J. W., Watt, S. M., Molgaard, H. V.: Lineage
promiscuity in hemopoetic differentiation and leukaemia. Blood 67, 1 (1986).
18. Waldmann, T. A., Davis, M. M., Bongiovanni, K. F., Korsmeyer, S. J. : Rearrangements
of genes for the antigen receptor on T cells as markers of lineage and clonality in 
human lymphoid neoplasms. N. Engl J. Med. 313, 776 (1985).
19. Furley, A. J. W., Chan, L. C., Mizutani, S., Ford, A. M., Weilbaecher, K., Pegram, S. M.,
Greaves, M. F. : Leukaemia 1, 644 (1987).
20. Tawa, A., Hozumi, N., Minden, M., Mak, T. W., Gelfand, E. W. : Rearrangement of
the T-cell receptor ß-chain gene in non-T-cell, non-B-cell acute lymphoblastic leukaemia 
in childhood. N. Engl. J. Med. 313, 1033 (1985).
21. Janossy, G., Сатрапа, D., Coustin-Smith, E., Timm, A.: Leukocytes methods. In:
Laboratory Manual. Immunofluorescence. Cawley, J. C. (Ed.), Churcill Livingstone, 
Edinburgh pp. 1, (1986).
22. Foroni, L., Catovsky, D., Rabbits, T. H., Luzzato, L.: DNA rearrangements of immuno­
globulin genes correlate with phenotypic markers in B cell malignancies. Mol. Biol. 
Med. 2, 3 (1984).
23. Foroni, L., Földi, J., Matutes, E., Catovsky, D., O’Connor, N. J., Baer, R., Forster, A.:
a, ß  and у T-cell receptor genes: rearrangements correlate with haematological pheno­
type in T cell leukaemias. Br. J. Haematol. 67, 307 (1987).
H aem ato lo g ia  23, 1990
K. Pálóczi et al.: Im m unophenotyping in ALs 209
24. Pessano, S., Palumbo, A., Ferrero, D., el al.: Subpopulation heterogeneity on human
acute myeloid leukaemia determined by monoclonal antibodies. Blood 64, 275 (J 984).
25. Griffin, J. D., Linch, D., Sabbath, K., Larcom, P., Schlossman, S. F. : A monoclonal
antibody reactive with normal and leukaemic human myeloid progenitor cells. Leu­
kaemia Res. 8, 521 (1984).
26. van der Schoot, C. E., von dem Borne, A. E. G. K., Tetteroo, P. A. T. : Characterisation
of myeloid leukemia by monoclonal antibodies, with an emphasis on antibodies against 
myeloperoxidase. Acta Haematol. 78, 32 (1987).
27. Morphologic, Immunologic and Cytogenetic (MIC) working classification of acute
lymphoblastic leukaemias. Report of the workshop held in Leuven, Belgium. Cancer 
Genet. Cytogenet. 23, 189 (1986).
28. Janossy, G., Coustan-Smith, E., Campana, D.: The reliability of cytoplasmic CD3 and
CD22 antigen expression in the immunodiagnosis of acute leukaemia: a study of 500 
cases. Leukaemia 3, 170 (1989).
H aem ato log ia  23, 1990

Haematologia 23 (4), pp. 211— 221 (1990)
Hairy Cell Leukemia. Immunological Study
Roman Stela2, S. Berceanu1, N . Munteanu1, Contanta Ursea1,
IOANA MOTOIU1, I. MORARU2
1 Clinic of Hematology — Fundeni Hospital, 258, Sos. Fundeni 72437 Bucharest; -Department 
of Immunology, Victor Babes Institute, Bucharest, Romania
(Received 12 April, 1987; accepted 7 July, 1989)
The study has been performed on peripheral blood and splenic malignant cells 
from 16 patients with hairy cell leukaemia (HCL). The cell surface markers were iden­
tified by rosette techniques and using monoclonal antibodies (m Ab). The surface 
markers’ expression of the hairy cells (HC) varied. The H receptors, the T-cell antigens, 
the HLA-DR antigens and smlgG were either expressed or not according to the af­
fected organ, the progress of illness, or the treatment. The surface pattern changed 
sometimes in the same patient during the progress of illness. These observations 
demonstrate that HCL is a unique disease with malignant cells characterized by a 
marked variability of the cell surface markers.
To demonstrate the ability of hairy cells to bind labile smlgG, the cells were 
studied by affinity chromatography on SpA-Sepharose 6MB and by ES-rosette assay. 
The percent of cells bound on SpA-Sepharose varied between 6% and 66%, repre­
senting the hairy cells with labile-bound smlgG. With affinity chromatography it was 
also possible to separate the hairy cells with a special phenotype: T^ T4! Tg Tj/ 
surface membrane labile-bound IgG 1 (lIgG+) FcR+, HLA-DR+ EACD+ (Ripley 
rosette forming cells), resembling a normal subset of large granular lymphocytes 
(LGL). The percentage of these cells varied between 60% and 86% of the bound cells. 
These observations suggest that in HCL, the malignant transformation might involve 
a common progenitor for the B, T and LGL lineages, the hairy cell being a hybrid 
type of malignant cell. Its main immunological peculiarity is the marked mobility of 
the surface membrane structures and hence the lability (plasticity) of the surface markers' 
expression.
Keywords: affinity chromatography, hairy cell, pathogeny, surface markers 
Introduction
It is generally admitted that the hairy cell represents a special type of malig­
nant B-cell [1, 2, 3], although it often displays some features which are character­
istic for T-cells [4], or macrophages. Recent data [5, 6] have shown that some­
times hairy cells express simultaneously markers characteristic for different cell- 
lineages. Therefore, it was suggested that in hairy cell leukemia the malignant 
disturbance induces the appearance of a hybrid neoplastic line [6]. The following 
communication presents data in support of this hypothesis. Sixteen patients ad­
mitted to the Clinic of Haematology in the last 5 years were investigated. The 
malignant cells were studied using monoclonal antibodies, rosette-tests and affinity 
chromatography on SpA-Sepharose 6 MB. The effect of splenectomy and/or che­
motherapy upon the hairy cell surface markers is also discussed.
VSP Utrecht, Tokyo 
Akadémiai Kiadó, Budapest
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Materials and Methods
Cells.
Mononuclear cells were purified from the peripheral blood and/or spleen 
of 16 patients by sodium metrizoat-Ficoll centrifugation [7]. The mononuclear 
cells were again separated by centrifugation over dense Ficoll-Hypaque (specific 
gravity 1084). The cells at the interface represented the fraction enriched in HC. 
In all experiments, the Ficoll preparations were stained to exclude granulocyte 
contamination. Hairy cell leukaemia is characterized by an almost complete mono­
cytopenia and by a deficiency of circulating normal B-cells [8]. The purity of the 
HC fraction varied between 65% and 99% (99% in three cases with high percent 
of HC) in the peripheral blood and between 80% and 90% in the spleen, as 
confirmed by the presence of acid phosphatase resistant to tartaric acid (TRAP). 
The viability of cells was never below 95% as demonstrated by the trypan blue 
method.
Monoclonal antibodies (m Ab)
Purified m Ab preparations (belonging to the IgG1 isotype) directed against 
T3, T4, Tg, Tn and HLA-DR lymphocyte membrane antigens, were kindly sup­
plied by Dr. Chang Yi Wang (Memorial Sloan Kettering Cancer Center, New 
York, NY).
Staphylococcus protein (SpA) coated erythrocytes (ES reagent)
Bovine erythrocytes were coated with SpA as previously described [9].
ES-rosettes assay
Monoclonal antibodies were used in an ES-rosette assay as already de­
scribed [10]. Briefly, the suspension of cells in culture medium (2.5 x 10°) is in­
cubated for 30 min in ice with the respective monoclonal antibodies (0.005 ml). 
After three washings in cold culture medium, the cells are suspended in 0.2 ml 
culture medium and treated with 0.015 ml ES reagent. The mixtures are centri­
fuged at 100# for 10 min and incubated for 2 hr or overnight at 4 °C. The pellet 
is gently resuspended and treated with 0.030 ml of 0.2% toluidine blue in phos­
phate buffered saline.
Assay for labile-bound smlgG
Freshly prepared peripherial blood or splenic hairy cells (10(’/0.5 ml) were 
mixed with ES reagent and centrifuged at 4 °C for 10 min at 100#. The samples 
were stored at 4 °C overnight. The cells preincubated at 37 °C for 2 hr were 
washed with culture medium and rosetted with ES-reagent in the same con­
ditions.
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EACD (Ripely) — rosette assay
Freshly prepared cells (10f’/0.5 ml) were mixed with EACD reagent (human 
erythrocytes group 0 Rh-positive, sensitised with human anti CD serum 1 : 16,000). 
After centrifugation at 4 °C for 10 min at 100#, the samples were stored for 30 
min at room temperature, or overnight at 4 °C.
The HC nature of the rosette forming cells (E, ES, EACD and m Ab-ES- 
rosettes) was identified on the Romanowski stained preparations and by the 
presence of TRAP.
Affinity chromatography on SpA-Sepharose 6MB
SpA-Sepharose 6MB was prepared as previously described [10], and could 
bind 4 mg IgG/ml of packed gel. Cells were fractionated on SpA-Sepharose 6MB 
as previously described [11]. Briefly, about 5x10' cells suspended in 0.5 ml 
culture medium (RPMI containing 1 % N aN ;i and 0.5% from a solution of 10% 
gelatine in P.B.S.) were loaded on SpA-Sepharose 6MB in a small size plastic 
column (1 x5 cm) and incubated for 45 min at 4 °C. Unbound-cells were washed 
from the column with 25 ml of cold RPMI medium. The specifically-bound cells 
(with IgG on the surface) were eluted mechanically by adding 5 ml of RPMI 
medium warmed at 37 °C, and resuspending the gel on the upper part of the 
column. The procedure was repeated twice, and the eluted cells were collected by 
centrifugation. The unbound-cells as well as those retained on the column and 
eluted by resuspension were investigated for cell surface markers. The hairy 
cell nature of the rosette forming cells was identified on the Romanowski stained 
preparations and by the presence of TRAP.
TRAP activity was identified using the Li Cy, Yam Ly technique [12] and 
recently according to the technique described by Takashi Machii [13].
Transmission electron microscopy (TEM) was performed on 1 % osmium 
tetroxide — fixed PBMC (1 hr at 4 °C). The cells were then dehydrated and 
embedded in Epon 812. Thin sections cut with an ultramicrotome were stained 
with uranyl acetate and lead citrate [14].
Results
The diagnosis of HCL was made on the basis of the clinical picture, char­
acteristic cytology of the abnormal cells from the peripheral blood, from the 
bone marrow biopsy (performed in all cases) and from the spleen. The histo- 
pathological preparations from the bone marrow and spleen revealed the special 
disposition of HC. The percentages of HC were established by phase contrast 
microscopy and confirmed by the presence of acid phosphatase resistant to tar­
taric acid (TRAP) in all cases. The almost total replacement of splenic tissue by 
HC was confirmed by TRAP reaction. The transmission electron microscopy of 
the peripheral blood mononuclear cells was performed in all cases and showed 
morphologically typical HC, a proportion of which contained ribosome-lamellar 
complexes (myelinoid bodies).
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Table 1
Clinical and laboratory data of the HCL patients
N o. N am e Sex Age
(yrs)
W B C
c o u n t/m m 3
N r/m m 3 and  % 
o f  H C
Liver en ­
la rgem en t 
cm
Spleen 
en la rg e­
m ent, sm
T rea tm en t Progress o f  d isease C ause 
o f  dea th
l. SN -AО 50 1,600 520 (32) l 6 Corticotherapy
Splenectomy
72 months -
2. CG <? 53 5,200 3,200 (67) 3 10 Corticotherapy
Splenectomy
36 months
~
3. SA -A6 46 3,900 1,100 (30) l l lithium carbonate 
Corticotherapy
AIHA
36 months
sepsis
4. CN ■AО 59 4,600 2,150 (46) 10 12 lithium carbonate 
Corticotherapy
4 months acute fi- 
brynolysis
5. DR ■AО 59 16,200 15,400 (96) 1 3 CHOP progressive disease 
(fever, lymphnode 
enlargement)
18 months
sepsis
6. DZ -A6 43 5,400 4,200 (78) 1 4 CHOP
Corticotherapy
progressive disease 
12 months
sepsis
n CD $ 53 1,200 750 (62) 2 4 Corticotherapy AIHA broncho­
pulmonary infec­
tions 
2 months
sepsis
8. PV -AО 28 3,400 1,800 (53) 1 4 Splenectomy pulmonary tuber­
culosis treated 
and cured 
44 months
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9. GI ■AО 74 14,000 11,200 (80)
10. IL $ 49 2,200 1,200 (54)
M. MI 3 58 1,200 480 (50)
12. ME 3 35 1,600 350 (22)
13. TD 3 68 2,600 1,450 (56)
14. RC 3 52 2,100 840 (40)
15. IV 3 16,000 13,600 (85)
16. SN 3 48 4,500 2,475 (55)
НС =  hairy cells
AI HA =  autoimmune haemolytic anemia 
WBC =  white blood cells
2 5 CVP
Corticotherapy
14 months heart
failure
10 15 Splenectomy pulmonary tuber­
culosis 
2 months
sepsis
1 4 Splenectomy 6 months sepsis
3 2 Splenectomy 19 months —
1 3 Corticotherapy
Splenectomy
36 months
10 3 lithium carbonate
Corticotherapy
Splenectomy
hepatic cirrhosis 
2 months
acute
hepatic
failure
1 10 Corticotherapy
Splenectomy
14 months —
2 4 Corticotherapy
Splenectomy
36 months
N>
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Table 1 demonstrates some clinical and laboratory data of our patients 
at admission. Most of the patients (87%) were males of middle age. Only three 
patients (19%) had a leukemic spread, but in most of the cases a high proportion 
of the WBC were HC. The haemoglobin varied between 4.5 g% and 14 g%, the 
lowest values were observed in two cases of autoimmune haemolytic anemia 
(A1HA). The platelet count varied between 20,000 and 120.000. All of the patients 
had liver and spleen enlargement. Forty-three percent of the patients are still 
alive; the cause of death was sepsis in the majority of the cases.
Table 2
Surface markers of hairy cells*
Surface
m arkers
Specificity
N um ber and 
percent o f
cases
P ercen t o f  
positive  
cells
T, (CD;,) Pan T mature cells 9 (56.2) 18-86
T4 (CD,) helper T cells 7 (53.8) 23-77
T» (CD,) cytotoxic/suppressor T cells 9 (56.2) 17-79
T„ (CD,) sheep erythrocyte receptor 9 (56.2) 20-69
HLA-DR B-cells, monocytes, activated 
T-cells, leukemic cells 16 (100) 12-84
smlgG surface membrane stable bound IgG 11 (68.7) 12-52
,IgG surface membrane labile-bound IgG 10 (62.5) 6-81
FcR receptors binding IgG (EA-positive 
cells) 16 (100) 60-82
Fc;-R receptors binding human IgG 
(EACD-positive cells) 14 (87.5) 0 -65
* Splenic and/or peripheral blood hairy cells
Table 2 gives the results with surface markers of peripheral blood and splenic 
hairy cells. It can be seen that HLA-DR antigens and Fc receptors were expressed 
by HC in all cases, the percentages of positive cells varying between 12 — 84% 
and 60 — 82%, respectively. In most of the patients, the HC were also EACD- 
positive. The T-cell antigens were expressed in over 50% of the cases. Only about 
31 % of cases were E negative and 25% were smlgG negative. The HC presented 
a large variability regarding the expression of surface markers. The E receptors, 
the T-cell antigens, the HLA-DR antigens and smlgG were expressed or not 
according to the affected organ, the course of illness or the treatment. Sometimes 
the surface pattern changed in the same patient during the course of the disease.
Affinity chromatography on SpA-Sepharose 6MB and ES-rosettes assay 
demonstrated the ability of HC to bind labile smlgG. The percent of cells bound 
on SpA-Sepharose — representing the HC carrying mainly labile-bound JgG — 
varied between 6% and 66%.
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Table 3
Surface markers of peripheral blood and splenic hairy cells separated by affinity 
chromatography on SpA-Sepharose 6MB
P eriphe ra l b lood Spleen Peripheral b lood
M arkers U n­ U n­ U n-
I nitial B ound bound Initial Bound b o u n d Initia l B ound , ,hound
cells cells cells cells cells cells cells cells cells
T3+ 55 81 20 62 86 14 55 67 29
n 40 50 10 47 51 12 45 65 27
T8+ 55 60 9 70 81 9 55 67 0
TÍ, 50 62 8 58 67 2 52 60 20
DR + 29 37 28 19 29 18 72 84 59
EA + 72 73 74 80 81 82 79 72 73
EACD + 22 36 1 25 28 2 12 20 1
sm!gG + 46 6 NT 30 8 2 44 12 4
5x 107 cells/0.5 ml were introduced in the column and 66% were bound on SpA-
Sepharose
NT — not tested
Table 4
Surface markers of peripheral blood hairy cells 
separated by affinity chromatography on SpA-Sepharose 6MB
N o ' M arkers In itial cells
Bound
cells
U n b o u n d
cells
T3+ 2 5 3 0 10
T  + 1 4 9 1 8
9* * T +z  1 s 7 2 0 0
T  + 1 и 0 0 0
DR 1 2 0 4 4 3
EA + 7 8 85 7 0
EACD + 18 2 4 1
smIgG + 3 4 8 4 0
T3+ 3 9 5 7 2 8
n 2 0 13 33
V ' 51 56 2
T  +P 1 1 1 6 0 6 7 10
DR + 3 5 3 6 3 3
EA + 8 0 85 7 0
EACD + 0 0 0
smlgG + 5 0 4 9 1 0
* 5x 107 cells/0.5 ml medium were introduced in the column and 6% were bound 
on SpA-Sepharose
** 5x 107 cells/0.5 ml medium were introduced in the column and 55% were bound 
on SpA-Sepharose
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In Table 3, the surface markers of peripheral blood HC (before and after 
splenectomy) and splenic HC separated by affinity chromatography on SpA- 
Sepharose 6MB are shown. The percentages of cells expressing T-cell markers 
and EACD-positive cells are much diminished in the unbound population (espe­
cially the T3, T 8 and T31-positive cells). After splenectomy, the percentages of 
HLA-DR positive cells in all the three columns are much increased. Only a little 
part of the bound cells were ES-positive and represented the cells which had 
maintained the IgG molecule on their surface during the cell-release from the 
SpA-Sepharose.
Table 4 gives the results of surface markers of peripheral blood HC sepa­
rated by affinity chromatography in two patients. Six percent and 55%, respec­
tively of the cells introduced to the column were bound on SpA-Sepharose. The 
cell population bound on SpA-Sepharose was rich in HC positive for T3, Tg 
antigens and smlgG in both cases. In case No. 2 the HC were also EACD-positive. 
The HC bound on SpA-Sepharose expressed a special phenotype: T^ T4 Tg 
T/j Jg G + Fc+ D R + EACD*. The percent of cells with such a phenotype varied 
between 66% and 86% of the bound cells. The unbound HC had stable-bound 
IgG, presented lower percentages of T-cell antigens and were EACD-negative.
Table 5
Phenotypical changes induced by splenectomy
1 Appearance of new markers 1 case
2 Appearance of some antigens in a
higher percentage 4 cases
3 Transient expression of some antigens 3 cases
4 Maintainance of the same phenotype 1 case
5 Disappearance of some markers 1 case
Table 5 presents the phenotypical changes induced by splenectomy. In most 
of the cases (88.8%), splenectomy modified the surface phenotype by the appear­
ance or disappearance of some surface markers by the expression of some antigens 
in a higher percentage, or by the transient expression of some antigens.
Discussion
The presence of the labile-bound smlgG — as demonstrated by affinity 
chromatography and ES-rosette assay — and the ability of some hairy cells to 
form EACD (Ripley) rosettes are characteristic for the LGL lineage. By affinity 
chromatography on SpA-Sepharose 6MB, a cell-population enriched in hairy 
cells with a particular phenotypic pattern was separated: T3+ T£ Т / T^ iTgG + 
Fc+ R DR .This phenotype resembles those of a subset of normal LGL sepa­
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rated by affinity chromatography from the normal peripheral blood lymphocytes 
and normal splenocytes.
Recent data [15] have shown that the LGL with T3, T8 (or T4) and Tn 
antigens represent the cytotoxic T lymphocytes (CTL) which are sometimes FcR- 
positive. The latter feature explains the CTL binding on SpA-Sepharose. The 
few T4-positive cells among LGL population might represent either the NK sub­
population with T helper phenotype [16] or the CTL-T4 positive, MHC class II 
restricted [15]. However, the question regarding the relationship between these 
LGL subpopulations and HC remains open, further investigations are necessary.
It is known that all of the hairy cells — as well as LGL cells — express Tac 
receptors spontaneously. The T cells express these antigens only after the antigenic 
stimulation. It was also demonstrated that hairy cells have the ability of changing 
their phenotype in cultures with PHA. In these conditions the T _ IgG+ BAJ 
cells became E+ T + IgG-  BA, [17]. Our study showed that this phenomenon 
takes place also “in vivo” , after splenectomy.
Our observation demonstrated that the malignant LGLs display — in 
phase-contrast microscopy — similar characterics as hairy cells. In agreement 
with other workers [13] some of our unpublished observations have shown that 
leukemic LGL are positive for tartrate resistant acid phosphatase (TRAP). Our 
observation that some normal LGL present unicentric myelinoid bodies similar 
to those observed in hairy cells might be correlated to some recent data [18] 
which report that a subpopulation of LGL show a selective phagocytosis of 
Gram-positive bacteria, similarly to myelomonocytes.
These observations suggest that in hairy cell leukemia the malignant 
transformation involves a common progenitor for B cell, T cell and possibly for 
the LGL lineage. The phenotypical variants and their lability — the main im­
munological peculiarity of hairy cells — might be associated to the extreme mo­
bility of the surface membrane structures, demonstrated by the fast capping phe­
nomenon. In agreement with other authors [6] we believe that in hairy cell leu­
kaemia the malignant disturbance induces the appearance of a hybrid neo­
plastic line, or that the disease is linked to a major disturbance in stem cell com­
mitment. The hybrid types of malignant cells have also been described in leu­
kaemias and malignant lymphomas, in which the malignant transformation in­
volves a progenitor cell that may possess multiple maturational capacity [19, 
20, 21 ].
In conclusion, the results of the present study show that the hairy cell is a 
hybrid type of malignant cell. The main immunological peculiarity of this cell 
is the marked mobility of the surface membrane structures, and hence the lability 
(plasticity) of its immunophénotype. The surface pattern changed sometimes in 
the same patient, the surface markers were either expressed or not, according to 
the affected organ, the progress of the illness or the treatment, thus demon­
strating that HCL is an unique disease with malignant cells characterized by a 
marked variability of the surface antigenic structures.
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Distribution and Scatter of Yeast Cell Phagocytosis by 
Human Monocytes in an improved Glass Surface Assay
Leif Bjermer*, Leif A thlin, K erstin Sondell, Sture Eriksson and  Bo N orberg
Departments of Lung Medicine, Surgery, Internal Medicine, Geriatric Medicine and Blood 
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The assessment of yeast cell phagocytosis by glass-adherent monocytes was 
improved by ultrasonication of yeast cells prior to the experiments in order to prevent 
aggregation, restriction of measurements to completed engulfment regardless of the 
number of partides ingested, and stopping of phagocytosis before counting by main­
tained cooling and the addition of EDTA. The modifications provided a reduced disper­
sion of individual values, increased engulfment of yeast cells, and decreased numbers 
of yeast cells only adherent to the monocyte membrane. The improvement made the 
method more convenient for the study of engulfment by monocytes.
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Introduction
The Hed technique of studying yeast cell phagocytosis by glass-adherent 
neutrophils [1] was moditied by Athlin and co-workers and found useful for the 
study of the effects of some antineoplastic agents on monocyte phagocytosis, both 
on the adherence step and the engulfment step [2]. The scatter of individual values 
was, however, inconveniently wide and skew [3].
The aim of the present study was to improve assessment of yeast cell phago­
cytosis by glass-adherent monocytes. The study was restricted to the engulfment 
stage of phagocytosis. The modifications introduced consisted of ultrasonification 
of the yeast cells in order to reduce aggregation, counting of engulfment as an 
all-or-none process in the individual monocyte (fraction of monocytes with at least 
one ingested yeast cell), maintenance of ice-cool temperature by keeping the 
samples on an ice bed during counting, and addition of 1 mM EDTA to the cold 
stopping of the phagocytosis process [4, 5].
Materials and Methods
Blood sampling
Heparinized blood, 16 IU/ml was obtained from blood donors at the Blood 
Centre of the hospital as in previous studies [2, 3]. The processing of the sample 
was started within one hour and finished within 6 hours after blood collection.
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Isolation o f mononuclear leukocytes
Mononuclear leukocytes (MNLs) were isolated from peripherial blood by 
the one-step metriozate-Ficoll procedure, using Lymphoprep® (Nycomed, Oslo, 
Norway). The MNLs were then washed twice in phosphate-buffered saline (PBS) 
and resuspended in “complete medium” to a concentration of 5x10° cells/ml.
Incubation for monocyte adherence to the glass surface
MNLs, 1 X 10e cells in complete medium, were then seeded on sterile slides 
in Petri dishes and incubated in a humified chamber with 5% C 0 2 at +  37 °C to 
allow the monocytes to adhere to the glass surface. For the removal of lymphocytes 
from the preparation, the slides were rinsed with pre-warmed complete medium 
at +37 °C. The remaining cells were stained for non-specific esterase, (data not 
shown).
Preparation o f yeast cell suspension
Baker’s yeast (Saccharomyces cerevisiae) was suspended in saline, washed 
twice, boiled 30 min, washed twice again, and labelled with fluorescein isothiocya­
nate, FITC (Merck, Darmstadt, FRG) in carbonate buffer, pH 10.2, 108 cells per 
ml of FITC buffer with a FITC concentration of 0.1 mg/ml for 60 min at +  37 °C. 
The cells were washed three times with saline, re-diluted to 108 cells per ml, and 
frozen at —17 °C in 0.5 ml aliquots. Before the experiment, the FITC-labelled 
yeast cells were opsonized with autologous serum (0.5 ml mixed with 0.5 ml of the 
FITC-labelled yeast cells), incubated at +37°C for 30 min. The cell suspension 
was then washed twice and resuspended in 2 ml of saline. Ultrasonication was 
performed in a continuous cycle for one minute to prevent yeast cell aggregation 
(Branson Sonofier, Cell Disruptor B15).
Phagocytosis experiments
Opsonized yeast cells labelled with FITC, 5 x 10(i yeast cells in 200 pi saline 
were added to the slides and incubated for 30 min at +37°C in 5% C 0 2. The 
ratio of effector/target cells was 0.5—l.OxlO2. The preparation of test samples 
(n =  38) was modified compared to that of previous control (n = 304) by ultra­
sonication of yeast cells to prevent aggregation. Phagocytosis was stopped by 
dipping the slides in ice-cold PBS, pH 7.4. In the test samples, ice-cold temperature 
was maintained during the counting procedure by the use of an ice bed. The stop­
ping of phagocytosis in the test samples was further improved by addition of 
EDTA, 1 mM (5). The fluorescence of non-ingested yeast cells was then 
quenched by dripping trypan blue in saline (Sigma, St. Louis, Mo, USA), 0.5 
mg/ml, onto the slides. The staining time was 10 s. The stain was decanted and 
the preparation was sealed with a coverslip. The fractions of monocytes without 
associated yeast cells, with only adherent yeast cell(s) and engulfed yeast cell(s)
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were counted in 50 consecutive monocytes at 320 x magnification with a Zeiss 
incident-light microscope.
Complete medium
The complete medium consisted of 165 ml heat-inactivated human serum, 7 
ml L-glutamine 20 mM, 500 ml RPMI 1640 medium (Flow Laboratories, Irvine, 
Ayershire, Scotland), and benzylpenicillin 2.4 /rg/ml.
Glassware
The glassware was thoroughly washed, rinsed in demineralized water and 
70% ethanol, and autoclaved at +120 °C for 20 min.
Statistics
Descriptive and analytical statistics (a two-tailed t-test) were performed by 
StatWorks™ (Heyden Son, London).
Results
It is evident from Figure 1A that ultrasonication of the yeast cell suspension, 
carefull control of the temperature after “stopping” of phagocytosis, and addition 
of EDTA to the steady-state suspension of cells improved the assessment of engulf- 
ment, the present marker of phagocytosis, from a median value of 65 % monocytes 
with at least one ingested yeast cell to 90% (p < 0.001). The improvement was 
associated with a conspicuous decrease in the scatter of individual values. How­
ever, the distribution still had a minor left skew (Fig. 1 A).
Corresponding to the improvement of engulfment (Fig. 1A), the yeast-to- 
monocyte adherence decreased (p < 0.001) with a concommittant decrease in 
dispersion of individual values. However, the adherence dispersion still had a 
minor right skew (Fig. IB). The changes depicted in Figure 1 (A and B) thus 
indicate a shift from phagocytosis recorded in the adherence step to phagocytosis 
recorded in the stage of performed engulfment.
The influence of cold shock with and without maintenance of ice-cool 
temperature was then studied (Fig. 2). Intermittent cooling with return to room 
temperature reduced engulfment to 27% of control values. When ice-cool tempe­
rature was maintained, engulfment was reduced to 15% of control values.
Addition of EDTA, 1 mM, reduced phagocytosis to 3%. Since EDTA by 
itself reduced phagocytosis to approximately 20% of control values (not shown), 
the effects of EDTA and maintained cooling were additive and virtually abolished 
engulfment after the first minute of control conditions (Fig. 2).
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Discussion
Phagocytosis is a labile series of events, which usually requires the proces­
sing of control and test samples from the same donor simultaneously [2, 3]. 
Present data are such control values from different experiment series, in which basic 
conditions were kept constant. The apparent improvement in the present test tech­
nique [4, 5] made a comparison with our previous controls feasible and unbiased.
The precision of phagocytosis assessment in glass-adherent monocytes was 
increased by the modifications introduced in the present study (Fig. 1). It is rea­
sonable to assume that meticulous stopping of yeast cell phagocytosis during coun­
ting after the incubation time — maintained cooling and addition of EDTA — was 
the essential modification. Each step alone suppressed engulfment down to 20% 
of control values [5]. The combined effect was additive and virtually abolished 
further engulfment (Fig. 2).
Fig. [A. The fraction of monocytes containing ingested yeast cells in our previous controls 
(white, n =  304) and in test samples (dark, n =  38). Shaded area shows overlapping. The 
distribution of values our previous controls was characterized by median 65 %, interquartile 
range 54—74 %, range 6— 96 %, skewness — 0 .568, kurtosis 0 .500, test samples by median 90%, 
interquartile range 86— 94 % , range 72— 100% , skewness — 0 .537, kurtosis — 0.445 
Fig. 1 B. The fraction of monocytes with only adherent yeast cell in our previous controls 
(white, n =  304) and in test samples (dark, n =  38). Shaded area shows overlapping. The 
distribution of values in our previous controls was characterized by median 12 %, interquartile 
range 6— 18% , range 2— 52% , skewness 1.467, kurtosis 2.705, test samples by median 2 %, 
interquartile range 2— 4 % , range 0 — 8 % , skewness 0 .626, kurtosis — 0.502
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Monocyte phagocytosis in vivo is a complex variable which involves adhe­
rence to a surface, locomotion, adherence between phagocyte and particle en- 
gulfment, processing, and secretion of degradation products [6, 7, 8]. One attrac­
tive aspect of the Hed technique is that phagocytosis is measured in surface- 
adherent phagocytes with discrimination of phagocyte-to-particle adherence and 
the subsequent step, complete engulfment of the particle. However, restriction to 
completed engulfment make repeated measurements more convenient and retain 
most of the information [2].
The dispersion of individual values in the measurement of monocyte function 
is a widely recognized phenomenon [9]. Jt is reasonable to assume that the disper­
sion reflects heterogeneity in the studied monocyte population as regards matura­
tion and differentiation. Although diversity is as fine as dispersion is foul, the 
phenomena may represent two sides of the same coin. Nevertheless, the present 
restrictions and modifications of assessing monocyte phagocytosis make the 
technique more precise and convenient.
Fig. 2. The control monocytes (CTRL) were allowed to ingest yeast cells for 30 minutes. The 
reaction was then stopped by dipping the slides in ice-cold phosphate-buffered saline (PBS), 
2 nil, containing 1 mM EDTA. Continuing of phagocytosis during temperature equilibrium 
with room temperature was then studied by addition of yeast cells to glass-adherent monocytes 
for one minute, adding 2 ml ice-cold PBS to the Petri dish, and then incubated at room tem­
perature for 30 minutes before counting (PBS I). The efficiency of maintained cooling was 
studied by keeping a parallel sample on ice for 30 minutes instead of incubation in room tem­
perature (PBS II). Addition of 1 mM EDTA to maintained cooling suppressed engulfment to 
a baseline value reflecting a one-minute period of active phagocytosis (EDTA). Mean of 6
experiments, +SEM
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A human glycophorine A specific murine monoclonal antibody mediates the 
antibody dependent killing of antibody sensitized human erythrocytes by human K 
cells (monocyte-free mononuclear cells). The overall level of killing is lower than that 
mediated by conventional, human anti-D antibodies but it is significant on each target 
cell.
Keywords: monoclonal antibody, glycophorine A, ADCC
Introduction
Antibody dependent cellular cytotoxicity (ADCC) is a link between cellular 
and humoral immune mechanisms. Effector cells of non-T and non-B phenotypes 
— K cells — are armed with antigen specific antibodies and lyse the sensitized target 
cells.
It has been shown that human antibodies are very efficient in mediating this 
reaction, while mouse monoclonal reagents induced a negligible level of killing 
if any.
Here we describe the results obtained with a murine monoclonal antibody 
to glycophorine A, which mediates an efficient cell mediated lysis of sensitized 
human erythrocyte target cells.
Materials and Methods
A4 a murine monoclonal antibody used in the experiments, was obtained from 
a fusion described previously [1 ]. The antigens were the erythrocytes which con­
taminated the peripheral blood mononuclear cell suspension. Agglutinations 
were evaluated in normal (physiological saline) or low ionic strength solution 
(LISS) in the presence or absence of anti-mouse immunoglobulin [2].
The effector function of antibody in ADCC was tested on human erythro­
cytes as target cells and K cells as effector cells used at 1 ; 5, 1 : 10 and 1 : 20 
ratios, respectively. A4 monoclonal antibody was used at a final dilution of 1 : 40.
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The tests were performed in round-bottomed microtitre plates [3]. The specific 
5]Cr release was calculated according to the following formula:
test cpm — spontaneous cpm
specific 51Cr release =  -----------------------—  x 100
total cpm — spontaneous cpm
Results and Discussion
A4 monoclonal antibody was selected on the basis of its capacity to induce 
strong agglutination of human glycophorine A positive erythrocytes. Glycophorine 
A negative erythrocytes were not agglutinated (personal communication of Pa­
tricia Tippett).
Monoclonal anti-glycophorine A antibody, A4, is of IgGl isotype, and 
agglutinates papain treated erythrocytes at 37 °C in physiological saline and in 
LISS at room temperature, respectively, in the presence or absence of anti-mouse 
immunoglobulin.
Table 1
ADCC activity of A4 monoclonal antibody
Red cell 
type LISS L IS S -A G T
1 : 5
A D C C  test 
with  A4
1 : 10 1 : 20
A D C C  
test with 
an t i -D  
1 : 10
Rh(d) 1. NT NT NT 1.2 NT 0
2. pos pos 4.5 6.1 NT 0
Rh( D) 1. pos pos 0 0.7 1.7 65
2. pos pos 1.3 1.8 2.3 33
3. pos pos 5.0 8.0 6.9 30
4. pos pos 3.1 6.8 7.0 56
5. pos pos 6.4 8.0 8.1 61
6. pos pos 5.1 7.0 6.9 37
7. pos pos 3.3 7.4 5.1 25
8. pos pos 5.2 8.6 7.6 56
9. pos pos 4.6 9.6 8.8 73
10. pos pos 5.1 8.0 6.9 62
NT =  not tested
ADCC reaction was calculated at different target/effector cell ratios (1 :5 , 1 : 10 
and 1 : 20) from triplicate culture samples.
1 : 40 dilution of cell culture supernatant
test cpm — spontaneous cpm
ADCC reaction (%) =  — ----------x 100
total cpm — spontaneous cpm
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The results are shown in Table 1. A4 monoclonal antibody mediates ADCC 
reaction on a broad variety of target cell types. The overall level of killing is, 
however, lower than that obtained by a human anti-D polyclonal typing reagent. 
This is presumable as polyclonal anti-D is able to bind multiple epitopes [4], 
although it is clear that A4 mediates killing.
It was shown previously in a mouse target cell system that monoclonal 
antibodies, reactive with various mouse cell surface antigens, mediate killing by 
human leukocyte effector cells [5]. The level of killing was variable depending on 
the specificity and the isotype of the antibody. Murine monoclonal anti-human 
antibodies of IgG3 isotype were found to be very effective in augmenting ADCC 
[6]. Human monoclonal anti-D antibodies of IgGl isotype were effective in 
inducing lymphocyte (K cell)-mediated ADCC reaction [7].
We have broadened specificity by using a glycophorine A specific IgGl 
murine monoclonal antibody in a human effector-target cell system. Generally, 
antibodies to the D antigen are used to evaluate the strength of ADCC reaction 
to K cell in clinical practice, however, the efficiency of killing depends on the Rh 
phenotype of the target cells.
A4 monoclonal antibody used in the described test system reacts with a 
narrow range of specificities, e.g. it is specific to the glycophorine A molecule on 
the human erythrocytes, which does not have a polymorphism similar to that of 
the Rh system. That is the reason why we have been able to get comparable levels 
of killing on a broad variety of erythrocyte target cells.
The system described here adds to the specificity of the ADCC reactions 
showing that the non-polymorphic human glycophorine A can also serve as a 
target antigen in K cell mediated killing.
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A population of 783 blood donors has been analyzed for serum cholinesterase 
variants resistant to dibucaine and fluoride. The incidence of these cholinesterase 
variants in the blood donors was lower than that found in other European countries.
Keywords: serum cholinesterase, genetic variants, Spanish blood donors
Introduction
The genetic polymorphism of serum cholinesterase (E.C.3.1.1.8) was first 
described by Bourne et al. (1952) and Forbat et al. (1953). The works of Kalow 
and Genest (1957), Harris and Whittaker (1961), and Liddell et al. (1962), have 
allowed the elaboration of a genetic model suitable for studying this agent. The 
biosynthesis of human serum cholinesterase (acetylcholine acetylhydrolase) is 
controlled by four allelic genes which function at the locus E“. These are E“ for 
the usual type, Ej for the dibucaine-resistant type, E[ for the fluoride-resistant type 
and Ej for the silent gene. The variant of serum cholinesterase is controlled by 
the E2 locus and can be identified only by electrophoretic techniques, Harris et 
al. (1963). It seems to be completely independent of all other variants.
The analysis of the genetic polymorphism of serum cholinesterase is impor­
tant for two reasons: first, the frequency and distribution of the cholinesterase 
types in a population is interesting; and secondly, due to the various mutations 
of this enzyme, therapeutical accidents may occur (sometimes severe apnoea as a 
result of the administration of suxamethonium or derivatives of succinylcholine 
in general anesthesia), or toxic symptoms may arise (due to the use of chemical 
derivatives or anticholinesterase pesticides in industry or agriculture).
The object of this work was to determine the frequency of serum cholineste­
rase variants resistant to dibucaine (Ea) and to sodium fluoride (Ef), in a popula­
tion of blood donors of the Instituto Espanol de Hematologia y Hemoterapia of 
Madrid.
Another aim was to contribute data which may reduce one of the many risks 
of blood transfusions.
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Materials and Methods
The 783 persons involved in this study were blood donors, 557 men and 
226 women, 21 to 65 years of age.
Samples of 5 ml venous blood were collected in tubes without anticoagu­
lant, and left to coagulate for 1 to 2 hours at 37 °C. Thereafter, they were centri­
fuged at 2.000 r.p.m. for 10 min., and the serum without visible hemoglobin was 
aspirated and transferred to sterile tubes. Sera with signs of hemolysis were not 
used in the assay. The evaluations were made on the same day as the collecting of 
the samples.
Serum cholinesterase activity was assayed by measuring the rate of hydro­
lysis of 5 X 10~5M benzoylcholin chloride photometrically at 240 nm in a M/15 
phosphate buffer pH 7.4 at 26.5 °C by the method of Kalow and Lindsay (1955). 
Dibucaine numbers, i. e. percentage inhibition of enzymic activity produced by 
10~’M dibucaine, were measured by the method of Kalow and Genest (1957) and 
fluoride numbers (percentage inhibition of enzymic activity produced by 5 x 10°M 
sodium fluoride) according to Harris and Whittaker (1961). Both DN and FN 
are characteristic constants for each individual: the normal homozygotes (E“, 
Ei) have a DN of 80 + 3; in the normal and atypical enzymes of the heterozygotes, 
the DN is 62 + 8; and in the atypical homozygotes the DN is 22 + 6. The num­
bers corresponding to fluoride are, respectively: 61 + 6; 48 + 9; and 23 + 5.
Results
Of the 783 individuals analysed in this work, 773 (98.72%) were the normal 
type E“E“; 7 (0.89%) were E“E,;and no individuals were found to be EaE?. The 
genetic frequency for Ea was 0.0044. There were 3(0.384%) individuals that were 
; and no individuals were type E)E]. The genetic frequency for Ej was 0.0019.
Table 1
G e n o ty p e
D N  (dibuca ine num ber)
1ST of  
individuals
M ean
S tan d a rd
dev iat ion
Eï Eï 773 80.31 1.40
EÏEÎ 7 64.50 0.41
E)E? 0 — —
In Table 1 the means and standard deviation of the DN obtained in the 
distinct genotypes are given.
In Table 2 the means and standard deviation of the FN obtained in the 
distinct genotypes are shown.
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Table 2
G enoty pe
F N  (fluoride num ber)
N 7 o f  
individuals
M ean
S tan d a rd
dev iat ion
EjE" 773 60.55 1.40
EÏEf 3 52.00 0.87
EfEf 0 — —
Discussion
Our average values for the DN and FN are in agreement with values re­
ported by other authors in different ethnic groups.
Population genetic studies on cholinesterase polymorphism revealed an in­
teresting general observation: all cholinesterase variants seem to be very rare in 
Negroid populations. The allele E* (variant resistant to Dibucaine) is most fre­
quent in Causasoids, whereas the frequency is relatively low in all the other human 
race groups. Information concerning the fluoride-resistant and the variant of the 
“silent” gene is rather limited. Although both of them are very rare, some authors 
found remarkably high frequencies in various populations (E, in several Eskimo 
groups according to Scott et al. 1970 and Gutsche et al. 1967; E1, in Punjab popula­
tion, according to Singh et ah, 1971).
Table 3
Incidence of serum cholinesterase dibucaine-resistant variant in European populations
Popula t io n №  Indiv. Homozyg. Heterozyg.
G en e
F requency  
o f  EJ
A u th o r
French 1.522 57 0.0187 Schaap et al. (1967)
Yugoslavs 248 — 7 0.0141 Fraser et al. (1966)
Portuguese 179 — 6 0.0168 Kattamis et al. (1962)
Greeks 360 — 13 0.0181 Kattamis et al. (1962)
Greeks 561 — 16 0.0143 Morrow et al. (1965)
Greeks 218 1 10 0.0252 Neumann et al. (1968)
Bulgarians 108 — 2 0.0093 Steegmüller (1975)
Czechoslovakians 262 — 19 0.0362 Goedde et al. (1963)
Germans (Berlin) 1.000 — 23 0.0115 Prokop (1971)
Germans 280 — 7 0.0125 Steegmüller (1975)
British 703 — 27 0.0192 Kattamis et al. (1962)
Danish 1.278 1 32 0.0133 Hanel et al. (1978)
Spanish (donors) 783 -- 7 0.0044 Present study
4* H aem ato log ia  23, 1990
236 A. Casado et al.: Serum cholinesterase in blood donors
The distribution of the Cd component does not show a clear geographical 
or racial variation, in many populations of different racial or geographical origin 
similar frequencies could be detected, yet with respect to average values, it can 
be stated that the highest incidence of C°+ is found among the Caucasoids.
The frequencies obtained in our donor population correspond to previous 
affirmations: the genetic frequency for the variant resistant to dibucaine is 0.0044, 
the genetic frequency of the variant resistant to fluoride is 0.0019.
Table 3 shows the incidence of the cholinesterase resistant to dibucaine in 
the different European populations. In our donor population its frequency is the 
lowest. Table 4 shows the incidence of fluoride-resistant cholinesterase in some
Table 4
Incidence of serum cholinesterase fluoride-resistant variant in European populations
Popula t io n №  Indiv. H om ozyg .  Hete rozyg. F requency 
o f  gene E*
A u th o r
Germans 801 12 0.0075 Goedde et al. (1964)
Germans 280 4 0.0071 Steegmüller (1975)
Bulgarians 108 1 0.0046 Steegmüller (1975)
Icelanders 128 -  3 0.0117 Neumann et al. (1968)
Greeks 218 -  7 0.0161 Neumann et al. (1968)
Danish 1.278 -  3 0.0012 Hanel et al. (1978)
British students 780 5 0.0032 Whittaker (1968)
Spanish (donors) 783 -  3 0.0019 Present study.
European populations; the frequency in our studied population was low, only 
the Danish population showed a lower incidence. Based on these results and values 
obtained in 1973 by Goedde et ah, 1973 for Andalucía (0.0040 for E*) and Spain 
Central Meseta population (0.0094) we suggest that these low frequencies are 
due to a racial or anthropological characteristic of the Spanish population.
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Adhesive Properties of Blood Cells
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The adhesive interactions of the cells with each other and with the extracellular 
matrix (ECM) are important for their normal growth and differentiation. Currently, 
very little is known concerning the adhesive and cell recognition factors that maintain 
cell-to-cell contacts in haemopoietic tissues. The majority of peripherial blood cells are 
known to possess an ability to interact with each other (aggregation phenomenon) or 
with various artificial materials, which has important implications for medicine, 
particularly in the fields of thrombosis, vascular prosthetics and dialysis. On the other 
hand, recent studies indicate that blood cells can interact with the main important 
components of ECM, such as collagen, fibronectin, etc. These data, as well as the newly 
discovered receptor structures for various adhesive proteins on the surface of blood 
cells suggest that the haemopoietic tissue has a diverse function involving interaction 
with the ECM.
Keywords: adhesive protein receptors, cell attachment proteins, cell-to-cell 
and cell-to-matrix interactions, haemopoietic tissues, lymphoid and myeloid cells
Introduction
The haemopoietic tissues are situated in different parts of the body. All 
mature and some immature myeloid and lymphoid cells circulate because they 
exist in a free and mobile state.
However, in some stages of haemopoiesis they require a certain immobility 
as does every tissue cell. This is provided by specific cell-to-cell and cell-to-matrix 
interactions [1]. The adhesive cell-to-cell contacts take part in the processes of 
leukocyte migration into extravascular tissues, T-lymphocyte interaction with 
target cells, homing and recirculation of lymphoid cells [1, 2]. The interactions 
between cell-to-matrix adhesive receptors and their cognate protein ligands are 
essential for the movement of haemopoietic cells from and to the bone marrow 
and lymphoid tissues during the process of their differentiation and maturation. 
They are important also for the mobility of some mature blood cells during their 
penetration and functioning in the extravascular space [2].
In this brief review we summarize the recent data in this field and try to 
clarify the relationship between the adhesive properties of blood cells and some 
of their functions.
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General Adhesive Receptors on the Surface of Blood Cells and 
Their Cognate Ligands
It has become apparent that several specialized cell membrane structures, 
similarly to the antigen-binding receptors on lymphoid cells, may serve as recogni­
tion sites and convey crucial signals to haemopoietic cells upon appropriate 
occupation by ligands. The mechanism by which haemopoietic cells recognize 
and adhere to specific sites in the ECM, as well as to other cells, has been inten­
sively investigated during the past few years [2, 3]. There is evidence, indicating 
that several cell surface receptors from the integrin superfamily of cell adhesion 
molecules (I-SCAM) are located on the surface of blood cells [2]. The I-ESCAM 
proteins include cell-to-matrix and cell-to-cell adhesion receptors-heterodimers
Table 1
“Integrin superfamily” of adhesive protein receptors
Recep to r Cognate  ligand D is t r ibu t ion F unc t ion
VLA-l 9 T*-ly, liver, muscle skin, 
fibroblasts, HTLV-IT, 
NHCL
not normalf?) arthrit. 
patients
VLA-2 collagen T*-ly, platelets coagulation
VLA-3 collagen, lami­
nin Fn
kidney, thyroid Ly, Mo, 
basement membranes, 
preMo
T-cell ontogeny, malignant 
transformation, haemo­
poietic cells, metastasis
VLA-4 0 thymus, bone marrow, 
most HCL, (T, B, 
myelomas)
anchorage of lymphocytes 
in bone marrow
VLA-5 Fn Ly, Mo, platelets, thymus, 
bone marrow
blood cell maturation, 
homing phenomena, 
anchorage of blood cells
VLA-6 ? mammary epithelial cells unknown (?cell-ECM 
interaction)
GpHb/HIa vitronectin, 
Fn, Fng, 
VWF
platelets coagulation
LFA-1 GAP Ly antigen-independent Ly, 
adhesion, immunological 
response
Mac-1 ?C3bi Mo, granulocytes adhesion to endothelial 
cells in vessel wall
p i50, 95 ?C3bi Mo, granulocytes adhesion to endothelial 
cells in vessel wall
Ly: lymphocytes, *: activated Ly, Fng: fibrinogen, GAP: general adhesive protein, 
Mo: monocytes, HTLV-IT and NHCL: lymphoid cell lines, other abbreviations: see in text
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conditionally divided into three subgroups (Table 1): (i) VLA (Very late antigens) 
[2], (ii) lymphocyte functional antigen-1 (LFA-1); macrophage antigen-1 (Mac-1); 
and p-150,95 proteins [4]; (iii) major surface glycoproteins [5]. All or most of 
these receptors can recognize ligands which contain Arg-Gly-Asp or closely 
related amino acid sequences [1, 2]. It is extremely interesting that the I-ESCAM 
proteins exhibit a significant structural homology, and are also homologous to 
other proteins, such as the immunoglobulin superfamily, major histocompatibility 
antigens, some hormonal receptors, as well as most cell attachment proteins [32]. 
This suggests a close genetical relation between them, which, however, is beyond 
the frame of this review. According to Edelman [32] most of these proteins 
originate from the exone conversion (or duplication) of the more ancient I-ESCAM 
superfamily gene.
Which are the known adhesive ligands in the haemopoietic tissues?
According to the latest data, the bone marrow stroma consists of various 
attachment proteins, such as type I, III, and IV collagens, fibronectin (Fn), 
laminin, and proteoglycans [6]. These proteins are also structural components 
of the vessel wall [7, 8]. In soluble form Fn, and vitronectin are major cell-adhesive 
glycoproteins, present in mammalian plasma [7, 8].
Up to now, more than 10 types of collagen have been well characterized. 
Collagen types I and III are the major collagenous components of the vessel 
wall [8], while collagen types IV and V are predominantly restricted to the base­
ment membranes. Immunohistochemical studies suggest a close association of 
collagen types I and III to Fn, while a second structural adhesive glycoprotein- 
laminin is colocalized with collagen types IV and V [7, 8].
Perhaps the most studied component of the ECM is Fn [7]. This glyco­
protein dimer (mol.w. 220 kDa) is predominantly associated with the ECM of 
many tissues, and can act as a bifunctional ligand between cells and collagen [7]. 
It is widely accepted that Fn participates in numerous biological phenomena, 
including cell adhesion and migration, embryonic differentiation, malignant trans­
formation, wound healing, etc. [7].
The basement membranes are also adhesive extracellular matrices, and 
consist mainly of collagenous and noncollagenous proteins. The latter are still 
incompletely characterized, but are known to include a great amount of laminin 
[9]. It consists of three polypeptide chains (A, Bl, B2) linked by disulfide bonds, 
which migrate on SDS polyacrylamide gels under reducing conditions with 
apparent molecular weights of 400 kDa, and 210, 230 kDa, respectively.
The other adhesive protein, vitronectin, is a monomeric glycoprotein 
detected as a mixture of 75 kDa and 65 kDa polypeptides [10]. Vitronectin binds 
to heparin, collagen, and a variety of cultured cells. It mediates biological effects 
in vitro similar to those of Fn and laminin [10].
Among the adhesive protein receptors on blood cells, the VLA-1 and 
VLA-2 were originally defined by Hemler et al. in 1983 as heterodimers appear­
ing 2 — 4 weeks after in vitro activation of T lymphocytes [11]. Subsequently 
three additional heterodimers (VLA-3, VLA-4 and VLA-5) were discovered,
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and found to belong to the same protein family [12]. A sixth distinct heterodimer 
VLA-6 has recently been discovered, but its influence on haemopoietic cells has 
not yet been analysed [13]. The results of biochemical and immunological studies 
indicate that each VLA protein is composed of distinct a-subunit, which is non- 
covalently associated with a common Д-subunit [12]. Amino-terminal sequence 
analysis of the five VLA Д-subunits revealed striking homologies within the group 
as well as with Д-subunits from heterodimers belonging to the other families [2].
Except for granulocytes and red (mature) blood cells, nearly all cell types 
express one or more VLA complexes (Table 1). VLA-1 and VLA-2 expression 
is restricted to activated T lymphocytes and a few T lymphoblastoid cell lines [11 ], 
whereas VLA-4 is expressed on nearly all lymphocytes, monocytes and related 
cell lines [12]. Both VLA-2 and VLA-5 are measured on activated platelets [13]. 
VLA-5 is present on the myeloid cell lines K-562 and K-937, and is immuno- 
chemically identical with the Fn receptor [14]. A combination of functional and 
structural approaches suggests that similar Fn receptors are present in many 
haemopoietic cells, for example bone marrow cells [6] and several pre B-lymphoid 
cells and B-myelomas [15] immature thymocytes [16], T-lymphoma [17], mono­
cytes and macrophages [18], proerythroid cells and erythroid cell lines [22]. 
The data obtained in our laboratory also showed that a subpopulation of human 
peripherial lymphocytes [19] and rat lymphocytes from different lymphoid 
tissues [20] possess a similar Fn-binding capacity.
LFA-1, Mac-1 and p-150,95 adhesive receptors of the second integrin family 
subgroup, are also composed of noncovalently linked heterodimers, which also 
have distinct a-subunits with mol.w. of 180, 170 and 150 kDa, respectively [2, 4]. 
The Д-subunit (mol.w. 95 kDa) has been shown to be identical in all three proteins. 
LFA-1 is typical for lymphocytes, while Mac-1 and p-150,95 are expressed on 
the surface of monocytes and granulocytes [2].
Various cytoadhesive proteins have been discovered on platelet membranes 
during the past few years [5]. According to the “classical concept” the platelets 
possess numerous glycoproteins (Gp) divided into three large groups — Gp I, 
II and 111 [5]. In general, Gp lb is responsible for the platelet adhesion to the 
endothelial cover of the vessel wall [13], while Gp lib  and III are related to 
platelet aggregation phenomena [5]. Gp lib  and Ilia, exist as a noncovalent 
complex in the platelet membrane, and are one of the most studied members 
of I-ESCAM (Table 1). This glycoprotein complex serves as a receptor for four 
proteins: Fn, fibrinogen, Yon Willebrand factor, and vitronectin [1, 2].
Other specific adhesive receptors besides the integrin family members are 
also present on the surface of lymphocytes [21]. These receptors are related to 
the capacity of these cells to locate and enter lymphoid organs by a series of 
adhesive interactions called “homing” phenomena [21]. The lymphocyte homing 
receptors are cell surface glycoproteins. They are responsible for the adherence 
to cognate ligands, located on the high endothelial vessels (HEV-ligands). The 
mouse lymph-node homing receptor is an extensively glycosylated branched- 
chain polypeptide [21].
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Adhesive Interaction and Haemopoiesis
Blood cell production is a developmental process requiring close cell-to-cell 
association between haemopoietic cells and their supportive stromal cells. These 
stromal cells secrete regulatory factors that promote differentiation and matura­
tion of blood cells. Currently, very little is known about the adhesive and cell 
recognition factors maintaining cell-to-cell contacts in haemopoietic tissues. 
Since actively dividing haemopoietic progenitor cells are preferentially associated 
with the stromal layer of bone marrow cultures [23], it is possible that certain 
components of this matrix are important for the maintenance of haemopoiesis. 
This possibility is suggested by the observation that inhibitors of the matrix 
formation decrease stem cell production, whereas compounds that stimulate 
matrix production increase stem cell proliferation [23].
The most studied component of ECM, associated with haemopoiesis, is 
Fn [7]. The immunofluorescence studies of the developing bone have indicated 
that haemopoietic colonies are associated with Fn-rich areas of the bone mar­
row [6, 23]. This suggests a possible important role of this protein in anchoring 
haemopoietic cells to the stroma. Bone marrow precursors of erythrocytes interact 
with Fn and the loss of Fn adhesion results in the release of the cells into the 
circulation [22]. The data showing that both immature erythroid and myeloid 
cell lines can adhere to Fn [23] are in agreement with the above concept. Adhesion 
occurs via the same cell attachment domain (110 kDa fragment) that functions 
in the fibroblast adhesion [23]. Moreover antibodies to the 145 kDa plasma 
membrane glycoprotein (structurally and immunologically similar to fibroblast 
Fn receptor) can prevent haemopoietic cell adhesion [23]. It was shown that 
human, rabbit and mouse reticulocytes attach specifically to Fn [22]. Remodelling 
of the reticulocyte plasma membrane during maturation in vivo is indeed accom­
panied by the loss of adhesion to Fn [22]. The spleen is one of the sites where 
reticulocytes lose their ability to attach to Fn [22].
The adhesion is also an essential mechanism for T lymphocyte differen­
tiation in the lymphoid organs [21]. Recent data [6] show that the Fn receptor 
structures are preferentially expressed in the proliferating subpopulations of 
thymocytes. Based on these data, it appears that the Fn receptor activity is impor­
tant during the early phase of thymocyte development, and disappears after cell 
differentiation [16, 17].
There are insufficient data concerning the role of other matrix proteins. 
In general these studies reported a weak adhesion of haemopoietic cells to laminin 
and collagen [6], but further investigations are necessary in this field.
Adhesive Properties of Lymphocytes
Although lymphocytes are relatively nonadhesive and immotile in circula­
tion or in vitro conditions, they acquire these characteristics after penetration
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into the tissues [3]. The lymphocytes undergo adhesion to endothelial cells and 
migration is observed in vivo under certain circumstances [21]. The factors 
responsible for these changes are however unknown. Some adhesive receptors 
binding the lymphocytes, and molecules such as Fn in the ECM regulate the 
adhesion and locomotion of the contacting cells. It seems that Fn is the most 
important protein involved in the lymphocyte adhesive interactions. Gardarelly 
and Pierschbacher [16] were among the first authors who discussed the role of 
Fn in lymphocyte adhesion. As mentioned above, the results obtained in our 
laboratory suggest the presence of a subpopulation of human peripherial lympho­
cytes, which shows an ability to interact with both immobilized and soluble 
Fn [19]. In other experiments with rats [20] we demonstrated the important role 
of Fn in the lymphocytes anchorage during their functional distribution in the 
peripheral lymphoid tissues. An investigation of 12 lymphoid cell lines showed 
that 5 of them, adhering to Fn, had B-cell characteristics, while neither T-cell 
lines nor pre B-cell lines were observed to adhere [15]. Kurki et al. [24], however, 
reported that T-lymphocytes adhere predominantly to Fn, and the mitogen 
stimulation additionally promotes this phenomenon.
In a previous paper [19] we reported on the inhibition of lymphocyte 
adhesion on Fn-coated surface in the presence of soluble Fn. We suppose that 
interaction of the lymphocyte Fn receptor with solid phase-immobilized Fn 
leads to cell adhesion, while preliminary saturation of the receptor inhibits the 
process. As shown in Table 1, there are at least three receptors for Fn on the 
surface of haemopoietic cells (VLA-3, -5 and Gp Ilb/IIIa), but with the exception 
VLA-5, their presence on lymphocytes has not been studied [1].
We found no information concerning the adhesive interaction of lympho­
cytes with other matrix components, such as laminin, vitronectin or proteogly­
cans. It seems that lymphocytes adhere poorly to collagen, but they are able to 
attach to and migrate in three dimensional collagen matrices [1, 3].
As metioned above, the lymphocytes have various adhesive receptors which 
mediate cell-to-cell interactions that are important for the realisation of homing 
phenomena [21]. At present, at least two independent homing receptors exist 
in vertebrates lymphocytes: one for peripherial lymphnode vessels, and another 
for Payer patch vessels (or appendix in humans) [21]. Other authors [21] demon­
strated that lymphocytes adhere to the endothelial cells in vitro as a result of 
specific receptor-ligand interactions. According to the latest data LFA-1 is such 
a receptor (see above). After the interaction the cells transmigrate across the 
endothelial cell layer into the lymphoid organ tissue [8], B cells moving vectorially 
toward the follicules (B cell domain), and T-cells toward the T-cell domains [21].
The specific movement of lymphocytes from blood to tissues occurs not 
only during their normal traffic of recirculation and homing, but also when the 
effector T lymphocytes enter sites of inflammation, for example virus infection 
or allografts [21]. In chronic inflammatory sites on the blood vessels endothelial 
cells there are receptors similar in structure to the normal lymphocyte homing 
receptor [27].
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Macrophage, Monocyte, and Neutrophil Adhesion
It seems that the macrophages (monocytes), as well as the neutrophils 
display both active and passive modes of adhesion. The active response of macro­
phages to the substrate is probably a manifestation of their phagocytic properties. 
It has been suggested, that the spreading of macrophages on a substrate is an 
attempt of the cells to phagocytose a particle of infinite diameter [3].
Adhesion to the substrate, as well as the spreading reaction, has been shown 
to require serum in experiments with both neutrophils and monocytes [3]. Macro­
phages can normally synthesize Fn [18]. This protein is a normal component of 
the surface coat of human neutrophils [3]. Binding of Fn to the neutrophils (via 
a specific receptor — see above), results in the activation of the phagocytic 
response of these cells, and induces the production of a chemotactic factor, 
stimulating neutrophil substrate adhesion [25]. Fn has also been shown to pro­
mote the attachment of Staphylococcus aureus to neutrophils, even though it 
was not able to promote neutrophil phagocytosis of bacteria [3].
Little information is available on the interaction of macrophages and 
neutrophils with other components of the ECM. Jmmunocytochemical attempts 
to identify laminin were unsuccessful [6]. Nevertheless, monocytes and macro­
phages can interact with collagen [26], and this results in an augmented secretion 
of cytokines and prostaglandins. Evidence for a monocyte (macrophage) collagen 
receptor was obtained through affinity isolation of a 125/150/180 kDa structure 
from the promonocyte cell line U-937 [1].
The specific I-ESCAM receptors (Mac-1 and P150,95) on the surface of 
macrophages and granulocytes are responsible for their interaction with the 
endothelial cells. Mac-1 is also a receptor for the C3bi component of complement 
and is simultaneously involved in monocyte and neutrophil adhesion. The 
second antigen, PI50,95 appears to have functions similar to those of Mac-1, 
but displays somewhat different cell distribution [1, 2]. The importance of the 
Mac-l/pl50,95 family in leukocyte function is underestimated due to the exis­
tence of the human genetic disease termed leukocyte adhesion deficiency (LAD) 
[27]. Patients with LAD are deficient in their cell surface expression of LFA-1, 
Mac-1 and p i50,95 [2] and suffer from recurrent life-threatening bacterial 
infections. Leukocytes from these patients show profound defects in virtually all 
adhesion-related functions [27].
Platelet Adhesion
The adhesion of platelets to a substrate is the initiating event in their basic 
function that results in the release of platelet content and platelet aggregation, 
which in turn leads to clot formation [3]. Because of the importance of platelet 
adhesive interactions in vivo, sophisticated strategies for studying adhesion and 
aggregation under in vitro conditions have been developed. In this paper we 
discuss platelet substrate adhesion only.
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The identity of the connective tissue components that are the substrates 
for platelet adhesion is controversial [3]. Following trauma, platelets adhere to 
the underlying connective tissues, especially to those containing collagen [28]. 
The interaction of platelets with collagen is an important early event in haemostasis 
and thrombosis. According to the “classical concept” the adhesion of platelets 
to collagen exposed in injured blood vessels is the first step of a complex process 
leading to platelet activation and clot formation. Native collagen is a substrate 
for platelet adhesion, whereas thermally denaturated collagen is not [28]. It 
seems that most probable candidate for a specific collagen receptor structure on 
the platelet surface is VLA-2 (see above), possibly located in a Gp la—Ha frac­
tion [13].
Fn is also the substrate for platelet adhesion and can participate in the 
mechanisms of platelet aggregation with collagen [29]. Platelet «-granules also 
contain a significant amount of Fn which can be released during aggregation. 
This activity is realised by two separate receptors: VLA-5, which is specific for Fn, 
and Gp lib —Ilia, which shares Fn binding activity with three other adhesive 
proteins (vitronectin, fibrinogen and Von Willebrand factor [2, 12]. The possible 
role of adsorbed fibrinogen in platelet adhesion has been mentioned previ­
ously [30].
Another plasma protein necessary for platelet adhesion is the Von Wille- 
brand’s factor [31]. Patients lacking this protein exhibit inefficient platelet-sub­
strate adhesion [2, 31]. The functional importance of membrane Gp lib — Ilia 
on the surface of human platelets is indicated by their lack or severe decrease 
of human platelets from patients with Glanzmann’s thrombasthenia [31]. These 
platelets are unable to aggregate in response to reagents such as ADP, thrombin, 
collagen or epinephrine.
Platelet-subendothelial adhesion is impaired also in patients with Bernard- 
Soulier syndrome [2]. In this case certain membrane glycoproteins present in 
normal platelets, are apparently missing.
In conclusion blood cells seem to possess a greater variety of cell-to-matrix 
and cell-to-cell adhesion capabilities than suspected previously. It should be 
emphasized that the above interactions are quite likely to play an important role 
in the functional behaviour of these cells. In our opinion future investigations 
should be aimed at: (i): studying the adhesive receptor phenotype of blood cells, 
especially that of lymphocytes; (ii): demonstrating cell-environmental adhesion 
relations in the processes of myelopoiesis and lymphopoiesis. Moreover, it would 
be of great importance to elucidate the role of the adhesive events in both normal 
haemopoiesis and processes of malignant transformation and dissemination in 
neoplastic haemopathies; (iii): clarifying the role of the adhesive properties of 
immature and mature blood cells in their circulation, homing and functioning.
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